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ABSTRACT OF THE DISSERTATION
The Mechanobiology of Elbow Contracture: Pathogenesis and Prevention
by
Chelsey L. Dunham
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2020
Research Advisor: Spencer Lake, Ph.D.
Post-traumatic elbow contracture is a multi-tissue pathology which develops in up to 50%
of patients following elbow trauma (e.g., fracture, dislocation). It is unclear which periarticular
soft tissues are driving the functional deficit following injury because it is not possible in clinical
settings to isolate each soft tissues’ mechanical and biological contributions to elbow
contracture. Therefore, an animal model is needed to identify the primary periarticular soft
tissue(s) which contribute to contracture. The first animal models of contracture were developed
in the knee; however, these studies are not generalizable to the elbow due to anatomical and
functional differences between these two joints. Thus, we developed a model of post-traumatic
elbow contracture in the rat and can now investigate each periarticular soft tissues’ contribution
to motion loss, which will ultimately inform the development of tissue targeted treatment
strategies. Current strategies to manage elbow contracture (e.g., physical therapy, surgery) rarely
restore range-of-motion to pre-injury levels. These strategies are often not effective because they
physically disrupt the periarticular soft tissues rather than treat the underlying pathology.
Previously, stem cells have been used in animal models of soft tissue fibrosis in an effort to
prevent tissue hypertrophy and functional loss. However, these treatments exhibited
unpredictable results which ranged from transient benefits to amplified pathology. Hence, a
xvii

mechanism is needed to improve stem cell efficacy following injection. In this work, mechanical
memory will be used to direct stem cells toward positively influencing tissue regeneration in
vivo.
The studies presented in this dissertation aimed (1) to evaluate mechanical and biological
changes in the periarticular soft tissues from our rat model of elbow contracture to ultimately
identify the primary contributor(s) to motion loss, and (2) to determine in vitro if adipose-derived
stem cells (ASCs) exhibit mechanical memory and to examine if treatment with soft primed
ASCs will reduce fibrosis and improve elbow function in our rat model after injury. Following
injury, flexion-extension and pronation-supination developed motion loss differently throughout
immobilization and uniquely responded to joint reloading during subsequent free mobilization in
our rat elbow contracture model. However, the motion lost was more severe in flexion-extension
than in pronation-supination. The anterior capsule, ligaments, and cartilage were identified as the
primary contributors to contracture in flexion-extension. Physiological testing confirmed that
muscle was not a permanent contributor to elbow contracture in our rat model. Biological
characterization of the anterior capsule and lateral collateral ligament identified that hypertrophy
as a result of fibrosis likely caused the deficit in joint mechanics. To prevent fibrosis in these
tissues, a biological treatment strategy was developed using mechanically primed ASCs. Soft
primed ASCs displayed a delayed stiffness response demonstrating that these cells exhibit
mechanical memory in vitro. Injecting these soft primed ASCs into the anterior capsule of our rat
elbow contracture model decreased capsular fibrosis and hypertrophy and increased range-ofmotion compared to untreated animals. Overall, this work has significantly advanced our
understanding of post-traumatic elbow contracture as well as presented a biologically motivated
treatment strategy to prevent motion loss following elbow trauma in our rat model.
xviii

Chapter 1: Introduction
1.1 Motivation and specific aims
Post-traumatic joint contracture (PTJC) develops in up to 50% of patients following
elbow injury (i.e., fracture, dislocation) and is more frequently observed than joint instability [13]. Restoring motion is a complex challenge because elbow contracture is an unpredictable,
multi-tissue pathology [4, 5]. However, in clinical settings it is not possible to isolate each
periarticular soft tissues’ mechanical and biological contributions to elbow PTJC. Therefore, it
remains unclear why the elbow is susceptible to contracture.
An animal model is needed to identify the primary periarticular soft tissue(s) which
contribute to contracture. Interestingly, the first animal models of PTJC were in the knee. The
animal models of knee contracture (1) evaluated motion loss as a result of different periods of
immobilization and subsequent joint reloading, (2) determined muscles/tendons and remaining
intact connective tissues (i.e., capsule, ligament, cartilage) contribution to joint mechanics, and
(3) evaluated biological changes in these soft tissues via histology and genetic/protein expression
[6-14]. But these studies in knee contracture models cannot be directly translated to the elbow
because of anatomical and functional dissimilarities between these two joints. So, we developed
a model of post-traumatic elbow contracture in the rat [15]. Now, periarticular soft tissue
mechanics and biology can be investigated to determine which tissue(s) are the primary
contributors to elbow contracture and hence should be targeted with a treatment strategy to
prevent motion loss after injury.
Current strategies to manage elbow contracture (i.e., physical therapy, surgery) rarely
restore range-of-motion (ROM) to pre-injury levels and 20% of patients require revision surgery
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for repeat contracture [16, 17]. These strategies are often not effective because they physically
disrupt the periarticular soft tissues rather than treat the underlying pathology driving the fibrotic
response. Previously, stem cells have been used in animal models of soft tissue fibrosis in an
attempt to prevent tissue hypertrophy and function loss [18-20]. However, these treatments
exhibited unpredictable results which ranged from short-term benefits to augmented pathology.
The limited efficacy of stem cells in vivo demonstrates that a mechanism is needed to improve
cell response following injection. Mechanical memory or pre-conditioning will be used in this
work to direct stem cells toward positively influencing tissue regeneration in a wound
environment.
Overall, the work presented in this dissertation aimed (1) to evaluate mechanical and
biological changes in the periarticular soft tissues from our rat model of elbow contracture to
identify the primary tissue contributor(s) to ROM loss following injury, and (2) to determine in
vitro if adipose-derived stem cells (ASCs) exhibit mechanical memory and to examine if
treatment with soft primed ASCs will reduce fibrosis and improve elbow function in our rat
model after injury. Successful completion of these aims will not only identify which tissue(s)
drive ROM loss in elbow contracture but will also demonstrate that ASCs can be mechanically
primed to decrease fibrosis and improve joint function in our clinically relevant animal model of
elbow contracture. A large potential clinical impact of this work exists since the stem cell
population in this study is not genetically or biochemically manipulated before injection, but
instead pre-conditioned by the stiffness of the culture environment during cell expansion. The
results of this study will not only contribute to anti-fibrotic treatment strategies in orthopaedic
soft tissues but may also benefit other organ system commonly affected by this pathology.
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1.2 Summary of chapters
Chapter 2 reviews human elbow PTJC, including how elbow trauma alters joint function
as well as existing treatment strategies. It also provides a summary of studies which used animal
models to understand contracture etiology. Information about the first animal model of elbow
contracture is presented because it will be used throughout this work to investigate biological and
mechanical mechanisms responsible for the motion lost after injury. In addition, fibrosis is
defined and studies using stem cells to prevent this pathology are discussed. A concept called
mechanical memory is introduced which will be used in this work to enhance the effectiveness of
stem cell therapies.
In chapter 3, our rat model of elbow contracture is evaluated to determine if the motion
lost after injury and immobilization is permanent following a period of joint reloading. A custom
designed flexion-extension mechanical testing system is used to examine injured limbs after 42
days of immobilization followed by 42 days of free mobilization (i.e., no immobilization, free
cage activity; 42/42 IM-FM). After mechanical testing, morphological changes are observed in
the anterior capsule via histology.
Chapter 4 presents a custom mechanical testing system designed to quantify pronationsupination ROM in our rat model of elbow PTJC. Injured limbs are tested after 42 days of
immobilization (42 IM) or 42/42 IM-FM. At both time points, ROM parameters in flexionextension, collected in previous studies and chapter 2, and pronation-supination are correlated to
identify if both types of motion respond similarly to immobilization and free mobilization.
The same mechanical testing systems presented in the previous two chapters are used in
chapter 5 to determine if contracture development is dependent on the duration of
3

immobilization and to examine how contracture responds to different periods of joint reloading.
Flexion-extension and pronation-supination are examined in our rat model of elbow PTJC after
3, 7, 21, or 42 IM, or after 42 days of immobilization with either 21 or 42 days of free
mobilization (42/21 or 42/42 IM-FM, respectively). The anterior capsule and joint surfaces are
assessed via histology to characterize changes in morphology over time.
In chapter 6, sequential dissection flexion-extension mechanical testing is completed to
evaluate periarticular soft tissue contribution to elbow contracture in our rat model. Injured limbs
are tested after 42 IM, or 42/21 or 42/42 IM-FM. To isolate tissue contribution to overall joint
mechanics, limbs are first tested with all soft tissues intact, then with the muscles/tendons
removed, and finally after the subsequent removal of the anterior capsule. Total extension is
measured to ascertain the relative contributions of the muscles/tendons, capsule, and the
remaining intact tissues (i.e., ligaments and cartilage) to elbow contracture.
The primary outcomes presented in previous chapters were from post-mortem joint
mechanical testing, which may have underestimated muscle contribution. Chapter 7 examines
active and passive muscle physiology testing in the biceps brachii after 42 IM or 42/42 IM-FM.
Structural changes within muscle are shown via histology (i.e., fiber cross sectional area) and
immunohistochemistry (i.e., extracellular matrix area fraction). Muscle genetic expression is also
assessed to identify changes in extracellular matrix production and regulation.
In chapter 8, tissue specific biological and mechanical changes in the anterior capsule and
lateral collateral ligament (LCL) are investigated to establish what pathology directed their
contribution to elbow contracture, which was previously shown in chapter 6. Capsules and LCLs
were characterized after 42 IM or 42/42 IM-FM. LCL mechanics and morphology is evaluated
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by a uniaxial ramp-to-failure test in a custom designed testing system, which held the joint at 90°
flexion during loading, and contrast enhanced micro-computed tomography, respectively.
Biochemical analysis of capsule and LCL collagen and sulfated glycosaminoglycan content is
quantified by colorimetric assays. An amino acid analyzer is used to identify collagen peaks for
immature and mature collagen crosslinks in both tissues.
Chapter 9 presents mechanical memory as a tool to improve control of stem cell response
following injection in vivo. Primary subcutaneous ASCs are soft primed on ~1 kPa hydrogels for
two weeks followed by transfer to stiff (~120 kPa) hydrogels for an additional one or two weeks.
Cell morphology and activity is visualized by immunolabeling techniques to determine if soft
priming delays cell response to stiffness, ultimately postponing ASC transition to the pro-fibrotic
phenotype. Two million of these soft primed ASCs are injected into our rat model of elbow
PTJC three days post-injury. After 21 days of immobilization, flexion-extension joint mechanics
and histology are evaluated to discover if there is any functional and biological benefit following
treatment, respectively. ASC cytokine secretion is also quantified to assess what signals
produced by these soft primed cells may direct resident cell populations toward a more
regenerative phenotype.
Finally, chapter 10 summarizes the major results and conclusions of this work. It also
presents several future directions to study how the soft primed ASCs direct the therapeutic
benefit observed in vivo (e.g., immunomodulation and in vivo cell tracking) as well as how soft
primed ASCs retain memory of their past culture environments (e.g., epigenetics).
Overall, this work has significantly advanced our understanding of post-traumatic elbow
contracture as well as presented a biologically motivated treatment strategy to prevent motion
5

loss following elbow trauma in our rat model. Developing a clinically relevant animal model of
elbow PTJC allowed multi-scale evaluation of contracture etiology during immobilization and
response to joint reloading during free mobilization, which was previously not possible due to
the lack of an appropriate model. In clinical settings it was unknown which periarticular soft
tissue(s) contributed to contracture. This work identified the capsule, ligaments, and cartilage as
the primary tissues driving the functional deficit in our rat elbow PTJC model. However, it was
unclear what pathology led to these changes in mechanics. Histology, contrast enhanced microcomputed tomography, collagen biochemistry and collagen crosslinks showed that tissue
hypertrophy (i.e., fibrotic scarring) was a primary factor causing the restricted joint motion after
trauma in our animal model. With this knowledge, a tissue specific treatment strategy was
developed using mechanically primed ASCs to mitigate the fibrotic response and decrease
motion loss following injury. This was the first therapy to mitigate joint contracture that did not
use a genetic or pharmacologic strategy, but instead mechanically pre-conditioned cells during
expansion to improve their efficacy following injection. While these soft primed ASCs were
successful in limiting orthopaedic soft tissue fibrosis, these cells may also potentially benefit
other organ systems commonly affected by this pathology.
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Chapter 2: Background
2.1 Post-traumatic elbow contracture
2.1.1 Elbow contracture in clinical settings
The elbow is second most commonly dislocated joint in adults and the most commonly
dislocated joint in the pediatric population [1, 2]. After elbow dislocation, post-traumatic joint
contracture (PTJC) is more frequently observed in clinic than joint instability [1]. PTJC develops
in up to 50% of patients whom experience elbow injury (e.g., dislocations, fractures) [3, 4].
Restoring joint motion is a difficult, time-consuming, and costly challenge because elbow
contracture is an unpredictable, multi-tissue pathology [5, 6]. Elbow dislocations and fractures
often damage the surrounding periarticular soft tissues including the anterior capsule,
lateral/medial collateral ligaments, muscles, tendons, and cartilage [2, 6, 7]. However, it is
difficult to determine the extent to which each tissue contributes to elbow contracture because in
clinic it is not possible to specifically isolate each tissues’ mechanical and biological
contributions to PTJC. Thus, it remains unclear why the elbow is highly susceptible to
contracture.
Elbow function depends on the integrity of the soft tissues surrounding the joint [8].
While all the periarticular soft tissues aid articulation or provide stability to the elbow, their form
and function are different. The capsule is a synovial-lined membrane that encloses the
articulating joint surfaces [9]. It helps to resist valgus stress, distraction, and hyperextension [10,
11]. The lateral and medial collateral ligaments provide rotational stability [10, 12]. Of particular
interest to this work, the lateral collateral ligament (LCL) provides varus stability and is
primarily loaded during 80-100° of flexion [12, 13]. Muscle-tendon complexes near the elbow
9

stabilize and align the joint during articulation by force applied from contraction [12, 14-16].
During articulation, joint cartilage is loaded in both shear and compression [17, 18].
The elbow range-of-motion (ROM) required for most activities of daily living in both
flexion-extension and pronation-supination is 100° [11, 19-21]. Specifically, ROM in flexionextension is typically defined between ~30-130°, while pronation-supination is defined as ~50°
of rotation in both directions [11, 22, 23]. PTJC causes debilitating motion loss in both flexionextension and pronation-supination, and patients with contracture often lose ~35-55° of motion
in flexion-extension [11, 20-22, 24, 25].
Clinically, elbow contracture has been attributed to the shortening of the collateral
ligaments and capsule as well as arthrosis [5, 9, 19]. However, clinical practice has primarily
focused on changes to the elbow anterior capsule. Based on observations after injury, the capsule
has been reported to exhibit (1) hypertrophy due to increased, disorganized collagen, (2)
hypercellularity, specifically fibroblasts/myofibroblasts and mast cells, and (3) decreased
proteoglycan content [21, 26-30]. Several studies completed by Hildebrand and colleagues have
rigorously evaluated patient anterior capsule biopsies collected 5-25 months post-injury [31-33].
Following injury in the anterior capsule they identified (1) altered genetic expression of
extracellular matrix (ECM) proteins and regulators (i.e., increased collagen type I, III, and V,
matrix metalloproteinase-1 and -2 (MMP-1 and -2); decreased tissue inhibitor of
metalloproteinase-1 and -2 (TIMP-1 and -2)), (2) increased α-smooth muscle actin (αSMA)
protein expression which corresponded with an increase in the number of myofibroblasts, and (3)
increased percentage of mast cells and neuropeptides.
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The changes observed clinically in the anterior capsule are representative of soft tissue
fibrosis. Fibrosis is the excessive accumulation of ECM proteins and often occurs when collagen
synthesis exceeds the rate at which it is degraded [34]. It often arises when the wound healing
response fails to terminate. Myofibroblasts are believed to drive tissue fibrosis due to their
increased production of collagen and enhanced ability to contract the ECM as a result of
increased αSMA expression [35]. It is unknown whether fibrosis can be completely prevented or
reversed [34].
The current options to manage joint contracture include nonsurgical and surgical
intervention strategies. Nonsurgical treatment options include, but are not limited to, serial
casting, static and dynamic splinting, continuous passive motion, and manipulation [21]. Early
mobilization is often recommended following elbow injury, but limited literature exists which
provides standardized guidelines for elbow rehabilitation after trauma [7]. While some motion
will be restored with physical therapy, rarely does the elbow return to pre-injury ROM and 1215% of these patients will require surgical intervention [21, 23]. Surgical treatment options most
commonly include open or arthroscopic soft tissue release [19, 21]. However, there is a wide
range (5-73%) for risk of complications and 10-20% of patients will require a second surgery for
repeat contracture [20, 21, 36]. Most of these strategies also focus primarily on restoring motion
in flexion-extension, yet significant motion loss can also occur in pronation-supination. While
forearm pronation can be partly compensated for by shoulder abduction, there is no body motion
to replace supination [11]. Elbow arthroscopy does not reliably address pronation-supination
and, while better managed with open surgery, it is associated with high postoperative morbidity
and slow recovery [37]. Overall surgery is effective to some extent, but it is not the ultimate
solution because soft tissue contractures are diffuse and not easily localized [38]. Therefore, a
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systematic approach evaluating biological and mechanical changes to all elbow periarticular soft
tissues is needed to ultimately develop tissue targeted treatment strategies to prevent contracture.

2.1.2 Joint contracture animal models
An animal model of joint contracture is required to specifically isolate each periarticular
soft tissues’ biological and mechanical contributions to contracture. Interestingly, animal models
of PTJC were first developed in the knee. Rat models of immobilization-only knee contracture
(i.e., no injury) have been predominately used to evaluate PTJC by surgically implanting an
internal fixator (e.g., Kirschner wire (K-wire)) to immobilize the joint [39-44]. Significant ROM
loss developed in these models after 2-4 weeks of immobilization [41, 45]. The amount of joint
motion lost was directly dependent on the duration of immobilization [39, 40, 46]. Specifically,
Trudel et al. found that ROM loss increased over 2-16 weeks of immobilization, with the
maximum motion loss occuring at 16 weeks (~60° lost), after which additional periods of
immobilization did not restrict joint motion further [40]. As few as four weeks of immobilization
caused irreversible motion loss, where subsequent periods of free mobilization (i.e., no
immobilization, free cage activity) could not completely restore joint motion [42].
Muscles/tendons were found to contribute to knee contracture after 2-4 weeks of
immobilization, but their contribution was reversible following periods of free mobilization [4,
43, 44]. However, muscle/tendon contribution was likely underestimated in these models as there
was no direct tissue injury and voluntary contractions during immobilization possibly limited
contracture development because the knee was still weightbearing. The remaining connective
tissues (i.e., capsule, ligaments, cartilage) dominated contracture after 4-32 weeks of
immobilization and their contribution was irreversible with subsequent periods of free
mobilization [4, 43]. Connective tissue contracture was attributed to alterations in the capsule
12

(i.e., hypertrophy, hypercellularity, increased adhesions, disorganized collagen, altered collagen
crosslinking) and cartilage (i.e., atrophy, surface irregularities, decreased chondrocytes and
matrix) [39, 42, 44, 46-48]. But, none of this previous work isolated the ligamentous tissue for
either biological or mechanical evaluation.
A more severe model of knee contracture in the rabbit included a surgically induced
injury followed by internal immobilization with a K-wire [49-51]. In this model, permanent
contracture occurred after eight weeks of immobilization (~40-60° lost) and only a small amount
of motion was gained after 8-16 weeks of free mobilization (~20-25° gained) [49, 50]. Periods of
free mobilization longer than 16 weeks did not improve joint ROM further [49]. In this model,
biological changes to the capsule were primarily evaluated and included (1) altered genetic
expression of ECM proteins and regulators (i.e., increased collagen type I, II, and III, and MMP1, and decreased TIMP-1), (2) increased protein expression of αSMA and mast cells, and (3)
abnormal collagen organization [33, 51, 52].
A few studies using these animal models attempted to prevent soft tissue fibrosis and
ROM loss with varied intervention strategies. In one study, Monument and colleagues delivered
Ketotifen subcutaneously in a rabbit model of knee contracture with injury and immobilization
[53, 54]. Ketotifen is an FDA approved drug which inhibits mast cell degranulation. In the
capsule, Ketitofen treatment decreased protein expression of αSMA and collagen type I as well
as the number of myofibroblasts and mast cells. However, it had little functional efficacy and
only improved ROM ~15°. Interestingly, a randomized clinical trial with 145 patients that
evaluated Ketotifen versus placebo in elbow PTJC found that patients treated with Ketotifen
exhibited no significant improvement in flexion-extension ROM and 45% required surgical
intervention [55]. Another study in the rabbit knee delivered a recombinant antibody, which
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targeted collagen type I, via a peristaltic pump into the joint articular cavity [56]. But following
treatment, the joint still exhibited significant contracture (~40° lost).
Previous studies utilizing animal models of knee contracture have provided a large
volume of information on joint mechanics after immobilization and free mobilization as well as
biological characterization of the capsule and cartilage. However, a need still exists to evaluate
other periarticular soft tissues’ contributions to PTJC as well as develop new treatment strategies.
These studies in knee contracture models also cannot be directly translated to the elbow because
of anatomical and functional differences between these two joints. As mentioned earlier, the
elbow is not only capable of flexion-extension but can also pronate and supinate which allows
precise positioning of the forearm and hand in space. During these types of elbow motion, the
periarticular soft tissues provide stability to the highly congruent articulating surfaces. Therefore,
an animal model of elbow PTJC is needed to evaluate tissue- and joint-level changes in biology
and mechanics to ultimately develop tissue targeted treatment strategies.
We developed a model of post-traumatic elbow contracture in the rat [57]. Long-Evans
rats were carefully selected based on anatomical (i.e., presence of a joint capsule, separate radius
and ulna) and functional (i.e., flexion-extension, pronation-supination, use of forelimbs in nonweightbearing activities) similarities to the human elbow. Unilateral injury was surgically
induced to replicate soft tissue damage that often occurs during elbow dislocation. Two surgical
protocols of varying severity were used: anterior capsulotomy (injury I) and anterior
capsulotomy with LCL transection (injury II). Immediately following surgery, the injured
forelimb was immobilized in a flexed position using an external soft bandage wrap for 42 days.
Post-mortem flexion-extension joint mechanics showed decreased total ROM for both types of
injury with the most severe injury exhibiting the lowest total ROM (control ~100°, injury I ~65°,
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injury II ~50°). Histological evaluation of the anterior capsule from both types of injury
exhibited hypercellularity, and increased adhesions and tissue thickness. Future work will use
this animal model to investigate mechanisms responsible for elbow PTJC and methods to
decrease motion loss following injury.

2.2 Stem cell injection therapies for fibrosis
2.2.1 Fibrosis
On a tissue-level, fibrosis is the excessive accumulation of ECM proteins [34]. Fibrosis
on a cell-level is driven by myofibroblasts, which are the primary ECM secreting cells [58, 59].
Following trauma fibroblasts accumulate in the wound site within 3-5 days and become active
myofibroblasts within 8-9 days [60]. Fibroblast to myofibroblast transition depends on
mechanics (e.g., ECM stiffness, intracellular tension) and the expression of local growth factors
like transforming growth factor β1 (TGFβ1) [58, 59, 61, 62]. Myofibroblasts are identified via
their expression of αSMA, which is essential for their production of intracellular tension [61, 6365].
In normal wound healing, myofibroblasts remodel the ECM through synthesis and
organization of proteins to mechanically stabilize injured tissue [60, 65, 66]. However, in
fibrosis, myofibroblast persistence and excessive contraction leads to tissue stiffening and
impaired function [60, 65]. Normal healthy tissue is ~0.5-5 kPa, while fibrotic tissue is ~25-100
kPa [65, 67-70]. Normal wound healing turns fibrotic when a tissue experiences a continuous
mechanical or chemical insult (i.e., chronic inflammation), excessive ECM protein synthesis
(i.e., collagen), and/or downregulation of ECM protein regulators (i.e., matrix degrading
enzymes) [71]. Once present, fibrosis is self-sustaining due to a positive feedback loop in which
increasing ECM stiffness or tension begets increased αSMA expression in myofibroblasts
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leading to increased intracellular force production followed by increased ECM tension [61, 62].
Overall, fibrosis is the result of cell dysregulation ultimately leading to tissue disfunction.

2.2.2 Stem cell injection therapies
Stem cells serve as a promising therapeutic for fibrosis because they have the potential to
modify the ECM microenvironment to protect resident cell populations from damage and
promote regeneration [72]. While many in vivo studies and clinical trials have evaluated stem
cell therapies, only key studies in which stem cells were used to treat either fibrosis or improve
healing following musculoskeletal injury will be reported herein. A study that injected one
million bone-marrow derived mesenchymal stem cells (BD-MSCs) into a mouse model of
kidney fibrosis observed decreased interstitial volume and collagen content in the kidney, but did
not prevent renal failure or improve survival rate [73]. Thus, while a stem cell injection
improved the biological phenotype, it did not provide a long-term functional benefit.
Three separate studies injecting 2-5 million BD-MSCs into rodent models of myocardial
fibrosis yielded highly variable results. One study showed that BD-MSC injection improved
cardiac function and decreased collagen volume compared to untreated animals, but injected
animals still exhibited significantly different outcomes compared to healthy controls [74]. In
another study, four weeks after BD-MSC injection, left ventricular stroke volume and ejection
fraction was increased compared to untreated animals [75]. However, these benefits were
temporary and disappeared six months after injection. Finally, a study showed that BD-MSC
injection into fibrotic myocardium led to pathological calcifications and ossifications at the
injection site [76]. Overall BD-MSC injections into animal models of soft tissue fibrosis
exhibited unpredictable results which ranged from an attenuated, transient benefit to damaging
pathology.
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Similar results occurred when stem cells were injected to improve healing following
musculoskeletal injury. In a rat rotator cuff tendon injury and repair model, one million BDMSCs were injected in a fibrin glue during repair to improve enthesis healing [77]. Two weeks
after repair and BD-MSC injection, tendons exhibited significantly improved mechanical
properties including increased maximum force and stiffness compared to control. Once again,
these benefits were transient and did not continue four weeks after repair. Adipose-derived stem
cells (ASCs) implanted into a meniscal defect in a rabbit significantly improved healing as
shown through histological scoring for the defect surface indentation, chondrocyte cellularity,
collagen organization and matrix staining [78]. However, in this study no analysis was
performed to evaluate if there was a corresponding functional benefit. A clinical study evaluating
a rotator cuff tear treatment randomized 70 patients into two groups which received either a
repair only or a repair with the tendon surface coated in approximately five million ASCs in
fibrin glue [79]. While there was no change in ROM following treatment with ASCs, there was a
decrease in the re-tear rate from ~29% in the repair only group to ~14% in the repair with ASC
treatment. In general, treating musculoskeletal injuries with stem cells has resulted in limited
biological benefits but no corresponding improvement in function long-term.
Based on these studies, a need exists to improve the efficacy of stem cell treatments.
Most importantly, stem cell injections must reliably ameliorate, rather than contribute to,
fibrosis. Thus, a mechanism is needed to control or direct cell response following injection, so
the outcomes are more predictable and beneficial to tissue regeneration.

2.3 Mechanical memory
Mechanical memory is the concept that cells can be mechanically pre-conditioned or
primed toward or against a pro-fibrotic phenotype [65, 80]. In other words, the stiffness of the
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culture environment can influence cell behavior even after the cells are removed from the
priming substrate. Hence, mechanical memory can be used as a tool to design cell populations,
without genetic manipulation, to positively influence tissue regeneration following injection into
a pathological environment [69].
Balestrini and colleagues first provided evidence of mechanical memory in rodent
primary lung fibroblasts [65]. Lung fibroblasts were mechanically pre-conditioned on a collagencoated silicone substrate with an elastic modulus of ~5 kPa (i.e., healthy tissue) for 14 days and
then were transferred to a ~100 kPa (i.e., fibrotic tissue) substrate for an additional 14 days. At
the end of the culture period, soft primed cells exhibited decreased αSMA expression compared
to cells cultured only on ~100 kPa or tissue culture plastic (TCP, ~3 GPa). Conversely, when
fibroblasts were pre-conditioned on a ~100 kPa substrate followed by culture on a ~5 kPa
substrate, the cells retained expression of αSMA. As mentioned earlier, αSMA is a pro-fibrotic
(myofibroblast) marker [61, 63-65]. Thus, priming on a soft substrate can delay the fibroblast to
myofibroblast transition, while priming on a stiff substrate can sustain activation of the profibrotic phenotype.
Cancer cell lines have shown that mechanical memory can also influence cell activity.
MDA-MD-231 cells, a breast cancer cell line, were cultured on ~1 kPa polyacrylamide hydrogels
functionalized with collagen for nine days followed by an additional nine day culture on TCP
[80]. These soft primed cells exhibited decreased proliferation compared to cells cultured only on
stiff (~100 kPa) hydrogels and TCP. Another study using MCF-10A cells, a breast cancer
epithelial cell line, showed that priming on ~0.5 kPa collagen-functionalized polyacrylamide
hydrogels for three days followed by culture on ~50 kPa hydrogels for an additional two days
decreased cell migration speed compared to cells only cultured on ~50 kPa [81]. This study also
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showed that increasing the duration of priming led to more pronounced mechanical memory or a
stronger desensitization to their subsequent culture environment.
Stem cells have also exhibited mechanical memory. BD-MSCs were cultured on
phototunable hydrogels with a stiffness of ~10 kPa for 10 days followed by an additional 10-day
culture at ~2 kPa [82]. Despite the transition to the softer culture surface, the cells preconditioned on the stiff substrate remained biased toward osteogenic differentiation. However,
this study did not evaluate the effect of pre-conditioning stem cells on a soft substrate which
therapeutically would be more beneficial.
Li and colleagues pre-conditioned BD-MSCs on ~5 kPa fibronectin-coated silicone
substrates for three passages then transferred the cells to ~100 kPa substrates for two additional
passages [69]. These soft primed cells exhibited significantly decreased αSMA expression
compared to cells primed on stiff (~100 kPa) substrates and were not different compared to cells
only cultured on ~5 kPa substrates. In this study, two million of these soft primed BD-MSCs
were applied via fibrin glue onto a skin wound in a mouse model of hypertrophic scarring. At the
wound site, soft primed BD-MSCs increased cellularity and vascularity, and decreased αSMA
expression and collagen density. While this was the first study to show a biological benefit from
mechanically primed cells in vivo, the primary outcomes were from histology with indirect
measurements of tissue mechanics. In future stem cell injection studies, it will be important to
demonstrate that the resulting biological benefits translate to mechanical or functional
improvements. Overall, pre-conditioning stem cells on a soft substrate appears to not only
protect against the development of a pro-fibrotic phenotype in vitro but also potentially in vivo,
which would increase the regenerative potential of a stem cell therapy in clinical situations.
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Chapter 3: Persistent motion loss after free
joint mobilization in a rat model of posttraumatic elbow contracture1
3.1 Introduction
Post-traumatic joint contracture (PTJC) as a result of injury to the elbow is a common
and challenging clinical problem because the elbow is anatomically and biomechanically one of
the most complex joints in the body [1, 2]. The highly congruent joint surfaces of the three bones
that comprise the elbow create a complex articulation that allows precise positioning of the
forearm and hand in space [3]. Joint articulation is stabilized by several surrounding periarticular
soft tissues (i.e., capsule, ligaments, tendons, muscles). Trauma to the elbow often disrupts the
periarticular structures, potentially causing changes in ligament tension, bone anatomy, or
cartilage congruity, which leads to an onset of PTJC. Injury is poorly tolerated in the elbow, such
that even relatively minor damage can result in significant functional impairment affecting
routine daily and vocational activities [4]. Because injury severity does not always correlate with
the degree of functional deficit, predicting who is at risk for developing PTJC is difficult and
presents a significant clinical challenge in managing elbow injuries with contracture. Thus, there
is a critical need to study the development of elbow PTJC in a relevant model.
Our group previously developed an animal model of elbow PTJC [5]. We demonstrated
that elbow contracture could be induced in Long-Evans rats by surgically creating a soft tissue
injury, followed by 42 days of immobilization. Our animal model was evaluated biomechanically

1

Reprinted from: Dunham CL, Castile RM, Havlioglu N, et al. 2017. Persistent motion loss after free joint
mobilization in a rat model of post-traumatic elbow contracture. J Shoulder Elb Surg 26: 611-618.
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in flexion-extension and histologically and was found to replicate characteristics similar to the
human condition, including decreased total range-of-motion (ROM) and neutral zone (NZ)
length as well as increased cellularity, adhesion, and capsule thickness. However, more research
is needed to determine whether symptoms of PTJC persist long-term in this animal model. Longstanding contracture would indicate that periarticular joint tissues are permanently altered, which
would further validate the use of our rat elbow model for studying PTJC pathophysiology and
treatment methodologies. Therefore, the objective of this study was to evaluate whether
decreased joint mechanics induced by injury and immobilization resolves after free mobilization
in our recently developed rat model of elbow PTJC.

3.2 Methods and materials
Animal model. Long-Evans rats (Charles River Laboratories International, Wilmington,
MA, USA) were selected and used based on criteria previously described [5]. Briefly, these
animals were evaluated based on their (1) anatomical similarities, (2) functional ROM of the
joint, and (3) use of their upper extremities. Anatomically, Long-Evans rats exhibit many
features that are analogous to the human elbow, in which three bones (humerus, radius, and ulna)
form a complex articulation. The periarticular structures surrounding the elbow are also similar
to human anatomy.
Injury model. Male Long-Evans rats (250-300 g) were randomized into three surgical
groups (sham, injury I, injury II) and a group of age-matched control animals. The study used 40
rats initially. After four samples were excluded because of dissection and testing abnormalities,
36 rats were included (n = 7-10/group). Clinically relevant elbow injuries were surgically created
to replicate varying degrees of soft tissue injury seen in elbow subluxation/dislocation, as
described previously [5]. Briefly, the animals in each surgical group were anesthetized, and
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surgery was performed under sterile conditions on the left limb: sham (superficial lateral incision
without violation of joint structures), injury I (anterior capsulotomy), and injury II (anterior
capsulotomy combined with lateral collateral ligament transection). Sham animals were used to
evaluate the effect of joint immobilization combined with a minor surgical procedure (superficial
lateral incision) but no periarticular joint tissue injury. Thus, sham represents the least severe
injury (i.e., no joint injury with immobilization), and injury II represents the most severe injury
(i.e., anterior capsulotomy and lateral collateral ligament transection with immobilization).
Animals received single doses of antibiotic (7.5 mg/kg enrofloxacin; Bayer Health LLC,
Shawnee Mission, KS, USA) and nonsteroidal anti-inflammatory drug (5 mg/kg carprofen;
Pfizer Animal Health, New York, NY, USA) preoperatively via subcutaneous injection and one
dose of analgesic (0.5 mL of 5 mg/mL bupivacaine; Hospira, Lake Forest, IL, USA)
postoperatively via subcutaneous injection under the closed incision. Contralateral (CL) and
control limbs were not injured and served as comparisons.
After surgery, operated limbs were immobilized in flexion (151° ± 2°) for 42 days. CL
limbs and control animals were not immobilized and allowed unrestricted motion. As previously
described, the injured limbs were immobilized using tubular elastic netting (Nich Marketers Inc.,
Gulf Breeze, FL, USA) and self-adhering Vetrap bandaging (3M, St. Paul, MN, USA) [5]. An
access hole was cut to leave the CL limb unconstrained. During the 42-day immobilization
period, animals were evaluated five times per week to ensure the injured limb was constrained
and to identify any pain or distress. Clean wraps were applied weekly. Additional details
regarding animal care and observation during the immobilization period were previously
reported [5]. Any time an animal was rewrapped, any sores or cuts caused by scratching or
rubbing of the wrap were treated topically with antibiotic powder/cream (nitrofurazone; Neogen
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Corp., Lexington, KY, USA; or silver sulfadiazine; Dr. Reddy’s Laboratories Louisiana,
Shreveport, LA, USA) or chafing cream (Prestige Brands, Tarrytown, NY, USA). After 42 days,
the wrapping restraints were removed, and animals were allowed unrestricted cage activity for
the remaining 42 days to allow mobilization of their left limb. At the conclusion of the free
mobilization period, animals were euthanized by CO2 inhalation and immediately stored in a
-20°C freezer.
Mechanical testing. Mechanical testing was performed on the injured and CL limbs for
each animal so paired comparisons could be made in addition to comparisons with controls.
Forelimbs were prepared for mechanical testing as described previously [5]. To summarize,
forelimbs were skinned, the glenohumeral joint was disarticulated, and the paw was removed.
The humeral head and distal ulna/radius were secured in test fixtures. In the test setup, the limb
was aligned to allow smooth articulation of the joint and had a starting position of ~90° flexion.

Figure 3.1 (A) Schematic of torque-angle loading curve with parameters quantified for flexion-extension
biomechanical joint testing. The light gray circles are data from a representative sample. The black line for neutral
zone (NZ) stiffness/length is the average of the loading and unloading curves. (Ext. = extension, Flex. = flexion,
ROM = range-of-motion). (B) Average curves for each injury, contralateral (CL), and control groups demonstrate
decreased joint motion in flexion-extension for injured limbs after free mobilization. (dashed line = injured limb,
solid line = CL and control limbs).
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A custom mechanical testing system was used to evaluate rat elbow stiffness and joint
contracture in flexion-extension. The design of this system and post-test analysis were published
previously and were similar to other setups used to test animal limbs in flexion-extension [5, 6].
Force and displacement data from the fifth cycle were converted to torque and angular
position for flexion-extension. A custom-written Matlab program (MathWorks, Natick, MA,
USA) analyzed the torque-angle curves to quantify joint motion in flexion-extension (Figure
3.1A). Flexion-extension measurements include total ROM, ROM midpoint, maximum flexion,
maximum extension, NZ length, flexion stiffness, extension stiffness and NZ stiffness. ROM
data (i.e., total ROM, ROM midpoint, NZ length) represent a measure of joint contracture,
whereas stiffness values (i.e., NZ, flexion, extension) represent various aspects of overall joint
stiffness. Total ROM is the sum of the angular positions of the limits of motion in either
direction. The ROM midpoint shows the relative shift of the overall curve, which can
demonstrate decreased joint motion. The NZ region falls between the linear fits of flexion and
extension stiffness. As defined previously, NZ stiffness and length are averages of the loading
and unloading curves in that region [5]. Post-test analysis also calculated the average curves for
each group by averaging the maximum extension, maximum flexion, and both end points of the
NZ stiffness/length curve within each group to present a graphic visualization of qualitative
differences in joint motion between groups (Figure 3.1B).
Histological analysis. After mechanical testing, a subset of three samples per group that
exhibited average joint motion in mechanical testing were prepared for histologic assessment
using standard protocols, as described previously [5]. Three sagittal sections (5 µm thick) were
cut for each limb and stained with hematoxylin and eosin. A musculoskeletal pathologist
completed a blind analysis on each anterior capsule, and semiquantitative scores were assigned
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for biological characteristics of interest (i.e., adhesion, fibrosis, cellularity, inflammation,
synovial proliferation, and vascularity) using the same evaluation criteria used previously [5].
Briefly, adhesion, fibrosis, and synovial proliferation were scored as present or absent, cellularity
was scored as minimal, mild, moderate, or marked, and inflammation was scored as none, mild,
moderate, or marked. Vascularity was scored as < 6 vessels, 6-10 vessels, and > 10 vessels per
field at 40x magnification. Capsular thickness was also measured on each section and reported
semiquantitatively to account for variation in absolute capsule thickness values for sections cut at
different depths and varying angular orientations. Specifically, numeric scores were averaged
across each group, normalized by the thickness of the control capsules, and converted to a
symbolic grading scheme for comparison between groups: < 0 µm (- -), 0-150 µm (-), 151-300
µm (+), 301-450 µm (+ +), 451-600 µm (+ + +) and > 600 µm (+ + + +).
Statistical analysis. One-way analysis of variance (ANOVA) tests were used to compare
mechanical test parameters between (1) control and injured limbs for each group and (2) control
and CL limbs for each group. ANOVAs were run separately because (1) data for injured and CL
limbs are not independent and (2) this enabled comparison of injured-only and CL-only groups.
When there was significance, post hoc Bonferroni analyses compared each experimental group
with control. We also evaluated side-to-side limb difference with paired t tests to compare
injured limbs with CL limbs for each group. Correlations between mechanical testing
measurements, including data from all groups (i.e., sham, injury I, injury II, control, and CL
limbs) were computed and r values reported. The statistical analysis was performed in GraphPad
Prism (GraphPad Software Inc., La Jolla, CA, USA). Significance was defined as p < 0.05.

3.3 Results
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Qualitatively, group-averaged mechanical test data show differences in the overall
loading profiles for flexion-extension after free mobilization when each injured group was
compared with its respective uninjured CL group and control (Figure 3.1B). Average curves for
injured limbs (i.e., dashed line in Figure 3.1B) have decreased total ROM, NZ length, and
maximum extension as well as increased NZ stiffness (Figure 3.1B, inset) and ROM mid-point
compared with uninjured CL and control (i.e., solid lines), thereby illustrating qualitatively that
joint mechanics remain altered even after free mobilization. Among the different injury groups,
injury II exhibited the most apparent qualitative differences compared with CL and control.
Quantitatively, injury I and injury II demonstrated significantly smaller total ROM values
than control (p = 0.032 and 0.007, respectively) and their CL limb (p = 0.016 and 0.011,
respectively; Figure 3.2A, Table 3.1). Injury I and injury II had significantly greater ROM
midpoint values than control (p = 0.031 and 0.020, respectively) and their CL limb (p = 0.020
and 0.001, respectively; Figure 3.2B, Table 3.1). Injury I and injury II had significantly smaller
NZ length than their CL limb (p = 0.024 and 0.006, respectively; Figure 3.2C, Table 3.1).
Importantly, total ROM, ROM midpoint, and NZ length exhibited the most drastic impairment

Figure 3.2 Quantitative results from flexion-extension joint mechanics: (A) total range-of-motion (ROM), (B) ROM
midpoint, and (C) neutral zone (NZ) length were significantly different for injury I (anterior capsulotomy) and injury
II (anterior capsulotomy with lateral collateral ligament transection). Data are shown as average ± standard
deviation. # p < 0.05 different from control. * p < 0.05 different from contralateral (CL) limb. (diagonally shaded
bars = injured limb, solid bars = uninjured CL and control limbs).
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Table 3.1 Quantitative results for flexion-extension joint mechanics: total range-of-motion (ROM), ROM midpoint,
and neutral zone (NZ) length values.

Group

Number

Total ROM (°)

ROM Midpoint (°)

NZ Length (°)

Control

9

98.7 ± 14.6

82.9 ± 8.2

70.3 ± 17.6

Sham

7

85.2 ± 10.7

87.4 ± 5.2

56.7 ± 10.4

Sham CL

7

103.6 ± 19.9

85.6 ± 4.4

74.9 ± 21.0

Injury I

10

79.4 ± 13.9*

92.3 ± 8.9*

52.9 ± 13.6

Injury I CL

9

104.4 ± 26.5

79.4 ± 8.3

73.2 ± 23.4

Injury II

10

75.3 ± 19.7*

92.9 ± 6.4*

52.3 ± 17.8

Injury II CL

9

105.4 ± 9.5

80.9 ± 7.9

75.3 ± 10.2

Data are shown as average ± standard deviation. The bold values indicate difference from contralateral (CL) limb
and * values indicate difference from control (p < 0.05). (injury I = anterior capsulotomy, injury II = anterior
capsulotomy with lateral collateral ligament transection).

for the most severe injury (injury II), while the least severe injury (sham) did not exhibit any
statistically significant differences compared with controls and CL limbs.
Maximum extension values for injury I and injury II were significantly different from
control (p < 0.0002 and 0.0001, respectively) and the three experimental groups (sham, injury I,
and injury II) were significantly different from their CL limb (p = 0.046, < 0.0001, and 0.0002,
respectively; Table 3.2). There were no significant differences for any group in maximum
flexion and extension stiffness. For flexion stiffness, only sham was significantly different from
its CL limb (p = 0.027).
Total ROM and NZ length values exhibited a statistically significant and strong
correlation (p < 0.0001, r = 0.970; Figure 3.3A). Total ROM and ROM midpoint values were not
significantly correlated (p = 0.594, r = -0.078; Figure 3.3B). NZ length and ROM midpoint
values showed a significant yet moderate correlation (p = 0.031, r = -0.312; Figure 3.3C).
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Table 3.2 Quantitative results for flexion-extension joint mechanics: range-of-motion (ROM) limits and stiffness
values.

Group

Number

Maximum Limits (°)

Stiffness (N-mm/°)

Extension

Flexion

Extension

Flexion

Control

9

33.6 ± 7.4

132.2 ± 13.6

0.70 ± 0.47

0.91 ± 0.38

Sham

7

44.8 ± 4.1

130.0 ± 9.7

0.70 ± 0.30

0.83 ± 0.30

Sham CL

7

33.8 ± 9.3

137.4 ± 12.2

0.85 ± 0.45

0.78 ± 0.19

Injury I

10

52.5 ± 10.2*

132.0 ± 12.4

0.82 ± 0.41

0.77 ± 0.17

Injury I CL

9

27.2 ± 7.0

131.6 ± 20.9

0.80 ± 0.21

0.72 ± 0.27

Injury II

10

55.2 ± 11.6*

130.5 ± 11.9

0.68 ± 0.24

0.76 ± 0.13

Injury II CL

9

28.2 ± 5.3

133.6 ± 11.9

0.71 ± 0.24

0.71 ± 0.26

Data are shown as average ± standard deviation. The bold values indicate difference from contralateral (CL) limb
and * values indicate difference from control (p < 0.05). (injury I = anterior capsulotomy, injury II = anterior
capsulotomy with lateral collateral ligament transection).

Figure 3.3 Correlations included data from all sham, injury I (anterior capsulotomy), injury II (anterior capsulotomy
with lateral collateral ligament transection), control, and contralateral (CL) limbs and were evaluated for
relationships between (A) total range-of-motion (ROM) and neutral zone (NZ) length, (B) total ROM and ROM
midpoint, and (C) NZ length and ROM midpoint for flexion-extension after free mobilization (p < 0.05).

Altered biological properties in the anterior capsule persisted in injured limbs after free
mobilization compared with control and CL (Figure 3.4, Table 3.3). Specifically, injured limbs
showed increased adhesion to osseous surfaces, evidence of fibrosis, and thicker capsule/scar
tissue compared with control and CL limbs. No groups showed evidence of inflammation,
synovial proliferation, or increased vascularity. The only difference between control and CL
limbs in all of the metrics assessed occurred in sham CL thickness, which was smaller than
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Figure 3.4 Representative sagittal histology (H&E) of control and injured limbs show joint anatomy and general
morphologic characteristics (scale bar = 1000 μm) as well as a magnified view of the anterior capsule (region
corresponding to dashed box, scale bar = 50 μm). (C = capsule, H = humerus, R = radius).
Table 3.3 Histological evidence of the anterior capsule showed altered tissue properties for free mobilization limbs
compared with control and contralateral (CL) joints (n = 3/group).

Group

Adhesion

Fibrosis

Cellularity

Inflammation

Control

-

-

+

-

-

-

+

Sham

+

+

+

-

-

++

+

Sham CL

-

-

+

-

-

--

+

Injury I

+

+

+

-

-

++++

+

Injury I CL

-

-

+

-

-

-

+

Injury II

+

+

+

-

-

+++

+

-

-

+

-

-

-

+

Injury II CL

Synovial
Thickness Vascularity
Proliferation

Thickness grading scheme: < 0 µm (- -), 0-150 µm (-), 151-300 µm (+), 301-450 µm (+ +), 451-600 µm (+ + +),
and > 601 µm (+ + + +). (injury I = anterior capsulotomy, injury II = anterior capsulotomy with lateral collateral
ligament transection).

control. The largest difference between injured and uninjured limbs occurred in capsule
thickness.

3.4 Discussion
This study shows that our rat elbow model of PTJC exhibits impaired joint function that
persists even after joint free mobilization. Flexion-extension biomechanical joint testing
demonstrated a decreased total ROM and NZ length and an increased ROM midpoint for injured
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limbs compared with uninjured control and CL limbs after free mobilization. Compared with our
previous data for limbs at the end of the immobilization period, the free mobilization limbs
exhibited ~11%, ~8%, and ~20% increases in total ROM for sham, injury I, and injury II,
respectively [5]. However, after FM, total ROM values were still ~16%, ~22%, and ~26%
decreased compared with control and CL limbs for sham, injury I, and injury II, respectively.
Even though injured limbs did regain some motion after free mobilization, the ROM lost after
immobilization was never fully regained for any group. Biomechanical parameters of contracture
(total ROM, ROM midpoint, and NZ length) were slightly altered for sham limbs (Figures 3.1B
and 3.2), demonstrating some effect caused by immobilization without joint injury. However,
these parameter values for the sham group were not significantly different from control or CL
limbs (Figure 3.2), demonstrating that soft tissue injury combined with immobilization is
necessary to develop more consistent and persistent joint contracture long-term (i.e., injury I and
injury II). The severity of the induced injury correlated with the amount of total motion loss, with
injury II animals exhibiting the most dramatic differences compared with control and CL limbs.
Therefore, the injury and immobilization protocol developed in our previous study not only
altered joint mechanics immediately after an immobilization period but also induced changes that
remained long-term, which is similar to persistent symptoms common to patients with elbow
PTJC [5, 7-10].
To our knowledge, there are no previous animal models of elbow injury. Previous work
has focused on understanding PTJC in rabbit or rat knees and then extrapolated results to the
elbow joint [6, 11, 12]. Hildebrand and colleagues developed a rabbit knee model of PTJC by
surgically removing 5 mm2 cortical windows from non-articulating surfaces of the medial and
lateral femoral condyles and then immobilizing the joint in a flexed position for 56 days using
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internal fixation [6]. These rabbit knees lost ~25-30° ROM when loaded in extension [6, 13, 14].
Nesterenko et al. reported a similar change in rabbits using a related injury and immobilization
protocol, with ~20° loss of extension [12]. These studies developed contracture using a more
severe injury to initiate joint motion loss that remained after free mobilization. However, we
have shown that contracture can persist using a less severe injury that mimics soft tissue damage
which occurs during elbow dislocation and a clinically relevant immobilization protocol in our
rat model, which is specific to the complex elbow joint.
Compared with these previous studies, our current work found similar biomechanical
results after free mobilization of the injured joint. After free mobilization, total ROM decreased
an average of 20° compared with control and CL limbs (Figure 3.2A). Although there was
improvement with free mobilization compared with injury and immobilization only, no group
regained all motion, demonstrating that contracture persists long-term in flexion-extension. A
similar trend was found when measuring NZ length (Figure 3.2C). A deficiency in NZ length is
clinically relevant because it represents functional ROM and corresponds to the amount of
motion possible before a larger force is required to further joint movement. Total ROM and NZ
length also showed a significant and strong, positive correlation demonstrating a direct
relationship between these two parameters (Figure 3.3A).
ROM midpoint values also showed altered joint function by the increase in the relative
shift of the overall curve for injured groups compared with control and CL limbs (Figure 3.2B).
The increase in ROM midpoint demonstrates a shift of joint motion toward more flexion;
however, with no significant changes in maximum flexion, the shift in ROM midpoint most
strongly corresponds to a change in maximum extension (Figure 3.1B, Table 3.2). In our injury
model, the clinically motivated surgical injury includes an anterior capsulotomy and/or a lateral
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collateral ligament transection, or both. Because the posterior capsule is not injured during
surgical intervention, only maximum extension (and not maximum flexion) would be expected to
be altered, as shown in Figure 3.1B and reported in Table 3.2.
The correlation of total ROM and NZ length with ROM midpoint both have a weak to
moderate r value, thus exhibiting the lack of a strong relationship between these parameters
(Figures 3.3B-C). This demonstrates that a shift in ROM midpoint does not reflect a similar
change in total ROM or NZ length. Ultimately, this shows that the overall shift in joint motion
can correspond to a change in the maximum limits without causing a similar change in total
ROM or NZ length, yet still be indicative of joint motion loss.
Histologically, the injury and immobilization protocol developed previously induces
changes in the capsule tissue that remain after free mobilization [5]. The persistent alterations in
the capsule are similar to what has been reported for human patients. Specifically, previous
studies of human tissues have reported thickened capsular tissue and evidence of capsular
fibrosis, which is consistent with our findings (Figure 3.4, Table 3.3) [3, 7, 15, 16]. In addition,
human data also exhibit limited neovascularization and synovial proliferation, similar to our
observations [17]. Surprisingly, similar histologic results were observed for all three injury
groups (sham, injury I, and injury II), which was unexpected because injury I and injury II
involved direct disruption of the anterior capsule during surgery. Also surprising was the
increased capsule thickness and decreased ROM did not correspond to increased stiffness in the
injured limbs. However, there may be other features of the capsule we did not evaluate
histologically (e.g., different collagen type and collagen organization) that could result in the
decreased joint mechanics in injury I and injury II but not in sham as well as explain why the
stiffness was not altered. We also focused our histological analysis on the anterior capsule, but
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other periarticular joint tissues could also be affected and potentially contribute to the altered
joint mechanics of injury I and injury II. A more in-depth biological evaluation is needed to
identify distinctions among these three different groups. However, the persistent histological
changes after free mobilization demonstrate the clinical relevance of this model to develop
contracture long-term within the elbow.
This study is not without limitations. First, rats are quadruped animals and thus use their
upper extremities in different way than humans (i.e., locomotion) and bear different loads
humans. However, this species/breed of rat was carefully selected to match key similarities to
humans (i.e., range/types of motion and similarity in joint articulations) to maximize the clinical
relevance of this animal model [5]. Second, the mechanical testing was completed post-mortem.
Post-mortem testing only divulges information about the passive mechanical properties of tissue.
Ongoing work is investigating the properties of active tissue testing to evaluate physiological
changes in muscle strength. Third, free mobilization was only evaluated once, at 42 days, after
the injury and immobilization protocol. However, Evans and colleagues showed that after 45
days of immobilization in the rat knee, there were no additional differences in the ROM that was
regained in the joint after 35 days of free mobilization [18]. Because no additional improvements
occurred in the rat knee after 35 days of free mobilization, our 42 days of free mobilization is a
reasonable time point for evaluation. Future research could examine other time points of free
mobilization to evaluate the persistence of PTJC symptoms in the rat elbow.
Although no active therapy was used in this study to mobilize the joint following injury
and immobilization, free cage activity alone was not enough to restore joint motion,
demonstrating that our animal model of post-traumatic elbow contracture exhibits significant
contracture that persists after free mobilization. Biomechanical quantification of flexion39

extension motion exhibited a decreased total ROM and NZ length and increased ROM midpoint,
which are all clinically relevant measurements of joint function. Future investigations will use
this animal model to evaluate pronation-supination joint motion and use genetic/biochemical
assays to identify biological changes within the elbow that contribute to contracture.
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Chapter 4: Pronation-supination motion is
altered in a rat model of post-traumatic
elbow contracture1
4.1 Introduction
Traumatic injury to the elbow (e.g., dislocation and fracture) often leads to subsequent
post-traumatic joint contracture (PTJC). More so than other joints, the elbow is especially
susceptible to contracture making it a common and challenging clinical problem. The elbow is
anatomically and biomechanically one of the most complex joints in the body due to the highly
congruent joint surfaces of the three bones that create the joint [1-3]. Articulation of these bones
is stabilized by periarticular soft tissues (i.e., capsule, ligaments, tendons, and muscles), which
are often disrupted when the elbow is injured. Damage to these tissues is poorly tolerated and
even a relatively minor injury can result in significant functional impairment, making it difficult
to predict who is at risk for developing contracture [4]. Due to the clinical challenge of managing
elbow injuries, there is a need to develop an animal model of post-traumatic elbow contracture to
understand its etiology and to ultimately develop new intervention and treatment strategies,
which is not possible with a clinical study.
Previously, our group developed an animal model of elbow PTJC in Long-Evans rats by
surgically creating clinically relevant soft tissue injuries followed by 42 days of unilateral joint
immobilization [5, 6]. Our animal model exhibited joint motion loss in flexion-extension and
changes to the joint capsule which were consistent with patterns reported for human tissue [5].

1

Reprinted from: Dunham CL, Castile RM, Chamberlain AM, et al. 2017. Pronation-supination motion is altered in
a rat model of post-traumatic joint contracture J Biomech Eng-T ASME 139: 071011.
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At the end of the 42 days of immobilization, the constraint was removed to allow free
mobilization of the joint for an additional 42 days. Importantly, joint motion loss in flexionextension and capsular changes persisted even after the free mobilization period, providing
further validation for this animal model of joint contracture [6]. Our previous work only
evaluated the limb in flexion-extension; however, the elbow plays a critical role enabling
pronation-supination motion of the forelimb (Figure 4.1).
A majority of current work on PTJC focuses only on disfunction in flexion-extension [79]. However, both flexion-extension and pronation-supination are clinically significant motions,
essential for most daily and vocational activities. For pronation-supination, the range-of-motion
(ROM) necessary for daily living in humans is ~50° of motion in both supination and pronation
[9]. The shoulder can compensate to a limited extent for pronation loss, but no upper extremity
movement can replace supination [10]. Motion loss in pronation-supination is not consistently or
completely restored using common therapies applied to restore motion loss in flexion-extension,
and thus, recovery of pronation-supination may require a more invasive and higher-risk surgical
intervention [11]. The ability to identify improvements for therapies in pronation-supination was

Figure 4.1 Schematic of pronation-supination motion in the rat forelimb.
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previously limited by the lack of an appropriate animal model.
Studying pronation-supination in previous animal models was not possible due to the
structure and function of the joint studied (i.e., knee) [10, 12, 13]. However, our animal model is
specific to the elbow and, unlike other models, has the ability to evaluate pronation-supination
[5]. Furthermore, a key criterion that informed the selection of Long-Evans rats for our animal
model was the degree to which the forelimb of this breed of rat can pronation and supinate,
which is similar to patterns in humans for given sets of functional tasks (i.e., forward reach and
return food to mouth) [14-16]. Our previous study only evaluated flexion-extension; therefore,
the objective of this study was to mechanically quantify pronation-supination in different injury
models to determine if significant differences compared to control or contralateral (CL) persist
long-term in our animal elbow contracture model. We hypothesized that pronation-supination
motion would be altered similarly as our results in flexion-extension, specifically that the most
severe injury model would experience the largest amount of motion loss compared to control and
CL, which would persist even following free mobilization of the joint.

4.2 Methods and materials
Animal model. Long-Evans rats (Charles River Laboratories International, Wilmington,
MA, USA) were used based on criteria previously described [5, 6]. Briefly, these animals were
selected because of similarities to human anatomy, functional ROM, and use of their upper
extremities. Functionally, Long-Evans rats not only exhibit flexion-extension but also pronationsupination, which differentiates them from other animal species we considered and even other
breeds of rats [14-17]. Specifically, Long-Evans rats supinate their paws during feeding, pronate
during reaching, and show overall forelimb rotation throughout other cage activities [14, 16].
Since both flexion-extension and pronation-supination are clinically significant motions of the
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Figure 4.2 Schematic of the experimental method timeline. At each analysis time point mechanical testing was
performed. (lightning bolt = surgery, oval = analysis time point).

human elbow, similarities of joint motions to humans were an important factor in selecting
Long-Evans rats for the animal model utilized in this study.
Injury model. This study was approved by our university’s Institutional Appropriate
Care and Animal Use Committee (IACUC). The experimental design was similar to what was
previously described, in which male Long-Evans rats (250-300 g, 8-10 weeks old) were
randomized into three surgical groups (sham, injury I, and injury II) and a group of age-matched
control animals [5, 6]. Animals in each group were anesthetized and surgery was performed on
the left limb by an orthopedic surgeon: sham (superficial lateral incision without violation of
joint structures), injury I (anterior capsulotomy), and injury II (anterior capsulotomy with lateral
collateral ligament transection) (Figure 4.2). Sham animals were evaluated to understand the
effect of joint immobilization without periarticular joint tissue injury. Animals received single
doses of antibiotic (7.5 mg/kg enrofloxacin; Bayer Health LLC, Shawnee Mission, KS, USA)
and nonsteroidal anti-inflammatory drug (NSAID) (5 mg/kg carprofen; Pfizer Animal Health,
New York, NY, USA) preoperatively via subcutaneous injection and one dose of analgesic (0.5
cc of 5 mg/mL bupivacaine; Hospira, Lake Forest, IL, USA) postoperatively via subcutaneous
injection under the closed incision. Control and CL limbs served as comparisons to
injured/immobilized limbs.
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After surgery, injured limbs were immobilized in flexion for 42 days using a protocol
described previously, while CL limbs and control animals were allowed unrestricted motion
(Figure 4.2) [5, 6]. Animals were checked five times per week to ensure the injured limb was
constrained and to identify any signs of pain or distress. When an animal’s injured limb was
rewrapped, any sores or cuts caused by scratching or rubbing of the bandaging restraints were
treated topically with antibiotic powder/cream (nitrofurazone; Neogen Corp., Lexington, KY,
USA, and silver sulfadiazine; Dr. Reddy’s Laboratories Louisiana, Shreveport, LA, USA) and/or
chaffing cream (Prestige Brands, Tarrytown, NY, USA). After 42 days of immobilization, half of
the animals were sacrificed (42 IM) and half had their bandages removed and were allowed
unrestricted cage activity for an additional 42 days (42/42 IM-FM) (Figure 4.2). After either the
immobilization or free mobilization period, animals were sacrificed via CO2 inhalation and
immediately stored in a -20°C freezer.
Across the four groups (injury I, injury II, sham, and control), this study used a total of 60
male Long-Evans rats with n = 6/group for 42 IM and n = 9/group for 42/42 IM-FM. Three and
four animals were excluded from the 42 IM and 42/42 IM-FM time points, respectively, due to
dissection/sample preparation (i.e., limb potting issues) and testing abnormalities (i.e., outliers
due to extreme rotation and non-smooth rotation of the limb outside of the system prior to
mechanical testing). After removing these few samples, a total of 93 limbs were included in the
dataset.
Mechanical testing. Mechanical testing was performed on both injured and CL limbs
from each animal as well as unilateral limbs from controls. Forelimbs were prepared for
mechanical testing as described previously [5, 6]. Limbs were first loaded in flexion-extension
and then in pronation-supination (flexion-extension mechanical data were published previously
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[5, 6]). A preliminary study that repeated flexion-extension testing after pronation-supination
testing (n = 20 animals; age- and sex-matched) confirmed that no joint damage occurred in the
initial mechanical testing that would affect the joint mechanics in pronation-supination.
Consistent flexion-extension results before and after pronation-supination testing also
demonstrated that no joint damage occurred as a result of pronation-supination mechanical
testing.
A novel mechanical test setup was designed and built to evaluate rat elbow stiffness and
joint contracture in pronation-supination (Figure 4.3A). To the best of our knowledge, it is the
first system to quantify pronation-supination joint motion in an animal model. The pronationsupination test setup is a modification of the equipment utilized in our flexion-extension test
system [5]. A linear actuator and load cell are used to apply a linear displacement and measure
the force, respectively (TestResoures, Shakopee, MN, USA). A vertical rack and pinion gear
converts the linear displacement to rotational motion, which allows for load-controlled cyclic
testing. In the test setup, the limb was potted so the radius and ulna could move relative to each

Figure 4.3 (A) The biomechanical test system uses a rack and pinion gear to convert linear displacement to
rotational cyclic loading of the rat elbow in pronation-supination. Specimens were secured with ulna-radius and
humerus fixtures. A load cell was used to measure the axial force. (B) The test system loaded with a rat elbow.
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Figure 4.4 (A) Schematic of the torque-angle loading curve with parameters quantified for pronationsupination. The light gray circles are data from a representative sample. The black line for the neutral zone
(NZ) stiffness/length is the average of the loading and unloading curves. (Pro. = pronation, ROM = range-ofmotion, Sup. = supination). Average curves for each injury group and contralateral (CL) for pronationsupination at (B) 42 IM and (C) 42/42 IM-FM. These average curves represent the mean of all the animals
tested per group without the standard deviation to make the differences between curves more apparent. (dashed
line = injured limb, solid line = CL and control limbs).

other, which allowed smooth articulation of the joint (Figure 4.3B). At the beginning of the test,
the joint was placed in ~90° flexion with the paw in a neutral position of ~0° (Figure 4.1). After
the limb was secured, it was cyclically loaded to ± 0.85 N (corresponding to ± 11.75 N-mm of
torque) for five cycles at 0.3 mm/sec. Preliminary testing was used (1) to determine how to align
the limb in a neutral (0°) starting position, (2) to ensure the limb rotational axis in the test setup
was centered on the applied torque, and (3) to determine that the torque limits were sufficient to
mechanically probe pronation-supination motion, without damaging tissues of the elbow joint.
Force and displacement data from the fifth cycle were converted to torque and angular
position for pronation-supination data. Torque-angle curves were analyzed with a custom written
MATLAB program (Mathworks, Natick, MA, USA) to quantify elbow joint motion in
pronation-supination (Figure 4.4A). Pronation-supination measurements included total ROM,
neutral zone (NZ) length, NZ stiffness, pronation stiffness, and supination stiffness; similar
parameters were previously defined for the loading curves of flexion-extension tests [5, 6].
Briefly, the NZ is the flatter/linear region of the curve that falls between the loading and
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unloading curves of pronation and supination. It is a clinically relevant parameter because the
NZ represents the functional ROM, specifically it is the amount of motion possible before a
larger force is required for further joint movement [5, 6]. Stiffness is defined as the linear region
of the loading curves for pronation and supination and the average of the loading and unloading
curves for the NZ [5, 6]. It is calculated as the slope of a linear fit of these regions. Average
loading curves were also created by averaging the points of maximum supination, maximum
pronation, and both end points of the NZ stiffness/length curves within each group to show
qualitative representations of joint motion. Group-averaged values were used to plot average
curves for each group (control, sham, injury I, and injury II) for both 42 IM and 42/42 IM-FM.
Statistical analysis. One-way analysis of variance (ANOVA) tests compared to
mechanical test parameters between (1) control and injured limbs for each group, and (2) control
and CL limbs for each group, enabling comparisons of injured-only and CL-only groups.
ANOVAs were also separated because injured and CL limbs are not independent measures.
When significance was found during the ANOVA analyses (p < 0.05), post-hoc t tests with
Bonferroni corrections were used to compare each experimental group to control. Side-to-side
limb differences were evaluated with paired t tests to compare injured limbs to CL limbs within
each group. Correlations between mechanical testing parameters in flexion-extension and
pronation-supination were completed with data from all groups (i.e., sham, injury I, injury II,
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Figure 4.5 Total range-of-motion (ROM) for (A) 42 IM and (B) 42/42 IM-FM was decreased in injured limbs
compared to contralateral (CL). Neutral zone (NZ) length for (C) 42 IM and (D) 42/42 IM-FM was also
decreased compared to CL. Data are shown as average ± standard deviation. * p < 0.05 different from CL limb.
(diagonally shaded bars = injured limb, solid bars = uninjured CL and control limbs).
Table 4.1 Quantitative results for pronation-supination joint mechanics: total range-of-motion (ROM) and neutral
zone (NZ) length values.

Group

Number

Total ROM (°)

NZ Length (°)

42 IM

42/42 IM-FM

42 IM

42/42 IM-FM

42 IM

42/42 IM-FM

Control

4

9

159.7 ± 17.7

143.8 ± 26.3

107.1 ± 21.0

91.3 ± 13.4

Sham

4

6

145.3 ± 10.6

137.6 ± 34.2

95.6 ± 11.1

95.1 ± 25.4

Sham CL

5

7

193.0 ± 35.6

158.9 ± 27.3

129.1 ± 23.1

104.5 ± 24.1

Injury I

6

8

149.1 ± 19.9

134.6 ± 26.6

98.8 ± 20.0

84.7 ± 20.8

Injury I CL

6

8

177.4 ± 25.3

164.6 ± 20.3

117.2 ± 19.1

109.1 ± 20.8

Injury II

6

8

122.7 ± 46.6

136.0 ± 13.9

74.2 ± 34.8

86.2 ± 13.4

Injury II CL

6

8

161.1 ± 52.2

173.0 ± 25.5

107.3 ± 41.0

114.6 ± 21.6

Data are shown as average ± standard deviation. The bold values indicate difference from contralateral (CL) limb (p
< 0.05). (injury I = anterior capsulotomy, injury II = anterior capsulotomy with lateral collateral ligament
transection).
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control, and CL limbs) in order to identify relationships between different types of joint motion
in our animal model [5, 6]. All statistical analyses were performed in GraphPad Prism (GraphPad
Software Inc., La Jolla, CA, USA).

4.3 Results
Qualitatively, the group-average mechanical test data exhibited differences in the overall
loading profiles when comparing each injured group to its respective uninjured CL group (Figure
4.4B-C). Average curves for the injured limbs (i.e., dashed lines) showed less total ROM and
shorter NZ length compared to CL curves (i.e., solid lines) at 42 IM, indicating side-to-side
differences in pronation-supination joint motion in this model. Side-to-side differences persisted
at 42/24 IM-FM, illustrating that pronation-supination motion remains altered even after a period
of joint free mobilization. Injury II exhibited the most severe differences compared to CL for
both 42 IM and 42/42 IM-FM. Interestingly, CL curves exhibited increased total ROM compared

Table 4.2 Quantitative results for pronation-supination joint mechanics: neutral zone (NZ), pronation and supination
stiffness values.

Group

Pronation Stiffness
(N-mm/°)

Supination Stiffness
(N-mm/°)

NZ Stiffness
(N-mm/°)

42 IM

42/42 IM-FM

42 IM

42/42 IM-FM

42 IM

42/42 IM-FM

Control

0.58 ± 0.11

0.54 ± 0.22

0.45 ± 0.12

0.33 ± 0.14

0.019 ± 0.008

0.017 ± 0.012

Sham

0.66 ± 0.15

0.48 ± 0.21

0.31 ± 0.067

0.54 ± 0.12

0.012 ± 0.008

0.017 ± 0.018

Sham CL

0.41 ± 0.16

0.48 ± 0.14

0.43 ± 0.12

0.52 ± 0.17

0.011 ± 0.007

0.015 ± 0.005

Injury I

0.69 ± 0.27

0.54 ± 0.16

0.35 ± 0.12

0.48 ± 0.13

0.013 ± 0.004

0.012 ± 0.009

Injury I CL 0.44 ± 0.28

0.47 ± 0.19

0.54 ± 0.21

0.45 ± 0.20

0.008 ± 0.010

0.009 ± 0.013

Injury II

0.78 ± 0.37

0.66 ± 0.15

0.29 ± 0.087

0.53 ± 0.27

0.024 ± 0.018

0.015 ± 0.012

Injury II CL 0.47 ± 0.50

0.50 ± 0.11

0.57 ± 0.080

0.50 ± 0.13

0.012 ± 0.012

0.011 ± 0.007

Data are shown as average ± standard deviation. The bold values indicate difference from contralateral (CL) limb (p
< 0.05). (injury I = anterior capsulotomy; injury II = anterior capsulotomy with lateral collateral ligament
transection).
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Figure 4.6 Correlations include data from all sham, injury I (anterior capsulotomy), injury II (anterior capsulotomy
with lateral collateral ligament transection), control, and contralateral (CL) limbs and were evaluated for
relationships between flexion-extension and pronation-supination for total range-of-motion (ROM) at (A) 42 IM
and (B) 42/42 IM-FM, and neutral zone (NZ) length at (C) 42 IM and (D) 42/42 IM-FM (p < 0.05).

to the control curve at 42 IM and 42/42 IM-FM.
Quantitatively, pronation-supination mechanical testing identified significant alterations
in side-to-side differences but did not exhibit significant changes compared to control in our
animal model of PTJC. After immobilization, injury II total ROM was significantly smaller than
its CL limb (p = 0.030), while injury I and injury II NZ length were significantly smaller than
their CL limbs (p = 0.029 and 0.026, respectively; Figures 4.5A and 4.5C, Table 4.1). Following
free mobilization, values for injury I and injury II were significantly smaller than their CL limbs
for total ROM (p = 0.014 and 0.003, respectively) and NZ length (p = 0.004 and 0.011,
respectively; Figures 4.5B and 4.5D, Table 4.1). Pronation stiffness was only significantly
increased for injury II compared to CL at 42/42 IM-FM (p = 0.034) (Table 4.2). Supination
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stiffness was significantly increased for sham and injury II compared to CL at 42 IM (p = 0.025
and 0.002, respectively; Table 4.2). There were no significant differences for any group in NZ
stiffness (Table 4.2).
Correlations between pronation-supination and flexion-extension for total ROM and NZ
length values exhibited statistically significant and moderate correlations at 42 IM (p = 0.0002, r
= 0.60, and p < 0.0001, r = 0.63, respectively; Figures 4.6A and 4.6C). At 42/42 IM-FM, the
correlation between joint motions was statistically significant but weakly correlated for total
ROM and NZ length (p = 0.030, r = 0.32, and p = 0.048, r = 0.29, respectively; Figures 4.6B and
4.6D).

4.4 Discussion
This study shows that our hypothesis was partially confirmed because our rat elbow
model of PTJC exhibited impaired side-to-side function in pronation-supination motion that
persisted long-term after joint free mobilization. Pronation-supination demonstrated a decreased
total ROM and NZ length for injured limbs compared to uninjured CL limbs at both 42 IM and
42/42 IM-FM. There was also little to no improvement in pronation-supination when comparing
42 IM to 42/42 IM-FM; thus, after free joint mobilization, injured limbs never regained all lost
motion when compared to CL. Contrary to our hypothesis, injured limbs did not exhibit
significant differences compared to control limbs, and thus, pronation-supination is not as
severely impacted in our animal model as flexion-extension. However, side-to-side differences
(i.e., between limbs from the same animal) represent clinically relevant comparisons because a
patient’s ROM in their injured forearm is typically compared to the motion of their uninjured
arm rather than to that of a “normal” or control individual. Previously, animal models of knee
contracture have compared the CL to the injured limb and thus demonstrate that the CL limb is
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an established control [18-20]. Therefore, the injury-immobilization protocol developed in our
previous study not only induced mechanical changes that remained long-term in flexionextension but also in pronation-supination, mimicking long-term symptoms common to human
patients [5-9, 11].
Pronation-supination mechanical testing at 42 IM found decreased total ROM, where
sham and injury I lost ~8° and injury II lost ~23° when compared to control (Figure 4.5A). At
42/42 IM-FM, the limbs did regain some motion compared to control; however, injury I and
injury II remained decreased (Figure 4.5B). Interestingly, when compared to CL the differences
in total ROM lost at 42 IM were sham ~25°, injury I ~16°, and injury II ~24° (Figure 4.5A). At
42/42 IM-FM, total ROM loss persisted for sham ~13°, injury I ~18°, and injury II ~21° when
compared to CL (Figure 4.5B). This data showed that side-to-side differences remain
significantly decreased for total ROM after free mobilization for injury I and injury II. A similar
trend was found for NZ length in pronation-supination when compared to either control or CL
(Figures 4.5C-D). Clinically, a decreased NZ length shows that a limited amount of motion is
possible before requiring a larger force to move the limb further, which means that the functional
ROM of the joint is decreased in injured limbs. While there were significant changes in ROM
measurements, which are indicative of contracture, there were limited changes in all three
stiffness measurements demonstrating that no persistent changes occurred in joint stiffness
(Table 4.2). Different from our previous biomechanical results in flexion-extension, for
pronation-supination there is limited improvement after free mobilization compared to CL,
demonstrating that contracture is maintained long-term in this motion [5, 6].
While there were only minor differences between the injury groups, there was a trend for
increasing motion loss with increasing injury severity following free mobilization in our animal
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model of elbow PTJC. Similar to our previous results in flexion-extension, injury II exhibited the
most severe difference compared to its CL [5, 6]. Hence, these injury-dependent differences have
motivated our selection of utilizing the injury II surgical protocol in future studies using this
animal model.
An unexpected result in pronation-supination is that total ROM and NZ length of CL
limbs were increased compared to control limbs, which were expected to be similar [19].
However, none of the CL limbs from injury groups were statistically different compared to
control limbs (Figure 4.5). Slight increases in mechanical parameters for CL joints could be
attributed to the animals compensating for the lost motion of the injured limb, especially since
there is no body motion to compensate for pronation-supination [21]. Therefore, the significant
differences in total ROM and NZ length at 42 IM and 42/42 IM-FM in this animal model were
the result of an increased in CL limbs and a decrease in injured limbs rather than strictly being
due to decreased parameter values in injured limbs (Figure 4.5). It is also possible that the
significant side-to-side differences after free mobilization are due to the injured limbs regaining
motion similar to the controls, while the uninjured CL limbs maintained the motion gained
during immobilization. Regardless of motion recovery, differences in pronation-supination still
exist in this animal model following free mobilization demonstrating that it is has persistently
altered side-to-side motion. A successful treatment for pronation-supination motion would
equilibrate the side-to-side differences, such that both limbs from the same animal exhibit similar
motion.
We previously evaluated biological changes to the anterior joint capsule via histological
analysis [5, 6]. At 42 IM and 42/42 IM-FM, the capsule exhibited increased adhesions and
thickness compared to control and CL limbs. Since the anterior capsule extends proximally from
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the ulna coronoid process and radial fossa, increased adhesions and capsular thickness following
injury could potentially inhibit the ability of the radial head to rotate during pronation-supination,
limiting total ROM [21]. While we have not yet evaluated biological changes to the lateral
collateral ligament following injury, scar tissue formed during healing could also potentially
contribute to limited pronation-supination.
While earlier studies of joint contracture using animal models have yielded significant
insight, these models are limited anatomically and functionally considering issues specific to the
complex elbow joint. As many previous studies have used rat or rabbit knee models, one
limitation in these previous approaches was the ability to evaluate only flexion-extension motion
[10, 12, 13, 19]. A majority of current surgical interventions (i.e., elbow arthroscopy, elbow
contracture release, etc.) also primarily address flexion-extension motion; however, the forearm
is capable of pronation-supination, which cannot be fully compensated for by other arm or body
movements [21]. Surgical intervention intending to improve pronation-supination motion often
requires invasive, open surgical procedures, which pose significant risk to nearby neurovascular
structures [11]. The ability to evaluate both flexion-extension and pronation-supination in our
model increases the clinical relevance compared to previous models and expands the range of
potential studies that can be performed utilizing this model system. Research in a clinically
relevant model of the elbow is needed to better understand the pathogenesis of contracture in a
joint as complex as the elbow, so better prevention and treatment strategies can be developed for
both types of motion.
Correlations between flexion-extension and pronation-supination in total ROM and NZ
length at 42 IM and 42/42 IM-FM exhibited a positive, significantly correlated relationship.
Total ROM and NZ length at 42 IM exhibited moderate r values demonstrating that these two
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types of motion display an overall increasing trend, where greater/less motion in flexionextension corresponds to greater/less motion in pronation-supination. Both total ROM and NZ
length at 42/42 IM-FM had low r values representing a weak relationship between flexionextension and pronation-supination after joint reloading. Thus, free mobilization does not affect
flexion-extension and pronation-supination motion in the same way or to the same extent. In
other words, improved mobility in one type of motion from free mobilization does not guarantee
similar improvement in the other motion. Similarly, Ling et al. found that total ROM in flexionextension and pronation-supination was independent of each other after surgical release in
human elbows and concluded that these motions should be managed as two separate entities
[22]. Thus, it is imperative to study both types of motion and to consider each motion
individually when developing treatment and rehabilitation strategies in the future.
This study is not without limitations. First, all mechanical testing was completed ex vivo
and post-mortem, which only represents the passive mechanical properties of tissues. Our group
is currently investigating the active mechanical properties of muscle to evaluate any
physiological and mechanical changes. During mechanical testing, it was difficult to perfectly
align limbs in a neutral (0°) starting position, so there is likely very small variation in the starting
position. However, this would not affect total ROM, NZ length, and any stiffness values
reported. Second, only one time point for free mobilization (i.e., 42 days) was evaluated. A
previous study demonstrated that rat knees immobilized for 21 days and subsequently
remobilized did not exhibit any additional improvement in ROM after 35 days of free
mobilization; however, future studies could evaluate other time points of free mobilization to
characterize the persistence of PTJC symptoms in the elbow [23]. Third, this study only
evaluated male rats, however, we plan to evaluate female rats in the future.
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In conclusion, this study demonstrates that our animal model of post-traumatic elbow
contracture exhibits motion that is altered in pronation-supination, although to a lesser extent
than the previously reported impairment to flexion-extension motion. To the best of our
knowledge, this is the first time an animal model has been used to evaluate pronation-supination
motion. Side-to-side comparisons showed significantly decreased total ROM and NZ length of
the injured limbs compared to uninjured, CL limbs. Weak correlations between flexion-extension
and pronation-supination following free mobilization demonstrated that these different motions
do not respond similarly to passive motion and further support the notion that both types of
motion should be evaluated separately when developing a therapy/treatment strategy [11]. Future
investigations will use this animal model to study which soft tissues surrounding the elbow
contribute to contracture by evaluating active mechanics and genetic expression of muscle as
well as capsular contribution to passive mechanics to understand which tissues should be
targeted when developing a therapy for elbow contracture.

4.5 References
[1] King GJ, Morrey BF, and An K-N. 1993. Stabilizers of the elbow. J Shoulder Elb Surg 2:
165-174.
[2] Safran MR and Baillargeon D. 2005. Soft-tissue stabilizers of the elbow. J Shoulder Elb Surg
14: S179-S185.
[3] Cohen MS, Schimmel DR, Masuda K, et al. 2007. Structural and biochemical evaluation of
the elbow capsule after trauma. J Shoulder Elb Surg 16: 484-490.
[4] Jawa A, Jupiter JB, and Ring D. 2012. Pathogenesis and classification of elbow stiffness.
Operative Elbow Surgery Edinburgh: Churchill Livingstone/Elsevier 409-16.
[5] Lake SP, Castile RM, Borinsky S, et al. 2016. Development and use of an animal model to
study post‐traumatic stiffness and contracture of the elbow. J Orthop Res 34: 354-364.
[6] Dunham CL, Castile RM, Havlioglu N, et al. 2017. Persistent motion loss after free joint
mobilization in a rat model of post-traumatic elbow contracture. J Shoulder Elb Surg 26: 611618.
58

[7] Charalambous CP and Morrey BF. 2012. Posttraumatic Elbow Stiffness. J Bone Joint Surg
94: 1428-1437.
[8] Lindenhovius AL and Jupiter JB. 2007. The posttraumatic stiff elbow: a review of the
literature. J Hand Surg 32: 1605-1623.
[9] Myden C and Hildebrand K. 2011. Elbow joint contracture after traumatic injury. J Shoulder
Elb Surg 20: 39-44.
[10] Hildebrand KA, Holmberg M, and Shrive N. 2003. A new method to measure posttraumatic joint contractures in the rabbit knee. J Biomech Eng-T ASME 125: 887-892.
[11] Keener JD and Galatz LM. 2011. Arthroscopic management of the stiff elbow. J Am Acad
Orthop Surg 19: 265-274.
[12] Nesterenko S, Morrey ME, Abdel MP, et al. 2009. New rabbit knee model of posttraumatic
joint contracture: indirect capsular damage induces a severe contracture. J Orthop Res 27: 10281032.
[13] Trudel G and Uhthoff HK. 2000. Contractures secondary to immobility: is the restriction
articular or muscular? An experimental longitudinal study in the rat knee. Arch Phys Med Rehab
81: 6-13.
[14] Whishaw IQ and Pellis SM. 1990. The structure of skilled forelimb reaching in the rat: a
proximally driven movement with a single distal rotatory component. Behav Brain Res 41: 4959.
[15] Whishaw IQ, Gorny B, Foroud A, and Kleim JA. 2003. Long–Evans and Sprague–Dawley
rats have similar skilled reaching success and limb representations in motor cortex but different
movements: some cautionary insights into the selection of rat strains for neurobiological motor
research. Behav Brain Res 145: 221-232.
[16] Sacrey L-AR, Alaverdashvili M, and Whishaw IQ. 2009. Similar hand shaping in reachingfor-food (skilled reaching) in rats and humans provides evidence of homology in release,
collection, and manipulation movements. Behav Brain Res 204: 153-161.
[17] Aoki S, Sato Y, and Yanagihara D. 2012. Characteristics of leading forelimb movements for
obstacle avoidance during locomotion in rats. Neurosci Res 74: 129-137.
[18] Trudel G, Uhthoff HK, Goudreau L, and Laneuville O. 2014. Quantitative analysis of the
reversibility of knee flexion contractures with time: an experimental study using the rat model.
BMC Musculoskel Dis 15: 338.
[19] Abdel MP, Morrey ME, Grill DE, et al. 2012. Effects of joint contracture on the
contralateral unoperated limb in a rabbit knee contracture model: a biomechanical and genetic
study. J Orthop Res 30: 1581-1585.

59

[20] Abdel MP, Morrey ME, Barlow JD, et al. 2012. Myofibroblast cells are preferentially
expressed early in a rabbit model of joint contracture. J Orthop Res 30: 713-719.
[21] Bryce CD and Armstrong AD. 2008. Anatomy and biomechanics of the elbow. Orthop Clin
N Am 39: 141-154.
[22] Ling SK, Lui TH, Faan YS, et al. 2014. Post-traumatic elbow rotational stiffness. Shoulder
Elbow 6: 119-123.
[23] Evans EB, Eggers G, Butler JK, and Blumel J. 1960. Experimental immobilization and
remobilization of rat knee joints. J Bone Joint Surg 42: 737-758.

60

Chapter 5: Temporal patterns of motion in
flexion-extension and pronation-supination in
a rat model of post-traumatic elbow
contracture1
5.1 Introduction
Elbow post-traumatic joint contracture (PTJC) affects up to 50% of patients who
experience elbow trauma, including dislocations and fractures [1-3]. More so than any other
joint, the elbow is particularly susceptible to contracture as a result of its highly congruent joint
surfaces and soft tissue constraints [4]. Injury to the elbow damages the periarticular soft tissues
(i.e., capsule, ligaments, tendons, muscles), which can potentially alter their mechanical and
biological properties making elbow contracture difficult to manage and treat [5]. Clinical
evidence has suggested that the anterior capsule is a main contributor to contracture based on
biological changes to the tissue after injury [2, 4, 6, 7]. However, it is still unclear how these
biological changes develop over time and translate to loss in mechanical function. An animal
model can be useful to understand post-traumatic elbow contracture etiology to ultimately
develop new treatment and rehabilitation strategies.
Our group developed a rat model of post-traumatic elbow contracture, which exhibited
decreased range-of-motion (ROM) in flexion-extension and pronation-supination after surgically
inducing unilateral soft tissue injuries and joint immobilization for 42 days [8, 9]. After this
period of immobilization, we found that a subsequent period of 42 days of free mobilization (i.e.,
1

Reprinted from: Dunham CL, Castile RM, Havlioglu N, et al. 2018. Temporal Patterns of Motion in Flexionextension and Pronation-supination in a Rat Model of Posttraumatic Elbow Contracture. Clin Orthop Relat R 476:
1878-1889.
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joint no longer immobilized) did not fully restore rat elbow ROM [8, 10]. Histological analysis
of the anterior capsule at both time points showed changes that are consistent with clinical
reports for human tissue, including increased cellularity and thickness [2, 4, 6, 7, 9, 10].
Although this previous work focused on endpoints to establish our rat elbow contracture model
and demonstrate persistent ROM loss, we did not examine how elbow contracture develops
throughout the period of immobilization or how elbow ROM recovers during the subsequent
period of free mobilization [8-10].
Previously, in immobilization-only rat models of knee contracture with no soft tissue
injury, the knee exhibited decreased ROM after 14 days of immobilization [11, 12]. Trudel et al.
evaluated 224 days of free mobilization after 56 days of knee immobilization in the rat and found
that ROM initially improved but eventually plateaued after 56 days of free mobilization, beyond
which no motion was gained [12, 13]. A similar timeline of contracture development and ROM
response to free mobilization has not been previously reported in the elbow. A timeline of
contracture etiology would allow us to determine when treatment strategies should be applied in
our rat elbow contracture model to augment their potential benefit to improve elbow ROM.
Immobilization-only rat knee contracture models also described biological changes to the
anterior and posterior joint capsule that included (1) hypercellularity from 3-14 days of
immobilization, which decreased after 112 days of immobilization, and (2) increased capsule
myofibroblasts, thickness, and adhesions after 7-14 days of immobilization, which all continued
to increase with time [11, 14, 15]. In contrast, a study that evaluated rat knee contracture after
traumatic injury reported that myofibroblasts decreased after 56 days of immobilization and
remained decreased after an additional 112 days of free mobilization [16]. We seek to determine
if similar biological changes occur over time in the anterior capsule of our rat elbow PTJC
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model, which might support the altered ROM and thus serve as a potential target for treatment.
To consider how other periarticular soft tissues might be affected in our rat elbow contracture
model, we also seek to evaluate biological changes to the elbow surfaces focusing on cartilagecartilage and cartilage-capsule interactions.
Building on our previous work, the objectives of this study were (1) to quantify the
mechanics of contracture over time in our rat model of post-traumatic elbow contracture
throughout immobilization and free mobilization, and (2) to determine what changes occur in
capsule and joint surface morphology that might be able to account for the altered mechanics. To
fully evaluate and demonstrate the timeline of biological and mechanical changes in our rat
elbow contracture model, we included some previously reported data at the endpoints of
immobilization and free mobilization [8-10].

5.2 Methods and materials
Animal and injury model. Long-Evans rats (Charles River Laboratories International,
Wilmington, MA, USA) were selected based on criteria previously described [8-10]. Briefly,
these animals exhibit similarities to human anatomy, including bony architecture and
periarticular soft tissues, functional ROM, and use of their upper extremities, including the
ability to exhibit both elbow flexion-extension and pronation-supination distinguishing LongEvans rats from other breeds [17-20].
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Figure 5.1 Schematic of the experimental method timeline. At each analysis time point mechanical testing (n =
8/group) and histology (n = 3/group) was performed. (lightning bolt = surgery, oval = analysis time point).
Table 5.1 Group naming convention (n = 8/group).

Injury

Days of
immobilization (IM)

Days of
free mobilization (FM)

Total days
in study

Control

No

0

3, 7, 21, 42, 63, 84

3, 7, 21, 42, 63, 84

3 IM

Yes

3

0

3

7 IM

Yes

7

0

7

21 IM

Yes

21

0

21

42 IM

Yes

42

0

42

42/21 IM-FM

Yes

42

21

63

42/42 IM-FM

Yes

42

42

84

Group

Controls were age-matched at each time point and allowed unrestricted, free cage activity.

The Institutional Animal Care and Use Committee (IACUC) approved experimental
design randomized male Long-Evans rats (250-300 g, 8-10 weeks old) into a surgical (injured)
and control group. Animals in the injured group were anesthetized and an anterior capsulotomy
with lateral collateral ligament transection was surgically induced in the left limb to simulate soft
tissue damage seen in elbow dislocation. Animals received a single dose each of antibiotic (7.5
mg/kg enrofloxacin; Bayer Health LLC, Shawnee Mission, KS, USA) and a nonsteroidal antiinflammatory drug (5 mg/kg carprofen; Pfizer Animal Health, New York, NY, USA)
preoperatively by subcutaneous injection. A single dose of analgesic (0.5 cc of 5 mg/mL
bupivacaine; Hospira, Lake Forest, IL, USA) was administered postoperatively by subcutaneous
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injection under the closed incision. After surgery, injured limbs were immobilized in flexion
following a protocol previously described [9, 10]. Briefly, injured limbs were immobilized with
tubular elastic netting (Nich Marketers Inc., Gulf Breeze, FL, USA) and self-adhering Vetrap
bandaging (3M, St. Paul, MN, USA), and an access hole was cut to leave the contralateral (CL)
limb unconstrained. CL limbs and control animals were uninjured and allowed unrestricted
motion and were used as comparisons to injured limbs.
In this study, the presented data were obtained from a total of 96 male Long-Evans rats.
Results from 32 of these animals were published previously: 16 animals were from a study that
established our rat model of elbow contracture after injury and 42 days of immobilization,
whereas the other 16 demonstrated persistent ROM loss after an additional period of 42 days of
free mobilization (Table 5.1) [8-10]. It is difficult to understand the full timeline of contracture
development during immobilization and response to free mobilization without data from these
endpoints; thus, inclusion of these data enable comparison of all time points throughout these
two periods. New data were acquired in the present study for 64 male Long-Evans rats that were
randomized into four groups (n = 8/group): 3, 7, or 21 days of immobilization (IM) or 42 days of
immobilization with 21 days of free mobilization (42/21 IM-FM) (Figure 5.1, Table 5.1).
Animals were checked five times per week to ensure the injured limb was fully
constrained and to identify any signs of pain or distress. When the injured limb was rewrapped,
any sores or cuts caused by scratching or rubbing of the bandage were treated topically with
antibiotic powder/cream (nitrofurazone; Neogen Corp., Lexington, KY, USA, and silver
sulfadiazine; Dr. Reddy’s Laboratories, Shreveport, LA, USA) and/or chafing cream (Prestige
Brands, Tarrytown, NY, USA). After 42 days of immobilization, one group of animals had their
bandages removed and were allowed unrestricted cage activity for an additional 21 days (42/21
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IM-FM). At each of the time points, animals were euthanized by CO2 inhalation and immediately
stored in a -20°C freezer.
Mechanical testing. Mechanical testing was performed on both limbs from each animal
in the injured group and on unilateral (left) limbs from control animals. Forelimbs were prepared
for mechanical testing as described previously [9, 10]. Limbs were first tested in flexionextension and then in pronation-supination using custom test setups, which both use a rack and
pinion gear to convert linear displacement to rotational loading of the rat elbow [8, 9]. Prior
results confirmed that no joint damage occurred during flexion-extension testing that would
negatively impact the joint during the subsequent pronation-supination testing [8].
Each limb was cyclically loaded for five cycles to ± 0.75 N (± 11.25 N-mm of torque)
and ± 0.85 N (± 11.75 N-mm of torque) at 0.3 mm/sec for flexion-extension and pronationsupination, respectively [8, 9]. Force and
displacement data from the fifth cycle were
converted to torque and angular position. A
custom-written Matlab program (Mathworks,
Natick, MA, USA) was used to analyze the torqueangle curves to quantify elbow motion.
Measurements included total ROM, neutral zone
(NZ) length, and ROM midpoint (Figure 5.2) [8-

Figure 5.2 A representative data set (light gray
circles) and its average curve (black line) are shown
to define torque-angle loading/unloading curve
parameters. (NZ = neutral zone, ROM = range-ofmotion).

10]. The NZ is the relatively flat linear region
between the loading and unloading curves of the
maximum limits and is defined in degrees based
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on the x-axis of the torque-angular position plot (Figure 5.2). Joint behavior in the NZ represents
the functional ROM or the amount of motion possible before a larger force is required to move
the joint further. ROM midpoint quantifies the relative shift of the overall torque-angle curve,
which can indicate altered motion relative to control and is calculated by finding the middle (or
center) of the maximum limits of the torque-angle curve. Previously, we noted that in pronationsupination, it was difficult to align limbs in a neutral starting position; although this does not
affect total ROM or NZ length, it could shift maximum motion limits, so no ROM midpoint
values were reported for pronation-supination [8]. Average loading curves for each group were
computed by averaging the points of maximum motion (flexion/pronation or
extension/supination) and both endpoints of the NZ to show qualitative representations of joint
motion. Group-averaged values were used to plot average curves for each time point.
Histological analysis. After mechanical testing, a subset of limbs at each time point (n =
3/group), which exhibited average joint motion in both flexion-extension and pronationsupination, was prepared for histological analysis using standard protocols described previously
[9]. Three sagittal sections (5 µm thick) per stain were cut and stained with hematoxylin and
eosin (H&E) and toluidine blue. Blinded sections were scored by a musculoskeletal pathologist
to analyze the anterior capsule using a semiquantitative scoring method for several biological
characteristics of interest (i.e., adhesions, fibrosis, cellularity, inflammation, myofibroblasts,
proteoglycans) using the same evaluation criteria used previously [9, 10]. Each parameter
received a symbolic score based on specific criteria: adhesion was scored as present (+) or absent
(-); fibrosis was scored as < 30% (+), 31-60% (+ +), or > 60% (+ + +); cellularity was scored as
minimal (+), mild (+ +), moderate (+ + +), or marked (+ + + +); and inflammation was scored as
none (-), mild (+), moderate (+ +), or marked (+ + +). Myofibroblasts were scored as mild (+),
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moderate (+ +), or marked (+ + +);
and matrix proteoglycans were
scored as weak to mild (+), moderate
(+ +), or strong (+ + +). Capsular
thickness was also measured on each
section and reported
semiquantitatively to account for
variation in capsule thickness
throughout the tissue volume and for
varying angular orientation of
histological sections through the
joint. Numeric scores were averaged
Figure 5.3 (A) A schematic of the rat elbow identifies the opposing
and non-opposing joint surfaces as the purple- and orange-shaded
regions, respectively. Representative sagittal histology sections
(toluidine blue) with a total score of (B) zero and (C) five are shown
for the non-opposing joint surfaces. (scale bar = 100 µm).

across each group, normalized by the
thickness of the corresponding CL
capsule, and converted to a symbolic

grading scheme for comparison between groups: 0-150 µm (-), 151-300 µm (+), 301-450 µm (+
+), 451-600 µm (+ + +), and > 600 µm (+ + + +).
These blinded histological sections were also semiquantitatively scored to analyze the
opposing and non-opposing joint surfaces, which represent cartilage-cartilage and cartilagecapsule interactions, respectively, using the modified Mankin scoring system (Figure 5.3A) [21].
The opposing and non-opposing joint surfaces were evaluated to assess changes within these soft
tissues (capsule, cartilage) resulting from the altered mechanical and biological environment in
our injury-immobilization model. Cartilage-capsule interaction was evaluated at the humeral and
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radial points of contact because of the anatomic configuration of the rat elbow, namely that the
ulna does not directly contact the capsule. Joint surface structure, cellularity, matrix, and
tidemark integrity were evaluated, and the total score was computed as the sum of the scores
from these four categories. Each category score was converted to a symbolic score based on
specific criteria: structure was scored as normal (-), surface irregularities (+), or surface
irregularities with tissue overgrowth (+ +); cellularity was scored as normal (-), diffuse
hypercellularity (+), cloning (+ +), or hypocellularity (+ + +); matrix was scored as normal (-),
slight (+), moderate (+ +), or severe reduction (+ + +) based on proteoglycan content and
metachromasia; and tidemark integrity was scored as intact (-) or crossed by blood vessels (+).
Representative sections with a total score of zero and five illustrate non-opposing joint surfaces
that were either not or moderately affected by elbow contracture, respectively (Figures 5.3B-C).
Statistical analysis. A power analysis (power = 0.8; α = 0.05) determined that n =
7/group was required for joint mechanical tests to detect ROM differences of 15° with a standard

Figure 5.4 Average curves for (A) flexion-extension and (B) pronation-supination qualitatively illustrate contracture
etiology. (dashed line = control limb, solid line = injured limb). Limbs were evaluated after 3, 7, 21, or 42 days of
immobilization (IM) or after 42 days of immobilization with either 21 or 42 days of free mobilization (42/21 or
42/42 IM-FM, respectively). Average curves for flexion-extension 42/42 IM-FM and pronation-supination 42 IM
and 42/42 IM-FM were published previously [8, 10].
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deviation of 10°. One-way analysis of variance (ANOVA) tests were conducted to compare
mechanical test parameters between (1) injured and control limbs for each time point, and (2) CL
and control limbs for each group (tests performed separately because injured and CL limbs are
not independent measures). When significance was found during ANOVA, post hoc Bonferroni
corrections were used to compare each group with control and each sequential time point. Sideto-side limb comparisons were evaluated with paired t tests to determine differences between
injured and CL limbs at each time point. Statistical significance was defined as p < 0.05. All
statistical analysis was performed in GraphPad Prism (GraphPad Software Inc., La Jolla, CA,
USA).

5.3 Results
Group-averaged mechanical test data qualitatively showed changes with time in the
overall loading profiles for the injured limbs (i.e., solid-colored lines) in flexion-extension and
pronation-supination when compared with control (i.e., black dashed lines) and CL (not shown)
(Figures 5.4A-B). In flexion-extension, 3 IM showed a larger total ROM and NZ length than
control (Figure 5.4A). However, as the time of immobilization increased, the injured limb
average curve shifted further to the right and showed increasingly larger losses in total ROM and
NZ length. When the limb was no longer immobilized during free mobilization, the average
curve shifted back to the left toward control with most of the increase in total ROM and NZ
length having occurred by 42/21 IM-FM. There appeared to be limited changes to the average
curve with an additional 21 days of free mobilization (42/42 IM-FM). In pronation-supination,
all time points up to and including 21 IM showed increased total ROM and NZ length compared
with control (Figure 5.4B). By 42 IM the average curve showed a qualitatively small decrease in
the total ROM and NZ length compared with control. Surprisingly, neither duration of free
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Figure 5.5 Quantitative results are shown for elbow contracture etiology in flexion-extension: (A) total range-ofmotion (ROM), (B) neutral zone (NZ) length, and (C) ROM midpoint. Limbs were evaluated after 3, 7, 21, or 42
days of immobilization (IM) or after 42 days of immobilization with either 21 or 42 days of free mobilization (42/21
or 42/42 IM-FM, respectively). Data are shown as mean ± standard deviation. # p < 0.05 different from control. * p
< 0.05. Data for flexion-extension at 42 IM and 42/42 IM-FM were published previously [9, 10].
Table 5.2 Quantitative results for elbow contracture etiology in flexion-extension: total range-of-motion (ROM) and
neutral zone (NZ) length, and ROM midpoint values (n = 8/group).

Group

Total ROM (°)

NZ Length (°)

ROM Midpoint (°)

Control

102.6 ± 10.8

69.0 ± 11.5

80.4 ± 10.6

3 IM

114.1 ± 6.9

86.5 ± 7.3*

85.9 ± 4.9

3 IM CL

115.4 ± 11.7

83.9 ± 15.1*

83.7 ± 5.4

7 IM

102.6 ± 10.7

73.6 ± 11.2

89.0 ± 4.9

7 IM CL

117.8 ± 5.9*

89.9 ± 9.6*

85.7 ± 6.4

21 IM

69.5 ± 12.6*

47.5 ± 11.1*

112.3 ± 4.7*

21 IM CL

118.2 ± 9.9*

89.1 ± 8.7*

86.3 ± 4.4

42 IM

54.8 ± 14.2*

30.6 ± 9.8*

117.2 ± 11.6*

42 IM CL

100.9 ± 11.8

67.7 ± 12.3

87.2 ± 7.2

42/21 IM-FM

82.3 ± 9.5*

53.6 ± 8.1*

101.7 ± 5.9*

42/21 IM-FM CL

114.9 ± 7.2

80.1 ± 6.3

84.2 ± 3.1

42/42 IM-FM

72.8 ± 19.1*

44.0 ± 14.4*

92.1 ± 6.3*

42/42 IM-FM CL

99.5 ± 20.5

66.7 ± 18.0

81.3 ± 8.5

Data are shown as average ± standard deviation. The bold values indicate difference from contralateral (CL)
limb and * values indicate difference from control (p < 0.05). Data for flexion-extension at 42 IM and 42/42 IMFM were published previously [9, 10].

mobilization (42/21 or 42/42 IM-FM) resulted in any changes in the average curve.
Qualitatively, these curves not only illustrated elbow contracture etiology, but also demonstrated
variation in response specific to motion types (flexion-extension versus pronation-supination).
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Quantitatively, flexion-extension total ROM was decreased at 21 and 42 IM compared
with control (p < 0.001 and < 0.001, respectively; Figure 5.5A, Table 5.2). Although total ROM
increased from 42 IM to 42/21 IM-FM (p < 0.001), values at 42/21 and 42/42 IM-FM were still
decreased compared with control (p = 0.002 and < 0.001, respectively) and were not different
from each other (p > 0.999). NZ length was initially increased at 3 IM compared with control (p
= 0.002) but was decreased by 21 and 42 IM (p < 0.001 and < 0.001, respectively; Figure 5.5B,
Table 5.2). Similar to total ROM, NZ length increased from 42 IM to 42/21 IM-FM (p = 0.001),
but values at 42/21 and 42/42 IM-FM were still decreased compared with control (p = 0.011 and
< 0.001, respectively) and were not different from each other (p = 0.800). ROM midpoint was
increased at 21 and 42 IM compared with control (p < 0.001 and < 0.001, respectively; Figure
5.5C, Table 5.2) but were not different from each other (p > 0.999). Despite a decrease in ROM
midpoint from 42 IM to 42/21 IM-FM (p = 0.004), values at 42/21 and 42/42 IM-FM were both
still increased compared with control (p < 0.001 and 0.007, respectively) and were not different
compared with each other (p = 0.248). Total ROM, NZ length, and ROM midpoint all exhibited
a change from 7 to 21 IM (p < 0.001, < 0.001, and < 0.001, respectively); however, only NZ
length changed from 21 to 42 IM (p = 0.025).
Quantitatively, pronation-supination total ROM was increased at 3 and 7 IM compared
with control (p < 0.001 and 0.001, respectively; Figure 5.6A, Table 5.3) and were not different
from each other (p > 0.999). Similarly, NZ length was increased at 3 and 7 IM compared with
control (p < 0.001 and 0.001, respectively; Figure 5.6B, Table 5.3) and were not different from
each other (p > 0.999). However, NZ length was decreased compared with control at 42 IM (p =
0.021) [8]. Both total ROM and NZ length exhibited a decrease from 21 to 42 IM (p = 0.001 and
< 0.001, respectively). There were no changes at 42/21 and 42/42 IM-FM with control for either
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Figure 5.6 Quantitative results are shown for elbow contracture etiology in pronation-supination: (A) total range-ofmotion (ROM) and (B) neutral zone (NZ) length. Limbs were evaluated after 3, 7, 21, or 42 days of immobilization
(IM) or after 42 days of immobilization with either 21 or 42 days of free mobilization (42/21 or 42/42 IM-FM,
respectively). Data are shown as mean ± standard deviation. # p < 0.05 different from control. * p < 0.05. Data for
pronation-supination at 42 IM and 42/42 IM-FM were published previously [8].
Table 5.3 Quantitative results for elbow contracture etiology in pronation-supination: total range-of-motion (ROM)
and neutral zone (NZ) length (n = 8/group).

Group

Total ROM (°)

NZ Length (°)

Control

154.9 ± 22.2

103.2 ± 17.0

3 IM

216.1 ± 26.5*

144.2 ± 16.2*

3 IM CL

199.3 ± 26.8*

127.1 ± 11.9

7 IM

202.2 ± 32.0*

138.4 ± 25.4*

7 IM CL

191.4 ± 26.7*

129.0 ± 28.1

21 IM

181.9 ± 25.3

123.3 ± 18.1

21 IM CL

188.5 ± 24.9

128.6 ± 19.0

42 IM

122.7 ± 46.6

74.2 ± 34.8*

42 IM CL

161.1 ± 52.2

107.3 ± 41.0

42/21 IM-FM

142.2 ± 17.4

93.8 ± 8.8

42/21 IM-FM CL

178.4 ± 21.9

120.6 ± 14.9

42/42 IM-FM

136.0 ± 13.9

86.2 ± 13.4

42/42 IM-FM CL

173.0 ± 25.5

114.6 ± 21.6

Data are shown as average ± standard deviation. The bold values indicate difference from contralateral (CL)
limb and * values indicate difference from control (p < 0.05). Data for pronation-supination at 42 IM and 42/42
IM-FM were published previously [8].
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Figure 5.7 Representative sagittal histology (toluidine blue) of control and injured limbs illustrate joint anatomy and
general characteristics of the anterior capsule at each time point. Overall, injured limb anterior capsules exhibit
increased myofibroblasts, proteoglycans, and thickness compared with control. (C = capsule, H = humerus, R =
radius, scale bar = 1 mm).

Figure 5.8 Representative sagittal histology (H&E) of control and injured limbs show the anterior capsule at each
time point. Overall, injured limb anterior capsules exhibit increased cellularity and fibrosis compared with control.
(scale bar = 50 µm).

total ROM (p > 0.999 and 0.953, respectively) or NZ length (p > 0.999 and 0.416, respectively);
these measures were also not different from each other at either time point (p > 0.999 and >
0.999, respectively; Figure 5.6).
Overall, data for CL and control limbs were very similar; comparisons between injured
and CL limbs matched the injured-control comparisons for flexion-extension and pronationsupination (Tables 5.2 and 5.3).
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Table 5.4 Histological evaluation of the anterior capsule (n = 3/group).

Group

Adhesion Fibrosis Cell. Inflammation Myofibro.

Proteoglycans

Thickness

Control

-

-

+

-

+

+

-

3 IM

+

+

+

+

++

++

+++

3 IM CL

-

-

+

-

+

+

-

7 IM

+

+

++

+

+

++

++++

7 IM CL

-

-

+

-

+

+

-

21 IM

+

+

++

+

++

++

+

21 IM CL

-

-

+

+

+

+

-

42 IM

+

+

++

-

++

++

++

42 IM CL

-

+

+

-

+

+

-

42/21 IM-FM

+

+

++

+

++

+

+++

42/21 IM-FM CL

-

-

+

+

+

+

-

42/42 IM-FM

+

+

+

-

++

++

+++

42/42 IM-FM CL

-

-

+

-

+

+

-

Thickness grading scheme: 0-150 µm (-), 151-300 µm (+), 301-450 µm (+ +), 451-600 µm (+ + +) and > 601
µm (+ + + +). Data for 42 IM and 42/42 IM-FM were published previously [9, 10]. (Cell. = Cellularity, CL =
contralateral limb, Myofibro. = Myofibroblasts).

Injured limbs exhibited qualitatively altered biological properties throughout
immobilization and free mobilization as shown through overall joint morphology, anterior
capsule appearance, and blinded histological scoring (Figures 5.7 and 5.8, Table 5.4). At all time
points, the anterior capsule from the injured limbs exhibited evidence of fibrosis and increased
adhesions to osseous surfaces compared with control. Inflammation was increased up to and
including 21 IM as well as at 42/21 IM-FM compared with control. Cellularity was increased
from 7 IM to 42/21 IM-FM compared with control, whereas myofibroblasts exhibited an early
increase at 3 IM but only showed persistently increased numbers from 21 IM onward. Compared
with control, proteoglycans were increased at all time points except 42/21 IM-FM. The anterior
capsule exhibited increased thickness compared with control at all time points with the largest
increase at 7 IM. Evaluation of the CL anterior capsule demonstrated that it was similar to
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Table 5.5 Histological evaluation of the non-opposing joint surfaces (n = 3/group).

Group

Structure

Cellularity

Matrix reduction

Tidemark integrity

Total score

-

-

-

-

0

++

+

++

+

6

+

-

-

-

1

++

+

++

+

6

-

-

-

-

0

++

+

++

-

5

-

-

-

-

0

++

+

+

-

4

-

-

-

-

0

++

+

+

+

5

-

-

-

-

0

++

+

+

-

4

-

-

-

-

0

Control
3 IM
3 IM CL
7 IM
7 IM CL
21 IM
21 IM CL
42 IM
42 IM CL
42/21 IM-FM
42/21 IM-FM CL
42/42 IM-FM
42/42 IM-FM CL
(CL = contralateral limb).

control at all time points (Table 5.4). Of the 42 scores for CL limbs (seven criteria x six time
points), only three were different compared with control: 42 IM CL exhibited evidence of
fibrosis and 21 IM and 42/21 IM-FM CL had increased inflammation.
The non-opposing joint surface of injured limbs (reflecting cartilage-capsule interactions)
qualitatively displayed more severely altered biological properties than the opposing joint
surface (representative of cartilage-cartilage interactions) throughout immobilization and free
mobilization. At all time points, the non-opposing joint surface of injured limbs exhibited surface
irregularities with tissue overgrowth and diffuse hypercellularity (Table 5.5). Moderate matrix
reduction was observed from 3 to 21 IM injured limbs with consistent slight matrix reduction
from 42 IM to 42/42 IM-FM. Blood vessels were only observed to cross the tidemark at 3 and 7
IM and 42/21 IM-FM in injured limbs. The only non-opposing joint surface for CL limbs that
was different compared with control was at 3 IM, where surface irregularities were observed
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Table 5.6 Histological evaluation of the opposing joint surfaces (n = 3/group).

Group

Structure

Cellularity

Matrix reduction

Tidemark integrity

Total score

Control

-

-

-

-

0

3 IM

+

-

-

-

1

3 IM CL

-

-

-

-

0

7 IM

+

-

-

-

1

7 IM CL

-

-

-

-

0

21 IM

+

-

-

-

1

21 IM CL

-

-

-

-

0

42 IM

+

-

-

-

1

42 IM CL

-

-

-

-

0

42/21 IM-FM

+

+

+

-

3

42/21 IM-FM CL

-

-

-

-

0

42/42 IM-FM

+

-

-

-

1

42/42 IM-FM CL

-

-

-

-

0

(CL = contralateral limb).

(Table 5.5). The opposing joint surface of injured limbs displayed surface irregularities at all
time points (Table 5.6). No other biological properties for injured limbs were different compared
with control for the opposing joint surface, except for 42/21 IM-FM, which exhibited diffuse
hypercellularity and slight matrix reduction. No opposing joint surface for CL limbs was
different compared with control (Table 5.6).

5.4 Discussion
Our group developed a rat model of post-traumatic elbow contracture, which exhibited
decreased ROM [8-10]. Although our previous work focused on endpoints to establish our rat
model of elbow contracture, we did not at that time quantitatively evaluate elbow ROM over
time throughout contracture development during immobilization and joint response to free
mobilization. Results in this study detail a timeline of contracture etiology, showing significant
ROM loss 21 days after injury and immobilization and biological changes in the anterior capsule
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including increased adhesions, myofibroblasts, and thickness. These findings will help identify
(1) when treatment strategies should be applied in our rat model to enhance their potential
benefit, and (2) potential targets for treatment.
This study is not without limitations. First, because rats are quadruped animals, their
upper extremities experience different loads than humans. In our animal model, the injured
forelimb is immobilized using an external bandage to prevent weightbearing, which more closely
simulates the human condition than Kirschner wire or external fixator approaches used in
previous studies [22-24]. Because this could cause compensation or increased ROM in the
contralateral limb, we primarily focused on differences between injured and control limbs.
Similarly, the species and breed of rat used in this study were carefully selected to match key
similarities to human anatomy and function to maximize clinical relevance of this animal model,
which will allow us to complete testing and evaluation of different treatment strategies for elbow
contracture [8-10].
Second, although some of the presented data were collected in separate studies, the
surgical and animal care techniques used, the animal housing environment, and other husbandry
factors had little to no effect on the results; specifically, joint mechanics of control animals in
each study were not different. As a result, all control data were combined into one group.
Joint mechanics data supported distinctly different temporal patterns for flexionextension and pronation-supination during contracture development in immobilization and joint
response to free mobilization. Contracture severity in our rat elbow model exhibited a timedependent response to immobilization in flexion-extension with the largest ROM loss occurring
at 42 days of immobilization compared with control (Figures 5.5). A similar joint response was
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shown previously in rat models of immobilization-induced knee contracture with no injury [12,
25]. For pronation-supination, however, injured limbs exhibited increased total ROM and NZ
length at early time points indicative of joint instability resulting from surgically induced injury.
Specifically, transection of the lateral collateral ligament created an observable posterolateral
rotary instability at the time of surgery, similar to what has been reported for analogous injury in
human patients [26]. This instability likely contributed to the early increase in pronationsupination and may have more predominantly affected this type of motion because the lateral
collateral ligament provides varus and rotational stability in the elbow [27, 28]. Contracture
development was not as severe in pronation-supination as in flexion-extension, similar to what
was reported previously, suggesting that contracture may develop at different time scales for
each type of motion [8].
Elbow response to free mobilization was also different in flexion-extension compared
with pronation-supination. In flexion-extension, ROM only increased after 21 days of free
mobilization, suggesting that more time in free mobilization would most likely not improve joint
function further. Rat models of immobilization-induced knee contracture exhibited similar
results, where 28 days of free mobilization showed limited gain in motion initially, but then
plateaued [13]. Unlike flexion-extension, free mobilization appeared to have no effect on
pronation-supination.
In this study, the anterior capsule expressed similar changes as in human patients and rat
models of immobilized-induced knee contracture including upregulated adhesions, cellularity,
thickness, and evidence of fibrosis (Table 5.4) [2, 4, 6, 7, 14, 29-32]. Myofibroblasts potentially
play an important role in contracture because some studies have hypothesized that the
extracellular matrix synthesized by myofibroblasts causes persistent ROM loss [7, 14, 33].
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Clinical descriptions of myofibroblast regulation after elbow injury have been conflicting. Most
studies have reported increased myofibroblasts post-injury, whereas one study reported that
myofibroblasts decreased after an initial increase [6, 33-35]. Our results showed early
myofibroblast upregulation that was maintained long term, indicating a potential role in
contracture in our rat model. Surprisingly, none of the evaluated biological responses appeared to
directly support the time course of contracture in our rat model. Therefore, other capsular
features could contribute to the altered joint mechanics, including collagen density, organization,
and crosslinking [29].
Clinically, the anterior capsule has been reported to be the primary contributor to elbow
contracture; however, other periarticular soft tissues may also contribute [4, 6, 7, 35, 36]. Joint
surface damage is common after elbow trauma and can result as secondary degeneration after
contracture [23, 37]. Rat models of immobilization-induced knee contracture have exhibited
minor changes in the non-opposing joint surface, including adhesions, matrix reduction, and
surface irregularities [25, 38-40]. Our rat joints exhibited similar changes that persisted
throughout immobilization and free mobilization (Table 5.5). Because the non-opposing joint
surface represents an area of cartilage-capsule interaction, intracapsular adhesions to the cartilage
surface have been suggested to alter shear stress applied to the joint surface, which has been
linked to increasing pro-inflammatory mediators [11, 23, 25]. Therefore, it is possible that
biological and mechanical changes to the anterior capsule in our rat model of elbow contracture
could influence the non-opposing joint surface by altering its biomechanical loading
environment and biochemical signaling [37].
In contrast, the opposing joint surface exhibited few changes with most parameters
exhibiting no difference compared with control (Table 5.6). Previous work with the rat knee
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immobilization models exhibited more severe degeneration, including surface irregularities,
matrix reduction, and decreased cellularity for the opposing joint surface [39-42]. However,
these studies did not all prevent weightbearing during immobilization. Thus, joints likely
experienced static compression that may have led to more severe changes [23, 25, 38, 41-43].
Interestingly, there was an increase in the total score for both the non-opposing and
opposing surfaces after 42 days of immobilization with 21 days of free mobilization (42/21 IMFM), which is the time point at which motion was regained during free mobilization. The altered
loading environment resulting from joint reloading during free mobilization may have applied
new stresses to the joint, perhaps causing microdamage to these surfaces and increasing
degeneration at this time point [23].
To our knowledge, this study represents the first quantitative evaluation of elbow
contracture throughout periods of immobilization and free mobilization in an animal model. Our
data reiterate the need to develop treatment and rehabilitation strategies that consider both elbow
motions and perhaps manage them separately [8, 32]. Although the etiology of contracture
described in this study cannot directly inform clinical practice, results illustrate the time course
of contracture and help narrow the window for appropriate application of intervention strategies
to maximize potential benefit in our rat model of elbow contracture. Rigorous evaluation of these
treatments strategies in our rat model will elucidate concepts that may be clinically translatable
and/or yield insights that can inform clinical perspectives.
In conclusion, we found that contracture development during immobilization and
response to free mobilization are motion-specific, meaning that distinctly different temporal
patterns exist for changes in flexion-extension and pronation-supination in our rat model of post81

traumatic elbow contracture. Future work will also determine how individual joint tissues such as
muscles, capsule, and ligaments contribute to the development and persistence of contracture in
our rat elbow model. This work will help identify potential tissue-specific targets for
development of preventive treatments strategies to be evaluated in our rat model of PTJC.
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Chapter 6: The role of periarticular soft
tissues in persistent motion loss in a rat
model of post-traumatic elbow contracture1
6.1 Introduction
Post-traumatic contracture develops in 50% of patients who experience elbow injury (i.e.,
dislocation or fracture), in part because the congruent joint architecture and soft tissue constraints
of the elbow are often disrupted as a result of injury [1, 2]. Restoring elbow range-of-motion
(ROM) following injury and contracture is a difficult, time-consuming, and costly challenge
because it is a multi-tissue pathology. Current treatment strategies such as physical therapy or
surgical intervention do not target all fibrotic tissues in the elbow, which include muscles,
tendons, capsule, ligaments, and cartilage [3]. However, the extent to which these tissues
contribute to contracture over time in the elbow is unknown.
Previous studies of immobilization-induced knee contracture animal models (i.e., no joint
injury) showed that the contribution of capsule/ligaments/cartilage and muscles/tendons to
contracture exhibited a time-dependent increase and decrease, respectively, throughout the
course of immobilization and subsequent free mobilization (i.e., joint no longer immobilized) [47]. However, these findings in the knee cannot be directly translated to the elbow because of the
anatomical and functional differences in these two joints. To our knowledge, no study has
evaluated these specific tissue contributions to contracture in the elbow. Despite clinical
evidence indicating the capsule is a primary contributor to persistent elbow contracture on the

1

Reprinted from: Dunham CL, Castile RM, Chamberlain AM, and Lake SP. 2019. The Role of Periarticular Soft
Tissues in Persistent Motion Loss in a Rat Model of Posttraumatic Elbow Contracture. J Bone Joint Surg 101: e17.
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basis of biological changes observed in the tissue, no study has specifically isolated the
mechanical contribution of the capsule to loss of elbow ROM [2, 8-10].
We previously developed an animal model of post-traumatic elbow contracture that
exhibited significant loss of flexion-extension ROM [11, 12]. In addition to the altered joint
mechanics, biological changes were histologically observed in the anterior capsule (i.e.,
increased thickness, adhesions, and myofibroblasts) and non-opposing joint surfaces (i.e.,
cartilage-capsule interactions indicative of arthrosis), consistent with clinical observations [1113]. This animal model allows evaluation of the role of periarticular soft tissues in elbow
contracture and elucidation of which soft tissues primarily cause motion loss will aid
development of tissue targeted treatment strategies to prevent elbow contracture. The objective
of this study was to evaluate the passive contributions of muscles/tendons, capsule, and
ligaments/cartilage to the loss of elbow extension caused by contracture. We hypothesized that
all tissues would substantially contribute to elbow contracture after immobilization, but that only
the capsule, ligaments, and cartilage would contribute after free mobilization because muscle
mechanics were reported to recover after joint reloading [14]. At all time points, we
hypothesized that the capsule would be the primary contributor to contracture on the basis of
persistent biological changes observed in human patients and in our rat model [2, 8-10, 13].

6.2 Methods and materials
Animal and injury model. On the basis of previously described criteria including
similarities to human anatomy and functional upper extremity ROM, male Long-Evans rats (250350 g, 8-10 weeks old; Charles River Laboratories International, Wilmington, MA, USA) were
selected and randomized into injury and control groups [11, 12]. A power analysis (power = 0.8;
α = 0.05) determined that seven rats per group were required for joint mechanical tests to detect
87

Figure 6.1 Schematic of the experimental method timeline. At each analysis time point sequential dissection
mechanical testing (n = 8/group) was performed. (lightning bolt = surgery, oval = analysis time point).

differences in ROM 15° with a standard deviation of 10°; a slightly more conservative group size
was chosen (eight rats per group per time point). The animal injury and immobilization protocol
used in the present study was previously developed by our group and was approved by
Institutional Animal Care and Use Committee (IACUC) [11, 12]. Briefly, animals in the injury
group were anesthetized and a unilateral surgical procedure, including an anterior capsulotomy
with lateral collateral ligament transection, was performed to replicate the soft tissue damage that
occurs during elbow dislocation. The injured limbs were then immobilized in a flexed position
immediately after the surgical procedure. The contralateral limbs and the animals in the control
group were neither injured nor immobilized.
Animals were evaluated after 42 days of immobilization (42 IM) to understand the
contribution of soft tissue to contracture development or after 42 days of immobilization with
either 21 or 42 days of free mobilization (42/21 or 42/42 IM-FM, respectively) to understand
how the soft tissue contribution changes after joint reloading (Figure 6.1). During free
mobilization, the immobilization bandage was removed, and animals were allowed unrestricted
cage activity. At each time point, animals were killed via CO2 inhalation overdose and stored
immediately in a -20°C freezer.
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Figure 6.2 Schematic and images of a rat forelimb at each testing condition: full (all soft tissue intact), no muscle
(muscles and tendons removed), and no muscle/capsule (muscles/tendons and anterior capsule removed). For each
condition, the left and right images are a sagittal and coronal view of the rat forelimb, respectively. (scale bar = 1
cm).

Mechanical testing. Post-mortem, the forelimbs were prepared and subjected to flexionextension mechanical testing with use of previously described protocols [11, 12]. Each limb was
tested a total of three times to evaluate the contribution of periarticular soft tissues to elbow
contracture. Flexion-extension mechanical testing was completed with (1) all soft tissues intact
(full), (2) muscles and tendons removed (no muscle), and (3) muscles/tendons and anterior
capsule removed (no muscle/capsule) (Figure 6.2). Because the synovial membrane is a few cell
layers thick, it was difficult to remove it from the capsule during dissection, so both were
released for the third testing condition [15]. One individual performed all dissections to ensure
consistency within the study.
To start each test, limbs were placed at 90° of flexion and then cyclically loaded to ± 0.75
N (± 11.25 N-mm of torque) for five cycles at 0.3 mm/sec. Force-displacement data from the
fifth cycle were converted to torque-angular position and analyzed with the use of a custom
MATLAB program (MathWorks, Natick, MA, USA). Measurements included start position,
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Figure 6.3 (A) Graph showing a torque-angle loading curve in flexion-extension with parameters identified for a
representative data set (light gray circles) and corresponding average curve (black line). Average curves for (B) 42
days of immobilization (42 IM), and 42 days of immobilization with either (C) 21 or (D) 42 days of free
mobilization (42/21 or 42/42 IM-FM, respectively) qualitatively illustrate extension contracture for each testing
condition. For each time point, the control group is represented by gray lines. (NM = no muscle, NMC = no
muscle/capsule).

total extension, and extension neutral zone (NZ) length (Figure 6.3A). The extension NZ length
is the linear region between the start position and the loading/unloading curves of maximum
extension. Clinically, extension NZ length represents the amount of motion possible in elbow
extension before a larger external force is applied to move the joint further. Analysis was focused
on extension because data from our previous studies showed no significant change in flexion
with contracture [11, 12]. Total extension and extension NZ length data are presented as a
percentage of the control, where a value of 100% represents no difference between the injured or
contralateral (CL) and control limb. The average point of maximum extension and both end
points of the extension NZ were calculated to present a qualitative representation of joint motion.
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Figure 6.4 Quantitative results for the starting position of the (A) control, (B) injured, and (C) contralateral (CL)
limbs for each condition at each time point, demonstrating consistent orientation across dissection states in the setup
of each test. Data are shown as mean ± standard deviation. There were no significant differences between the full, no
muscle (NM), and no muscle/capsule (NMC) conditions at each time point for the control, injured, or CL limbs.

Group averaged values were utilized to plot average curves for each testing condition at each
time point. Extension lost is the difference in total extension between injured and control limbs
in the full condition.
Statistical analysis. At each time point, repeated measures one-way analysis of variance
(ANOVA) was used to compare mechanical test parameters for each group for the three test
conditions: (1) full, (2) no muscle, and (3) no muscle/capsule. When ANOVA analysis showed
significant results, post-hoc Bonferroni corrections were used to compare each test condition. No
statistical analyses were completed across different time points. Significance was set as p < 0.05
and trending at 0.05 < p < 0.1. All statistical analysis was performed in GraphPad Prism
(GraphPad Software Inc., La Jolla, CA, USA).

6.3 Results
The starting position was evaluated to determine if joints were consistently placed in the
same orientation in the mechanical testing system across the three testing conditions. There were
no significant differences in the starting positions for the full, no muscle, and no muscle/capsule
conditions among the control, injured or CL limbs at any time point (Figures 6.4A-C),
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Figure 6.5 Quantitative results for the injured limb (A) total extension and (B) extension neutral zone (NZ) length
presented as a percentage of the control at each time point for each testing condition. Data are shown as mean ±
standard deviation. The dashed line indicates the control (100%). * p < 0.05. Trending toward significance, ♦ 0.05 <
p < 0.1. (NM = no muscle, NMC = no muscle/capsule).

demonstrating consistent and repeatable testing before and after sequential dissections within a
given group.
At 42 IM, the full condition for the injured limb had a very short extension NZ length, the
curve of which shifted away from the control (Figure 6.3B). Although the no muscle condition
qualitatively resulted in a small shift toward the control (Figure 6.3B), it represented a 9%
increase in total extension compared with the full condition (p = 0.017; Figure 6.5A). With
subsequent removal of the anterior capsule, the average curve of the no muscle/capsule condition
nearly overlapped with the control (Figure 6.3B), representing a 71% and 80% increase in total
extension compared with the no muscle and full conditions, respectively (p = 0.006 and 0.003,
respectively; Figure 6.5A). For NZ length, the no muscle condition showed no change compared
with the full condition; however, the value for the no muscle/capsule condition exhibited a 78%
increase compared with those of both the no muscle and full conditions at 42 IM (p = 0.005;
Figure 6.5B).
At 42/21 and 42/42 IM-FM, there was a qualitative increase in extension for the full
condition compared with that of the same group at 42 IM (Figures 6.3C-D). Interestingly, after
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Figure 6.6 Quantitative results for the contralateral (CL) limb (A) total extension and (B) extension neutral zone
(NZ) length presented as a percentage of the control at each time point for each testing condition. Data are shown as
mean ± standard deviation. The dashed line indicates the control (100%). There were no significant differences for
either parameter among the full and no muscle conditions, the full and no muscle/capsule conditions, or the no
muscle and no muscle/capsule conditions at each time point. (NM = no muscle, NMC = no muscle/capsule).

muscles/tendons were released at 42/21 IM-FM, there was neither a change in the average curve
nor a significant difference in either parameter evaluated (Figures 6.3C and 6.5). A small shift in
the average curve occurred only after release of the capsule (Figure 6.3C), representing a 22%
significant increase in extension NZ length compared with the no muscle condition (p = 0.042;
Figure 6.5B). At 42/21 IM-FM, total extension for the no muscle/capsule condition trended
toward significantly larger values compared with the no muscle and full conditions (Figure
6.5A), and extension NZ length values for the no muscle/capsule condition showed a trend
toward significant increases compared with the full condition (Figure 6.5B). The average curves
at 42/42 IM-FM exhibited similar changes: the no muscle condition did not alter the curve and
there was only a slight shift toward the control after the removal of the capsule (Figure 6.3D).
However, at 42/42 IM-FM neither total extension nor extension NZ length exhibited any
significant differences among the full, no muscle, and no muscle/capsule conditions (Figure 6.5).
Because removal of the muscles/tendons and capsule at both time points in free mobilization did
not cause a return to control level, it appears that the other remaining, full tissues (i.e., ligaments
and cartilage) must contribute to contracture at these time points.
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In the contralateral limbs, there were no
significant differences in total extension or
extension NZ length across any test conditions
at any time points (Figures 6.6A-B). CL data
were also not different compared with control,
with average total extension and extension NZ
length values at 97% of the control.
The amount of extension lost in the
Figure 6.7 Plot of extension lost during immobilization
(white circle) and free mobilization (gray circles). Data
in plot are shown as mean ± standard deviation. In
addition, a table shows the percentage contribution of
the periarticular soft tissues to elbow contracture at
each time point.

injured limbs was 55° at 42 IM, with the
muscles/tendons and capsule contributing 10%
and 90% to elbow contracture, respectively

(Figure 6.7). Twenty-one days of free mobilization reduced extension loss to 25°, with
contributions of the muscles/tendons and capsule decreased to 1% and 47%, respectively; the
ligaments/cartilage contributed 52% to contracture at this time point. Surprisingly, at 42/42 IMFM, the contributions of the muscles/tendons and capsule to contracture decreased to 0% and
26%, respectively, whereas the contribution of the ligaments/cartilage increased to 74%.

6.4 Discussion
The contribution of periarticular soft tissues to post-traumatic elbow contracture is
dependent on time and the relative amount of joint mobility. Immediately following
immobilization, the anterior capsule was the primary contributor to elbow contracture. However,
reloading the joint during free mobilization shifted the soft tissue response to be increasingly
dominated by the remaining, intact tissues (i.e., ligaments and cartilage). Surprisingly, as the
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duration of free mobilization increased, so did the contribution of the ligaments/cartilage to
elbow contracture.
Muscles/tendons were responsible for 10% of elbow contracture at 42 IM (Figure 6.7).
This limited yet significant contribution after immobilization was consistent with other findings,
which showed that active and passive muscle mechanics were significantly altered at 42 IM
(Figures 6.3B and 6.5) [14]. Thus, muscle contributes to early elbow contracture. However,
during free mobilization, the contribution of muscles/tendons decreased, demonstrating that prior
alterations to these tissues recovered with joint reloading (Figures 6.5 and 6.7). These results
were also consistent with data that showed active and passive muscle mechanics were not
significantly different compared with control at 42/42 IM-FM [14]. Similarly, studies of
immobilization-induced knee contracture animal models have demonstrated that the contribution
of muscles/tendons after immobilization decreased with time [4-6].
In our previous study utilizing the same rat model of elbow contracture, total ROM in
flexion-extension only increased until 21 days of free mobilization [13]. The initial gain in
motion was likely the result of increased muscular forces across the elbow [16]. A longer period
of free mobilization did not increase elbow ROM in these previous studies because the
active/dynamic muscles/tendons had already recovered (Figure 6.7) [13]. Thus, in this animal
model, muscles/tendons are not permanent contributors to post-traumatic elbow contracture and
should not be the focus of tissue targeted treatment strategies.
After immobilization, the capsule was responsible for 90% of the motion lost as a result
of contracture (Figure 6.7). In an immobilization-induced knee contracture model, Chimoto et al.
similarly reported that the capsule substantially contributed to reduced extension following
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immobilization [15]. During free mobilization, the percentage of contribution and the amount of
extension lost because of the capsule decreased with time, demonstrating that the capsule was
not the only periarticular soft tissue responsible for motion loss during this time period (Figures
6.5 and 6.7). Clinically, the contribution of non-capsular tissues to elbow contracture has been
shown by the persistence or recurrence of joint motion loss following either open or arthroscopic
anterior capsule release [3, 17, 18]. In such patients, full ROM is rarely restored and secondary
operations are even indicated in 12-15% of cases to further extract fibrotic joint tissues [19].
Although the ligaments/cartilage did not contribute to contracture after immobilization,
these tissues were responsible for 52% and 74% of the motion lost at 42/21 and 42/42 IM-FM,
respectively (Figure 6.7). Interestingly, although the percentage of contribution to these
structures to elbow contracture increased over time during free mobilization, the amount of
extension lost remained the same (Figure 6.7). Ligament thickening was visually observed
during dissections of limbs at both free mobilization time points, suggesting that ligament
scarring/hypertrophy led to the increasing contribution to contracture. The increasing
contribution of ligaments/cartilage could also be a result of mechanical and biochemical
interactions of the pathological capsule with the surrounding ligaments and cartilage in the joint
following trauma. Previous histological evaluation in this animal model found more damage and
degeneration in the non-opposing joint surface (i.e., cartilage-capsule) compared with the
opposing joint surface (i.e., cartilage-cartilage) [13]. Thus, the cartilage in the non-opposing joint
surface could be interacting with the pathological capsule and responding to the altered
mechanical and biological environment, resulting in secondary degeneration after contracture
[17, 20]. An immobilization-induced knee contracture model also exhibited evidence of
cartilage-capsule interaction, showing proliferation and adhesion of connective tissue during free
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mobilization [21]. Reloading the joint during free mobilization could also cause micro-damage to
both the capsule and ligaments/cartilage, which could alter tissue mechanical load and biological
signaling to ultimately affect the tissue contribution to elbow contracture [7].
Lindenhovius and Jupiter stated that the timing of treatment is associated with the
outcome of motion improvement in the elbow, and that the longer intervention is delayed, the
larger the contribution of muscles, tendons, and cartilage [3]. Although the present study
demonstrates that muscles/tendons were not permanent contributors to elbow contracture, the
results did support a time dependent response of the capsule and ligaments/cartilage. In
conclusion, it appears that the capsule, ligaments, and cartilage were all persistent contributors to
permanent contracture in our rat model of elbow contracture and should be considered during
development of tissue targeted treatment strategies. Ongoing evaluation of various treatment
strategies in this rat model will elucidate concepts that may be clinically translatable.
There are limitations and additional aspects of this study to consider. First, rats are
quadruped animals, hence their forearms experience different loads than humans. However, in
our animal model, the injured forelimb is immobilized to prevent weightbearing by using an
external bandage which more closely mimics the human condition following trauma. Second, the
evaluation of the periarticular soft tissue contribution to elbow contracture only isolated the
muscles/tendons and anterior capsule. However, the results showed that the remaining intact
tissues (i.e., ligaments and cartilage) dominated contracture during free mobilization. Future
work will evaluate ligament mechanics to understand the way they contribute to contracture.
Third, although our previous work evaluated morphological changes in muscle, capsule, and
cartilage [11-13], future work will also study biological changes in the capsule, including
evaluation of protein content and matrix organization.
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Chapter 7: Muscle does not drive persistent
post-traumatic elbow contracture in a rat
model1
7.1 Introduction
Post-traumatic elbow contracture is difficult to manage and treat because of the extensive
periarticular soft tissue pathology that contributes to contracture. The affected periarticular soft
tissues may include muscles, tendons, capsule, ligaments, and cartilage [1]. Muscles near the
elbow stabilize and align joint surfaces during articulation by force transmitted through active
contraction and passive contributions from extracellular matrix (ECM) [2-5]. In response to
traumatic injury and immobilization, muscle may contribute to reduced joint mobility through
multiple adaptations. Decreased loading can lead to loss of muscle fiber contractile protein
(atrophy), thereby reducing muscle active force and joint torque [6]. In addition, in response to
post-traumatic inflammatory signaling, muscle may experience a pathological increase in ECM
content (fibrosis) causing its passive resistance to joint motion to increase [7].
Immobilization-only rat models of knee contracture previously evaluated how
muscles/tendons contributed to overall limb mechanics [6, 8, 9]. In these models, joint motion
loss immediately after immobilization was believed to be caused by muscles/tendons, but these
changes were reversible [6, 8]. Thus, muscles/tendons were suggested to be transient
contributors to knee contracture [6, 9, 10]. However, these models did not evaluate the effect of
local injury with immobilization on muscle. Clinical observations have suggested that the close

1

Reprinted from: Dunham CL, Chamberlain AM, Meyer GA, and Lake SP. 2018. Muscle does not drive persistent
posttraumatic elbow contracture in a rat model. Muscle Nerve 58: 843-851.
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proximity of the elbow capsule, ligaments, and muscles could cause these tissues to contribute to
motion loss after traumatic joint injury [11]. Specifically, local inflammation combined with
immobilization could cause maladaptation and persistent pathology. No published work has
evaluated the role of local tissue injury in muscle adaptation to joint immobilization. However,
tenotomy models of unloading in the upper extremity, which involve tendon injury, demonstrate
persistent muscle atrophy and fibrosis after reloading, suggesting that inflammation and
unloading may play a synergistic role in the development of persistent pathology [12, 13].
Our group previously developed a rat model of post-traumatic elbow contracture that
resulted in significant motion loss in flexion-extension and pronation-supination that persisted
after free mobilization [14-16]. Although the injury induced in our rat model of elbow
contracture did not directly damage the tendons or muscles, the inflammatory environment
surrounding them was altered due to the injury induced in the anterior capsule and lateral
collateral ligament. Because muscle is sensitive to inflammation, it could influence muscle
adaptation to immobilization and subsequent free mobilization, and drive muscle contribution to
contracture [17].
The objective of this study was to evaluate the contribution of muscle to post-traumatic
elbow contracture. The goal was specifically to evaluate temporal changes in active and passive
muscle structure-function-composition relationships with immobilization and free mobilization
in the context of soft tissue injury. We hypothesized that active and passive muscle properties
would be significantly altered and contribute to contracture after injury and immobilization and
that these changes would partially persist after free mobilization.

7.2 Methods and materials
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Animal and injury model. Long-Evans rats (Charles River Laboratories, Wilmington,
MA, USA) were selected based on previously described criteria, including similarities to human
anatomy, function range-of-motion (ROM), and upper extremity use, especially in flexionextension and pronation-supination [14-16]. In this Institutional Animal Care and Use
Committee (IACUC) approved study, 78 male Long-Evans rats (250-300 g, 8-10 weeks old)
were randomized into two groups, surgical (injured) and control. The same animal injury and
immobilization protocol was used as previously developed by our group [14, 15]. Briefly,

Figure 7.1 (A) Schematic of the experimental method timeline. At the designated time points, gene expression
analysis (n = 5/group), mechanical testing (n = 7/group), and histology/IHC (n = 3/group) was performed. (lightning
bolt = surgery, arrowhead = gene expression analysis, pointed square = mechanical testing and
histology/immunohistochemistry (IHC)). (B) The biomechanical test system used to evaluate active and passive
muscle mechanics. The bath was Ringer’s solution (pH ~7.5, 37°C). The actuator contained a load cell which was
used to measure force. In the inset image, the electrodes provided stimulation during active mechanical testing. The
muscle is fixed to the testing system by sutures tied through the distal and proximal tendons.
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animals in the injured group were anesthetized, and unilateral surgery consisting of an anterior
capsulotomy with lateral collateral ligament transection was performed to replicate the soft tissue
injures that occur during elbow dislocation. The surgical approach included (1) splitting the
muscular layer between the anconeus and extensor carpi ulnaris and, more deeply, splitting the
extensor carpi radialis brevis; (2) isolating and dividing the anterior capsule; (3) severing the
lateral collateral ligament complex; and (4) closing the muscle fascial layer with suture and skin
with staples. The brachialis and biceps brachii muscles were not violated during the procedure.
After surgery, injured limbs were immobilized in a flexed position (~153°) [14, 15]. Control
animals were neither injured nor immobilized and served as comparisons to injured animals.
Animals were randomized into two groups, including injured and age-matched controls,
and biceps brachii muscles were mechanically evaluated after 42 days of immobilization (42 IM)
or after 42 days of immobilization with 42 days of free mobilization (42/42 IM-FM) during
which the immobilization bandage was removed and the animals were allowed unrestricted cage
activity (n = 7/group per time point, 28 total animals; Figure 7.1A). After mechanical testing,
these muscles were subsequently used for histology and immunohistochemistry. Additional
animals were randomized into two groups for gene expression analysis, including injured and
age-matched controls, with the biceps brachii and brachialis muscles evaluated after 3, 7, 21, and
42 IM, and 42/42 IM-FM (n = 5/group per time point, 50 total animals; Figure 7.1A). Significant
elbow contracture was previously established in our animal model after 42 IM, and we also
showed persistent motion loss up until 42/42 IM-FM [14, 15]. Thus, these time points represent
key points of evaluation after contracture development and long-term contracture, respectively.
Early time points were evaluated to detect biological changes after injury that might support the
changes that were observed in joint mechanics.
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The biceps brachii and brachialis muscles from our rat model of elbow contracture were
isolated for evaluation because they are major elbow flexor muscles [18]. Although both muscles
were used in gene expression analysis, pilot testing revealed that only one muscle per animal
could be reliably evaluated using mechanical testing because of technical limitations. The biceps
brachii was selected for mechanical evaluation because its ability to generate force has been
reported to be compromised in flexed elbow positions, whereas the brachialis showed
intermediate force generation over all elbow positions [18]. Because our animal model included
immobilization in a flexed position, resulting in a flexion contracture, the biceps brachii was
deemed most likely to exhibit altered mechanical properties [14, 15]. Animals for mechanical
testing were humanely killed by thoracotomy and aortic dissection, whereas animals for gene
expression were killed via CO2 inhalation overdose.
Mechanical testing. Active and passive mechanical testing were performed on whole
biceps brachii muscle of both injured and control limbs by using an ex vivo muscle physiology
testing system (Aurora Scientific, Aurora, Ontario, Canada; Figure 7.1B). Animals were
anesthetized with isoflurane at 2.5-4% via nasal inhalation. The biceps brachii of the left limb for
both injured and control animals was isolated and sutured through the proximal and distal
tendons. The muscle was then excised and immediately placed in Ringer’s solution (pH ~7.5,
37°C). The proximal tendon was secured to a fixed post while the distal tendon was attached to
the lever arm. A load cell in-line with the lever arm allowed force measurement throughout
mechanical testing. After it had been secured in the test system, the muscle was flanked by
parallel plate electrodes, allowing electrical stimulation.
Muscle slack length (Ls) was set as the length at which passive tension first registered
above zero. Maximum tetanic tension was determined by increasing muscle length incrementally
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from Ls and stimulating tetanic contraction (0.3 msec pulse width, 330 msec duration, 225 Hz) at
supramaximal voltage until a plateau in force was reached. Supramaximal voltage was set at
slack length by increasing the voltage input until a plateau in force occurred, demonstrating full
activation of the muscle. Active mechanical testing was completed within 30 minutes of muscle
excision, and 15 minutes of muscle relaxation/equilibration was allowed between active and
passive testing. Passive mechanics were evaluated via stress-relaxation tests in which muscle
was stretched at a rate of two Ls/sec in 10% Ls increments either to failure or to 120% Ls,
whichever was reached first, with two minutes of relaxation between each increment. Active and
passive mechanical properties were normalized to muscle physiological cross-sectional area
(PCSA): PCSA = (muscle weight x cos(pennation angle)) / (optimum fiber length x muscle
density) [19]. On the basis of previous literature, pennation angle and muscle density were
defined as 0° and 1.05 g/cm3, respectively [18]. Muscles were weighed after all mechanical
testing was completed.
Histology and immunohistochemistry. After mechanical testing, all muscles were flash
frozen in liquid nitrogen cooled isopentane and immediately stored at -80°C. Three muscles per
group that exhibited average active and passive mechanical testing data were cut in 10 µm
transverse sections on a cryostat at -24°C. Serial sections (n = 5/muscle) were stained with
hematoxylin and eosin (H&E) to view overall fiber morphology. To quantitate muscle fiber
cross-sectional area and ECM area fraction, serial sections were immunolabeled with primary
antibodies for laminin and collagen type (Col) I, respectively (Ab11575 and Ab34710,
respectively; Abcam, Cambridge, United Kingdom). Muscle sections were treated with blocking
buffer (2% bovine serum albumin) and incubated with primary antibodies for one hour, followed
by incubation with an Alexa Fluor 499 goat antimouse secondary antibody (Life Technologies,
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Table 7.1 TaqMan Probes designed and synthesized by Applied Biosystems used in qPCR.

Name

Primer

Assay ID

Transforming growth factor β1

TGFβ1

Rn00572010_m1

Transforming growth factor β3

TGFβ3

Rn00565937_m1

SMAD family member 2

Smad2

Rn00569900_m1

SMAD family member 3

Smad3

Rn00565331_m1

α-Smooth muscle actin

αSMA

Rn01759928_g1

Matrix metallopeptidase-2

MMP-2

Rn01538170_m1

Matrix metallopeptidase-9

MMP-9

Rn00579162_m1

Tissue inhibitor of metallopeptidase-1

TIMP-1

Rn01430873_g1

Tissue inhibitor of metallopeptidase-2

TIMP-2

Rn00573232_m1

Connective tissue growth factor

CTGF

Rn01537279_g1

Collagen type I

Col I

Rn01463848_m1

Collagen type III

Col III

Rn01437681_m1

Collagen type IV

Col IV

Rn01482927_m1

Collagen type VI

Col VI

Rn01429556_m1

Myogenic differentiation 1

MyoD

Rn00598571_m1

Myogenin

Myog

Rn00567418_m1

Myostatin

MSTN

Rn00569683_m1

Decorin

DCN

Rn01503161_m1

Biglycan

BGN

Rn01529736_m1

Glyceraldehyde-3-phosphate dehydrogenase

GAPDH
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Rn01775763_g1

Carlsbad, CA, USA) for 30 minutes. Quantitation of muscle fiber cross-sectional area was
performed on laminin stained sections with a custom macro in ImageJ (National Institutes of
Health, Bethesda, MD, USA). Quantitation of ECM area fraction was performed on Col I stained
sections with an ImageJ pixel counter plug-in. Image processing settings were standardized
across all sections.
Quantitative real-time polymerase chain reaction. The biceps brachii and brachialis
muscles were harvested from injured and control animals via sterile dissection within 20 minutes
after they had been killed. After dissection, tissue was immediately flash frozen and stored at
-80°C until RNA isolation was completed by using RNeasy Plus and RNase-free DNase set
(Qiagen, Hilden, Germany). RNA quality was evaluated with an RNA Nano kit (Agilent, Santa
Clara, CA, USA); all samples had at least 300 ng RNA with a RNA integrity number > 7.
Complimentary DNA was synthesized with a SuperScript VILO kit (Invitrogen, Carlsbad, CA,
USA), and TaqMan (Applied Biosystems, Foster City, CA, USA) primers were used to evaluate
the expression of genes related to fibrosis, ECM regulation, collagen, proteoglycans, and
myogenesis (Table 7.1). All reactions were performed in triplicate, and quantitation was
performed with the 2-∆∆CT method, with expression levels normalized to glyceraldehyde 3phosphate dehydrogenase and control animals at each time point [20].
Statistical analysis. Unpaired t tests were used to compare injured animals to controls at
each time point for (1) active stress, (2) passive stress, (3) fiber area, and (4) ECM area fraction.
Gene expression was evaluated across immobilization time points only via one-way analysis of
variance (ANOVA); when significance was found, post hoc t tests with Bonferroni corrections
were used to compared data at individual time points. Unpaired t tests were used to compare
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Figure 7.2 (A) Active stress of injured limbs biceps brachii at 42 IM was significantly decreased compared with
control. (B) Peak and (C) equilibrium passive stress-strain curves of the biceps brachii; includes only strains at
which all samples have data. Evaluation was completed at 42 days of immobilization (42 IM) or after 42 days of
immobilization with 42 days of free mobilization (42/42 IM-FM). Only 42 IM injured limbs exhibited significantly
different stresses compared with control; 42/42 IM-FM was not different compared with control. (D) Peak and (E)
equilibrium passive stress-muscle length curves of the biceps brachii qualitatively represent the effect of muscle
shortening. Data are shown as mean ± standard deviation. * p < 0.05 at 42 IM. ** p < 0.01 at 42 IM. (circles =
injured limbs, squares = control limb).

gene expression at 42/42 IM-FM and 42 IM. All statistical analyses were performed in GraphPad
Prism (GraphPad Software Inc., La Jolla, CA, USA), and significance was defined as p < 0.05.

7.3 Results
In general, muscle from injured limbs exhibited differences compared with muscle from
control at 42 IM, but by 42/42 IM-FM there were no differences between injured and control
muscles (Figure 7.2). Active stress was significantly decreased in injured limb muscle at 42 IM
compared with control (p = 0.009; Figure 7.2A). Peak passive stress at 42 IM was significantly
increased in injured limb muscle at 10% strain as well as from 50-70% strain compared with
control (Figure 7.2B). Equilibrium passive stress at 42 IM was significantly increased in injured
limb muscle at 20% strain and from 40-70% strain compared with control (Figure 7.2C).
Qualitatively, similar results were evident for peak and equilibrium passive stress versus muscle
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Figure 7.3 (A) Biceps brachii muscle length at maximum tetanic contraction was significantly decreased at 42 IM
only compared with control. (B) Muscle weight was not significantly different at either time point. Evaluation was
completed at 42 days of immobilization (42 IM) or after 42 days of immobilization with 42 days of free
mobilization (42/42 IM-FM). Data are shown as mean ± standard deviation. ** p < 0.01.

length curves (Figures 7.2D-E, not evaluated statistically). Injured limb muscle length at
maximum tetanic tension was significantly decreased compared with control at 42 IM (p =
0.001; Figure 7.3A), but muscle weight was not significantly different at either time point
(Figure 7.3B). Raw forces exhibited similar results at 42 IM and 42/42 IM-FM for active and
passive mechanical testing (data not shown).
H&E stained sections revealed moderate fiber atrophy at 42 IM but no gross
morphological pathology (Figure 7.4A). Fiber area was quantitated on laminin labeled sections
(Figure 7.5A), in which injured limb muscle was significantly decreased compared with control
at 42 IM (p = 0.0005), but was not different from control at 42/42 IM-FM (Figure 7.4B).
Extracellular matrix area fraction, which was computed by using Col I labeled sections (Figure
7.5B), was not significantly different in injured limb muscle at either 42 IM or 42/42 IM-FM
compared with control (Figure 7.4C). In addition, markers of muscle regeneration (i.e., centrally
located myonuclei) were not observed at either time point [21].
A heap map in Figures 7.6A-B summarizing all gene expression results illustrates small
changes in injured limb muscle, where values ~1 indicate no difference compared with control.
Statistical analyses and more detailed results are also provided in Figures 7.6C and 7.7,
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Figure 7.4 (A) Representative transverse histology (H&E) of the biceps brachii from control and injured limbs after
42 days of immobilization (42 IM) or 42 days of immobilized followed by 42 days of free mobilization (42/42 IMFM). Quantitative measures computed from fluorescent muscle sections: (B) fiber area and (C) extracellular matrix
(ECM) area fraction at both time points. Although there were no significant changes in ECM area fraction at either
time point, fiber area was significantly decreased at 42 IM compared with its respective control. Data are shown as
mean ± standard deviation. *** p < 0.001. (scale bar = 200 µm).

Figure 7.5 Representative transverse sections of biceps brachii from control and injured limbs immunolabeled for (A)
laminin (green), and (B) collagen type I (green) and nuclei (blue) after 42 days of immobilization (42 IM) or 42 days
of immobilized followed by 42 days of free mobilization (42/42 IM-FM). (scale bar = 200 µm).

respectively. Gene expression varied by muscle, with different expression patterns evident for
biceps brachii and brachialis.
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Figure 7.6 Quantitative polymerase chain reaction: Fold change in (A) biceps brachii and (B) brachialis muscles of
injured limbs evaluating expression of genes for fibrosis, extracellular matrix (ECM) regulators, collagen,
myogenesis, and proteoglycans (yellow and blue correspond to increased or decreased expression, respectively,
whereas white represents no change relative to control). (C) At left: One-way ANOVA during immobilization only,
including a heat map representing p values. At right: Results of unpaired t tests that compared injured limbs at 42
IM and 42/42 IM-FM. Open data cells represent when the p value was not significant. Evaluation was completed at
3,7, 21, or 42 days of immobilization (IM) or after 42 days of immobilization with 42 days of free mobilization
(42/42 IM-FM). (αSMA = α-smooth muscle actin, BGN = biglycan, BI = biceps brachii, BR = brachialis, Col =
collagen, DCN = decorin, MMP-2 = matrix metalloproteinase-2, MSTN = myostatin, Smad3 = SMAD Family
Member 3, TGFβ = transforming growth factor β, TIMP-2 = tissue inhibitor of metalloproteinase-2).

A few gene regulators of fibrosis and ECM exhibited small but significant changes.
Transforming growth factor β3 (TGFβ3), which is profibrotic, was the only gene significantly
altered during immobilization in both muscles (Figure 7.6C) [22]. Significant post hoc
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comparisons demonstrated early upregulation during immobilization, specifically at 3 IM
compared with 7 IM in the biceps brachii (Figure 7.7A) and at 7 IM compared with 42 IM in the
brachialis (Figure 7.7F). Another profibrotic gene, connective tissue growth factor (CTGF), was
also upregulated early during immobilization for both muscles (Figures 7.6A-B) [22].
Specifically, CTGF was significantly upregulated at 3 IM compared with 7, 21, and 42 IM
(Figure 7.7B). After free mobilization, the only significant change in expression was the
upregulation of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-2
(TIMP-2), which regulate ECM remodeling, in the brachialis (Figures 7.6B-C) [7]. Brachialis αsmooth muscle actin (αSMA) expression also varied significantly during immobilization and was
upregulated at 42 IM compared with 3 IM (p = 0.010).
Extracellular matrix genes for collagens and proteoglycans exhibited the largest number
of significant changes in expression over time. Several collagens varied significantly with time
during immobilization, but only Col IV was significantly altered in both muscles (Figure 7.6C).
Col IV was significantly increased at 42 IM compared with 7 IM in biceps brachii (Figure 7.7D)
and at 21 IM compared with 3 IM in the brachialis (Figure 7.7I). Col III in the biceps brachii and
Col I and VI in the brachialis also varied significantly during immobilization (Figure 7.6C).
However, only Col I in the brachialis exhibited significant post hoc comparisons, in which
expression was upregulated at 21 IM compared with 3, 7, and 42 IM (Figure 7.7H). All types of
collagen were significantly upregulated at 42/42 IM-FM compared with 42 IM in the brachialis
only (Figures 7.6C and 7.7H-I). Decorin, a proteoglycan, was also significantly upregulated in
the brachialis at 42/42 IM-FM compared with 42 IM (Figure 7.6C).
Similar to regulators of fibrosis and ECM, myogenic genes exhibited few significant fold
changes. MyoD, a myoblast differentiation regulator, and myostatin (MSTN), a negative
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Figure 7.7 Quantitative polymerase chain reaction: Fold change in (A-E) biceps brachii and (F-J) brachialis muscles
of injured limbs showing expression of (A,F) TGFβ3, (B,G) CTGF, (C,H) Col I, (D,I) Col IV, and (E,J) MSTN.
Evaluation was completed at 3,7, 21, or 42 days of immobilization (IM) or after 42 days of immobilization with 42
days of free mobilization (42/42 IM-FM). Data are shown as mean ± standard deviation. * p < 0.05. ** p < 0.01. ***
p < 0.001. **** p < 0.0001. (Col = collagen, CTGF = connective tissue growth factor, MSTN = myostatin, TGFβ3 =
transforming growth factor β3).
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regulator of muscle growth and regeneration, varied significantly only with time during
immobilization in the biceps brachii (Figures 7.6A and 7.6C) [23]. Post hoc comparisons
revealed that biceps brachii MyoD expression was downregulated at 21 IM compared with 3 and
7 IM (p = 0.029 and 0.049, respectively), whereas MSTN expression was significantly
upregulated at 7 IM compared with 42 IM (Figure 7.7E). In both muscles, MSTN expression was
significantly downregulated at 42 IM compared with 42/42 IM-FM (Figure 7.6C), but returned to
control/baseline levels by 42/42 IM-FM (Figures 7.6A-B, 7.7E, and 7.7J).

7.4 Discussion
In this study, the evaluated muscles in our rat model of post-traumatic elbow contracture
exhibited significantly altered tissue-level mechanics immediately after immobilization that
returned to normal after free mobilization. Changes in passive and active mechanics occurred
concurrently with tissue-level structural alterations (i.e., decreased muscle length and fiber crosssectional area), but these changes resolved under free mobilization. Gene expression yielded
small but significant changes throughout immobilization and after free mobilization, highlighting
the complexity of gene regulation in morphologic and functional muscle adaptations to joint
contracture.
Muscle mechanical properties have been shown to depend on muscle length in addition to
muscle activation and tension [24]. When muscle was immobilized in a shortened position,
altered active and passive forces correlated with decreased muscle length, weight, and fiber
diameter, similar to our muscle at 42 IM (Figures 7.3 and 7.4B) [24-26]. But, these changes were
not permanent, and muscle was able to recover morphologically and functionally after a free
mobilization period [24, 25]. However, the role of soft tissue injury in functional recovery was
not evaluated.
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Compared with control, injured limb biceps brachii exhibited significantly decreased
fiber area and active stress and increased passive stress at 42 IM (Figures 7.2 and 7.4). Atrophic
changes (i.e., decreased muscle length and fiber area) were expected after immobilization
because previous studies reported muscle atrophy in the rodent ankle after 4-6 weeks of ankle
immobilization [25, 27]. Thus, decreased muscle length and fiber area likely contributed to the
decreased active force generation at 42 IM (Figures 7.2-7.4), which could reduce joint torque and
ultimately contribute to the decreased joint motion at 42 IM [14]. In addition, injured limb
muscles began passive mechanical testing in a shortened position compared with control at 42
IM (Figures 7.2D-E); thus, moving the injured limb to the same joint angle as control would
require increased passive stress, demonstrating impaired joint function at 42 IM due to the
shortened muscle length. Even though muscle forces were normalized to PCSA, there was still a
deficit in mechanics after immobilization, demonstrating that other factors might also
compromise muscle force generation at 42 IM.
The ECM plays a key role in passive muscle mechanics by transmitting force generated
by muscle fibers and providing passive resistance to joint motion [5]. Previous studies reported
increased ECM production (i.e., Col I and III) in muscle after immobilization [25, 27]. In our rat
model of elbow contracture, passive stress was increased at 42 IM in injured limb muscle but
was not supported by a significant increase in ECM area fraction (Figure 7.4C). However, ECM
accumulation may be influenced by passive stretch and muscle activation [24]. For example,
previous work showed no change in ECM content when muscle was periodically activated over a
reduced ROM [28]. Although the injured limb of our animal model was immobilized using a
bandage wrap, the animals may still have activated their muscles in this fixed position, which
may have inhibited excessive ECM accumulation [14].
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Despite no difference in the amount of ECM between injured and control muscles (Figure
7.4C), the ECM still likely contributed to the altered muscle passive mechanics because the raw
forces and passive stresses were both significantly increased compared with control. Therefore,
altered collagen organization and crosslinks or changes to other ECM components (i.e.,
proteoglycans) may be responsible for increased passive stiffness at 42 IM [6, 29, 30]. The
passive properties could also be influenced by changes to crosslinks between actin and myosin
filaments and/or non-contractile proteins within the sarcomere cytoskeleton (i.e., titin, desmin)
[24]. Nonetheless, changes to muscle mechanics, length, and fiber area were not permanent after
free mobilization (Figures 7.2-7.4). Overall, in our rat model of elbow contracture, the altered
morphology and mechanics of injured limb muscle at 42 IM indicate detrimental remodeling of
the ECM during immobilization; however, subsequent reparative remodeling likely occurred
during free mobilization because changes did not persist at 42/42 IM-FM.
Clinically, joint contracture is believed to result from periarticular soft tissue fibrosis,
which is defined as an excessive increase in ECM due to a pathologic tissue repair response [7,
31, 32]. Specifically, collagen is synthesized at a rate that exceeds its degradation and may be
exacerbated by an imbalance of MMP and TIMP, which degrade ECM proteins and inhibit ECM
protein degradation, respectively [7, 33]. Both muscles exhibited significant changes in collagen
during immobilization, but, at 42/42 IM-FM, significance existed only for the brachialis (Figures
7.6-7.7). Although MMP and TIMP did not vary significantly over time during immobilization in
either muscle, MMP-2 and TIMP-2 in the brachialis were significantly upregulated at 42/42 IMFM (Figure 7.6). MMP-2 upregulation (1) could be indicative of increased matrix remodeling
rather than fibrosis and (2) is associated with the formation of new myofibers which supports the
potential of muscle growth [7].
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CTGF was upregulated early during immobilization for both muscles but varied
significantly only with time for the biceps brachii (Figures 7.6-7.7). Expression of CTGF was
previously reported to be upregulated in fibrotic tissue where it mimics the effects of TGFβ,
increasing the production of ECM proteins such as fibronectin and collagen [7]. Therefore, the
early increase in CTGF and the significant changes in TGFβ3 throughout immobilization may
support the subsequent increase in collagen expression (Figures 7.6-7.7), but the significant
collagen upregulation did not occur until after free mobilization.
The adaptive matrix expression changes that were observed in muscle from our rat model
of elbow contracture were more likely indicative of muscle remodeling during immobilization
and remodeling/growth during free mobilization rather than fibrosis [33]. Although MSTN, a
negative regulator of muscle growth and regeneration, was significantly upregulated early during
immobilization in the biceps brachii, it returned to control/baseline expression by 42/42 IM-FM
(Figures 7.6-7.7) [7]. Muscle growth during free mobilization is supported by collagen and
MMP-2 upregulation at 42/42 IM-FM, which is indicative of ECM remodeling and the formation
of new myofibers [7].
Although we did see significant changes in muscle gene expression, these changes were
very small. Even though some genes changed significantly over time for both muscles, there
were limited significant post hoc comparisons between specific time points. Significant changes
occurred most often for the brachialis. The distinction in expression between injured limb
muscles and the evaluated time points may indicate a biological or functional imbalance in
muscle that may contribute to overall joint contracture at 42 IM [2, 5, 14, 23].
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The induced injury did not include any direct damage to the tendons or muscles analyzed;
therefore, changes that were observed in this study could underestimate muscle contribution to
contracture in human patients with more severe injuries. However, the focus of our model was to
replicate soft tissue damage after elbow dislocation, which consistently affects the anterior
capsule and lateral collateral ligament more than muscle. Although the muscles that were
analyzed were not directly injured, the inflammatory environment surrounding them was altered
(shown via histological evaluation of the anterior capsule) [34]. Because muscle is sensitive to
inflammation, the altered inflammatory response of the capsule may have influenced muscle
repair, regeneration, and growth through local and circulating inflammatory cytokines [17].
Although this study did not directly evaluate inflammation in muscle, it did demonstrate that
damage to the anterior capsule and lateral collateral ligament did not induce permanent changes
in the muscle [25]. Future work will evaluate how inflammation affects all periarticular soft
tissues in our rat elbow contracture model.
This study has some limitations. First, mechanics and morphology were evaluated only in
the biceps brachii muscle, whereas gene expression was evaluated in the biceps brachii and
brachialis muscles. Although there were no significant differences in mechanics, ECM area
fraction, and collage gene expression at 42/42 IM-FM in injured limb biceps brachii compared
with control, collagen gene expression in the brachialis was significantly upregulated at 42/42
IM-FM and so could potentially exhibit altered mechanics and ECM area fraction at this time
point. However, as previously discussed, only one muscle could be reliably used for mechanical
evaluation. Second, Col I was used to quantify ECM area fraction. Although Col I is the primary
fibrous protein in muscle ECM, the interstitial matrix that surrounds muscle fibers is also
composed of fibronectin, perlecan, and Col III and V [7, 29]. Third, we used only young adult
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rats, which are representative of a young patient population [35]. However, the ability of muscle
to recover after a period of unloading declines with age, so it is likely that our data would
underestimate muscle contribution to contracture in an older patient population [19]. Finally, our
rat model of post-traumatic elbow contracture did not allow us to determine whether changes in
muscle were due to either injury or immobilization. We previously showed that an
immobilization-only group did not cause permanent elbow contracture and, hence, would not be
an appropriate model to evaluate contracture [14, 15]. An injury without immobilization group
was not used because (1) the joint would be unstable after injury induction and would likely
dislocate, causing additional uncontrolled joint damage, and (2) it is not representative of how
these injuries are treated clinically.
In conclusion, the altered mechanics, morphology, and gene expression in injured limb
muscles after immobilization were likely due to structural alterations (i.e., decreased muscle
length and fiber cross-sectional area) and ECM remodeling. These changes recovered after free
mobilization, thereby suggesting that muscle is not a permanent contributor to elbow contracture
in our animal model. Future work will use our rat model of post-traumatic elbow contracture to
evaluate the contributions of other periarticular soft tissues (i.e., anterior capsule, lateral
collateral ligament) to contracture.
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Chapter 8: Increased volume and collagen
crosslinks drive soft tissue contribution to
post-traumatic elbow contracture in an
animal model1
8.1 Introduction
The elbow is the second most commonly dislocated joint in adults and the most
commonly dislocated joint among the pediatric population [1, 2]. Following elbow dislocation,
post-traumatic joint contracture (PTJC) is more frequently observed in clinic than joint instability
and develops in up to 50% of patients whom experience elbow injury [1, 3]. Range-of-motion
(ROM) less than 100° in flexion-extension has been associated with significant patient-reported
functional limitations and patients with post-traumatic elbow contracture often exhibit ~45-65°
of motion [4-8]. Preventing or restoring elbow motion loss can be a difficult, time-consuming
and costly challenge because contracture is a multi-tissue pathology and response to treatment is
highly variable [4, 9]. Non-surgical (e.g., serial casting, static/dynamic splinting, continuous
passive motion) and surgical (e.g., open/arthroscopic soft tissue release) treatment options are
used to mitigate motion loss; however, the revision rate for repeat contracture is approximately
20% and elbow range-of-motion rarely returns to pre-injury levels [7].
Elbow function depends on the integrity of the soft tissues surrounding the joint [10].
Clinically, elbow contracture has been attributed to the shortening or fixation of the capsule and
ligaments [9, 11]. However, in the clinical setting it is not possible to specifically isolate each of

1

Reprinted from: Dunham CL, Steenbock H, Brinckmann J, et al. Increased volume and collagen crosslinks drive
soft tissue contribution to post-traumatic elbow contracture in an animal model. In Review JOR.
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these tissues’ mechanical and biological contributions to PTJC. Previously, we developed a rat
model of elbow PTJC and showed significant ROM loss in flexion-extension as well as
biological changes observed histologically in the anterior capsule (i.e., increased thickness,
adhesions, and myofibroblasts) and non-opposing joint surface (i.e., cartilage-capsule
interactions indicative of arthrosis) which were consistent with clinical observations [12-14]. We
also showed that muscles/tendons and the anterior capsule contributed approximately 10% and
90% to elbow contracture after 42 days of immobilization, respectively [15]. However, after a
subsequent period of free mobilization (i.e., unrestricted cage activity), the anterior capsule and
ligaments/cartilage were responsible for approximately 26% and 74% of the lost joint motion,
respectively [15]. While these previous studies identified the tissues which altered joint function,
potential changes within these tissues that caused the restricted motion were not examined. The
objective of this study was to evaluate the anterior capsule and lateral collateral ligament (LCL)
to determine mechanical and biological tissue specific changes that caused their functional
contribution to elbow contracture.
While both the capsule and LCL provide stability to the highly congruent joint surfaces
of the elbow, their form and function are different. The capsule is a synovial-lined membrane
that encloses the articulating joint surfaces [11] and helps resist valgus stress as well as
distraction and hyperextension [6, 16]. The LCL extends from the lateral epicondyle of the
humerus near the axis of rotation to the crista supinatoris of the ulna [17]. The LCL provides
varus and rotational stability to the elbow and is primarily loaded during 80-100° of flexion [17,
18]. During elbow dislocation, the capsule and LCL are nearly always injured; our rat model of
elbow contracture mimics this damage by surgically inducing an injury to both tissues [12, 13].
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Previous studies in animal models of knee contracture have focused primarily on the
capsule, while no previous studies have characterized ligamentous changes due to contracture. In
animal models of knee contracture with and without injury followed by immobilization, capsule
collagen density was not significantly different in contracted limbs compared to control [19-21],
but there was a significant decrease in glycosaminoglycan density [21]. Interestingly, in a rabbit
model of immobilization-only knee contracture (i.e., no injury), tissue that was harvested near
the joint line of the knee exhibited increased collagen crosslinks in immobilized limbs compared
to control [22]. While insightful, these previous studies in the knee are not generalizable to the
elbow because of anatomical and functional differences between these two joints. However,
based on this previous work, we hypothesized that a significant increase in tissue volume, as a
result of increased extracellular matrix protein deposition, and crosslinking would drive capsule
and LCL contribution to elbow contracture in our rat model.

8.2 Methods and materials
Animal model. Male Long-Evans rats (250-350 g, 8-10 weeks old; Charles River
Laboratories, Wilmington, MA, USA) were carefully selected based on anatomical and
functional similarities to the human elbow including the presence of a joint capsule, the ability to
not only flex-extend but also pronate-supinate, and the ability to use forelimbs in non-weight
bearing functions. In this Institutional Animal Care and Use Committee (IACUC) approved
study, we used a previously developed injury and immobilization protocol [12, 13]. Briefly,
animals were randomized into control and injured groups. Injured animals were anesthetized and
unilateral surgery (anterior capsulotomy with LCL transection) was performed to replicate soft
tissue damage that often occurs during elbow dislocation. Injured limbs were immobilized in a
flexed position using an external bandage immediately after surgery. The control group was
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Figure 8.1 Schematic of the experimental timeline. At each time point, lateral collateral ligament (LCL) mechanical
testing (n = 8/group), contrast enhanced micro-computed tomography (n = 3/group), biochemistry (n = 6/group), and
non-enzymatic collagen crosslink content analysis (n = 5/group) was performed. (lightning bolt = surgery, oval =
time point).

neither injured nor immobilized. Elbow periarticular soft tissues (capsule, LCL) were evaluated
after 42 days of immobilization (42 IM) to understand changes to these tissues as a result of
contracture or after 42 days of immobilization followed by 42 days of free mobilization (42/42
IM-FM) to understand how tissues were altered following joint reloading (Figure 8.1). The
external immobilization bandage was removed for the free mobilization period, and animals
were allowed unrestricted cage activity. At each time point, animals were sacrificed via CO2
inhalation overdose.
LCL mechanical testing. After sacrifice at each time point, animals (n = 8/group) were
stored immediately in a −20°C freezer. Prior to dissection, animals were thawed for 24 hours and
then forelimbs were prepared using methods described previously [12, 13]. Briefly, all skin was
removed, the glenohumeral joint was disarticulated, and the paw resected. All surrounding soft
tissues (e.g., muscles, tendons, capsule) were removed to isolate the medial and lateral collateral
ligaments. The proximal humerus and distal radius/ulna were secured in polycarbonate tubes
using hardening putty (Bondo, 3M, Maplewood, MN, USA) as described previously [12, 13].

126

Figure 8.2 (A) The biomechanical test system used to evaluate the lateral collateral ligament (LCL) with the joint
held fixed at 90° flexion. (B) The load from the linear actuator was applied perpendicular to the radius/ulna (LCL
outlined with the dotted lines).

A custom mechanical test system was designed and built to evaluate LCL mechanics
(Figure 8.2A). The device used one actuator of a planar biaxial mechanical test system
(TestResources, Shakopee, MN, USA) to apply linear displacement and measure force with a
single axis load cell (TestResources). The angle specification platform allowed the joint to be
held at a fixed flexion angle during testing. Joints were tested at 90° flexion because a previous
study which physiologically loaded human cadaver elbows determined that the LCL was most
engaged between 80-100° of joint flexion [18]. After securing the potted ends of each limb in the
custom fixtures of the mechanical test system, the medial collateral ligament was transected so
that only the LCL remained intact. A uniaxial ramp-to-failure test was performed at a rate of 0.05
mm/sec, and load was applied perpendicular to the radius/ulna (Figure 8.2B). After testing, the
maximum force from the ramp-to-failure test was analyzed using a custom written Matlab
program (Mathworks, Natick, MA, USA).
LCL tissue volume. After sacrifice at each time point, animals (n = 3/group) were stored
immediately in a −20°C freezer. Forelimbs were prepared similarly as those for LCL mechanical
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testing. After the medial and lateral collateral ligaments were isolated, the joints were fixed at
90° flexion with 10% neutral buffered formalin for 72 hours and then stained with 3%
phosphomolybdic acid in 70% ethanol for 72 hours to enhance soft tissue contrast. A micro-CT
scanner (µCT40; ScanCo, Medical, Zurich, CH) was used to scan the forelimbs in 2% agarose
inside a 30-mm-diameter tube with the following parameters: 15 µm3 isometric voxel size, 70
kVp x-ray tube potential, 300 ms integration time, and 114 µA x-ray intensity. Dragonfly
software (Object Research Systems, Montreal, Quebec) was used to draw regions-of-interest
throughout the z-stack of images for each limb to calculate LCL total volume. Due to the
complex geometry and the difficulty identifying a consistent landmark to standardize the
measurement of the ligament cross-sectional area, the total volume of the LCL was used as a
more conservative measurement to normalize the maximum force. Hence, LCL maximum force
and normalized maximum force (instead of stress) are reported herein.
Biochemistry. After sacrifice at each time point, capsule (n = 6/group) and LCL (n =
6/group) tissues were immediately isolated, flash frozen in liquid nitrogen, and stored in a −80°C
freezer. When ready for analysis, tissues were thawed for five minutes, weighed, and lyophilized
for 24 hours. The tissues were then digested in papain solution (1.25 U/mL papain, 0.084 M
sodium phosphate, 0.05 M cysteine-HCl, 1% v/v 0.5 M EDTA, 99% v/v H2O; pH 6.5) at 65°C
for 18 hours. Aliquots of the tissue-papain digest were taken for separate analyses to evaluate
collagen and sulfated glycosaminoglycan content via colorimetric assays [23-25].
To evaluate collagen content, aliquots of the tissue-papain digest were first diluted with
excess papain and hydrolyzed with 4N NaOH in an autoclave at 122°C and 15 psi for 20
minutes. After the samples returned to room temperature, 4N HCl was added to neutralize the
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solution pH. Chloramine-T solution (0.062 M chloramine-T, 20.7% v/v H2O, 26% v/v
isopropanol, 53.3% v/v stock buffer (0.28 M citric acid, 0.85 M sodium acetate, 0.85 M sodium
hydroxide, 1.2% v/v acetic acid, 98.8% v/v H2O)) was added to the samples and incubated at
room temperature for 20 minutes. Lastly, Ehrlich’s solution (1.17 M Ehrlich’s, 70% v/v
isopropanol, 30% v/v perchloric acid) was added to the samples and incubated at 65°C for 20
minutes. All samples were evaluated in triplicate on a 96-well plate and read immediately on a
spectrophotometer (2300 Multimode Reader, Perkin Elmer, Waltham, MA, USA) at an
absorbance wavelength of 550 nm. Hydroxyproline concentration was calculated based on a
linear standard solution of trans-4-hydroxy-L-proline and converted to collagen content by
multiplying by 7.46, which reflects the average hydroxyproline composition of collagen in
mammalian tissue [26].
Aliquots of the tissue-papain digests were plated in triplicate on a 96-well plate and 1,9dimethlylemethylene blue dye (0.029 M sodium formate, 0.050 mM 1,9-dimethylemethylene
blue, 0.5% v/v ethanol, 70% v/v H2O, 29.5% v/v formic acid; pH 3) was added to each sample
and read immediately on a spectrophotometer at an absorbance wavelength of 525 nm. The
sample sulfated glycosaminoglycan concentration was calculated based on a linear standard
solution of chondroitin sulfate.
Collagen crosslinks. After sacrifice at each time point, capsule (n = 5/group) and LCL (n
= 5/group) tissues were immediately isolated, placed into 400 µL phosphate buffered saline, and
stored in a −20°C freezer. When samples were ready for analysis, they were first reduced by
sodium borohydride (25 mg/mL NaBH4 in 0.05 M NaH2PO4, 0.15 M NaCL; pH 7.4) for one hour
on ice followed by 1.5 hours at room temperature to stabilize acid-labile collagen crosslinks.

129

Samples were then hydrolyzed in 6 N HCl at 110°C for 24 hours. The hydrolyzates were
precleared by solid phase extraction to remove the bulk of non-crosslinked amino acids (Aspec
Gilson, Middleton, WI, USA). Dried eluates were re-dissolved in sodium citrate loading buffer
(pH 2.2) and analyzed on an amino acid analyzer (Biochrom 30, Biochrom, Cambridge, United
Kingdom) using a three-buffer gradient system and post column ninhydrin derivatization. The
column was eluted at a flow rate of 15 mL/hour at 80°C for (1) five minutes with sodium citrate
buffer (pH 4.25), (2) 40 minutes with sodium citrate buffer (pH 5.35), and (3) 20 minutes with
sodium citrate/borate buffer (pH 8.6). Retention times of individual crosslinks were established
with authentic crosslink compounds. Quantitation was based on ninhydrin generated leucine
equivalence factors (DHLNL (dihydroxylysinonorleucine) and HLNL (hydroxylysinonorleucine)
= 1.8; HP (hydroxylysyl pyridinoline) and LP (lysyl pyridinoline) = 1.7) [27]. The number of
crosslinks was normalized to the collagen content which was analyzed from an aliquot of
hydrolyzed samples to solid phase preclearance.
Statistical analysis. A two-way ANOVA for time and injury was used to compare all
experimental results. When significance was found, post-hoc Bonferroni analyses were used to
compare each injured group (42 IM, 42/42 IM-FM) to its respective control (42 FM, 84 FM).
Statistical analysis was performed in Prism (GraphPad Prism Software, La Jolla, California,
USA) with significance defined as p < 0.05.

8.3 Results
All animals were included in each analysis (LCL Mechanical Testing: 32/32; LCL Tissue
Volume: 12/12; Biochemistry: 24/24; and Collagen Crosslinks: 20/20), no adverse events
occurred in any experimental group, and p-values for all results are reported in the plots.
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In the three-dimensional tissue
volume images, control limb LCLs at 42 and
84 FM exhibited a similar volume and
triangular-like geometry (Figure 8.3A).
Injured limb LCLs at 42 IM and 42/42 IMFM were qualitatively larger structures
compared to their respective controls. Based
on the asymmetric shape of the injured limb
LCLs, there appeared to be an irregular
deposition of fibrotic tissue or scar with
hypertrophy primarily through the
Figure 8.3 (A) Contrast enhanced micro-computed
tomography three-dimensional images representative of
injured and control limbs at each time point with the
lateral collateral ligament (LCL) pseudo-colored aqua
(scale bar = 1 mm). Evaluation was completed at 42 days
of immobilization (42 IM) or after 42 days of
immobilization with 42 days of free mobilization (42/42
IM-FM). (B) LCL tissue volume increased with injury.
Data are shown as mean ± standard deviation. ** p < 0.01.

midsubstance and around the lateral
epicondyle. LCL volume increased
significantly with injury; however, only
injured limb LCLs at 42/42 IM-FM were
significantly increased compared to controls

at 84 FM (Figure 8.3B). Thus, fibrotic scar tissue was not only deposited during immobilization
but also throughout the subsequent period of free mobilization.
The LCL maximum force significantly increased with time (Figure 8.4A). However, the
magnitude of change was relatively small and likely caused by overall rat growth due to aging.
The rats in this study were classified as young adults (~300 g) and gained weight throughout the
study duration as described previously [12, 13, 28]. However, this change in rat size was similar
for each group and hence there were no significant differences in maximum force between
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Figure 8.4 Lateral collateral ligament (A) maximum force increased with time and (B) normalized maximum force
(maximum force/tissue volume) decreased with injury. Evaluation was completed at 42 days of immobilization (42
IM) or after 42 days of immobilization with 42 days of free mobilization (42/42 IM-FM). Data are shown as mean ±
standard deviation. **** p < 0.0001.

Figure 8.5 Capsule: (A) Collagen content increased with injury, however, (B) collagen density (collagen
content/tissue wet weight), (C) sulfated glycosaminoglycan content, and (D) sulfated glycosaminoglycan density
(sulfated glycosaminoglycan content/tissue wet weight) did not exhibit significant differences. Evaluation was
completed at 42 days of immobilization (42 IM) or after 42 days of immobilization with 42 days of free mobilization
(42/42 IM-FM). Data are shown as mean ± standard deviation.

injured or control limb LCLs at either time point (Figure 8.4A). Volume was used, instead of
cross-sectional area, to normalize the maximum force as a more conservative measure of LCL
geometry. The normalized maximum force significantly decreased with injury, and post-hoc
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Figure 8.6 Lateral collateral ligament: (A) Collagen content increased with injury, but (B) collagen density (collagen
content/tissue wet weight) did not exhibit any significant differences. (C) Sulfated glycosaminoglycan content and
(D) density (sulfated glycosaminoglycan content/tissue wet weight) increased with injury and time, but also had a
significant interaction between these two factors. Evaluation was completed at 42 days of immobilization (42 IM) or
after 42 days of immobilization with 42 days of free mobilization (42/42 IM-FM). Data are shown as mean ±
standard deviation. *** p < 0.001. **** p < 0.0001.

analyses showed that values for injured limb LCLs were significantly decreased at 42 IM and
42/42 IM-FM compared to the respective control LCLs (Figure 8.4B).
Extracellular matrix protein expression was dependent on the type of tissue, but both
tissues exhibited hypertrophy. The total amount of collagen in the capsule significantly increased
with injury (Figure 8.5A); which was consistent with previous joint histology showing increased
capsule thickness in injured limbs at 42 IM and 42/42 IM-FM compared to their respective
controls [12, 13]. However, when collagen content was normalized by wet weight, collagen
density in the capsule did not exhibit any significant differences (Figure 8.5B). Sulfated
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Figure 8.7 Capsule: Immature collagen crosslinks, (A) DHLNL and (B) HLNL, decreased with time and only
DHLNL increased with injury. Mature collage crosslinks, (C) HP and (D) LP, increased with time and only LP
decreased with injury. Evaluation was completed at 42 days of immobilization (42 IM) or after 42 days of
immobilization with 42 days of free mobilization (42/42 IM-FM). Data are shown as mean ± standard deviation. * p
< 0.05. **** p < 0.0001.

glycosaminoglycan content and density also did not express any significant changes in the
capsule (Figures 8.5C-D).
LCL collagen content increased significantly with injury, with significantly increased
values for injured limbs at 42 IM and 42/42 IM-FM compared to control values at 42 and 84 FM,
respectively (Figure 8.6A). Similar to the capsule, collagen density in the LCL also did not
exhibit any significant differences at either time point (Figure 8.6B). While the interaction of
these factors was significant, both sulfated glycosaminoglycan content and density significantly
increased in the LCL with time and injury (Figures 8.6C-D). Sulfated glycosaminoglycan content
and density in injured limb LCLs were also significantly increased at 42 IM and 42/42 IM-FM
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Figure 8.8 Lateral collateral ligament: Immature collagen crosslinks, (A) DHLNL and (B) HLNL, decreased with
time and increased with injury. Only DHLNL exhibited a significant interaction between these two factors. Mature
collagen crosslinks, (C) HP and (D) LP, decreased with injury and only HP increased with time. Evaluation was
completed at 42 days of immobilization (42 IM) or after 42 days of immobilization with 42 days of free
mobilization (42/42 IM-FM). Data are shown as mean ± standard deviation. * p < 0.05. ** p < 0.01. *** p < 0.001.
**** p < 0.0001.

compared to control. The increased collagen and sulfated glycosaminoglycan content in injured
limb LCLs compared to control was consistent with the increased LCL tissue volume described
earlier (Figure 8.3B).
The expression of collagen crosslinks was also dependent on the tissue type but exhibited
similar trends. Overall, capsule DHLNL and HLNL (immature collagen crosslinks) significantly
decreased with time, while HP and LP (mature collagen crosslinks) significantly increased with
time (Figure 8.7). Only DHLNL significantly increased with injury and exhibited significant
increases in injured limb capsules at 42 IM and 42/42 IM-FM compared to controls (Figure
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Figure 8.9 Immature to mature collagen crosslink ratio ((DHLNL+HLNL)/(HP+LP)) decreased with time in the (A)
capsule and (B) lateral collateral ligament (LCL). Only the LCL increased with injury and had a significant
interaction between the two factors, injury and time. Evaluation was completed at 42 days of immobilization (42
IM) or after 42 days of immobilization with 42 days of free mobilization (42/42 IM-FM). Data are shown as mean ±
standard deviation. ** p < 0.01. **** p < 0.0001.

8.7A). Capsule LP significantly decreased with injury but did not exhibit any significant posthoc comparisons (Figure 8.7D).
In the LCL, DHLNL and HLNL significantly decreased with time and increased with
injury, but only DHLNL expressed a significant interaction between these two factors (Figures
8.8A-B). Both immature crosslinks were also significantly increased in injured limb LCLs at 42
IM and 42/42 IM-FM compared to respective controls. While only HP significantly increased
with time in the LCL, both HP and LP significantly decreased with injury (Figures 8.8C-D).
Only LP in injured limb LCLs was significantly decreased at both time points compared to its
respective controls (Figure 8.8D).
The ratio of immature to mature collagen crosslinks decreased significantly with time in
both the capsule and LCL (Figure 8.9). Only the LCL collagen crosslink ratio significantly
increased with injury, but also exhibited a significant interaction between these two factors, and
was significantly increased in injured limbs at 42 IM and 42/42 IM-FM compared to its
respective controls (Figure 8.9B).
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8.4 Discussion
Our previous work showed that the capsule and ligaments/cartilage were the primary
periarticular soft tissues that caused the persistent motion loss in our animal model of elbow
PTJC [15], so the objective of this study was to evaluate the anterior capsule and LCL to
determine tissue specific mechanical and biological changes that led to their contribution to
elbow contracture. Understanding these changes will ultimately help inform the development of
tissue targeted treatment strategies. We hypothesized that a significant increase in tissue volume,
as a result of increased extracellular matrix protein deposition and crosslinking, would drive
capsule and LCL contribution to elbow contracture in our rat model.
The total amount of extracellular matrix proteins was altered in both tissues, but the LCL
exhibited more significant changes compared to the capsule. The capsule and LCL each
exhibited a significant increase in collagen content with injury (Figures 8.5A and 8.6A).
However, sulfated glycosaminoglycan content was only significantly increased in injured limb
LCLs compared to control at both time points (Figure 8.6C). The increased collagen content in
the capsule is supported by previous evidence of capsular thickening observed histologically in
the same model of elbow contracture [12, 13]. Significantly increased collagen and sulfated
glycosaminoglycan content in injured limb LCLs was also consistent with increased 3D tissue
volume (Figure 8.3). Overall, increased quantities of extracellular matrix proteins were indicative
of capsule and LCL hypertrophy, likely initiated by a fibrotic wound healing response following
injury. Since the articulating surfaces of the elbow are highly congruent, increased tissue
volumes in injured limbs likely acted as physical barriers that limited joint motion.
While collagen content increased, there was not a corresponding increase in collagen
density for either injured capsules or LCLs compared to control at either time point (Figures
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8.5B and 8.6B). Animal models of knee contracture showed a similar result and biopsies from
patients with pulmonary fibrosis also showed no correlation between collagen density and the
degree of fibrosis or tissue stiffness [19-21, 29, 30]. The capsule also showed no changes in
sulfated glycosaminoglycan density, while injured LCLs exhibited a significant but small (~2%)
increase in sulfated glycosaminoglycan density at both time points (Figures 8.5D and 8.6D).
While these results conflict with a rabbit immobilization-only knee contracture model, which
reported a decrease in glycosaminoglycan density in immobilized limb capsules compared to
control, the tissues in this previous knee model did not experience any injury; thus, extracellular
matrix protein deposition may differ due to the lack of a wound healing response [21]. The
absence of large changes in extracellular matrix protein density in either capsules or LCLs
suggests that their contribution to elbow PTJC may be due to the overall increased tissue volume
and/or changes to tissue microstructural organization.
Clinically, trauma has been reported to cause abnormal collagen deposition and
organization which can impair function and ultimately cause increased adhesions and scar
formation [29]. In this study, injured limb LCLs exhibited significantly decreased force
compared to control at both time points when the maximum force was normalized to tissue
volume (Figure 8.4B). Thus, the increased LCL tissue volume was weaker compared to control,
perhaps because the hypertrophic tissue was disorganized. In animal models of knee contracture,
histological evaluation of the capsule from contracted limbs showed that collagen fibers
exhibited disordered alignment compared to control [19, 31]. The decreased normalized
maximum force in injured LCLs could also be partially due to the loading axis evaluated during
mechanical testing. The experimental test setup was designed so that the LCL would be
primarily loaded along its long axis as it deformed during testing; however, due to the complex
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geometry and orientation of the LCL, it is possible that the LCL experienced some off-axis
loading during the mechanical test. Also, given the large increase in total volume and, hence, the
larger joint area covered by the injured LCLs, it is possible that LCL mechanics could decrease
in one direction (i.e., on-axis loading), while simultaneously increase or become stiffer in other
directions (i.e., off-axis loading) due to the more random deposition of disorganized extracellular
matrix proteins.
Crosslinks organize adjacent collagen molecules so collagen fibers can withstand stress
[29]. Immature divalent crosslinks, DHLNL and HLNL, form rapidly as collagen is deposited
but decrease as connective tissues mature or age [30, 32]. Mature trivalent crosslinks, HP and
LP, are synthesized slowly (~4-6 weeks) and develop over time from immature crosslinks
DHLNL or HLNL [30, 33, 34]. In the current study, the expression of immature and mature
collagen crosslinks was similar in both the capsule and LCL, but the LCL exhibited more
significant changes between injured and control tissues. DHLNL was significantly increased in
injured limb capsules and LCLs compared to control at both time points, but HLNL was only
increased in injured limb LCLs (Figures 8.7A-B and 8.8A-B). Increased immature crosslinks in
injured limb capsules and LCLs is representative of new collagen synthesis which is consistent
with the increased tissue volume and collagen content in both tissues (Figures 8.3 and 8.5A-B)
[32]. Similarly, in a rabbit model of immobilization-only knee contracture (i.e., no injury), tissue
collected in proximity of the joint line also expressed significantly increased DHLNL and HLNL
crosslinks in immobilized limbs compared to control [22]. In the current study, both mature
crosslinks significantly decreased with injury in the LCL, but only LP was decreased in the
capsule (Figures 8.7C-D and 8.8C-D). The lower expression of HP and LP in injured limb
capsules and LCLs indicates that these tissues are less mature compared to control. Thus, the
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rapid deposition of new collagen following injury causes a build-up of immature LCL tissue,
which contributes to the lower normalized maximum force exhibited by injured limbs (Figure
8.4B).
The immature to mature collagen crosslink ratio was increased in injured limb LCLs at
both time points compared to control limbs, even though the mechanics were decreased (Figures
8.4B and 8.9B). Similarly, a study in murine cervical tissue during pregnancy also expressed an
increased immature to mature crosslink ratio as well as decreased ultimate stress [35]. The ratio
of immature to mature collagen crosslinks decreased with time in both the capsule and LCL
because of significant decreases and increases with time in immature and mature crosslinks,
respectively (Figure 8.9). In animal models of pulmonary fibrosis, DHLNL increased as early as
one week after fibrotic insult, while HP increased over 6-10 weeks following insult [33, 36].
Thus, the decreased crosslink ratio after free mobilization potentially relates to the conversion of
immature to mature crosslinks, suggesting maturation of the fibrotic scar tissue in the injured
limb capsules and LCLs during the period of joint reloading.
This study is not without limitations. First, the LCL maximum forces were likely
underestimated because the tissue in our test set up was not physiologically loaded and was
instead loaded uni-axially with the force applied perpendicular to radius/ulna. However, the LCL
mechanical testing set up was optimized to evaluate the LCL at 90° because the LCL was
reported to experience the highest loads when oriented between 80-100° flexion during 3D
kinematic testing of human cadaver elbows [18]. Second, the capsule was not mechanically
evaluated because its small size and irregular geometry made it difficult to isolate for tissue level
mechanical testing. Therefore, we previously used the indirect method of sequential dissections
to quantify its overall contribution to joint mechanics [15]. Lastly, the biochemical analysis
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utilized in this study only evaluated bulk collagen changes and did not identify specific types of
collagen.
Restoring joint motion in post-traumatic elbow contracture is a complex challenge
because little is understood about the biological changes in the periarticular soft tissues that drive
joint pathology and cause functional deficits. Previous work in our rat model of elbow
contracture identified the capsule and LCL as two of the primary tissues contributing to elbow
contracture [15]. The objective of this work was to determine mechanical and biological changes
within these tissues that caused their contribution to the motion lost. Overall, capsule and LCL
contribution to elbow contracture in our rat model resulted from increased tissue volume and
immature collagen crosslinks. More significant changes often occurred within the LCL compared
to the capsule, identifying the LCL as a potential candidate to target with a tissue specific
treatment strategy.
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Chapter 9: Soft primed adipose stem cells
exhibit mechanical memory and decrease
fibrosis and contracture in a rat elbow injury
model
9.1 Introduction
Fibrosis is the excessive accumulation of extracellular matrix (ECM) proteins which
causes soft tissue pathology and disfunction [1]. The negative functional consequences of these
ECM changes are readily apparent in advanced organ diseases such as idiopathic pulmonary
fibrosis, cirrhosis of the liver and chronic kidney disease, where regulatory mechanisms and
therapeutics have been most extensively studied, but fibrosis also has dramatic effects on
musculoskeletal tissues. Notably, fibrosis is believed to contribute to post-traumatic joint
contracture which affects approximately 50% of patients after injury and permanently limits joint
function [2-5]. Across conditions, fibrosis is thought to derive from a dysregulated wound
healing response. In response to injury, fibroblasts proliferate, and deposit and contract ECM to
mechanically stabilize the damaged tissue [6]. However, aberrant biochemical and mechanical
signaling at the wound site can prevent termination of this cellular response leading to the
overproduction of ECM and pathological stiffening of the tissue [6-9]. Because of the delicate
balance between the physiological and pathological response to injury, treating or preventing
fibrosis is challenging. Numerous pharmacological strategies have attempted to inhibit fibrotic
signaling (e.g., transforming growth factor β1 (TGFβ1)), prevent collagen synthesis (e.g.,
procollagen 1), or increase ECM break down (e.g., matrix metalloproteinases (MMPs)) [10-13].
While these treatments have been shown to slow the progression of fibrosis, they lack the ability
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to prevent organ disfunction and ultimately failure [12]. Similarly, pharmacological strategies to
minimize fibrosis in orthopaedic tissues have exhibited decreased fibroblast proliferation and
collagen deposition, but many of these changes have often not led to a corresponding
improvement in function [14-17]. Safety concerns also arise because these drugs have pleiotropic
effects and so their use could also alter angiogenesis, immunomodulation and cell proliferation in
non-fibrotic tissues [11, 13]. Therefore, these current treatments are likely insufficient because
they are incompletely effective.
Stem cells are a promising alternative to pharmacologic strategies to prevent fibrosis
because these cells have both the potential to modify the ECM microenvironment and promote
regeneration through cell-cell signaling [14, 18]. Unlike pharmacological strategies, stem cells
have the capacity to not only send but also receive signals from resident cell populations which
can harness adaptive cell-cell communication to further enhance wound healing [19]. These
bioactive signals secreted by stem cells are believed to be paracrine factors which contribute to
immunomodulation and regeneration [14, 20-22]. Numerous studies have attempted to treat
fibrosis in several different organs with stem cells but results ranged from limited benefits to
augmented pathology [23-25]. Similarly, in orthopaedic applications, while many animal studies
injecting either bone-marrow derived mesenchymal stem cells (BD-MSCs) or adipose-derived
stem cells (ASCs) showed histological improvements, few studies reported a corresponding
change in function which was often a transient improvement in tissue mechanics or gait [26-28].
In clinical trials to treat osteoarthritis, BD-MSC and ASC injections increased knee cartilage
thickness, but their effect on fibrotic changes and joint range-of-motion (ROM) was not
evaluated [29-31]. Kim et al. quantified shoulder joint ROM following ASC treatment after
rotator cuff repair but showed that there was no improvement over repair alone [32]. The
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variability in outcomes across stem cell-based therapies highlights a need to direct the response
of these cells in a wound environment.
Mechanical memory is the concept that cells can be mechanically pre-conditioned in
culture to delay their response to a subsequent environment. Balestrini and colleagues first
provided evidence of mechanical memory by priming rodent lung fibroblasts on either soft (~5
kPa; i.e., healthy tissue) or stiff (~100 kPa; i.e., fibrotic tissue) substrates for two weeks, then
transferred these cells to stiff or soft substrates, respectively, for an additional two weeks [33].
Soft primed cells exhibited decreased α-smooth muscle actin (αSMA) expression, a pro-fibrotic
marker, compared to cells only cultured on ~100 kPa or tissue culture plastic (TCP, ~3 GPa).
Conversely, stiff primed cells expressed increased αSMA compared to cells only cultured on ~5
kPa. Hence, cells can be directed solely by mechanical cues against or toward a pro-fibrotic
phenotype. More recently, BD-MSCs have similarly been shown to exhibit mechanical memory
[34, 35]. For therapeutic applications such as those discussed previously, isolated stem cells were
typically expanded on TCP prior to cell injection. Given our current understanding of mechanical
memory, we postulate that TCP expansion could direct cells toward pro-fibrotic behavior
causing them to contribute to, rather than mitigate, fibrosis.
Conversely, expansion of stem cells on soft substrates may ameliorate the fibrotic
response in vivo. Treatment with soft primed BD-MSCs improved healing in a rodent dermal
wound shown by decreased αSMA expression and collagen density compared to untreated
animals [34]. In another study, conditioned media from soft primed BD-MSCs was also able to
enhance dermal wound closure and re-epithelialization demonstrating that the soft primed cell
secretome alone could improve healing [36]. However, it is unclear whether soft primed BDMSCs can alter tissue mechanics or prevent fibrosis in a more complex biological environment
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(e.g., to increase ROM following musculoskeletal injury). In general, pre-conditioning stem cells
on soft substrates appears to not only protect against a pro-fibrotic phenotype in vitro but also
potentially in vivo, which would increase the regenerative potential of stem cell therapies in
clinical settings.
The objective of this study was to first determine if ASCs exhibit mechanical memory
and second to investigate if soft primed ASCs would beneficially remodel a complex orthopaedic
wound environment ultimately improving function after injury. First, we provide evidence that
ASCs, a more readily available source of autologous stem cells than BD-MSCs, exhibit
mechanical memory in vitro. Second, we demonstrate that soft primed ASCs mitigate the fibrotic
response in our rat model of post-traumatic elbow contracture, improving biomechanical as well
as histological outcomes. This evidence supports our hypothesis that soft priming delays ASC

Figure 9.1 Illustrative representation of study hypothesis. Pre-conditioning adipose-derived stem cells (ASCs) on a
soft substrate will delay cell transition to a pro-fibrotic phenotype when cultured on a stiff substrate (i.e., pathologic
environment), expanding ASC regenerative potential. Injecting soft primed ASCs into the anterior capsule will
decrease fibrotic scarring and increase ROM after injury in our rat elbow contracture model.
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transition to a pro-fibrotic phenotype, expanding their regenerative potential and improving
healing in complex tissue environments (Figure 9.1).

9.2 Methods and materials
Cell isolation. Subcutaneous adipose tissue was dissected from male Long-Evans rats
(250-350 g, 8-10 weeks old; Charles River Laboratories International, Wilmington, MA, USA)
under sterile conditions immediately following sacrifice by CO2 inhalation overdose. The
dissected adipose tissue was minced and put into 37°C pre-warmed digestive solution (0.1%
collagenase and 1% penicillin/streptomycin in low-glucose Dulbecco’s Modified Eagle’s
Medium (DMEM)) for one hour with gentle inversion every 10 minutes. The remaining solid
tissue was mechanically broken-down using forceps and the shredded tissue solution was then
incubated for 30 minutes at 37°C and 5% CO2. Following the incubation, the shredded tissue was
further dissociated by gentle pipetting. The cell suspension was then passed through a 70 µm
sterile filter and centrifuged at 1300 rpm for 10 minutes at 4°C. The cell pellet was resuspended
in standard growth media (10% fetal bovine serum (FBS) and 1% penicillin/streptomycin in lowglucose DMEM) and expanded in culture to passage four [37]. Cells were banked in cryostorage
prior to experimentation. In this study, flow cytometry was not used to identify a pure cell
population because ASCs were previously shown to be homogeneous in later passages [37].
Human subcutaneous ASCs were acquired as part of a study approved by the Human
Research Protection Office at the Washington University School of Medicine. Briefly, a ~100
mg biopsy of the subcutaneous adipose tissue in the calf was acquired during below-the-knee
amputation surgery. The biopsy was processed as described above for rat subcutaneous adipose
tissue, except that human ASCs were used at passage two. All cell culture experiments were
conducted in standard growth media at 37°C and 5% CO2 [37].
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Polyacrylamide gels. The preparation of polyacrylamide hydrogels was adapted from a
previously described protocol [38]. Briefly, polyacrylamide stock solutions were made to
achieve gels with elastic moduli of ~1 kPa (3% acrylamide and 0.1% bis-acrylamide in deionized
H2O) and ~120 kPa (15% acrylamide, 1.2% bis-acrylamide in deionized H2O). Stock solutions
were combined with a crosslinker and catalyst (10% ammonium persulfate and 0.11%
tetramethylethylenediamine (TEMED)) in polyacrylamide stock), and sandwiched between a 25
mm glass coverslip and a glass microscope slide. Prior to use, coverslips were functionalized in
a methacrylate solution (0.5% 3-(trimethyloxysilyl)propyl methacrylate and 0.3% acetic acid in
ethanol) to enable covalent attachment of the hydrogel, while microscope slides were treated
with dichlorodimethylsiloxane (DCDMS) to repel the hydrogel surface. After one hour,
polymerization was complete, and the gels were moved into a six-well culture plate. Gels were
rinsed with sterile phosphate buffered saline (1X PBS) to remove any residual unpolymerized
acrylamide. To allow for protein coating and cell adhesion, gels were then incubated twice with
sulfo-SANPAH (0.2 mg/mL in 50 mM HEPES, pH 8.5), activated with 365 nm ultraviolet light,
and then rinsed thoroughly with sterile 1X PBS. Gels were incubated with 10 µg/mL fibronectin
overnight at 37°C and 5% CO2.
ASCs were seeded on the polyacrylamide gels at low density to isolate the substrate
mechanical stimulus from cell-cell interactions. The number of cells seeded was optimized so
that the cell density at the end of the study was the same on each stiffness. Approximately 10001500 and 75-150 cells/well were seeded onto 1 and 120 kPa gels, respectively. Cells cultured on
either 1 or 120 kPa gels for two weeks were used to demonstrate that ASCs were
mechanosensitive and are referred to as Soft and Stiff, respectively (Figure 9.2, Table 9.1).
Mechanical memory was shown in ASCs by priming cells on 1 kPa for two weeks, then
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Figure 9.2 Schematic of the experimental method timeline. At the designated time points, immunohistochemistry (n
= 5/group, 10 cells per replicate), extracellular matrix labeling (n = 5/group, 10 cells per replicate), and adipokine
array or ELISA (n = 6) was performed. Adipose-derived stem cells (ASCs) were isolated from rat or human
subcutaneous adipose tissue expanded for four or two passages, respectively, and frozen down for storage. ASCs
were cultured on either 1 or 120 kPa polyacrylamide gels functionalized with 10 µg/mL fibronectin. (- - =
enzymatically transferred to new gel using 0.25% trypsin-EDTA, pointed square = immunohistochemistry, rectangle
= extracellular matrix labeling, arrowhead = adipokine array/ELISA).
Table 9.1 Group naming convention for in vitro studies.

Name

Transferred

Culture Period (weeks)
1 kPa

120 kPa

Soft

No

2

0

Stiff

No

0

2

Soft-to-Stiff (1)

Yes

2

1

Stiff-to-Stiff (1)

Yes

0

3

Soft-to-Stiff (2)

Yes

2

2

Stiff-to-Stiff (2)

Yes

0

4

enzymatically transferring the cells with 0.25% Trypsin-EDTA to new 120 kPa gels for either
one or two weeks (Soft-to-Stiff (1) or Soft-to-Stiff (2), respectively; Figure 9.2, Table 9.1). As a
control, ASCs were cultured on 120 kPa for two weeks, then enzymatically transferred using
0.25% Trypsin-EDTA to new 120 kPa gels for either one or two weeks (Stiff-to-Stiff (1) or Stiffto-Stiff (2), respectively; Figure 9.2, Table 9.1). Three-dimensional printed cylinders were used
to harvest cells only from the middle of the gels to avoid uneven edge effects.
The same protocol was used to make 1 kPa polyacrylamide gels to culture cells for in
vivo injection, but utilized 3” x 3.5” rectangular coverslips and 3.25” x 4” microscope slides (Ted
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Pella, Redding, CA, USA) to scale up cell numbers. The number of cells seeded on these large
gels was similarly optimized to limit cell-cell interaction through the culture period, so
mechanical stimulus was driven by the culture surface. Hence, approximately 12,500 cells/gel
were seeded. ASCs were cultured for two weeks on these large gels before they were harvested
with 0.25% Trypsin-EDTA for injection.
Immunohistochemistry. ASCs were fixed with 4% paraformaldehyde for 15 minutes
and then permeabilized with 1% triton-X for 15 minutes. For each six-well plate, five gels were
labeled with primary antibodies for either yes associated protein (YAP; 1:50; SC-101199, Santa
Cruz, Dallas, TX, USA) or αSMA (1:200; AB5694, Abcam, Cambridge, UK), while one gel
served as the isotype control labeled with IgG2aκ (1:50; 401501, Biolegend, San Diego, CA,
USA) or IgG (1:200; Poly29108, Biolegend), respectively. The antibodies and isotype controls
were diluted in 1.5% buffer serum (1.5% goat serum and 1% bovine serum albumin (BSA) in 1X
PBS) and incubated on the gels for 18 hours at room temperature. Alexa Fluor 568 goat antimouse (YAP) or Alexa Fluor 488 goat anti-rabbit (αSMA) (1:400; A1104 or A1108,
respectively, Life Technologies, Carlsbad, CA, USA) were diluted in 1.5% buffer serum and
incubated on the gels for one hour at room temperature. Gels labeled for YAP were also colabelled for F-actin (Conjugated Alexa Fluor 488 Phalloidin; 1:200; A12379, ThermoFisher,
Waltham, MA, USA) following the same protocol as the secondary antibodies. Cell nuclei were
labeled with DAPI (1:1000).
Five replicates, 10 cells per replicate, were imaged per group via confocal microscope
(DM6B Leica, Wetzlar, Germany; Figure 9.2, Table 9.1). Cells were selected for imaging on the
DAPI channel to eliminate experimental bias from viewing YAP or αSMA intensity or cell
morphology. Quantification of cell morphology was performed on images with a custom macro
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in ImageJ (National Institutes of Health, Bethesda, MD, USA). YAP and F-actin labeled cells
were used to evaluate cell area, actin coherency (i.e., alignment), and YAP nuclear/cytoplasmic
ratio. αSMA labeled cells were used to quantify the number of αSMA positive cells, which is a
pro-fibrotic (myofibroblast) marker [8, 33, 39]. Imaging, processing, and analysis settings were
standardized across all images.
Extracellular matrix labeling. Nascent ECM proteins were labeled following methods
previously described [40, 41]. For each six-well plate, five gels were pulse labeled the last two
days of the culture period with L-Azidohomoalanine (AHA; Click Chemistry Tools, Scottsdale,
AZ, USA) supplemented growth media (10% FBS, 0.9% sodium pyruvate, 0.1% ascorbic acid,
1% glutamax, 1% penicillin/streptomysin, 0.1% cystine, 0.2% AHA in DMEM without Lmethionine (21013024, ThermoFisher)), while one gel served as the control and was given
standard growth media. At the end of the culture period, the plasma membrane was labeled with
Cell Mask (1:250; C10045, ThermoFisher) for 30 minutes at 37°C and 5% CO2. AHA was then
labeled with 30 µM DBCO-488 (Click Chemistry Tools) for 40 minutes at 37°C and 5% CO2.
The gels were fixed with 4% paraformaldehyde for 15 minutes at room temperature. Cell nuclei
were labeled with DAPI (1:1000).
Five replicates, 10 cells per replicate, were imaged per group via confocal microscope
(DM6B Leica; Figure 9.2, Table 9.1). A custom macro in ImageJ was used to quantify the
nascent ECM of each cell. The plasma membrane label was used to identify the cell boundary.
Twenty radial intensity profiles emanating from the center of the cell were symmetrically
mapped and then truncated to include only the region outside of the cell. These 20 intensity
profiles were averaged for each cell. Heatmaps were generated by expanding the cell boundary
region-of-interest (ROI, determined from the plasma membrane label) 14.5 µm (~20 pixels) and
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measuring the mean intensity in the area between two ROI which was then plotted based on a
color scale representative of ECM intensity. The ROI expansion was repeated eight times. Any
matrix from other nearby cells was manually excluded from all quantification. Imaging,
processing, and analysis settings were standardized across all images.
Adipokine Array. Growth media was collected after 72 hours of culture for detection of
adipokines by Proteome Profiler (ARY016, R&D Systems, Minneapolis, MN, USA). Briefly, the
array membrane was blocked, incubated with growth media and detection antibody cocktail, and
detected with IRDye 800CW Streptavidin (1:10,000; 926-32230, LI-COR, Lincoln, NE, USA).
Membranes were then imaged on an Odyssey Scanner (9120, LI-COR). The Image Studio Lite
Ver 5.2 (LI-COR) was used to quantify the antibody intensities. These were background
subtracted and normalized to the average membrane intensity. The data are presented as a ratio
of intensities between groups (e.g., Soft/Stiff and Soft-to-Stiff (1)/Stiff-to-Stiff (1)). There were
six replicates per group (Figure 9.2, Table 9.1).
ELISA. Growth media was conditioned for 24 hours of culture and collected for
detection of MCP-1 by Quantikine ELISA (DCP00, R&D Systems). Briefly, growth media and
standards were incubated on the plate at room temperature for two hours, followed by
incubations with conjugate for one hour and substrate solution for 30 minutes. Finally, stop
solution was added and plate fluorescence was read at 450 nm (Synergy II, BioTek, Winooski,
VT, USA). Cells were trypsinized with 0.25% Trypsin-EDTA and counted via hemocytometer
for signal normalization. There were six replicates per group (Figure 9.2, Table 9.1).
Animal model. In this Institutional Appropriate Care and Animal Use Committee
(IACUC) approved study, twelve male Long-Evans rats were randomized into two groups (n =
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Figure 9.3 Schematic of the experimental method timeline. At the analysis time point flexion-extension mechanical
testing (n = 6/group) and histology (n = 6/group) was performed after 21 days of immobilization. Adipose-derived
stem cells (ASCs) were isolated from rat subcutaneous adipose tissue then cultured either on (1) fibronectin-coated 1
kPa polyacrylamide gels for two weeks or (2) tissue culture plastic (TCP) for one week before injection. (lightning
bolt = surgery, syringe = injection, oval = analysis time point).
Table 9.2 Group naming convention for in vivo studies (n = 6/group).

Name

Surgery

21 Days of Immobilization

Injection

Cell Culture Surface

Control

No

No

No

n/a

INJ

Yes

Yes

No

n/a

INJ-TCP

Yes

Yes

Yes

TCP

INJ-GEL

Yes

Yes

Yes

1 kPa Gel

Controls were age-matched and allowed unrestricted, free cage activity for 21 days. (TCP = tissue culture
plastic).

6/group): (1) INJ-TCP (injury + immobilization + TCP-expanded ASC injection), and (2) INJGEL (injury + immobilization + soft primed ASC injection; Figure 9.3, Table 9.2). We used a
previously developed injury and immobilization protocol, which surgically induced a unilateral
injury (anterior capsulotomy with lateral collateral ligament transection) to mimic soft tissue
damage that occurs as a result of elbow dislocation [42, 43]. Immediately following surgery, the
injured limbs were immobilized in a flexed position with an external bandage for 21 days. This
period of immobilization was selected because it was previously shown to be the earliest time
point at which significant contracture developed [4]. Data from control (no injury + no
immobilization) and INJ (injury + immobilization) animals were reported in previous studies and
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included again here for statistical comparison between control, untreated and treated groups [4,
42, 43].
Cell injections. ASCs were either soft primed for two-weeks on 1 kPa polyacrylamide
gels or expanded on TCP for one-week to replicate standard culture conditions used in previous
stem cell injection studies [23-25, 27-32]. ASCs were injected three days after the surgically
induced injury to target fibroblasts which proliferate and infiltrate the wound site 3-5 days postinjury and transition to pro-fibrotic myofibroblasts after 8-9 days (Figure 9.3) [6]. Prior to
injection, rats were anesthetized using isoflurane at 2.5-4% with an oxygen carrier via nasal
inhalation using a nose cone. The external immobilization bandage and staples used for skin
closure at the original surgery, which induced the injury, were removed. Animals received a dose
of a local analgesic (0.5 mL 5 mg/mL bupivacaine, Hospira, Lake Forest, IL, USA)
subcutaneously under the original incision 20 minutes before the cell injection. After 20 minutes,
the incision was re-opened with the tissue spreading technique to provide visual access to the
joint for injection. The suture used to close the muscle fascial layer at the original surgery was
used as a guide to inject the cells into the same location within the anterior capsule. Two million
soft primed or TCP expanded ASCs were injected anteriorly in 50 µL sterile saline using a 25gauge needle (INJ-GEL or INJ-TCP, respectively; Table 9.2). Following injection, the skin was
closed with suture glue (3M Vetbond Tissue Adhesive, St. Paul, MN, USA) and the injured limb
was immediately immobilized with the external bandage using the same protocol developed
previously [42]. After 21 days of immobilization, animals were sacrificed with CO2 inhalation
overdose and stored in -20°C.
Flexion-extension joint mechanics. Animals were thawed 24 hours prior to dissection
and prepared for mechanical testing as described previously [42, 43]. Briefly, forelimbs were
155

skinned, disarticulated at the glenohumeral joint, and the paw was removed. The proximal
humerus and distal ulna/radius were secured in test fixtures. A custom mechanical test system
was used to evaluate elbow ROM in flexion-extension. The system design and post-test analysis
were published previously [42, 43]. A custom written Matlab code (MathWorks, Natick, MA,
USA) converted the force-displacement data to torque-angular position which was analyzed to
quantify joint motion. ROM measurements included total ROM, neutral zone (NZ) length, NZ
stiffness, maximum flexion, and maximum extension. NZ length is a clinically relevant measure
defined as the amount of motion possible before increased force is required to move the joint
further.
Joint histology. After mechanical testing all forelimbs were prepared for histological
evaluation. Briefly, the elbow joints were fixed for 72 hours in 10% neutral buffered formalin at
90° flexion and then decalcified for 17 days in 14% ethylenediamine tetraacetic acid (EDTA, pH
7.2). The forelimbs were dehydrated in a series of 30%, 50%, and 70% ethanol washes and then
embedded in paraffin. For each limb, three 5-µm-thick sagittal sections were cut per stain.
Hematoxylin and eosin (H&E) and toluidine blue were used to evaluate biological characteristics
of interest including tissue thickness, adhesions, fibrosis, cellularity, inflammation, vascularity,
myofibroblasts, and proteoglycans following the same method used previously [4, 42, 43].
Blinded sections were scored by a musculoskeletal pathologist to analyze the anterior capsule
using the following symbolic scoring method: adhesions were scored as present (+) or absent (-);
fibrosis was scored as < 30% (+), 31-60% (+ +), or > 60% (+ + +); cellularity was scored as
minimal (+), mild (+ +), moderate (+ + +), or marked (+ + + +); inflammation was scored as
none (-), mild (+), moderate (+ +), or marked (+ + +); vascularity was scored as < 6 (+), 6-10, or
> 10 blood vessels per high power field at 40x; myofibroblasts were scored as mild (+), moderate
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(+ +), or marked (+ + +); and matrix proteoglycans were scored as weak to mild (+), moderate (+
+), or strong (+ + +). Capsular thickness was measured on each section and reported semiquantitatively to account for variation throughout the tissue volume. Numerical thickness values
were averaged across each group, normalized by the thickness of the corresponding uninjured
contralateral limb capsule and converted to a symbolic score: 0-150 µm (-), 151-300 µm (+),
301-450 µm (+ +), 451-600 µm (+ + +), and > 600 µm (+ + + +).
Statistical analysis. Quantifications of immunohistochemistry and ECM labeling images
and ELISA data were analyzed with a two-way analysis of variance (ANOVA) for stiffness and
priming with post-hoc Bonferroni comparisons between groups at each time point. Adipokine
array data were analyzed with a two-way ANOVA for stiffness and priming with post-hoc
Bonferroni comparisons corrected with False Discovery Rate using the Benjamini-Hochberg
method. Flexion-extension joint mechanics data were analyzed using a one-way ANOVA with
post-hoc Bonferroni comparisons between each group. All statistical analysis was performed in
GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA) and statistical significance was
defined as p < 0.05.

9.3 Results
Mechanical memory was first assessed in primary rat ASCs by changes in morphology
and αSMA expression. Qualitatively, cells cultured on soft substrates appeared smaller with a
less developed and organized cytoskeleton compared to those on stiff in all groups (Figure 9.4A).
Quantitatively, Soft exhibited decreased actin coherency (i.e., alignment) and αSMA positive
cells compared to Stiff (p < 0.0001 and < 0.0001, respectively); while the decreased cell area was
trending towards significance (p = 0.053; Figure 9.4B-D). After two weeks of soft priming ASCs
transferred to a stiff substrate for one week (Soft-to-Stiff (1)) retained these differences with
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Figure 9.4 (A) Representative images of rat adipose-derived stem cells (ASCs) immunolabeled for (top row) nuclei
(blue) and F-actin (green), and (bottom row) nuclei (blue) and α-smooth muscle actin (αSMA, magenta). (scale bar =
50 µm for all groups, except Stiff-to-Stiff (2): scale bar = 75 µm). Quantitative measures computed from fluorescent
images: (B) cell area, (C) actin coherency (alignment), and (D) αSMA positive cells. Data are shown as mean ±
standard deviation. ** p < 0.01. **** p < 0.0001.

decreased cell area, actin coherency, and αSMA positive cells compared to Stiff-to-Stiff (1) (p =
0.004, < 0.0001, and < 0.0001, respectively; Figures 9.4B-D). However, following an additional
week of culture on a stiff substrate, no significant difference in actin coherency or αSMA
positive cells was detected between groups (Figure 9.4C-D). Only cell area for Soft-to-Stiff (2)
remained decreased compared to Stiff-to-Stiff (2) (p = 0.002; Figure 9.4B). Quantitation of YAP
localization showed that the nuclear to cytoplasmic ratio was decreased on Soft compared to Stiff
(p < 0.0001), but there was no difference in either soft primed group compared to their respective
stiff controls (Figure 9.5). Overall, soft primed ASCs exhibit mechanical memory, retaining
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Figure 9.5 (A) Representative images of rat adipose-derived stem
cells (ASCs) immunolabeled for (top row) nuclei (blue) and Factin (green), and (bottom row) yes associated protein (YAP,
white). (scale bar = 50 µm for all groups, except Stiff-to-Stiff (2):
scale bar = 75 µm). Quantitative measures computed from
fluorescent images: (B) YAP nuclear/cytoplasmic ratio. Data are
shown as mean ± standard deviation. **** p < 0.0001.

morphological features of a soft environment for at least one-week, postponing ASC transition to
a pro-fibrotic phenotype.
To determine whether morphologic features of ASC mechanical memory translated to
changes in cellular function, ECM secretion was quantified on different substrate stiffnesses and
following transfer. Qualitatively, ASCs on soft substrates generated less ECM which appeared
globular and only close to the cell membrane, while those on stiff produced a larger ECM
network throughout which individual fibers could be observed (Figure 9.6A, top row). These
images also showed that ECM secretion was not symmetric around ASCs in any culture
condition. Qualitatively, heatmaps of signal intensity surrounding each cell body demonstrated
that ASCs on stiff substrates had a higher density of surrounding ECM compared to those on soft
(Figure 9.6A, bottom row). Quantitation of the intensity profile for Soft illustrated that ECM
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Figure 9.6 (A) Representative images of rat adipose-derived stem cells (ASCs) immunolabeled for (top row) nuclei
(blue outline), cell membrane (magenta outline) and extracellular matrix (white), and (bottom row) heatmap of
extracellular matrix intensity expression. (scale bar = 100 µm for all groups). Quantitative measures computed from
fluorescent images for the extracellular matrix intensity profile for (B) Soft and Stiff, and (C) Soft-to-Stiff (1) and
Stiff-to-Stiff (1). (dark line = mean, light lines = standard deviation). (D) Area under the curve for the extracellular
matrix intensity profiles for each group. Data are shown as mean ± standard deviation. ** p < 0.01. *** p < 0.001.

production was not only lower immediately next the cell membrane, but it also decreased at a
faster rate moving away from the membrane compared to Stiff (Figure 9.6B). The Soft-to-Stiff
(1) ECM intensity profile exhibited a similar shape as Stiff-to-Stiff (1), but the entire curve was
shifted down (Figure 9.6C). Quantification of the area under the curve for these ECM intensity
profiles showed that ECM production was decreased in Soft compared with Stiff and in Soft-toStiff (1) compared with Stiff-to-Stiff (1) (p = 0.0001 and 0.003, respectively; Figure 9.6D). Thus,
soft priming ASCs not only delayed the development of pro-fibrotic morphology but also
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Figure 9.7 Representative sagittal histology (toluidine blue) illustrate joint anatomy (top row scale bar = 1000 µm)
and general characteristics of the anterior capsule (bottom row scale bar = 400 µm) after 21 days of immobilization.
(C = capsule, H = humerus, M = muscle, R = radius, INJ-TCP= injured and injected with cells cultured on tissue
culture plastic (TCP), INJ-GEL= injured and injected with cells cultured on fibronectin-coated 1 kPa polyacrylamide
gel).
Table 9.3 Histologic evaluation of the anterior capsule (n = 6/group).

Name

Adhesion

Fibrosis

Cell.

Inflamm.

Vascularity Myofibro.

Proteo.

Thickness

Control

-

-

+

-

+

+

+

-

INJ

+

++

+

-

+

+

++

+

INJ-TCP

+

++

++

+

+

++

++

-

INJ-GEL

+

+

+++

+

+

++

++

-

Thickness grading scheme: 0-150 µm (-), 151-300 µm (+), 301-450 µm (+ +), 451-600 µm (+ + +), and > 601
µm (+ + + +). Data for control and INJ were scored and published previously [4]. (Cell. = Cellularity, Inflamm.
= Inflammation, Myofibro. = Myofibroblasts, Proteo. = Proteoglycans).

activity, demonstrating that mechanical memory is a tool that can be used to control cell
behavior.
To evaluate the effect of mechanical memory in an in vivo injury environment, soft
primed ASCs were injected into the anterior capsule of our rat elbow contracture model. ASCs
expanded on TCP were injected as a control to replicate culture conditions in previous stem cell
injection studies [23-25, 27-32]. Limbs harvested 18 days after injection (21 days after injury)
were evaluated histologically to identify the effect on the anterior capsule. Qualitatively, both
cell injection groups displayed an altered biological response as shown by the overall joint
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Figure 9.8 Quantitative results are shown for flexion-extension: (A) total range-of-motion (ROM), (B) neutral zone
(NZ) length, (C) NZ stiffness, (D) maximum flexion, and (E) maximum extension. Limbs were evaluated after 21
days of immobilization. Data are shown as mean ± standard deviation. # p < 0.05, ## p < 0.01, ### p < 0.001, ####
p < 0.0001 different from control. * p < 0.05. **** p < 0.0001. Data for control and INJ were published previously
[4]. (INJ-TCP = injured and injected with cells cultured on tissue culture plastic (TCP), INJ-GEL= injured and
injected with cells cultured on fibronectin-coated 1 kPa polyacrylamide gel).

morphology and appearance of the anterior capsule compared to INJ and control (Figure 9.7).
Blinded histological scoring of the anterior capsule semi-quantitatively reported these differences
(Table 9.3). INJ scores slightly varied with previous publications because these sections were
blinded and rescored with the data collected in this study; importantly, these small differences do
not alter the interpretation of the results [4]. While most histological parameters for INJ, INJTCP and INJ-GEL were increased compared to control, indicative of a wound healing response,
there were a few notable differences. While INJ-TCP and INJ-GEL capsule thickness was not
different compared to control, both groups exhibited increased myofibroblasts and inflammation.
Compared with INJ and INJ-TCP, INJ-GEL capsules exhibited decreased fibrosis and increased
cellularity suggestive of anti-fibrotic remodeling of the wound environment.
These limbs were also biomechanically tested to determine the effect of stem cell
treatment on joint stiffness and ROM. Mechanical testing in flexion-extension demonstrated that
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total ROM was decreased for INJ and INJ-TCP compared to control (p < 0.0001 and < 0.0001,
respectively; Figure 9.8A). However, INJ-GEL total ROM was not only increased compared to
INJ but was also not different compared to control (p = 0.026 and 0.087, respectively; Figure
9.8A). Similarly, NZ length, a measure of functional joint motion, was decreased for INJ and
INJ-TCP compared to control (p = 0.0002 and 0.0002, respectively), but was not different for
INJ-GEL (p = 0.123; Figure 9.8B). NZ stiffness was increased for INJ and INJ-TCP compared to
control (p = 0.014 and 0.0004, respectively) but again was not different for INJ-GEL (p > 0.999;
Figure 9.8C). Only maximum flexion INJ exhibited a small increase compared to control (p =
0.038; Figure 9.6D). Since the injured forelimb was immobilized in a flexed position, yielding a
flexion contracture (i.e., ROM only lost in extension), no large differences were expected in
maximum flexion which is consistent with previous results [4, 42, 43]. While INJ, INJ-TCP, and
INJ-GEL maximum extension were all increased compared to control (p < 0.0001, < 0.0001, and
0.0002, respectively), INJ-GEL was decreased compared to INJ (p < 0.0001; Figure 9.8E).
Therefore, injecting soft primed ASCs into the anterior capsule of our rat elbow contracture

Figure 9.9 Adipokine array results: Heatmap of normalized intensity ratio for Soft/Stiff and Soft-to-Stiff (1)/Stiff-toStiff (1) with statistical results from two-way Analysis of Variance (ANOVA) for stiffness and priming with posthoc Bonferroni corrected with False Discovery Rate (FDR) using the Benjamini-Hochberg method. Cytokines
reported within the table exhibited a ratio that was increased (> 1) on both soft culture conditions. Data are shown as
mean ± standard deviation. * p < 0.05. ** p < 0.01. (IGFBP-6 = Insulin-like growth factor-binding protein-6, MCP-1
= Monocyte chemoattractant protein-1).
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Table 9.4 Adipokine array statistical results, two-way analysis of variance (ANOVA) for stiffness and priming.

Two-way ANOVA

Cytokine

Stiffness

Primed

Interaction

0.0002***

0.0123*

0.5428

DDPIV (Dipeptidyl peptidase-4)
IGFBP-1 (Insulin-like growth factor-binding protein-1)

<0.0001****
<0.0001****

0.0010**
0.0023**

0.5842
0.8559

IGFBP-2 (Insulin-like growth factor-binding protein-2)

0.2319

0.9224

0.1503

IL-11 (Interleukin-11)

<0.0001****

0.0019**

0.7552

Leptin
RANTES

<0.0001****
0.0001***

0.0084**
0.0154*

0.5138
0.6790

Resistin

<0.0001****

0.0144*

0.4339

Endocan

0.0008***

0.4384

0.4583

Angiopoietin-like 3

FGF-21 (Fibroblast growth factor-21)
IGFBP-3 (Insulin-like growth factor-binding protein-3)

<0.0001****
0.0006***
0.3743
<0.0001****

0.7189
0.0602

IGFBP-5 (Insulin-like growth factor-binding protein-5)

<0.0001****

0.0063**

0.4495

LIF (Leukemia inhibitory factor)

0.1522

0.8277

0.1486

Lipocalin-2
Serpin E1

0.6176
0.1116

0.9644
0.8620

0.4283
0.0347*

TIMP-1 (Tissue inhibitor of metalloproteinases-1)

0.1501

0.0110*

0.7914

0.0004***

0.0147*

0.8004

<0.0001****

0.0035**

0.4344

0.0084**

0.0002***

0.1240

<0.0001****

0.0017**

0.9573

MCP-1 (Monocyte chemoattractant protein-1)

0.0001***

0.0372*

0.2116

M-CSF (Macrophage colony-stimulating factor)
TNF-α (Tumor necrosis factor-α)

0.4136
0.0001***

0.6550
0.0055**

0.3717
0.9884

0.8938

0.0224*

0.2378

IGF-I (Insulin-like growth factor-I)

0.0003***

0.0039**

0.9065

IGF-II (Insulin-like growth factor-II)

<0.0001****

0.0120*

0.3409

IL-6 (Interleukin-6)

0.0365*

0.4042

0.6633

IL-10 (Interleukin-10)

0.0001***

0.0038**

0.3146

Pref-1 (Preadipocyte factor-1)
RAGE

0.0003***
0.0004***

0.0433*
0.0298*

0.9058
0.3923

HGF (Hepatocyte growth factor)
ICAM-1 (Intracellular adhesion molecule-1)
IGFBP-6 (Insulin-like growth factor-binding protein-6)
IL-1β (Interleukin-1β)

VEGF (Vascular endothelial growth factor)

Data are shown as mean ± standard deviation. * p < 0.05. ** p < 0.01. *** p < 0.001. **** p < 0.0001.
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model improved joint function after injury compared to untreated animals and primarily was not
different from control.
Since injecting soft primed ASCs exhibited both biological and functional benefits in
vivo, cell secretion was investigated to identify cytokines which may contribute to this improved
wound healing response in our rat model of post-traumatic elbow contracture. Out of 30
cytokines evaluated via an adipokine array, only three exhibited increased (> 1) intensity ratios
on soft compared to stiff substrates in both conditions, where at least one ratio exhibited a
significant difference: Endocan, insulin-like growth factor-binding protein-6 (IGFBP-6), and
monocyte chemoattractant protein-1 (MCP-1; Figure 9.9 and Table 9.4). However, out of these
three cytokines, only MCP-1 had significantly increased expression following transfer (Soft-toStiff (1) to Stiff-to-Stiff (1) ratio).
To determine whether mechanical memory was limited to the rat model, we also assessed
the effects of mechanical priming in human ASCs. Similar to rat ASCs, human ASCs primed on
soft substrates appeared qualitatively smaller compared to those on stiff in all groups (Figure
9.10A). Quantitation of cell area demonstrated that Soft, Soft-to-Stiff (1), and Soft-to-Stiff (2)
exhibited decreased cell area compared to their respective controls (p < 0.0001, 0.0003, and <
0.0001, respectively; Figure 9.10B). Actin coherency was decreased on Soft compared with Stiff
and Soft-to-Stiff (2) compared with Stiff-to-Stiff (2) (p < 0.0001 and < 0.0001, respectively;
Figure 9.10C). Upregulated MCP-1 secretion in soft primed ASCs was also similarly conserved
between both species; specifically, it was increased in Soft compared with Stiff and Soft-to-Stiff
(1) compared with Stiff-to-Stiff (1) (p = 0.0002 and 0.0218, respectively; Figure 9.10D).
Quantitation of YAP localization showed that the nuclear to cytoplasmic ratio was decreased on
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Figure 9.10 (A) Representative images of human adipose-derived stem cells (ASCs) immunolabeled for nuclei
(blue) and F-actin (green). (scale bar = 50 µm). Quantitative measures computed from fluorescent images: (B) cell
area and (C) actin coherency (alignment). (D) Monocyte chemoattractant protein-1 (MCP-1) expression in human
ASCs. Data are shown as mean ± standard deviation. * p < 0.05. *** p < 0.001. **** p < 0.0001.

Figure 9.11 (A) Representative images of human adipose-derived
stem cells (ASCs) immunolabeled for (top row) nuclei (blue) and
F-actin (green), and (bottom row) yes associated protein (YAP,
white). (scale bar = 50 µm). Quantitative measures computed
from fluorescent images: (B) YAP nuclear/cytoplasmic ratio.
Data are shown as mean ± standard deviation. **** p < 0.0001.
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Soft compared to Stiff (p < 0.0001), but there was no difference in either soft primed group
compared to their respective stiff controls, similar to rat ASCs (Figure 9.11). Overall, human
ASCs not only exhibited mechanical memory similar to rat ASCs, but their response to substrate
stiffness was further delayed demonstrating that human cells potentially have the capacity to
retain information from their previous culture environment for a longer period of time than
animal cells. Thus, soft priming human ASCs has the potential to expand their regenerative
capacity in clinical settings by postponing their transition to a pro-fibrotic phenotype.

9.4 Discussion
Fibrosis is the result of persistent cell dysregulation during wound healing which leads to
the excessive accumulation of ECM and ultimately tissue disfunction [8, 14]. Previous attempts
have been made to use stem cells to prevent soft tissue fibrosis, however, the results were
unpredictable and ranged from short-term benefits to augmented pathology [23-32]. Hence, a
method is needed to improve the control of stem cell response following injection in vivo. In
mechanosensitive cells, mechanical memory, the ability to mechanically pre-condition cells, may
serve as a tool to direct cells against the development of a pro-fibrotic phenotype [33]. In this
work, we demonstrate that ASCs from both rat and human sources exhibit mechanical memory
in vitro, retaining morphological and functional features of a soft environment following transfer
to a stiff environment. These features suggest resistance to a pro-fibrotic phenotype
characterized by increased cell size, cytoskeletal alignment, expression of αSMA and secretion
of ECM. In line with these in vitro results, we find that injection of soft primed rat ASCs into an
injured in vivo environment reduced histological evidence of fibrosis and improved joint ROM.
Together, these findings suggest that exploiting mechanical memory is a promising tool to direct
ASCs to improve healing in complex wound environments.
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The mechanosensitivity of ASCs has been demonstrated by several groups as evidenced
by altered morphology and stiffness-driven differentiation [44, 45]. We additionally report that
ECM and cytokine secretion are altered by matrix stiffness (Figures 9.6 and 9.9, Table 9.4).
Furthermore, we show that ASCs exhibit mechanical memory. ASCs soft primed for two weeks
and subsequently cultured on stiff substrates for one week still exhibited decreased cell area,
actin coherency, and αSMA positive cells compared to cells only cultured on stiff substrates
(Figure 9.4). While most of these differences were lost after soft primed ASCs were cultured an
additional week on stiff substrates, the capability of ASCs to retain memory of their previous
culture environment for at least one week may be enough time to increase their regenerative
potential in vivo. Our in vivo data in our rat model of elbow contracture suggests that this is
likely.
Mechanical memory is not unique to ASCs. Previous work in lung fibroblasts and BDMSCs have demonstrated mechanical memory using pro-fibrotic cell markers like αSMA [33,
34]. However, these studies did not characterize the activity or function of soft primed cells.
Investigations evaluating mechanical memory in breast cancer cell lines (e.g., MDA-MD-231,
MCF-10A) showed that soft priming decreased proliferation rate and migration speed compared
to cells only cultured on stiff substrates, suggesting that at least some cellular functions also
exhibit mechanical memory [46, 47]. In this work, the effect of mechanical memory on ASC
activity was evaluated by the quantification of individual cell ECM production and cytokine
secretion. Soft primed ASCs, even after one week of culture on stiff substrates, produced less
ECM than cells cultured only on stiff substrates and maintained an altered cytokine secretion
profile (Figures 9.6 and 9.9, Table 9.4). Thus, soft priming not only delayed changes in
morphology but also in function.
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A first look into the possible mechanisms driving mechanical memory in rat and human
ASCs started with the evaluation of the mechanosensitive protein YAP. Since YAP is reported to
be nuclear on stiff and cytoplasmic on soft substrates, if it contributes to long-term maintenance
of cell mechanical memory then it would remain cytoplasmic in soft primed cells following
transfer to a stiff substrate [35, 48]. However, in vitro studies with soft primed rat and human
ASCs showed that YAP was nuclear at both time points following transfer (Figures 9.5 and
9.11). Consistent with recent reports, YAP does not likely drive long-term mechanical memory
[34, 49, 50].
Maintenance of mechanical memory in vitro suggests the possibility to pre-direct, or
prime, cells toward a specific function in vivo. Of course, functional changes in vitro do not
always translate to functional changes in vivo. Few groups have investigated the effects of
mechanical priming in vivo. Notably, Li and colleagues showed that injecting two million soft
primed BD-MSCs via fibrin glue onto a dermal wound in a hypertrophic scarring rodent model
improved histological parameters at the wound site (e.g., increased cellularity, decreased
collagen density) compared to untreated animals [34]. In a similar model, Yang et al. showed
that conditioned media from soft primed BD-MSCs enhanced dermal wound closure (e.g., reepithelialization) which provides evidence that indirect signaling from soft primed cells can
improve healing [36]. However, this previous work only reported indirect changes in tissue
mechanics (e.g., wound area/tension). We show that intra-articular injection of two million soft
primed ASCs into our rat model of elbow contracture not only reduced histological evidence of
fibrosis but also improved biomechanical measures of joint contracture. Evaluation of flexionextension joint mechanics demonstrated that injection of ASCs cultured on TCP (INJ-TCP) did
not improve elbow contracture, evidenced by decreased total ROM and NZ length with increased
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NZ stiffness compared with control. However, injection of ASCs cultured on soft substrates
(INJ-GEL) improved these parameters and this condition was not statistically different from
control (Figures 9.8A-C).
These functional changes were likely driven by an altered biological response in the
anterior capsule after cell injection. Histologically, we find evidence of cell- and tissue-level
changes including increased inflammation and cellularity and decreased fibrosis and thickness in
the ASC treated elbows (INJ-TCP and INJ-GEL) compared to INJ (Figure 9.7, Table 9.3). When
comparing INJ-TCP to INJ-GEL groups (i.e. the effect of mechanical priming), we find
decreased fibrosis and increased cellularity only. The similarity in myofibroblast number
between these groups was surprising, but this quantification does not account for myofibroblast
activity. It is possible that in the INJ-GEL group, the myofibroblasts are signaled to contribute to
ECM remodeling rather than fibrosis [33]. Similarly, while the quantity of inflammatory cells
was not different between INJ-TCP and INJ-GEL, the characteristics of these cells may be
altered by paracrine signals from soft primed ASCs such that they exhibit a pro-regenerative,
rather than pro-inflammatory phenotype. Our in vitro results suggest that soft primed ASCs,
compared with ASCs expanded on TCP, may also directly limit the fibrotic response in the
capsule because their ECM production remained decreased despite transfer to a stiff substrate
(Figure 9.6). Thus, soft primed cells may contribute less ECM at the wound site compared to
cells expanded on stiff substrates (e.g., TCP) and so have a greater potential to mitigate the
fibrotic response after injury. Overall, consistent improvements in all parameters evaluating
flexion-extension joint mechanics and morphology for INJ-GEL compared to untreated elbows
(INJ) suggest that soft primed ASCs decreased the fibrotic wound healing response leading to
enhanced joint function after injury.
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Stem cells have been described to influence the resident cell population by secreting
bioactive, trophic factors which modulate the immune response and stimulate regeneration [2022, 34, 51]. Previously, ASC conditioned media was shown to express elevated angiogenic
markers like interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), and MCP-1 [21].
In this study, we expanded our investigation to an array of 30 well-characterized cytokines to
investigate how soft priming alters ASC cytokine secretion. Of these 30 cytokines, only three
exhibited increased expression in both soft culture conditions compared to stiff (Figure 9.9,
Table 9.4). Interestingly, out of these three cytokines, only MCP-1 exhibited significantly
increased expression in soft primed ASCs following transfer to a stiff substrate (Figure 9.9).
MCP-1 plays an important role in wound healing by influencing the immune response after
injury [52]. It is a chemotactic factor for monocytes, memory T cells, and dendritic cells [53].
Some literature has shown that MCP-1 can activate macrophages and potentially alter their
polarization from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype [54, 55].
Additional studies evaluating the immunomodulatory role of MCP-1 are warranted to determine
if it is a primary factor driving the decreased fibrotic response and improved joint function after
injury in our rat model of elbow contracture.
Most studies evaluating the efficacy of stem cell therapies first expanded cells on stiff
substrates (e.g., TCP) prior to injection [23-25, 27-32]. Studies injecting BD-MSCs and ASCs
into fibrotic models or after musculoskeletal injury report variable results [23-32]. In our study,
we similarly find mixed outcomes for INJ-TCP, where histological evidence for altered cell and
tissue morphology does not translate to functional changes (Figures 9.7 and 9.8, Table 9.3).
Interestingly, Balestrini et al. and Yang et al. showed that lung fibroblasts and BD-MSCs,
respectively, were directed toward a pro-fibrotic phenotype when first cultured on a stiff
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substrate [33, 35]. Hence, mechanical memory can also bias cells toward fibrotic activation.
Therefore, the standard method to expand cell populations on TCP for therapeutic delivery has
the potential to attenuate cell regenerative capacity and accentuate pro-fibrotic behavior. Our in
vivo results suggest that soft priming is an effective method to avoid retention of TCP memory in
stem cell-based therapies.
We designed the in vivo model with clinical translation in mind. ASCs were injected
three days after injury to represent a more realistic patient time to treatment in clinical settings.
Additionally, this aligns with the time point at which fibroblasts infiltrate the wound site [6].
These fibroblasts typically develop a pro-fibrotic phenotype after 8-9 days [6]. Hence, we
hypothesize that aligning ASC application with this phenotypic shift maximizes their potential to
delay pro-fibrotic activation and enhance the regenerative potential of resident cell populations.
We additionally chose to evaluate ASCs, rather than BD-MSCs, due to their improved efficiency
of isolation and their increased use in clinical applications [18, 37]. In this study, we demonstrate
that human ASCs exhibit mechanical memory similar to rat ASCs and rat/human BD-MSCs [34,
35]. Specifically, we find that human ASCs displayed decreased cell area and actin coherency
on soft substrates compared to stiff and retained these changes at least a week longer than rat
ASCs following exposure to a stiff substrate (Figures 9.10A-C). Human soft primed ASCs also
exhibited persistently increased MCP-1 expression following transfer to a stiff substrate, similar
to rat ASCs (Figure 9.10D). Therefore, not only is mechanical memory a phenomenon that is
conversed between species, but it also has the possibility to enhance the therapeutic efficacy of
stem cells in clinical settings. In addition, soft priming does not involve genetic or
pharmacologic modification which increases its translational potential - not only for orthopaedic
applications, but also for other organ systems commonly affected by this pathology.
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Several questions from this study remain and provide motivation for future work. First,
this work does not delineate the mechanism(s) underlying soft priming. While we show that
YAP is nuclear on stiff and cytoplasmic on soft substrates, it likely does not control long-term
mechanical memory because it did not remain cytoplasmic in soft primed cells for either rat or
human ASCs (Figures 9.5 and 9.11) [48]. Changes in miR-21 expression and epigenetics have
been identified as potential factors which may contribute to long-term mechanical memory in
stiff primed BD-MSCs, however, more work is needed to understand the mechanism behind soft
priming [34, 56]. Second, this work did not evaluate how long ASCs remained in the joint space
or how long the functional improvements persisted. Future work could simultaneously answer
these questions using longitudinal cell tracking techniques (e.g., Quantum Dots) over a longer
time frame. These studies would also determine if additional cell injections were needed to
maintain these therapeutic benefits long-term. Third, it would be valuable to also examine
biological changes in vivo at earlier time points following injection to determine if
immunomodulation (e.g., altered macrophage activation and/or polarization) contributes to the
decreased fibrotic response and improved joint function in our animal model. Fourth, this work
did not compare culture expanded ASCs to naïve ASCs, injected immediately following
isolation. Since ASCs are derived from a soft tissue, they may potentially be primed by their
native environment in vivo. A study injecting ASCs immediately post-isolation would determine
if soft priming is necessary for this cell type to elicit an improved healing response. Finally,
while translationally relevant, our model of elbow contracture is a highly specific wound
environment. We believe that the soft primed ASCs could decrease the fibrotic response across a
number of tissue injury and disease environments, however more extensive experimentation will
be required to determine the extent of future applications.
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In conclusion, this study has shown that ASC mechanical memory can decrease soft
tissue fibrosis and increase joint function after injury in the rat elbow. Specifically, we find (1)
pre-conditioning ASCs on soft substrates delays activation of a pro-fibrotic phenotype and (2)
injection of soft primed ASCs into the elbow anterior capsule decreased capsular fibrosis and
increased elbow total ROM in flexion-extension after injury. To our knowledge, this is the first
study to demonstrate mechanical memory in ASCs and to provide evidence of improved
mechanics or function following treatment with soft primed stem cells. These findings suggest
that modifying the culture substrate for stem cell expansion has the potential to improve the
efficacy of stem cell-based therapies targeting fibrosis.
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Chapter 10: Conclusion & Future directions
10.1 Conclusion
Following the development of the first animal model of elbow contracture [1], these
studies isolated several periarticular soft tissues for biological and mechanical evaluation to
determine the extent of their contribution to the range-of-motion (ROM) lost. The knowledge of
which tissues cause post-traumatic joint contracture (PTJC) in the elbow will help direct the
development of tissue targeted treatment strategies. Current intervention strategies (i.e., physical
therapy, surgery) rarely restore ROM to pre-injury levels and 20% of patients require revision
surgery for repeat contracture [2, 3]. Since these existing strategies are primarily based on the
concept of physically disrupting elbow periarticular soft tissues and often have limited success, a
treatment is needed which instead seeks to biologically alter the underlying pathology to improve
joint function. This work presented a stem cell therapy which decreased ROM lost following
injury and immobilization due to decreased fibrosis in the anterior capsule of our rat elbow
contracture model. Therefore, across different length scales (i.e., cell-level to joint-level) in
biology and mechanics, this work provided insight into elbow contracture and its prevention
using a biological approach.
First, this work showed that our animal model of elbow PTJC developed permanent
motion loss in flexion-extension and pronation-supination. Specifically, an additional period of
free mobilization (i.e., free cage activity, no immobilization) was not enough to completely
restore the joint motion lost after injury and immobilization. While both types of motion were
altered, flexion-extension was more severely reduced than pronation-supination. In flexion179

extension, injured limbs exhibited decreased ROM compared to both control and contralateral
(i.e., uninjured, non-immobilized limbs from injured animals), while injured limbs in pronationsupination were only different compared to contralateral. A moderate correlation between
flexion-extension and pronation-supination ROM existed after immobilization, but following
free mobilization there was weak to no correlation. Hence, these two types of motion do not
respond to joint reloading similarly and may need to be treated separately.
Different periods of immobilization and free mobilization were then evaluated to
understand the timeline of how contracture developed and how it was altered following joint
reloading, respectively. In flexion-extension, injured limbs exhibited decreased ROM after 21
and 42 days of immobilization compared to control (21 and 42 IM). After 42 days of
immobilization, a limited amount of motion was recovered following 21 days of free
mobilization (42/21 IM-FM), but this improvement plateaued and there was no further gain in
motion with additional periods of free mobilization. Hence, injured limb ROM at all time points
during free mobilization remained decreased compared to control. In pronation-supination
injured limbs exhibited joint laxity or increased ROM at 3 and 7 IM compared to control. While
never decreased compared to control, pronation-supination decreased between 21 and 42 IM.
The elbow anterior capsule and joint surfaces were also evaluated to observe biological
changes over time throughout immobilization and free mobilization. At all time points injured
limb capsules showed the presence of adhesions, evidence of fibrosis, and increased tissue
thickness compared to control. However, inflammation was only identified between 3-21 IM and
at 42/21 IM-FM. Anterior capsule hypercellularity was evident between 7-42 IM and at 42/21
IM-FM. Injured limb non-opposing joint surfaces (i.e., cartilage-capsule interaction) displayed
more evidence of arthrosis than the opposing joint surfaces (i.e., cartilage-cartilage interaction)
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compared to control at all time points. Overall, changes in the injured limb anterior capsule were
more severe than those observed at the joint surfaces.
The contribution of each periarticular soft tissue to elbow contracture was then evaluated
via sequential dissection flexion-extension joint mechanics. Injured limb muscles/tendons and
anterior capsule contributed ~10% and ~90% to the motion lost at 42 IM, respectively. However,
the muscles/tendons did not significantly contribute to contracture following any period of free
mobilization. Thus, the capsule and ligaments/cartilage were responsible for ~47% and ~52% of
the motion lost at 42/21 IM-FM, and ~26% and ~74% after 42/42 IM-FM, respectively. Thus,
the capsule, ligaments, and cartilage were identified as the primary long-term contributors to
motion loss in our animal model of elbow PTJC and should be targeted with treatment strategies.
While the previous work evaluated periarticular soft tissue contribution to joint
mechanics, it may have underestimated muscle contribution because the testing was performed
post-mortem. Muscle is a dynamic tissue with both active and passive contributions related to
generating/supporting load [4]. Muscle physiology testing showed that active and passive stress
were decreased and increased at 42 IM compared to control, respectively, but there were no
differences at 42/42 IM-FM. The early alterations in muscle physiology were likely due to
structural changes (i.e., decreased muscle length and fiber cross sectional area) and extracellular
matrix (ECM) remodeling (i.e., altered genetic expression) in injured limbs compared to control.
Similar to muscle physiology testing, these biological changes recovered after joint reloading.
Therefore, muscle was not a permanent contributor to elbow PTJC in our animal model and so
likely does not need to be specifically targeted with a treatment strategy.
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Biological changes within the anterior capsule and lateral collateral ligament (LCL) were
investigated further to determine what pathology led to their contribution to the motion lost in
our animal model of elbow PTJC. Injured limb capsules and LCLs both had increased collagen
content, but no difference in collagen density, compared to control at 42 IM and 42/42 IM-FM,
which was consistent with the persistent increase in tissue volume. Both injured limb tissues also
expressed increased immature collagen crosslinks compared to control at both time points.
However, the upregulated immature collagen crosslinks are indicative of increased collagen
synthesis and hence increased tissue deposition [5]. Thus, hypertrophy of the injured limb
capsule and LCL was potentially the primary biological change driving tissue contribution to
elbow contracture. Interestingly, more significant differences occurred within injured limb LCLs
compared to the capsules, identifying the LCL as a key candidate to target with a tissue specific
treatment strategy.
Following the identification of the primary soft tissue contributors to elbow contracture,
treatments to prohibit fibrosis within these tissues could be investigated. Previous models of soft
tissue fibrosis attempted to use stem cell therapies to prevent excessive ECM deposition and
functional loss. However, these stem cell injections exhibited unpredictable results that ranged
from a transient benefit to augmented pathology [6-8]. In this work, mechanical memory was
used to improve control of stem cell response in vivo to make sure cells mitigate fibrosis rather
than contribute to it. Rodent primary subcutaneous adipose-derived stem cells (ASCs) that were
soft primed on ~1 kPa hydrogels for two weeks then transferred to stiff (~120 kPa) hydrogels for
an additional week showed decreased cell area, actin coherency (i.e., alignment), α-smooth
muscle actin (αSMA) expression (i.e., pro-fibrotic cell marker) and cell function (i.e., ECM
production) compared to cells only cultured on stiff hydrogels. Overall, data demonstrate that
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ASCs exhibit mechanical memory and soft priming delayed ASC development of a pro-fibrotic
phenotype. Injecting two million of these soft primed ASCs into our animal model of elbow
PTJC improved function following injury and immobilization. Specifically, flexion-extension
ROM in animals treated with soft primed ASCs was not different compared to control and
histological evaluation of the anterior capsule showed decreased fibrosis and tissue thickness
compared to untreated animals (i.e., injury and immobilization, but no cell injection). Monocyte
chemoattractant protein-1 (MCP-1) was identified as a paracrine signal secreted by soft primed
ASC which may beneficially alter the wound healing response to limit fibrosis and improve joint
function. Finally, human ASCs data demonstrated that mechanical memory is a phenomenon that
is conversed between species and thus has the possibility to enhance the therapeutic efficacy of
stem cells in clinical settings.
In summary, this work (1) established an animal model of permanent elbow contracture
which mimicked the human condition, (2) supported clinical observations that flexion-extension
and pronation-supination exhibit unique injury/healing responses, (3) identified the primary
periarticular soft tissues which caused permanent elbow contracture, (4) determined that fibrosis
in these tissues, specifically hypertrophy, led to the deficit in joint mechanics, and (5) showed
that injection of stem cells mechanically primed in soft microenvironments decreased fibrosis
and improved joint function in our animal model.

10.2 Future directions
10.2.1 Immunomodulation
Stem cells secret bioactive molecules that are immunomodulatory and create a
regenerative microenvironment [9, 10]. In particular, ASCs have been described to indirectly
affect regeneration by signaling to resident cell populations through cytokines or growth factors
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[11]. This work identified MCP-1 as a potential bioactive factor secreted by soft primed ASCs
which might contribute to the decreased fibrotic scarring of the anterior capsule and improved
joint function. MCP-1 recruits monocytes/macrophages and memory T cells to sites of
inflammation following tissue injury [12]. Macrophages mediate healing after injury by
destroying invading pathogens, clearing cellular debris, and expressing cytokines [13].
Insufficient macrophage response or activation after injury may contribute to impaired
healing [13]. For example, a full thickness dermal wound in an MCP-1-/- mouse exhibited
delayed re-epithelialization, angiogenesis, and collagen synthesis compared to wildtype [14].
Interestingly, there was no change in the number of macrophages at the wound site
demonstrating that MCP-1 likely influenced macrophage activation. In a diabetic mouse model,
macrophages from a dermal wound exhibited decreased MCP-1 genetic expression but had no
difference in chemotaxis compared to control [13]. Dermal wounds in this mouse model were
then treated with MCP-1, which led to an earlier macrophage response and significantly
enhanced wound closure. Additionally, this macrophage activation occurred on a timeline similar
to wound healing in control animals. Therefore, restoring macrophage response may improve
wound healing after injury.
Stem cells have also been shown to regulate macrophage polarization from a proinflammatory (M1) to an anti-inflammatory (M2) phenotype [11, 14]. Specifically, monocytes
cocultured with bone-marrow derived stem cells (BD-MSCs) were directed toward a M2
macrophage phenotype [15]. The M2 phenotype expressed low and high production of proinflammatory (i.e., IL-12) and anti-inflammatory (i.e., IL-10) cytokines, respectively. Therefore,
stem cells may not only activate macrophages but may also direct these cells toward an antiinflammatory phenotype to ultimately improve healing following injury. Based on the literature
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and this work identifying increased MCP-1 expression, soft primed ASC immunomodulation
warrants further investigation.
In this work, an important question to answer is if MCP-1 expression in soft primed
ASCs drives macrophage activation toward an anti-inflammatory (M2) phenotype. First, a
transwell assay could be used to see how signaling, not direct contact, between soft primed ASCs
and macrophages (Mφ) would alter macrophage polarization state (control condition). Another
option would be to use conditioned media from soft primed ASCs to culture macrophages (Mφ)
and then characterize their response. At the end of the culture period in either of these
techniques, macrophage polarization would be evaluated using flow cytometry or
immunohistochemistry with markers for the pro-inflammatory (M1; iNOS) and antiinflammatory (M2; CD163) macrophage phenotypes [11]. Second, siRNA or shRNA to
knockdown MCP-1 in soft primed ASCs could be used to specifically answer if MCP-1 secretion
by ASCs is driving macrophage polarization. However, before performing any experiments it
would be important to confirm that the knockout (KO) of MCP-1 does not alter ASC mechanical
memory. Thus, following two weeks of soft priming and subsequent transfer to a stiff substrate
for one week, MCP-1KO ASC morphology would need to be assessed by immunolabeling with
DAPI (nucleus) and Phalloidin (F-actin) to ensure maintenance of the delayed response to
stiffness. These soft primed MCP-1KO ASCs could then be cultured in a transwell assay with
macrophages (Mφ) and macrophage polarization would be evaluated using similar methods as
described previously. Again, conditioned media from soft primed MCP-1KO ASCs could be used
instead to culture macrophages (Mφ) to evaluate the effect of cell signaling on macrophage
polarization. If MCP-1 directs macrophages toward an M2 phenotype, then macrophage CD163
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expression would be decreased when cultured with soft primed MCP-1KO ASCs compared to soft
primed ASCs (control condition).
In vivo evaluation of macrophages would identify if an altered immune response caused
the biological and functional benefits reported following soft primed ASC injection into our
animal model of elbow PTJC. Early time points after injection (e.g., after 5, 7, and/or 10 days of
immobilization) should be used to evaluate changes in macrophages to determine if alterations in
the acute inflammatory response contribute to the improved wound healing. Evaluation at the
end of the study (after 21 days of immobilization) could also be used to identify any permanent
alterations in macrophage response or activation. Histological sections from the injured limbs
treated with two million soft primed ASCs injected three days post-injury would be
immunolabeled to evaluate the total number of macrophages (i.e., CD68 or CD206) and the
macrophage polarization state (i.e., iNOS and CD163 as markers for the pro-inflammatory (M1)
and anti-inflammatory (M2) macrophage phenotype, respectively) [11, 15, 16]. Labeling both the
general and polarization state macrophage markers would provide insight into whether the total
number of macrophages or their activation is driving the therapeutic benefit observed in our
animal model following cell injection. These results would be compared to sections
immunolabeled with the same markers from control and untreated animals (i.e., injury and
immobilization, but no cell injection).
Finally, to determine if MCP-1 expression drives the beneficial in vivo wound healing
response, two million soft primed ASCs transfected with siRNA or shRNA to knockdown MCP1 would be injected into our animal model of elbow PTJC three days post-injury. After 21 days
of immobilization, flexion-extension joint mechanics and histology would be used to examine
function and soft tissue biology, respectively. Joint sections would also be immunolabeled as
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described previously to identify any long-term alterations in macrophage response or activation.
If the biology and function do not improve following the injection of soft primed MCP-1KO
ASCs then MCP-1 is a primary cytokine which alters the acute immune response and enhances
tissue regeneration after injury.

10.2.2 Mechanical memory mechanotransduction and mechanism in vitro
Mechanotransduction is not only possible at the cell surface but can also occur within the
nucleus [17]. Mechanical signals reach the nucleus more rapidly than biochemical signals [1820]. In particular, the nuclear envelope is the force sensitive interface between the cytoskeleton
and chromatin. Stress applied to the nuclear envelope changes chromosome accessibility though
enzymatic modifications [19, 21]. So, gene expression can be either activated or silenced by the
acetylation or deacetylation/methylation of chromatin, respectively. For example, a study
showed that MCF-10As, a breast cancer epithelial cell line, cultured in three-dimensional soft
(~100 Pa) and stiff (~2 kPa) substrates exhibited thin euchromatin and heterochromatin bundles
at the nuclear periphery, respectively [21]. Another study demonstrated that the duration of
dynamic loading directly correlated with the amount of time heterochromatin persisted in BDMSCs [18]. While these studies have identified that the mechanical environment can alter the
epigenome, they have not investigated how long the original chromatin organization is
maintained following cell transfer to a new microenvironment. Further investigation is needed to
evaluate chromatin organization in mechanical memory and its effect on subsequent gene
expression.
Some stiffness-dependent downstream signaling and gene expression has been previously
identified and may influence the maintenance of mechanical memory. Specifically, myocardinrelated transcription factor (MRTF), serum response factor (SRF), and yes associated protein
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(YAP) signaling may contribute to the short-term maintenance of mechanical memory [17, 22,
23]. When on a stiff substrate, these signals localize in the nucleus and alter transcriptional
activity. For example, MRTF/SRF can promote downstream genetic expression of α-smooth
muscle actin (αSMA) and collagen type I, while YAP commonly upregulates connective tissue
growth factor (CTGF); all can contribute to the fibrotic response following injury [24-26]. But,
MRTF/SRF and YAP signaling are not likely controlling mechanical memory long-term because
both exhibit a fast turnover rate (e.g., 1-3 hours) and hence quickly respond to changes in
stiffness [27, 28]. Another study identified a micro-RNA, miR-21, as a potential genetic
regulator of mechanical memory [23]. Similar to the signaling factors previously described, miR21 expression is also upregulated on stiff substrates. Unlike the other factors, miR-21 has a
slower turnover rate (e.g., half-life ~5 days) and remains stable for several days after a cell is
transferred to a new culture environment.
Since all of these signaling factors are upregulated on a stiff microenvironment, previous
work sought to limit cell response to stiffness by preventing activation of these factors. However,
rather than genetically or biochemically altering the cell phenotype, this work used a soft
microenvironment to delay cell response to stiffness. But it remains unclear what factor(s) are
driving mechanical memory in soft primed cells. Therefore, opportunity exists to determine how
cells maintain or store information from their past culture environment long-term after soft
priming.
Since chromatin organization is a critical mediator of mechanotransduction, future
studies should determine if epigenetic changes are driving mechanical memory. As previously
mentioned, heterochromatin and euchromatin formed in response to stiff and soft
microenvironments, respectively [21]. Transmission electron microscopy (TEM) would be used
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to evaluate chromatin organization at the end of culture period in ASCs soft primed for two
weeks on ~1 kPa hydrogels then transferred to stiff (~120 kPa) hydrogels for one week. These
results would be compared to ASCs cultured for two weeks on stiff hydrogels subsequently
transferred to new stiff hydrogels for one week (control condition). Chromatin accessibility
could also be evaluated using ATAC-seq (Assay for Transposases-Accessible Chromatin using
sequencing) to serve as an indirect measure of chromatin organization. If chromatin organization
is driving mechanical memory in soft primed ASCs, then euchromatin or increased chromatin
accessibility would likely be observed even following cell transfer to a stiff microenvironment.
RNA-sequencing could be used to evaluate differences in downstream genetic expression in
these culture conditions to investigate what genetic regulators may contribute to the maintenance
of the chromatin organizational state.
Pharmacological treatment could determine if epigenetic changes in soft primed ASCs
are sufficient to delay cell response to stiffness. ASCs soft primed for two weeks then transferred
to stiff hydrogels would be treated with Lasonolide A or Calyculin A to induce chromatin
condensation. Cell morphology would then be assessed by immunolabeling with DAPI (nucleus)
and Phalloidin (F-actin). If euchromatin directs mechanical memory in soft primed cells,
treatment with Lasonolide A or Calyculin A would cause cells to lose the memory of their past
environment and direct them toward a stiff phenotype (e.g., increased cell area, actin coherency).
The ability to prolong mechanical memory by epigenetic state in soft primed cells could be
evaluated by treating ASCs soft primed for two weeks then transferred to stiff hydrogels for one
week with Trichostatin A or Suberanilohydroxamic acid (SAHA), which prevents chromatin
condensation. Similar immunolabeling methods to evaluate cell morphology would be used as
previously described. If chromatin organization state directs memory, then treatment with
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Trichostatin A or SAHA would augment the delayed cell response to stiffness (e.g., decreased
cell area, actin coherency).

10.2.3 Mechanical memory therapeutic benefit in vivo
Further investigation is needed to understand how long the injected soft primed ASCs
persist within the joint as well as what genetic regulators drive the beneficial wound healing
response following ASC injection. Quantum dots could be used to label soft primed ASCs, so
these cells could be tracked following injection into our animal model of elbow contracture via
imaging with IVIS (in vivo imaging system). Tracking the localization and persistence of these
cells in vivo would provide a time window of how long they may influence the wound healing
response following injection. Near-infrared (NIR) quantum dots would be used to allow deep
tissue visualization of the injected cells within the elbow [29]. However, before performing any
experiments it would be important to confirm that the NIR quantum dots do not alter ASC
mechanical memory. Thus, ASCs would be labeled with quantum dots then cultured for two
weeks on soft (~1 kPa) hydrogels and subsequently transferred to stiff (~120 kPa) hydrogels for
one week. ASC morphology would be assessed by immunolabeling with DAPI (nucleus) and
Phalloidin (F-actin) to ensure maintenance of the delayed cell response to stiffness. Two million
soft primed ASCs labeled with NIR quantum dots would then be injected into our animal model
of elbow PTJC three days post-injury. The animals would be imaged with IVIS every other day
for the study duration to track the injected cells.
Previously, rodent BD-MSCs and ASCs labeled with NIR quantum dots were visualized
in vivo only 1-2 weeks following injection [29-31]. However, the short presence of these cells
did not limit their effectiveness. de Witte and colleagues identified that a majority of the injected
cells were phagocytosed by macrophages which directed them toward an anti-inflammatory
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(M2) phenotype [32]. Therefore, elbow joint sections from animals treated with NIR quantum
dot labeled ASCs could be immunolabeled with a general macrophage marker (i.e., CD68 or
CD206) and an anti-inflammatory (M2) macrophage marker (i.e., CD163) to determine if these
ASCs colocalize with macrophages. Colocalization of soft primed ASCs with macrophages
following injection would suggest that these injected cells modulate the inflammatory response
during wound healing.
While this work showed that soft primed ASCs injected into our animal model of elbow
contracture decreased fibrosis in the anterior capsule via histological evaluation, additional
studies to understand what cellular changes drive this phenotype warrant further investigation.
Anterior capsules from our animal model of elbow contracture treated with two million soft
primed ASCs would be harvested to evaluate changes in genetic expression via RNAsequencing. These results would be to compared RNA-sequencing data from anterior capsules
harvested from untreated animals (i.e., injury and immobilization, but no cell injection). Overall,
RNA-sequencing may identify genetic regulators which could contribute to the in vivo
therapeutic benefit of the soft primed ASCs presented in this work.
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Appendix A: Unpublished data
A.1 Unpublished data

Figure A.1 Quantitative results are shown for flexion-extension (n = 8/group): (A) total range-of-motion (ROM), (B)
ROM midpoint, (C) neutral zone (NZ) length, (D) maximum flexion, (E) maximum extension, (F) NZ stiffness, (G)
flexion stiffness, and (H) extension stiffness. Left and right limbs were evaluated after 63 days of free mobilization
to identify if intra-animal limb differences exist in control animals. Data are shown as mean ± standard deviation.
Statistical analysis included a paired t test. * p < 0.05. Data for control left limbs were published, but included for
comparison [1].

[1]

Figure A.2 Biochemical evaluation of the anterior capsule (n = 5/group): (A) collagen content, (B) collagen density
(collagen content/tissue wet weight), (C) sulfated glycosaminoglycan content, and (D) sulfated glycosaminoglycan
density (sulfated glycosaminoglycan content/tissue wet weight) for sham, injury I (anterior capsulotomy), and injury
II (anterior capsulotomy with lateral collateral ligament transection). Evaluation was completed at 42 days of
immobilization (42 IM) or after 42 days of immobilization followed by 42 days of free mobilization (42/42 IM-FM).
Data are shown as mean ± standard deviation. Statistical analysis included one-way ANOVA tests to compare (1)
control and injured limbs for each group and (2) control and contralateral (CL) limbs because data for injured and
CL limbs are not independent; post-hoc Bonferroni analyses compared each experimental group to control. Intraanimal differences were evaluated with a paired t test for injured and CL limbs in each group. # p < 0.05 different
from control. * p < 0.05 different from CL. Data for Injury II were published, but included for comparison [2]. (- - =
control limbs, diagonally shaded bars = injured limbs, solid bars = uninjured CL limbs).

[2]

Figure A.3 Contrast enhanced micro-computed tomography (micro-CT) images of a control limb anterior capsule
(outlined with the dotted lines). Transverse section of a more (A) proximal and (B) distal region within the elbow
joint. The elbow was fixed at 90° flexion with 10% neutral buffered formalin for 72 hours and then stained with 3%
phosphomolybdic acid in 70% ethanol for 72 hours to enhance soft tissue contrast. A micro-CT scanner (µCT40;
Scanco, Medical, Zurich, CH) was used to scan the forelimbs in 2% agarose inside a 30-mm-diameter tube. Proof of
concept image demonstrating that the capsule could be visualized.

Figure A.4 Nuclear area measured from fluorescent images of primary (A) rat and (B) human adipose-derived stem
cells (ASCs). Data are shown as mean ± standard deviation. Statistical analysis included a two-way ANOVA for
stiffness and priming with post-hoc Bonferroni comparisons between groups at each time point. * p < 0.05. **** p <
0.0001. (n = 5/group, 10 cells per replicate).

[3]

Figure A.5 (A) Representative images of rat adipose-derived stem cells (ASCs) immunolabeled for (top row) nuclei
(blue) and F-actin (green), and (bottom row) yes associated protein (YAP, white). (10X scale bar = 50 µm, 40X Oil
scale bar = 10 µm). Quantitative measures computed from fluorescent images: (B) nuclear area, (C) cell area, (D)
actin coherency (i.e., alignment), and (E) YAP nuclear/cytoplasmic ratio. Data are shown as mean ± standard
deviation. Statistical analysis included an unpaired t test. There were no significant differences between groups. (n =
5/group, 10 cells per replicate).

[4]

Figure A.6 (A) Representative images of primary rat adipose-derived stem cells (ASCs), primary human ASCs, and
MCF-10A cells immunolabeled for (top row) nuclei (blue) and F-actin (green), and (bottom row) yes associated
protein (YAP, white). (scale bar = 50 µm). Quantitative measures computed from fluorescent images: (B) nuclear
area, (C) cell area, and (D) YAP nuclear/cytoplasmic ratio. Data are shown as mean ± standard deviation. Statistical
analysis included a two-way ANOVA for stiffness and cell type with post-hoc Bonferroni comparisons between
stiffness for each cell type. ** p < 0.01. **** p < 0.0001. Data for rat and human ASCs were shown previously in
Chapter 9 but were included for comparison (n = 5/group, 10 cells per replicate).
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Appendix B: Protocols
B.1 The role of periarticular soft tissue in elbow contracture
B.1.1 Potting limbs for mechanical testing
Safety.
• All work should be performed while wearing closed toed shoes, pants, lab coat, and gloves.
• All work with Bondo products should be performed within the fume hood.
Protocol.
1. Thaw the rat for 24 hours on top of and covered with a blue bench pad.
a. If the forelimb was already removed from the rat body, then thaw for one hour on
top of and covered with a blue bench pad.
2. After 24 hours, label a plastic weigh dish with the animal number/identification.
3. After you receive dissection training, complete dissection to remove the forelimb from the
body. Briefly:
a. Skin the forelimb, cut the clavicle, and remove the limb from the body.
b. Disarticulate the glenohumeral joint.
c. Remove the paw.
d. Wrap the limb in 1X PBS soaked gauze and put it in the weigh dish.
i. Make sure the limb remains moist and does not dry out.
4. When the dissections are complete, orient the limb in the weigh dish so the distal radius/ulna
(wrist) is pointed up or vertical and is exposed from the gauze.
a. Keep the gauze surrounding the rest of the limb soaked in 1X PBS.
b. Using a cotton tip, cover the exposed end of the limb with super glue.
c. Wait 10 minutes for the super glue to dry.
5. While waiting, prepare the pre-cut large diameter polycarbonate tubing (large pot):
a. File any residual plastic from the ends of the large pot.
b. File one end of the large pot so that it pressure-fits within the appropriate
test setup fixture.
i. Tape this end of the large pot so that the opening is half covered.

6. After 10 minutes, create the potting mixture:
a. Put two spoonfuls of Bondo into a medium plastic bag.
i. Avoid getting Bondo on the outside of the bag.
b. Put a small squirt (approximately the size of a dime) of Bondo red hardener into
the plastic bag.
c. Seal the plastic bag and mix quickly until a light gray-pink color is evenly
obtained throughout the mixture.
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d. Use the table edge to push the mixture down into the bottom of the plastic bag and
twist the bag to keep the mixture from being pushed back up.
e. Cut a small diagonal off of the bottom corner off the plastic bag.
7. Fill the taped large pot with the mixture until it comes out the half-taped end.
8. Insert the distal radius/ulna (i.e., super glued end of the limb) into the open end of the large
pot until the limb is about half-way submerged.
a. Wipe off any residual mixture that comes out the taped end of the large pot.
b. Cover the entire limb with 1X PBS soaked gauze and wait one hour for the
mixture to harden and dry.
9. After one hour, remove the tape from the large pot and file any extra hardened mixture off
the outside of the large pot.
10. File any residual plastic from the ends of the pre-cut small diameter polycarbonate tubing
(small pot).

11. Fill the open end of the small pot with super glue and insert the humeral head.
a. Hold for 10 seconds or until the glue sets.
b. Cover the entire limb with 1X PBS soaked gauze and wait 10 minutes for the
super glue to dry.
12. After 10 minutes, put super glue on the outside of the humerus which is exposed by the small
pot and wrap an orthodontic rubber band around this area.
a. Cover the entire limb with 1X PBS soaked gauze and wait 10 minutes for the
super glue to dry.
13. After 10 minutes, the limb is ready for mechanical testing.
a. If not testing immediately following the potting protocol, cover the limbs in 1X
PBS soaked gauze and store at 4°C until mechanical testing is performed
(maximum 1-2 hour delay).
Additional information.
• Potting limbs for LCL mechanical testing:
o Follow the dissection protocol above.
o Continue to dissect and remove all muscles/tendons and anterior/posterior
capsules from the limb.
▪ Only the medial and lateral collateral ligament should be intact.
▪ The medial collateral ligament (MCL) will be transected once the limb is
placed within the testing setup (see file Mechanical Testing_LCL Test
Setup).
o Pot both ends of the limb (i.e., humerus and radius/ulna) with the large pots
following the potting protocol above. Will not need small pots.
[7]

Materials.
Item
1X PBS, 1000 mL
Blue bench pads
Bondo body filler
Cotton tips
Forceps
Gauze
Lab tape
Large diameter polycarbonate
tubing (large pot)
Medium plastic bags
Metal file
Orthodontic rubber bands
Plastic spoons
Scalpel blades (size 11)
Scalpel handle
Scissors, bone
Scissors, dissection
Small diameter polycarbonate
tubing (small pot)
Super glue
Weigh dish

Company
Life Technologies
VWR
Grainger Inc.
McKesson
Fisher Scientific
Fisher Scientific
MidSci
McMaster-Carr

Catalog Number
14190136
56617-014
3RAP8
508715
16-100-120
22257155
MIDSCI-T25-3
8585K104

McMaster-Carr
Grainger Inc.
Amazon
Walmart
McKesson
McKesson
Fisher Scientific
Fisher Scientific
McMaster-Carr

1959T59
1NFN9
5/16” Medium 3.5 Oz Orthodontic
Elastic Rubber Bands
551573446
854370
487459
08-990
13-806-2
8585K102

McMaster-Carr
Fisher Scientific

7608A56
08-732-113
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B.1.2 Pronation-supination test setup
Safety.
• All work should be performed while wearing closed toed shoes, pants, lab coat, and gloves.
o May remove gloves only while touching the Computer Controller.
Protocol.
1. Equipment setup with load cell #2:

2. Turn on the red Start Knob beneath the Computer Controller.
a. Make sure the red indicator light above the Start Knob turns on.
3. On the Computer Controller, open the software in the following order and complete each
command sequentially:
a. MTL32
i. Open the shortcut, but do not change any settings.
b. TestBuilder
i. Open the shortcut.
ii. Click the icon “Open” → open folder “MTL32” →
open folder “Settings” → click “WUSTL-BiaxialSI.mss” → click “Open” → click “Online”.
c. LC Readouts 4-6 DOF
i. Open the shortcut.
ii. In the site ID enter WUSTL4 → click “Connect”.
iii. Click “Load Cell 2” to tare the load cell.
4. Load the desired mechanical test in the TestBuilder window by:
a. In the toolbar, click “Test” → open “Multi-Step Programming” → click the icon
“Open” → click “Yes” you want to proceed → open folder “MTL32” → open
“Rat_Elbow.tbm” → click “Open” → click “Replace” in the purple frame that
appears → click “Yes” you want to proceed with channel gains replaced → click
“Yes” you want to replace the limit settings.
b. In the Multi-Step Programming window, click the icon “Save”.
c. In the Multi-Step Programming window, click “Settings” and make sure the test
contains the following parameters for Axis 2 (only Axis 2 should be active; check
the small box to the right of the dropdown menu with the axis names):
i. Blocks = 5
ii. Step 1:
[9]

1. Axis 2, Alt Mode, Alt Mode = Uni2, Ctrl Mode = POS2
2. Set point = -0.85 N
3. Rate = 0.3 Hz
4. Start Point = Mean up
iii. Step 2:
1. Axis 2, Alt Mode, Alt Mode = Uni2, Ctrl Mode = POS2
2. Set point = 0.85 N
3. Rate = 0.3 Hz
4. Start Point = Max
iv. Make sure that the box next to the % Strain Inputs is not checked.
v. Click “Close” → click the icon “Save”.
5. In the TestBuilder window:
a. In the Multi-Step Programming window, click “Switch On” → click “Hi” (yellow
button).
b. In the Function Generator window, make sure only Axis 2 is turned on (noted by
a check in the small box to the right of the dropdown menu with the axis names
and the box second from left above is aqua).
i. Zero the current position by setting the Target Pt to 0 mm → click “Start
Ramp".
6. In the LC Readouts 4-6 DOF window, click “Load Cell 2” to tare the load cell again.
7. Orient the sample within the test setup by putting the small pot into the Humerus Fixture and
the large pot into the Ulna-Radius Fixture; secure each pot with the set screws.
a. Make sure to adjust the x-y-z position of the Humerus Fixture Stand so that the
limb is held at 90° and is completely level (within the same plane).
8. To run a test in the TestBuilder window:
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a. In the Function Generator window, click “DAQ Settings”.
i. Click “Create File” and select the location where you want to save the test
data and label the file with the following nomenclature
“Animal#_LimbSide_Date” (e.g., 5790_Left_04292015 or
5790_Right_04292015).
ii. Click “Save” → click “Close”.
b. In the Multi-Step Programming window, click “Reset” → click “Yes” you really
want to reset → click “Start Rec” → click “Start”.
[11]

i. At the end of the test, in the Function Generator set the Target Pt to 0 mm
and click “Start Ramp”.
ii. When actuator has stopped moving, click “Stop Rec”.
9. Between each test make sure to do the following:
a. In the Function Generator window within the TestBuilder window, zero the
current position of Axis 2 using the same method described previously in step 5.
b. Remove the limb and put in a new limb using the same method described
previously in step 7.
c. In the LC Readouts 4-6 DOF window, tare “Load Cell 2” again following the
same method previously in step 3.
d. Repeat step 8 to run another test.
10. To export data for analysis:
a. In the TestBuilder window toolbar, click “Export” → click “Export Data”.
b. In the DAQ Settings window within the TestBuilder window:
i. Select the desired file type for export (either CSV or Excel; CSV required
for MatLab analysis).
ii. Click “Browse Time Data” to select the desired file for export.
iii. Click “Export”.
c. Each test will have to be exported individually, so repeat step 10 for each test
completed.
11. Transfer data from the Computer Controller using a flash drive.
12. Clean up:
a. In the Multi-Step Programming window within the TestBuilder window, click
“Switch Off”.
b. Close all open windows on the Computer Controller.
c. Turn off the red Start Knob beneath the Computer Controller.
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i. Make sure the red indicator light above the Start Knob turns off.
d. Wipe down all surfaces of the test setup with a Clorox wipe.
i. If you touched the Computer Controller while wearing gloves, wipe it
down with a Clorox wipe.
Additional information.
• In order to manually adjust the position of the load cell, complete the following:
o In the Function Generator window within the TestBuilder window, click “Switch
On” → click “Hi” (yellow button).
▪ Select Axis 2 within the dropdown menu and make sure only it is turned
on (noted by a check in the small box to the right of dropdown menu with
axis names and the box second from the left above is aqua).
▪ In the Change Control Mode settings, make sure POS2 is selected.
▪ Manually adjust the position of the actuator (i.e., load cell) by setting the
Target PT to X mm → click “Start Ramp".
• Positive X will move the actuator in, while a negative X will move
the actuator out.
•

In order to set the load cell to a new zero position, complete the following:
o In the Function Generator window within the TestBuilder window, click “Switch
Off”.
o In the toolbar of the TestBuilder window, click “Setup” → click “Offset
Readout”.
o Select channel POS2 from the dropdown menu and make New readout value 0.00.
o Click “Offset” → click “Yes” you really want to offset readout.

•

In order to turn on the scope (X-Y Plot) to watch the test while it is running, complete the
following:
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o In the toolbar of the TestBuilder window, click “Utilities” → click “Scope”.
▪ Within the Scope window:
• Make sure the Y output is set to Uni 2 and the X output is set to
POS2 → click “Update”.
• Check small boxes next to Auto Scale Y-Axis and Auto Scale XAxis.
• Increase the number of data points shown from 1 to 100 in Skip
Pts.
• Click “Refresh” before each test begins.
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B.1.3 Lateral collateral ligament (LCL) test setup
Safety.
• All work should be performed while wearing closed toed shoes, pants, lab coat, and gloves.
o May remove gloves only while touching the Computer Controller.
Protocol.
1. Equipment setup with load cell #2:
a. Mount the camera above the limb, so the field-of-view (FOV) appears like the
image on the far right (include ruler within FOV).

2. Turn on the red Start Knob beneath the Computer Controller.
a. Make sure the red indicator light above the Start Knob turns on.
3. On the Computer Controller, open the software in the following order and complete each
command sequentially:
a. MTL32
i. Open the shortcut, but do not change any settings.
b. TestBuilder
i. Open the shortcut.
ii. Click the icon “Open” → open folder “MTL32” →
open folder “Settings” → click “WUSTL-BiaxialSI.mss” → click “Open” → click “Online”.
c. LC Readouts 4-6 DOF
i. Open the shortcut.
ii. In the site ID enter WUSTL4 → click “Connect”.
iii. Click “Load Cell 2” to tare the load cell.
4. Load the desired mechanical test in the TestBuilder window by:
a. In the toolbar, click “Test” → open “Multi-Step Programming” → click the icon
“Open” → click “Yes” you want to proceed → open folder “MTL32” → open
“Chelsey_LCLv2.tbm” → click “Open” → click “Replace” in the purple frame
that appears → click “Yes” you want to proceed with channel gains replaced →
click “Yes” you want to replace the limit settings.
b. In the Multi-Step Programming window, click the icon “Save”.
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c. In the Multi-Step Programming window, click “Settings” and make sure the test
contains the following parameters for Axis 2 (only Axis 2 should be active; check
the small box to the right of the dropdown menu with the axis names):
i. Step 1:
1. Axis 2, Ramp To, Ctrl Mode = POS2
2. Check box to the left of Rate/s
3. Set point = 40.0 mm
4. Rate = 0.05 Hz
5. Waveform = Ramp
6. Start Point = Min
i. Make sure that the box next to the % Strain Inputs is not checked.
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ii. Click “Close” → click the icon “Save”.
5. In the TestBuilder window:
a. In the Multi-Step Programming window, click “Switch On” → click “Hi” (yellow
button).
b. In the Function Generator window, make sure only Axis 2 is turned on (noted by
a check in the small box to the right of the dropdown menu with axis names and
the box second from left above is aqua).
i. Zero the current position by setting the Target Pt to 0 mm → click “Start
Ramp".
6. In the LC Readouts 4-6 DOF window, click “Load Cell 2” to tare the load cell again.
7. Orient the sample within the test setup by putting the large pot with the humerus into the
Humerus Fixture and the large pot with the radius/ulna into the Radial/Ulnar Fixture; secure
each pot with the set screws.
a. Make sure to adjust the angle and y position of the Radial/Ulnar Fixture Stand on
the Angle Specification Platform so that the limb is held at 90° and is completely
level (within the same plane).
b. Transect the medical collateral ligament (MCL).
8. To run a test in the TestBuilder window:
a. In the Function Generator window, click “DAQ Settings”.
i. Click “Create File” and select the location where you want to save the test
data and label the file with the following nomenclature
“Animal#_LimbSide_Date” (e.g., 5790_Left_04292015 or
5790_Right_04292015).
ii. Click “Save” → click “Close”.
b. Start recording a video with the camera.
c. In the Multi-Step Program window, click “Reset” → click “Yes” you really want
to rest → click “Start Rec” → click “Start”.
i. At the end of the test, click “Stop Rec” and stop camera video recording.
9. Between each test make sure to do the following:
a. In the Function Generator window within the TestBuilder window, zero the
current position of Axis 2 using the same method described previously in step 5.
b. Remove the limb and put in a new limb using the same method described
previously in step 7.
c. In the LC Readouts 4-6 DOF window, tare “Load Cell 2” again following the
same method previously in step 3.
d. Repeat step 8 to run another test.
10. To export data for analysis:
a. In the TestBuilder window toolbar, click “Export” → click “Export Data”.
b. In the DAQ Settings window within the TestBuilder window:
i. Select the desired file type for export (either CSV or Excel; CSV required
for MatLab analysis).
ii. Click “Browse Time Data” to select the desired file for export.
iii. Click “Export”.
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c. Each test will have to be exported individually, so repeat step 10 for each test
completed.
11. Transfer data from the Computer Controller using a thumb drive.
12. Clean up:
a. In the Multi-Step Programming window within the TestBuilder window, click
“Switch Off”.
b. Close all open windows on the Computer Controller.
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c. Turn off the red Start Knob beneath the Computer Controller.
i. Make sure the red indicator light above the Start Knob turns off.
d. Wipe down all surfaces of the test setup with a Clorox wipe.
i. If you touched the Computer Controller while wearing gloves, wipe it
down with a Clorox wipe.
Additional information.
• In order to manually adjust the position of the load cell, complete the following:
o In the Function Generator window within the TestBuilder window, click “Switch
On” → click “Hi” (yellow button).
▪ Select Axis 2 within the dropdown menu and make sure only it is turned
on (noted by a check in the small box to the right of dropdown menu with
axis names and the box second from the left above is aqua).
▪ In the Change Control Mode settings, make sure POS2 is selected.
▪ Manually adjust the position of the actuator (i.e., load cell) by setting the
Target PT to X mm → click “Start Ramp".
• Positive X will move the actuator in, while a negative X will move
the actuator out.
•

In order to set the load cell to a new zero position, complete the following:
o In the Function Generator window within the TestBuilder window, click “Switch
Off”.
o In the toolbar of the TestBuilder window, click “Setup” → click “Offset
Readout”.
o Select channel POS2 from the dropdown menu and make New readout value 0.00.
o Click “Offset” → click “Yes” you really want to offset readout.

•

In order to turn on the scope (X-Y Plot) to watch test while it is running, complete the
following:
o In the toolbar of the TestBuilder window, click “Utilities” → click “Scope”.
▪ Within the Scope window:
• Make sure the Y output is set to Uni 2 and the X output is set to
POS2 → click “Update”.
• Check small boxes next to Auto Scale Y-Axis and Auto Scale XAxis.
• Increase the number of data points shown from 1 to 100 in Skip
Pts.
• Click “Refresh” before each test begins.
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B.1.4 Muscle physiology testing
Safety.
• All work should be performed while wearing closed toed shoes, pants, lab coat, and gloves.
• While filling the dewer with liquid nitrogen wear cryo-gloves and safety glasses.
Solutions.
• In the fume hood, make 1 M HCl (total volume ~50 mL):
o 12.5 mL deionized H2O
o 4.106 mL HCl
o Add deionized H2O until the final volume of this solution is 50 mL.
o Store in the corrosive’s cabinet with the acids.
•

In the fume hood, make 1 M NaOH (total volume ~50 mL):
o 12.5 mL deionized H2O
o 2.64 mL NaOH
o Add deionized H2O until the final volume of this solution is 50 mL.
o Store in the corrosive’s cabinet with the bases.

•

NaHCO3 Solution
o 84 g NaHCO3
o 1 L deionized H2O

•

NaH2PO4 Solution
o 60 g NaH2PO4
o 1 L deionized H2O

•

MgSO4 Solution
o 60.2 g MgSO4
o 1 L deionized H2O

•

CaCl2 Solution
o 73.5 g CaCl2
o 1 L deionized H2O

•

Ringer’s Solution (total volume ~1 L):
o Must add chemicals below in the following order. Do not deviate.
o Solution will start cloudy but will become clear as stirred (500 stir speed).
o 500 mL deionized H2O
o 8.01 g NaCl
o 0.37 g KCl
o 24 mL NaHCO3 Solution
o 2 mL NaH2PO4 Solution
o 1.98 g Glucose (Dextrose)
o 2 mL MgSO4 Solution
o 4 mL CaCl2 Solution
o 0.01 g Curare
o Measure the pH, goal = 7.5
▪ Slowly add 1 M NaOH or 1 M HCl by dropper until the desired pH is
reached. Should not have to add a lot, if any.
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o Add deionized H2O until the final volume of this solution is 1 L.
o Store solution at 4°C.
Protocol.
Test preparation
1. Fill the test bath with Ringer’s solution.
2. Turn on heated circulating bath and set to 37°C.
3. Open LabView software for the desired test:
a. Active Muscle Testing
b. Passive Muscle Testing (file called “StressRelaxation2”)
4. Select a location to save your data and create a folder for each animal/muscle to be tested
using the following naming system: animal number/identification, limb side, muscle tested,
and date (e.g., 5097_Left_Biceps_01032020).
5. Turn on the three boxes:
a. Blue box on the top left shelf.
b. High-power bi-phase stimulator on the middle left shelf.
i. Make sure that it is set to stimulate at 80 V.
c. Dual-mode lever system on the bottom right shelf.

Dissection
1. Setup dissection station:
a. Put down a blue bench pad and tape down the nose cone.
b. Make sure you have dissection tools ready, including a scalpel handle, size 11
blades, dissection scissors, micro-dissection scissors, forceps, hemostat, needle
driver, gauze, and 5-0 coated vicryl suture with needle alloy.
2. Open/turn on large O2 tank secured next to the wall by the computer.
3. Open valve to the induction chamber and close valve to the nose cone.
4. Put rat into the induction chamber and turn on 5% isoflurane until anesthetized.
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5. Once rat breathing has stabilized, decrease isoflurane to 2.5%, open the valve to the nose
cone, close the valve to the induction chamber, and move the rat to the nose cone.
a. Closely, monitor rat breathing rate during dissection. If breathing rate increases
and/or limbs start to move turn up the percent isoflurane. If breathing becomes
shallow and/or paw color becomes pale-white turn down the percent isoflurane.
6. Put Altalube gently on both eyes using a cotton tip.
7. Skin the left arm and clear away soft tissue surrounding the desired muscle.
a. Make sure to have gauze ready to help control bleeding.
8. On the proximal tendon of the desired muscle use a needle driver and 5-0 coated vicryl suture
with needle alloy and use the following suturing procedure:
a. Tie two square knots around the tendon.
b. Pierce the tendon proximal to the previous two knots.
c. Tie two more square knots around the tendon.
d. Leave long strands of suture on either end and tie a loose knot leaving an open
loop → DO NOT PULL TIGHT.
9. On the distal tendon of the desired muscle use a needle driver and 5-0 coated vicryl suture
with needle alloy and use the following suturing procedure:
a. Tie two square knots around the tendon.
b. Pierce the tendon distal to the previous two knots.
c. Tie two more square knots around the tendon.
d. Leave long strands of suture on either end.
e. Thread the black lever arm from the test setup with one end of the suture and tie
three knots to secure it to the end of the tendon.
i. MAKE IT AS TIGHT AS POSSIBLE.
10. Cut the tendon above and below the proximal and distal suturing, respectively.
11. Move dissected muscle immediately to Ringer’s Solution in the test bath.
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Test setup
1. Put the black lever arm back onto the test system and secure it with an Allen wrench.
a. Make sure the black lever arm is completely vertical.
2. On the main GUI, located under the “Waveform Control” button, set the “length offset
(mm)” to -10 (because rat muscles are large).
3. Thread the open loop (proximal tendon) onto the cannula mount and pull the loop as tight as
possible within the cannula grove.
a. Make sure the muscle is slack and not pulled tight.
4. Create another loop around the cannula mount, pull tight within the cannula grove, and knot
twice.
5. On the main GUI, click “Set slack tension”:
a. Extend the muscle length using either the black knob to the left of the test setup or
the two black knobs on the track (front and back of the test setup).
b. Continue to lengthen the muscle until the new GUI flashes “Target voltage has
been reached” in green and red.
6. Measure the muscle length using an external ruler and record muscle length in mm.
Active muscle testing
• Must complete this entire test protocol within 30 minutes after muscle dissection.
1. Write in the following parameters on the main GUI near the “Controlling stimulus” button:
a. Pulse width (ms) = 0.3
b. Twitch selected
c. Frequency (Hz) = 225
d. Duration (ms) = 330
2. Above the “Save Record” button, write in the file path to the location of the folder previously
made to save the test data.
3. Under the “Save Record” button, write in Twitch1 and check the box next to “Auto save next
after contraction.”
a. Make sure that the file saves after the muscle stimulation and contraction.
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4. Check the box next to “Auto adjust cursors” below the voltage-time graph.
a. Using the cursors on the graph to calculate the ∆y (∆voltage) and record this
value; it will help determine if the force is increasing or decreasing.
5. Click the “Waveform Control” button on the main GUI and set the following parameters:
a. Amplitude (% LF) = 0
b. Hold (ms) = 120
c. Acquire time (s) = 1.8
6. Click “Generate Waveform”.
7. At slack length, on the main GUI click the “Capture” button to twitch the muscle.
a. Calculate the ∆y (∆voltage) for the twitch.
8. On the main GUI, located under the “Waveform Control” button, set the “length offset
(mm)” to a 10% increase in length and wait 30 seconds (e.g., original muscle length = 15
mm, 10% muscle length = 1.5 mm, and original length offset = -10 mm → set new length
offset = -8.5 mm).
a. Record length offset for each twitch.
9. After 30 seconds, click the “Capture” button and repeat the previous step (step 8).
a. Calculate the ∆y (∆voltage) for each twitch.
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b. Repeat steps 8-9 until the ∆y (∆voltage) decreases compared to previously
recorded values.
10. Write in the following parameters on the main GUI near the “Controlling stimulus” button:
a. Pulse width (ms) = 0.3
b. Train selected
c. Frequency (Hz) = 225
d. Duration (ms) = 330
11. Under the “Save Record” button, write in Train1 and check the box next to “Auto save next
after contraction.”
a. Make sure that the file saves after the muscle stimulation and contraction.
12. Click the “Waveform Control” button on the main GUI and set the following parameters:
a. Amplitude (% LF) = 0
b. Hold (ms) = 120,000
c. Acquire time (s) = 125
13. Click “Generate Waveform”.
14. From the twitch experiments, find the maximum ∆y (∆voltage) and the associated muscle
length (i.e., maximal twitch muscle length).
15. On the main GUI, located under the “Waveform Control” button, set the “length offset
(mm)” to 10% below the maximal twitch muscle length found in the previous step (step n)
and wait two minutes (e.g., actual maximal twitch muscle length = 25 mm (corresponding
length offset = 15 mm; because originally set to -10 mm) and 10% original muscle length =
1.5 mm → set new length offset = 13.5 mm).
a. Record length offset for each train.
16. After two minutes, click the “Capture” button.
a. Calculate the ∆y (∆voltage) for each train.
17. On the main GUI, located under the “Waveform Control” button, set the “length offset
(mm)” to 10% increase in length and wait two minutes (e.g., length offset = 13.5 mm and
10% original muscle length = 1.5 mm → set new length offset = 15 mm).
18. After two minutes, click the “Capture” button.
a. Calculate the ∆y (∆voltage) for each train.
19. Repeat steps 17-18 until the ∆y (∆voltage) decreases compared to previously recorded
values.
Passive muscle testing
1. On the main GUI, located under the “Waveform Control” button, set the “length offset
(mm)” to -10 mm and wait 15 minutes to allow muscle recovery/relaxation from active
muscle testing.
2. Turn off the blue box on the top left shelf.
3. After 15 minutes, measure the muscle length using an external ruler and record muscle length
in mm.
4. Click the “Waveform Control” button on the main GUI and set the following parameters:
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a.
b.
c.
d.
e.
f.

Lf (mm) = muscle length measured in previous step (step 3)
Amplitude (% LF) = 0
Velocity (Lf/s) = 2
Hold (ms) = 120,000
Return (Lf/s) = 2
Acquire time (s) = 125

5. Click “Generate Waveform”.
6. Under the “Save Record” button, write in Passive1 and check the box next to “Auto save
next after contraction.”
a. Make sure that the file saves after each stress relaxation test.
7. Click the “Capture” button.
8. On the main GUI, located under the “Waveform Control” button, set the “length offset
(mm)” to 10% increase in length and wait two minutes (e.g., length offset = -10 mm and 10%
original muscle length = 1.5 mm → set new length offset = -8.5 mm).
9. After two minutes, click the “Capture” button.
10. Repeat steps 8-9 until the muscle fails.
Post-mechanical testing
1. When the Passive Muscle Testing is complete, remove the muscle from the test setup and
remove the sutures from the muscle.
2. Put the muscle in a weigh boat, weigh, and record.
3. When done with the animal, sacrifice by a bilateral thoracotomy to collapse the lungs and
transect the right ventricle of the heart to bleed out.
a. Close or cover the chest cavity to prevent blood squirting on you.
Post-mechanical testing histology preparation
1. Fill dewer with liquid nitrogen.
2. Put 2-methylbutane into the small metal container and cover with aluminum foil.
3. Cut a small piece of cork and parafilm that will fit the muscle.
4. Put the parafilm on top of the cork and the muscle on top of the parafilm.
5. Put one dissection pin through each tendon or end of the muscle to secure it to the parafilm
and cork.
6. Cut a 4” x 4” piece of aluminum foil and using Sharpie write the name of the sample on the
foil, include the following information: animal number/identification, limb side, muscle
tested, and date (e.g., 5097 Left Biceps 01032020).
7. Turn the aluminum foil over so the writing is on the bottom and put it into -80°C to pre-chill.
8. Remove the aluminum cover on the metal container with the 2-methylbutane and put the
container into the dewer with liquid nitrogen so that it is 3/4 submerged.
9. Wait approximately one minute or until the rate of bubbling within the 2-methylbutane
decreases.
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10. Then drop the pinned muscle into the 2-methylbutane for 15-20 seconds.
a. Carefully remove the sample from the 2-methylbutane using long-nose forceps
and immediately put it into the -80°C on top of the pre-labeled aluminum foil.
11. Fold edges of the aluminum foil around the pinned muscle using the forceps to cover/seal it
completely.
a. Make sure to never touch the muscle or aluminum foil with your fingers/hands;
could create freeze/thaw issues.
12. Store muscle in aluminum foil at -80°C until ready to cryo-section for histology and/or
immunohistochemistry.
Clean up
1. After the muscle is removed from the test setup, use the vacuum to remove the Ringer’s
Solution.
2. Rinse the water bath with deionized H2O twice (use the vacuum to remove it).
3. Turn off the heat circulating bath, high-power bi-phase simulator on the middle left shelf, and
the dual-mode lever system on the bottom right shelf.
4. Turn off the anesthesia machine.
5. Close/turn off the large O2 tank secured next to the wall by the computer.
6. Clean the induction chamber, dissection space, and dissection tools.
7. Wipe down bench tops with 75% Ethanol.
Additional information.
• Ringer’s Solution should be replaced between each muscle tested.
•

Muscle maximum tetanic tension is the maximum ∆y (∆voltage) from the train experiments.

Materials.
Item
2-methylbutane (C5H12)
5-0 Vicryl suture with needle
Altalube ointment
Blue bench pads
Calcium chloride (CaCl2)
Cork sheet
Cotton tips
Curare
Dissection pins
Ethanol
Forceps
Forceps, extra long

Company
Fisher Scientific
Fisher Scientific
Sigma
VWR
Sigma
VWR
McKesson
Sigma
Fisher Scientific
Fisher Scientific
Fisher Scientific
Fisher Scientific
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Catalog Number
O3551-4
501180848
59390-198-50
56617-014
C5670-100G
23420-708
508715
T2379-100MG
NC9681411
04355223
13-812-39
10-316A

Gauze
Glucose (Dextrose)
Hydrochloric acid (HCl)
Hemostat
Isoflurane, 250 mL
Magnesium sulfate (MgSO4)
Monosodium phosphate (NaH2PO4)
Needle driver
Parafilm
Potassium chloride (KCl)
Razor blades
Scalpel blades (size 11)
Scalpel handle
Scissors, dissection
Scissors, micro-dissection
Sodium bicarbonate (NaHCO3)
Sodium chloride (NaCl)
Sodium hydroxide (NaOH)
Weigh dish

Fisher Scientific
Sigma
Sigma
Fisher Scientific
McKesson
Sigma
Sigma
Fisher Scientific
Fisher Scientific
Sigma
Fisher Scientific
McKesson
McKesson
Fisher Scientific
Fisher Scientific
Sigma
Sigma
Sigma
Fisher Scientific
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22-257-155
G8270-100G
258148-500ML
13-812-45
821218
M2643-500G
S3139-250G
08-966
13-374-12
P9541-500G
18100970
854370
487459
13-806-2
17-467-496
S5761-500G
S7653-1KG
72068-100ML
08-732-113

B.1.5 Histology for paraffin embedded rat forelimbs
Safety.
• All work should be performed while wearing closed toed shoes, pants, lab coat, and gloves.
• All work with 14% EDTA and formalin should be performed within the fume hood.
Solutions.
• In the fume hood, make 14% EDTA (total volume ~600 mL):
o It is best to make this at least the day before it is needed.
o Can also be made in bulk and stored for 1-2 weeks.
o Add 70 g EDTA to 350 mL distilled H2O, stirring constantly (400 stir speed).
o Add 15 mL Ammonium Hydroxide and wait 15 seconds.
o Repeat previous step two more times (overall, add 15 mL Ammonium Hydroxide
a total of three times).
o Add 150 mL distilled H2O and change stir speed to 700.
o Wait five minutes.
o Measure the pH, goal = pH 7.2
▪ Slowly add Ammonium Hydroxide by dropper until the desired pH is
reached.
• Wait 15 seconds between each addition of Ammonium Hydroxide.
•

Make 30%, 50%, and 70% Ethanol solutions using distilled H2O (make enough 30% and
50% Ethanol to fill each tube once; make enough 70% Ethanol to fill each tube twice).

Protocol.
1. Thaw the rat for 24 hours on top of and covered with a blue bench pad.
a. If the forelimb was already removed from the rat body, then thaw for one hour on
top of and covered with a blue bench pad.
2. Label a plastic weigh dish with the animal number/identification.
3. If limbs are already removed from the animal body proceed to the next step, otherwise after
you receive dissection training, complete dissection to remove the limb from the body.
Briefly:
a. Skin the forelimb, cut the clavicle, and remove the limb from the body.
b. Disarticulate the glenohumeral joint.
c. Remove the paw.
4. After you receive dissection training, complete dissection to remove excess muscle from the
limb.
a. Be careful to not dissect down too far and disrupt the tissue(s) of interest (e.g.,
anterior capsule).
b. Wrap the limb in 1X PBS soaked gauze and put it in the weigh dish.
i. Make sure the limb remains moist and does not dry out.
5.

Prepare the 90° limb mount:
a. Cut a thin popsicle stick in half and use a hot glue gun to glue the end of one cut
popsicle stick to the end of a whole popsicle stick to form an “L”.
i. Make sure that the two pieces of the stick are at 90° relative to each other.
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ii. Pay attention to orientation of the “L”. The whole popsicle stick should be
the vertical part of the “L”. However, the direction to which the half
popsicle stick is added is different for left and right limbs. Limbs should be
oriented so that the lateral collateral ligament (LCL) always faces out
(i.e., not against the sticks).
b. Use the remaining half popsicle stick and hot glue it on top of the vertical part of
the “L” so that the “L” is a level surface for the limb to rest on.

6. Put the limb on the “L”; limbs should be oriented on the “L” so the LCL faces out (i.e., not
against the sticks).
7. Put hot glue under and on top of the most proximal and distal ends of the humerus and
radius/ulna, respectively.
a. Pay attention to the joint angle. It should be at 90° like the popsicle sticks forming
the “L”.
b. Hold for approximately 10-15 seconds until the hot glue sets.
8. After the glue is dry, put a small rubber band around the most proximal and distal ends of the
humerus and radius/ulna, respectively.
9. Label the end of the vertical popsicle stick with the animal number/identification, including
the limb side (e.g., 5097 Left).

10. Put a maximum of three limbs into one 500 mL beaker and orient the limbs so that the long
vertical popsicle stick (with the limb label) is pointed up.
11. Put lab tape across the top of the vertical popsicle stick, as close to the top of the beaker as
possible, to keep the limb stationary.
a. Make sure that the limbs within the beaker are evenly spaced and not touching.
b. Put limbs from the same group (e.g., injury, treatment, limb side) within each
beaker to make it easier to keep track of limbs.
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12. Label each beaker with the following information:
a. Limb group, limb side, 10% Neutral Buffered Formalin, Your Initials, Date. (e.g.,
Injury II 42/42 IM-FM, Left, 10% Neutral Buffered Formalin, CLD, 01012020).
13. In the fume hood, add 10% neutral buffered formalin to the beaker until the limbs are
completely submerged.
14. Cover the beaker with parafilm and leave inside the fume hood for 24 hours.
15. After 24 hours, remove the parafilm and dispose of the formalin in an appropriately labeled
waste container.
a. It is easiest to remove formalin from the beaker, without disturbing the limbs, by
using a flask and tubing hooked up to the vacuum line in the fume hood.
b. Repeat steps 13 and 14.
16. After another 24 hours, remove the parafilm and dispose of the formalin in an appropriately
labeled waste container.
a. It is easiest to remove formalin from the beaker, without disturbing the limbs, by
using a flask and tubing hooked up to the vacuum line in the fume hood.
b. Repeat steps 13 and 14.
17. Make necessary volume required of 14% EDTA and label 50 mL conical tubes with the
following information for each limb:
a. Limb, limb side, 14% EDTA with Ammonium Hydroxide, Your initials, Date.
(e.g. 5097, Left, 14% EDTA with Ammonium Hydroxide, CLD, 01042020).
18. After another 24 hours, remove the parafilm and dispose of the formalin in an appropriately
labeled waste container.
a. It is easiest to remove formalin from the beaker, without disturbing the limbs, by
using a flask and tubing hooked up to the vacuum line in the fume hood.
19. Remove limb from the beaker and popsicle stick mount and put it into the appropriately
labeled 50 mL conical tube.
a. May need to cut down the distal and proximal humerus and radius/ulna,
respectively, so the limb fits within the tube. Make sure not to shatter the bones
too close to the joint.
20. Fill the tube with distilled H2O, cap the tube, and put on a rocker table for 15 minutes.
21. After 15 minutes, pour out the distilled H2O.
a. Pour into a separate waste beaker rather than directly into the waste in case the
limb is accidently dumped from the tube.
22. Repeat steps 20 and 21 two more times (a total of three washes with distilled H2O).
23. Pour out the distilled H2O, add 40 mL 14% EDTA to the tube, cap the tube, and put on a
rocker table for 24 hours.
24. After 24 hours, pour out 14% EDTA, add new 40 mL 14% EDTA, cap the tube, and put on a
rocker table.
a. Pour into a separate waste beaker rather than directly into the waste in case the
limb is accidently dumped from the tube.
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25. Every other day for the next 17 days: pour out 14% EDTA, add new 40 mL 14% EDTA, cap
the tube, and put on a rocker table.
a. Pour into a separate waste beaker rather than directly into the waste in case the
limb is accidently dumped from the tube.
26. Pour out the 14% EDTA, fill tube with distilled H2O, cap the tube, and put on a rocker table
for 15 minutes.
27. After 15 minutes, pour out the distilled H2O.
a. Pour into a separate waste beaker rather than directly into the formalin waste in
case the limb is accidently dumped from the tube.
28. Fill the tube with distilled H2O, cap the tube, and put on a rocker table for 15 minutes.
29. Repeat steps 27 and 28 one more time (a total of three washes with distilled H2O).
30. Pour out the distilled H2O, fill tube with 30% Ethanol, cap the tube, and put on a rocker table
for 30 minutes.
31. After 30 minutes, pour out the 30% Ethanol, fill tube with 50% Ethanol, cap the tube, and put
on a rocker table for 30 minutes.
32. After 30 minutes, pour out the 50% Ethanol, fill tube with 70% Ethanol, cap the tube, and put
on a rocker table for 30 minutes.
33. While waiting, label new 50 mL conical tubes with the following information:
a. Limb, limb side, 70% Ethanol, Lake Lab, Your initials, Date. (e.g. 5097, Left,
70% Ethanol, Lake Lab, CLD, 01222020).
34. After 30 minutes, pour out the 70% Ethanol and transfer limbs to the new appropriately
labeled 50 mL conical tubes.
35. Fill tube with 70% Ethanol, cap the tube, and submit to the MRC histology core.
Additional information.
• A week prior to finishing this histology protocol, fill out the online paperwork on iLabs
(https://wustl.ilabsolutions.com/account/login) to submit limbs to the MRC histology core.
o Typically, complete:
▪ Three 5 µm sections through the mid-plane (center) of the joint per limb.
▪ Stain for hematoxylin and eosin (H&E), toluidine blue, and unstained.
• Unstained sections should not be coverslipped.
Materials.
Item
10% Neutral buffered formalin
1X PBS, 1000 mL
50 mL Conical tubes
Ammonium hydroxide (NH4OH)
Blue bench pads
Ethylenediaminetetraacetic acid (ETDA)

Company
Sigma
Life Technologies
Fisher Scientific
BDH
VWR
BDH
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Catalog Number
HT501128-4L
14190136
14-432-22
BDH3014-500ML
56617-014
BDH9232-500G

Ethanol
Gauze
Glue (for hot glue gun)
Hot glue gun
Lab tape
Parafilm
Popsicle sticks
Scalpel blades (size 11)
Scalpel handle
Scissors, bone
Scissors, dissection
Small rubber bands

Fisher Scientific
Fisher Scientific
Michaels
Michaels
MidSci
Fisher Scientific
Michaels
McKesson
McKesson
Fisher Scientific
Fisher Scientific
Amazon

Weigh dish

Fisher Scientific
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04355223
22-257-155
M10203512
10145112
MIDSCI-T25-3
13-374-12
10094698
854370
487459
08-990
13-806-2
300 Rubber Bands
Small One Size 1/2'
08-732-113

B.1.6 Lateral collateral ligament (LCL) contrast enhanced µCT
Safety.
• All work should be performed while wearing closed toed shoes, pants, lab coat, and gloves.
• All work with Phosphomolybdic Acid (PMA) should be completed within the fume hood
while wearing double gloves.
Solutions.
• In the fume hood, make 3% PMA in 70% Ethanol:
o Based on the number of limbs to stain, calculate the desired solution amount
using the excel sheet “LCL Contrast Enhanced uCT_Calculate PMA”.
o To stain one limb, use the following:
▪ 70% Ethanol:
• Add 33.95 mL Ethanol to 14.55 mL distilled H2O
▪ 3% PMA in 70% Ethanol:
• Add 1.5 mL PMA to 48.5 mL 70% Ethanol
Protocol.
1. Thaw the rat for 24 hours on top of and covered with a blue bench pad.
a. If the forelimb was already removed from the rat body, then thaw for one hour on
top of and covered with a blue bench pad.
2. After 24 hours, label a plastic weigh dish with the animal number/identification.
3. If limbs are already removed from the animal body proceed to the next step, otherwise after
you receive dissection training, complete dissection to remove the limb from the body.
Briefly:
a. Skin the forelimb, cut the clavicle, and remove the limb from the body.
b. Disarticulate the glenohumeral joint.
c. Remove the paw.
4. After you receive dissection training, complete dissection to remove excess muscle from the
limb.
a. Be careful to not disrupt the tissue(s) of interest (e.g., LCL).
b. Wrap the limb in 1X PBS soaked gauze and put it in the weigh dish.
i. Make sure the limb remains moist and does not dry out.
5.

Prepare the 90° limb mount:
a. Cut a thin popsicle stick in half and use a hot glue gun to glue the end of one cut
popsicle stick to the end of a whole popsicle stick to form an “L”.
i. Make sure that the two pieces of the stick are at 90° relative to each other.
ii. Pay attention to orientation of the “L”. The whole popsicle stick should be
the vertical part of the “L”. However, the direction to which the half
popsicle stick is added is different for left and right limbs. Limbs should be
oriented so that the LCL always faces out (i.e., not against the sticks).
b. Use the remaining half popsicle stick and hot glue it on top of the vertical part of
the “L” so that the “L” is a level surface for the limb to rest on.
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6. Put the limb on the “L”; limbs should be oriented on the “L” so the LCL faces out (i.e., not
against the sticks).
7. Put hot glue under and on top of the most proximal and distal ends of the humerus and
radius/ulna, respectively.
a. Pay attention to the joint angle. It should be at 90° like the popsicle sticks forming
the “L”.
b. Hold for approximately 10-15 seconds until the hot glue sets.
8. After the glue is dry, put a small rubber band around the most proximal and distal ends of the
humerus and radius/ulna, respectively.
9. Label the end of the vertical popsicle stick with the animal number/identification, including
the limb side (e.g., 5097 Left).

10. Put a maximum of three limbs into one 500 mL beaker and orient the limbs so that the long
vertical popsicle stick (with the limb label) is pointed up.
11. Put lab tape across the top of the vertical popsicle stick, as close to the top of the beaker as
possible, to keep the limb stationary.
a. Make sure that the limbs within the beaker are evenly spaced and not touching.
b. Put limbs from the same group (e.g., injury, treatment, limb side) within each
beaker to make it easier to keep track of limbs.
12. Label each beaker with the following information:
a. Limb group, limb side, 10% Neutral Buffered Formalin, Your Initials, Date. (e.g.,
Injury II 42/42 IM-FM, Left, 10% Neutral Buffered Formalin, CLD, 01012020).
13. In the fume hood, add 10% neutral buffered formalin to the beaker until the limbs are
completely submerged.
14. Cover the beaker with parafilm and leave inside the fume hood for 24 hours.
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15. After 24 hours, remove the parafilm and dispose of the formalin in an appropriately labeled
waste container.
a. It is easiest to remove formalin from the beaker, without disturbing the limbs, by
using a flask and tubing hooked up to the vacuum line in the fume hood.
b. Repeat steps 13 and 14.
16. After another 24 hours, remove the parafilm and dispose of the formalin in an appropriately
labeled waste container.
a. It is easiest to remove formalin from the beaker, without disturbing the limbs, by
using a flask and tubing hooked up to the vacuum line in the fume hood.
b. Repeat steps 13 and 14.
17. Make necessary volume required of 3% PMA in 70% Ethanol and label 50 mL conical tubes
with the following information for each limb:
a. Limb, limb side, 3% Phosphomolybdic Acid in 70% Ethanol, Your initials, Date.
(e.g. 5097, Left, 3% Phosphomolybdic Acid in 70% Ethanol, CLD, 01042020)
18. After another 24 hours, remove the parafilm and dispose of the formalin in an appropriately
labeled waste container.
a. It is easiest to remove formalin from the beaker, without disturbing the limbs, by
using a flask and tubing hooked up to the vacuum line in the fume hood.
19. Remove limb from the beaker and popsicle stick mount and put it into the appropriately
labeled 50 mL conical tube.
a. May need to cut down the distal and proximal humerus and radius/ulna,
respectively, so the limb fits within the tube. Make sure not to shatter the bones
too close to the joint.
20. Fill the tube with distilled H2O, cap the tube, and put on a rocker table for 15 minutes.
21. After 15 minutes, pour out the distilled H2O.
a. Pour into a separate waste beaker rather than directly into the waste in case the
limb is accidently dumped from the tube.
22. Repeat steps 20 and 21 two more times (a total of three washes with distilled H2O).
23. Pour out the distilled H2O, add 3% PMA in 70% Ethanol to the tube, cap the tube, and put on
a rocker table for 72 hours.
24. Take to MRC imaging core to scan with µCT.
Additional information.
• Prior to starting this protocol, sign up online on iLabs
(https://wustl.ilabsolutions.com/account/login) to reserve time on the µCT40 Scanco.
o Previously, limbs in 2% agarose inside a 30 mm diameter tube were scanned
using the following settings:
▪ 15 µm3 isometric voxel size
▪ 70 kVp x-ray tube potential
▪ 300 ms integration time
▪ 114 µA x-ray intensity
[36]

Materials.
Item
10% Neutral buffered formalin
1X PBS, 1000 mL
50 mL Conical tubes
Blue bench pads
Ethanol
Gauze
Glue (for hot glue gun)
Hot glue gun
Lab tape
Parafilm
Phosphomolybdic acid (PMA)
Popsicle sticks
Scalpel blades (size 11)
Scalpel handle
Scissors, bone
Scissors, dissection
Small rubber bands
Weigh dish

Company
Sigma
Life Technologies
Fisher Scientific
VWR
Fisher Scientific
Fisher Scientific
Michaels
Michaels
MidSci
Fisher Scientific
Sigma
Michaels
McKesson
McKesson
Fisher Scientific
Fisher Scientific
Amazon
Fisher Scientific
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Catalog Number
HT501128-4L
14190136
14-432-22
56617-014
04355223
22-257-155
M10203512
10145112
MIDSCI-T25-3
13-374-12
319279-500ML
10094698
854370
487459
08-990
13-806-2
300 Rubber Bands
Small One Size 1/2'
08-732-113

B.1.7 Biochemistry
Safety.
• All work should be performed while wearing closed toed shoes, pants, lab coat, and gloves.
• All work with the following chemicals should be performed in the fume hood:
o Acetic acid
o Formic acid
o HCl
o Isopropanol
o NaOH
o Perchloric acid
▪ Use a glass pipette to transfer Perchloric acid.
▪ If undiluted, wear a lab coat with a lab apron on top and heavy duty acid
gloves; use one glass section of the fume hood as a face/body shield (with
arms inserted on either side of the glass section) and/or wear a face shield.
▪ If diluted, wear cotton lab coat with one pair of nitrile gloves; use one
glass section of the fume hood as a face/body shield (with arms inserted
on either side of the glass section) and/or wear safety glasses.
Solutions.
• Make all solutions below before starting this protocol.
• Vortex/stir solutions before pipetting into a new container.
Hydroxyproline assay (OHP)
• Papain Solution (total volume ~200 mL):
o 25 mg Papain
o 2.76 g Sodium phosphate
o 0.1576 g Cysteine-HCl
o 2 mL 0.5 M EDTA
o 150 mL deionized H2O
o Measure the pH, goal = 6.5
▪ Add 1 M NaOH by dropper until the desired pH is reached.
o Add deionized H2O until the final volume of this solution is 200 mL.
o Store solution as 10 mL aliquots in 15 mL conical tubes at -20°C.
▪ Solution is stable for one year at -20°C.
▪ Working solution can be stored at 4°C for 1-2 days.
•

In the fume hood, make Chloramine T Stock Buffer (total volume ~1 L):
o 54.6 g Citric acid (monohydrate)
o 70 g Sodium acetate
o 34 g NaOH
o 12 mL Acetic acid
o Add deionized H2O until the final volume of this solution is 1 L.

•

In the fume hood, make 4 M HCl (total volume ~50 mL):
o 12.5 mL deionized H2O
o 16.423 mL HCl
o Add deionized H2O until the final volume of this solution is 50 mL.
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o Store in the corrosive’s cabinet with the acids.
•

In the fume hood, make 4 M NaOH (total volume ~50 mL):
o 12.5 mL deionized H2O
o 10.561 mL NaOH
o Add deionized H2O until the final volume of this solution is 50 mL.
o Store in the corrosive’s cabinet with the bases.

•

In the fume hood, make 1 M NaOH (total volume ~50 mL):
o 12.5 mL deionized H2O
o 2.64 mL NaOH
o Add deionized H2O until the final volume of this solution is 50 mL.
o Store in the corrosive’s cabinet with the bases.

Dimethylmethylene blue assay (DMMB)
• 10 mg/mL Chondroitin Sulfate Standard (total volume ~5 mL):
o 50 mg Chondroitin sulfate
o 5 mL 1X PBS
o Store solution as 200 µL aliquots in Eppendorf tubes at -20°C.
▪ Solution is stable for six months at -20°C.
•

In the fume hood, make 1,9-dimethylemethylene blue dye (total volume ~1 L):
o Add 5 mL Ethanol into a 50 mL conical tube.
o 2.0 g Sodium formate
o 21 mg 1,9-dimethylemethylene blue
▪ Vortex until dissolved.
o Pour this mixture into an aluminum foil covered container with 500 mL deionized
H2O.
o Rinse the 50 mL conical tube with a series of deionized H2O washes (totaling 300
mL); so final volume of the solution in the beaker is 800 mL.
o Measure the pH, goal = 3.0
▪ Add Formic acid by dropper until the desired pH is reached.
o Add deionized H2O until the final volume of this solution is 1 L.
▪ Make sure final solution is protected by light (container and lid
completely covered in aluminum foil).
▪ Solution is stable for three months.

Ninhydrin total protein assay (NTP)
• In the fume hood, make 4 M Acetic Acid (total volume ~400 mL):
o Make at least two days before you need to make the Ninhydrin Working Reagent.
o 217.6 g Sodium acetate trihydrate
o 150 mL deionized H2O
o 40 mL Acetic acid
o Put solution on a hot plate with a stir bar:
▪ Recommended hot plate temperature is 30°C; maximum 60°C (any higher
will activate the reagents)
▪ 500 stir speed
o Will take several hours for the solutes to dissolve.
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o Store container in the flammables cabinet for 24 hours to allow complete ion
dissociation.
o After 24 hours, measure the pH, goal = 5.52
▪ Add 4 M HCl by dropper until the desired pH is reached (should require
less than 5 mL 4 M HCl).
• Adding more than 5 mL HCl will destroy this buffer.
▪ If the starting pH is within ±0.5 of goal pH (5.02-6.02) do not add any
HCl.
o Add deionized H2O until the final volume of this solution is 400 mL.
•

In the fume hood, make the Ninhydrin Working Reagent (total volume ~50 mL):
o 120 mg SnCl2
o 37.2 mL Ethylene glycol
▪ Dissolve with stirring (500 stir speed).
o 980 mg Ninhydrin
o 19.2 mL 4 M Acetic Acid
▪ Dissolve with stirring (500 stir speed).
o Color of the final solution should be a translucent light purple.
▪ If solutes appear to be dissolved, but the solution is a translucent light red
color, let it sit overnight at -20°C. Check the color of the solution the next
morning, it should now be a translucent light purple (if not, remake the
Ninhydrin Working Reagent).
▪ If the solution is dark purple, remake the 4 M Acetic Acid because too
much HCl was added while measuring the pH of the solution and so the
buffer is not good; then remake the Ninhydrin Working Reagent.
o Solution is stable for six months at -20°C.

•

Total Protein Standard
o The standard for the total protein assay is a factory stock “Amino Acid Collagen
Hydrolysate”.
▪ Aliquot the factory stock as 260 µL in Eppendorf tubes and store at -20°C.
• Each Eppendorf tube is enough to run two 96-well plates.
▪ Working aliquot can be stored at 4°C for 1-2 days.

Protocol.
• Plan your 96-well plates for all assays before starting this protocol. All samples and
standards must be run in triplicate.
• Vortex/stir solutions, samples, or standards before pipetting into a new container.
• If your standards curve is not linear, you must complete the protocol again because it is only
possible to analyze results if the standards curve is linear.
Wet weight
1. Remove sample from -80°C and wait 5 minutes.
2. Put sample on weigh paper, weigh, and record.
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Dry weight
1. Label a cryovial with the following information: Limb, limb side, tissue, your initials, and
date (e.g., 5097 Left, Anterior Capsule, CLD, 02012020).
2. Put the sample in the appropriately labeled cryovial and seal with parafilm.
a. Poke a small hole in the parafilm.
b. Will not need the cryovial screw top.
3. Lyophilize the sample for 24 hours.
a. You must be trained by a member of the Setton Lab before you use their
Lyophilizer.
b. After training, following the procedure below:
i. Turn on the freezer switch on the bottom right side.
ii. Push the refrigerator button and wait until the green light is at the bottom
of the curve before proceeding to the next step.
iii. Turn on the vacuum switch, then push the vacuum button (auto) and wait
until the green light is at the bottom of the curve before proceeding to the
next step. Vacuum will make a lot noise.
iv. Put samples in a glass container and then seal container with a rubber lid.
v. Turn dial 180° and make sure vacuum continues to hold green light at the
bottom of the curve.
vi. When finished:
1. Open a dial without a glass container 180° to release the pressure
and then remove your glass container with the samples.
2. Close both dials by turning back 180°.
3. Turn the refrigerator button off, then turn off the vacuum button,
and finally turn off the vacuum switch.
4. Check for frost build up inside the Lyophilizer. If there is frost,
wait one hour and then wipe off liquid.
4. After 24 hours, put sample on weigh paper, weigh, and record.
Sample digestion
1. Thaw Papain Solution.
2. Set oven to 65°C.
3. Label a cryovial with the following information: Limb, limb side, tissue, Papain Solution,
your initials, and date (e.g., 5097 Left, Anterior Capsule, Papain Solution, CLD, 02022020).
4. Put sample in the appropriately labeled cryovial, add 1 mL Papain Solution, cap the cryovial,
and vortex.
a. Make sure the sample is in the Papain Solution.
5. Digest the sample overnight (~18 hours) in a 65°C oven.
Hydroxyproline assay (OHP)
1. Turn on the autoclave and run the warm-up cycle (~20 minutes).
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2. Label three cryovials for each sample with the following information: Limb, limb side,
tissue, OHP, dilution, your initials, and date (e.g., 5097 Left, Anterior Capsule, OHP 1X,
CLD, 02022020).
3. Label one cryovial for each sample with the following information: Limb, limb side, tissue,
TP, dilution, your initials, and date (e.g., 5097 Left, Anterior Capsule, TP 1X, CLD,
02022020).
4. Complete sample dilution for OHP:
a. Remove samples from the oven and vortex.
b. Dilute the digested samples in Papain Solution using the following volumes
(optimized for rat anterior capsule and lateral collateral ligament (LCL)):
Dilution Factor
1X
2X
5X

Sample in Papain Solution (µL)
100
50
20

Papain Solution (µL)
0
50
80

i. Complete a dilution curve if it is unknown how much to dilute the sample
so it is within the standard curve.
5. Complete sample dilution for the Total Protein Assay (TP):
a. Vortex samples.
b. Dilute the digested samples in Papain Solution using the following volumes
(optimized for anterior capsule and LCL):
Dilution Factor
1X

Sample in Papain Solution (µL)
100

Papain Solution (µL)
0

i. Complete a dilution curve if it is unknown how much to dilute the sample
so it is within the standard curve.
6. Make the OHP Standards:
a. Label eight Eppendorf tubes and cryovials with the OHP concentration (µg/mL)
in the table below.
b. Make 10 mg/mL OHP stock: Add 20 mg Trans-4-OHP to 2 mL deionized H2O
and vortex until dissolved.
c. Make 1 mg/mL OHP stock: Add 0.5 mL 10 mg/mL OHP stock (made in step b)
to 4.5 mL 1X PBS and vortex.
d. Prepare OHP standards in Eppendorf tubes according to the table below:
i. First, add 1000 µL Papain Solution to each Eppendorf tube, then remove
the necessary volume of Papain Solution to reach the desired volume
Papain Solution. It is more accurate to remove the small volumes of
Papain Solution rather than adding the correct volume with a 1 mL
pipette.
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OHP Concentration
(µg/mL)
*Tube Labels*
0
5
10
20
30
40
60
100

Desired volume of
Papain Solution
(µL)
1000
995
990
980
970
960
940
900

Remove volume of
Papain Solution
(µL)
0
5
10
20
30
40
60
100

Add volume of 1 mg/mL
OHP stock (µL)
0
5
10
20
30
40
60
100

e. Add 100 µL of each standard from the Eppendorf tubes to the appropriate
cryovial.
7. Hydrolysis:
a. Add 100 µL 4 M NaOH to each cryovial (samples and standards) and vortex.
b. Loosen all caps and put in an Eppendorf tube rack in an autoclave tray.
i. Once you are in the autoclave room, add ~0.5” H2O to the autoclave tray
so that the tube rack is floating.
c. Autoclave using the liquid cycle (cycle for liquids under 0.5 L; 122°C at 15 psi
for 20 minutes).
i. Samples will be ready in approximately one hour and 40 minutes.
8. While waiting for the autoclave to finish, complete the following steps:
a. Set oven to 65°C.
b. In the fume hood, make the Chloramine T Oxidizing Solution:
i. Label a beaker with the following: Chloramine T Oxidizing Solution, your
initials, and date (e.g., Chloramine T Oxidizing Solution, CLD,
02022020).
ii. Based on the number of samples and standards, calculate the desired
solution amount using the excel sheet “Biochemistry_Calculate
Hydroxyproline Solutions”.
1. Calculations based on 1.41% (w/v) Chloramine T, 20.7% (v/v)
H2O, 26% (v/v) Isopropanol, 53.3% (v/v) Chloramine T Stock
Buffer.
iii. For one sample and eight standards (with an additional 8 samples to
account for error), use the following:
1. 0.144 g Chloramine T
2. 2.111 mL deionized H2O
3. 2.652 mL Isopropanol
4. 5.437 mL Chloramine T Stock Buffer
5. Cover the top of the beaker with aluminum foil to minimize
evaporation and dissolve with stirring (300 stir speed).
9. After the autoclave has finished, neutralize hydrolysis:
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a. Let samples and standards cool outside of the autoclave at room temperature for
five minutes or until cryovials reach room temperature.
b. Add 100 µL 4 M HCl to each cryovial and vortex.
c. Put TP labeled cryovials aside for later use in the total protein assay.
10. OHP Assay:
a. Add 600 µL Chloramine T Oxidizing Solution to each cryovial and vortex.
b. Let samples stand at room temperature for 20 minutes.
c. While waiting, in the fume hood, prepare the DMAB Colorizing Solution:
i. Label a beaker with the following: DMAB Colorizing Solution, your
initials, and date (e.g., DMAB Colorizing Solution, CLD, 02022020).
ii. Based on the number of samples and standards, calculate the desired
solution amount using the excel sheet “Biochemistry_Calculate
Hydroxyproline Solutions”.
1. Calculations based on 15% (w/v) Erlich’s, 60% (v/v) Isopropanol,
26% (v/v) Perchloric acid.
iii. When handling Perchloric acid remember:
1. Use a glass pipette to transfer Perchloric acid.
2. If undiluted, wear a lab coat with a lab apron on top and heavy
duty acid gloves; use one glass section of the fume hood as a
face/body shield (with arms inserted on either side of the glass
section) and/or wear a face shield.
3. If diluted, wear cotton lab coat with one pair of nitrile gloves; use
one glass section of the fume hood as a face/body shield (with arms
inserted on either side of the glass section) and/or wear safety
glasses.
iv. Measure Erlich’s and add to Isopropanol in beaker. However, it will only
dissolve once the Perchloric acid is added.
v. For one sample and eight standards (with an additional 8 samples to
account for error), use the following:
1. 1.779 g Erlich’s
2. 7.116 mL Isoproanol
3. 3.084 mL Perchloric acid
4. Cover the top of the beaker with aluminum foil to minimize
evaporation and dissolve with stirring (300 stir speed).
d. After 20 minutes, add 600 µL DMAB Colorizing Solution to each cryovial and
vortex immediately.
i. Vortexing immediately is critical to avoid phase separation between the
two solutions.
e. Incubate the samples in a 65°C oven for 20 minutes.
f. While waiting turn on the Setton Lab plate reader and set up.
i. You must be trained by a member of the Setton Lab before you use their
plate reader.
g. After 20 minutes, using a clear 96-well plate, first vortex each sample/standard
before plating and then plate 200 µL of each sample/standard in triplicate
following the plate design.
h. Read plate immediately on the plate reader at 550 nm.
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Dimethylmethylene blue assay (DMMB)
1. Make the DMMB standards:
a. Thaw 10 mg/mL Chondroitin Sulfate Standard aliquot.
b. Label seven Eppendorf tubes with the DMMB concentration (µg/mL) in the table
below.
c. Make 1 mg/mL standard: Add 900 µL Papain Solution to 100 µL 10 mg/mL
Chondroitin Sulfate Standard.
d. Make 200 µg/mL standard: Add 400 µL Papain Solution to 100 µL 1 mg/mL
standard.
e. Prepare DMMB standards in the Eppendorf tubes according to the table below:
i. First, add 500 µL Papain Solution to each Eppendorf tube, then remove
the necessary volume of Papain Solution to reach the desired volume
Papain Solution. It is more accurate to remove the small volumes of
Papain Solution rather than adding the correct volume with a 1 mL
pipette.
Concentration (µg/mL) Desired volume of Remove volume Add volume of 200
*Label tubes*
Papain Solution of Papain Solution µg/mL standard
(µL)
(µL)
(µL)
0
500
0
0
5
487.5
12.5
12.5
10
475
25
25
15
462.5
37.5
37.5
20
450
50
50
25
437.5
62.5
62.5
30
425
75
75
2. DMMB Assay:
a. Using a clear 96-well plate, first vortex each sample/standard before plating and
then plate 30 µL of each sample/standard in triplicate following the plate design.
b. Turn on the Setton Lab plate reader and set up.
i. You must be trained by a member of the Setton Lab before you use their
plate reader.
c. Add 125 µL 1,9-dimethylemethylene blue dye to all wells.
d. Read plate immediately on the plate reader at 525 nm.
Ninhydrin total protein assay (NTP)
1. NTP Assay:
a. Thaw Total Protein Standard for 30 minutes on ice.
b. While waiting for the standard to thaw:
i. Set oven to 85°C.
ii. Turn on the Setton Lab plate reader and set up.
1. You must be trained by a member of the Setton Lab before you use
their plate reader.
c. Using a clear 96-well plate, add the standard: 0, 1, 2, 4, 6, 8, 10, and 12 µL in
triplicate according to the plate design.
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d. Use the samples (TP labeled cryovials) previously set aside following
neutralization of hydrolysis: vortex and add 10 µL of each sample in triplicate
according to the plate design. Volume optimized for rat anterior capsule and LCL.
i. Add 1-10 µg of protein (max 25 µL sample) to each well according to the
plate design – use 10% of sample volume (if 200 µL total volume, use 2
µL), if too low then double volume.
e. Add 100 µL Ninhydrin Working Reagent to all wells.
f. Incubate the samples with the plate lid on in the 85°C oven for 10 minutes.
g. After 10 minutes, read plate immediately on the plate reader at 575 nm
Bradford total protein assay (BTP)
1. Remove 1X Dye Reagent (Coomassie Plus) from 4°C and let it warm to room temperature.
a. Invert a few times before use.
2. Make the Total Protein Standards:
a. Label nine Eppendorf tubes with the BTP concentration (µg/mL) in the table
below.
i. First, add 400 µL Papain Solution to each Eppendorf tube, then remove
the necessary volume of Papain Solution to reach the desired volume
Papain Solution. It is more accurate to remove the small volumes of
Papain Solution rather than adding the correct volume with a 1 mL
pipette.
Concentration (µg/mL)
*Label Tubes*
2000
1500
1000
750
500
250
125
25
0

Vial
1
2
3
4
5
6
7
8
9

Volume of Papain
Solution (µL)
0
125
325
175
325
325
325
400
400

Volume of BSA (µL)
300 Albumin stock
375 Albumin stock
325 Albumin stock
175 Vial #2
325 Vial #3
325 Vial #5
325 Vial #6
100 Vial #7
0

3. BTP Assay:
a. Using a clear 96-well plate, first vortex and then add 5 µL of each standard in
triplicate according to the plate design.
b. Use the samples (TP labeled cryovials) previously set aside following
neutralization of hydrolysis: first vortex and then add 5 µL of each sample in
triplicate according to the plate design.
c. Add 250 µL 1X Dye Reagent to all wells and mix thoroughly by pipetting up and
down.
d. Incubate at room temperature for 10 minutes.
h. While waiting, turn on the Setton Lab plate reader and set up.
ii. You must be trained by a member of the Setton Lab before you use their
plate reader.
i. After five minutes, read plate immediately on the plate reader at 595 nm.
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Additional information.
OHP Concentration (µg/mL)
*Tube Labels*
0
5
10
20
30
40
60
100

Total volume used
(µL)
100
100
100
100
100
100
100
100

Materials.
Item
1,9-dimethylmethylene blue (DMMB)
1X PBS, 500 mL
2 mL Internally threaded cryovials
4-(Dimethylamino) benzaldehyde (C9H11NO)
Acetic acid (C2H4O2)
Black rubber acid apron
Chloramine T hydrate
(CH3C6H4SO2N(Cl)Na•xH2O)
Chondroitin sulfate standards
Citric acid monohydrate (C6H8O7)
Conical tubes, 15 mL
Conical tubes, 50 mL
Eppendorf tubes, 1.5 mL
Ethanol
Ethylene glycol (C2H6O2)
Ethylenediaminetetraacetic acid (0.5 M EDTA)
Formic acid (HCOOH)
Hydrochloric acid (HCl)
Isopropanol (2-propanol)
L-Cysteine hydrochloride (C3H7NO2S•HCl)
Ninhydrin (C9H6O4)
Papain
Parafilm
Perchloric Acid (HClO4)
Pierce Coomassie (Bradford) Total Protein
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Total OHP
(µg)
0
0.5
1
2
3
4
6
10

Equivalent Collagen
(µg)
0
3.73
7.46
14.92
22.38
29.84
44.74
74.6

Company
Sigma
Gibco
Corning
Sigma
Sigma
VWR
Sigma

Catalog Number
341088-1G
14190-144
03-374-21
156477-100G
695092-500ML
470149-220
857319-100G

Sigma
Sigma
Fisher Scientific
Fisher Scientific
Fischer Scientific
Fisher Scientific
Fisher Scientific
Sigma
Sigma
Sigma
Sigma
Sigma
Fisher Scientific
Sigma
Fisher Scientific
Sigma
ThermoFisher

C9819
251275
14-959-49B
14-432-22
05-402
04355223
E178-1
E7889-100ML
F0507-100ML
258148-500ML
I9516-500ML
C1276-10G
AC415720100
P4762
13-374-12
311413-100ML
23200

Assay Kit
Sodium acetate trihydrate
(Ninhydrin Total Protein Assay)
Sodium acetate trihydrate (C2H9NaO5)
Sodium formate (CHNaO2)
Sodium hydroxide (NaOH)
Sodium hydroxide (NaOH)
Sodium phosphate monobasic (NaH₂PO₄•H₂O)
Tin (II) chloride anhydrous (SnCl2)
Total Protein Standard
(Amino Acid Collagen Hydrolysate)
Trans-4-hydroxyproline-L (C5H9NO3)
Vacuum Desiccator
Vacuum Desiccator Plate 230mm
Weigh Paper
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Fisher Scientific

50-492-908

Fisher Scientific
Fisher Scientific
Emsure
Sigma
Sigma
Fisher Scientific
Pickering Labs

S209-500G
AA3642436
EC# 215-185-5
415413-1L
567545
AAA1620222
012506C

Sigma
Fisher Scientific
Fisher Scientific
Fisher Scientific

H54409-10G
08-642-5
08-642-10
09-898-12A

B.2 Mechanical memory
B.2.1 Cell isolation and culture
Safety.
• All work should be performed while wearing closed toed shoes, pants, lab coat, and gloves.
Important.
• Turn on the germicidal light in the tissue culture hood for 30 minutes before and after you
complete all work.
• All steps should be performed under sterile conditions. Autoclave all dissection tools.
• Any item that enters the tissue culture hood should first be sprayed down with 75% Ethanol,
especially things coming from the water bath.
Solutions.
• Small Tissue Digestion Solution (total volume ~6 mL):
o Should be used for tissue 100-300 mg; should be put into a 15 mL conical tube.
o 5.2 mL DMEM
o 800 µL Collagenase
o 75 µL Dispase
o 60 µL Streptomycin/penicillin
•

Large Tissue Digestion Solution (total volume ~50 mL):
o Should be used for tissue > 300 mg; should be split evenly (~25 mL) into two 50
mL conical tubes.
o 47 mL DMEM
o 2.5 mL Collagenase
o 500 µL Streptomycin/penicillin

•

Standard Growth Media (total volume ~500 mL; 10% FBS, 1% streptomycin/penicillin):
o Put DMEM, streptomycin/penicillin, and FBS in a water bath set to 37°C to warm
for 30 minutes.
o After 30 minutes, inside the tissue culture hood, put approximately 250 mL
DMEM into a 500 mL stericup vacuum media filter.
o 50 mL FBS
o 5 mL Streptomycin/penicillin
o Add DMEM until the final volume of the solution is 500 mL.
o Put the lid on the stericup vacuum media filter, hook up the vacuum tubing, and
turn on the vacuum.
o Once the entire solution is filtered, turn off the vacuum, remove the top, and put
on the lid.
o Stable for one month at 4°C.

•

Freezing Solution (total volume ~4 mL; 90% FBS, 10% DMSO):
o Put FBS in a water bath set to 37°C to warm for 30 minutes.
o After 30 minutes, inside the tissue culture hood, in a 15 mL conical tube:
▪ 3.6 mL FBS
▪ 0.4 mL DMSO
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Protocol.
Tissue digestion
• Optimized for adipose tissue.
1. Make the correct amount of Tissue Digestive Solution according to the estimated amount of
total tissue that will be harvested for cell isolation.
a. Make sure to label the conical tube with the following information: Tissue
Digestive Solution, tissue, your initials, and date (e.g., Tissue Digestive Solution,
Adipose, CLD, 03042020).
2. Put the Tissue Digestive Solution and Standard Growth Media in a water bath set to 37°C to
warm for 30 minutes.
3. After 30 minutes, complete dissection to harvest tissue for cell isolation.
a. If > 300 mg of tissue, then mince tissue prior to putting it into the Tissue
Digestive Solution.
4. Put tissue harvested into the Tissue Digestive Solution and return the conical tube to the
water bath for one hour.
a. Every 10 minutes invert the conical tube with the tissue and Tissue Digestive
Solution.
5. After one hour, inside the tissue culture hood, pour contents of the conical tube into a 10 cm
sterile petri-dish.
6. Using sterile forceps, mechanically break down the tissue by pulling small pieces apart.
a. Complete this step within 20 minutes to minimize cell death due to large changes
in temperature and pH.
7. Put the lid on the petri-dish and put it in the incubator (37°C, 5% CO2) for 30 minutes.
8. After 30 minutes, inside the tissue culture hood, mechanically shred the tissue with forceps
and/or pipet the solution to further break down the tissue and then return the petri-dish to the
incubator for 10 minutes.
a. May need to repeat this process 1-2 times to completely break down tissue.
b. Recommend using a 5 mL serological pipette.
Cell isolation
• Optimized for adipose-derived stem cells.
1. After tissue is completely broken down, inside the tissue culture hood pass the cell
suspension through a sterile 70 µm filter fit to a 50 mL conical tube.
a. If the tissue is not broken down enough, it will clog the filter and so you will need
multiple filters to pass the cell suspension.
2. Put 5 mL Standard Growth Media in the culture dish to rinse it and wash any remaining cells
into solution, then pipet through the sterile 70 µm filter.
3. Centrifuge the 50 mL conical tube at 1300 rpm for 10 minutes at 4°C.
4. Inside the tissue culture hood, aspirate the supernatant and be careful to not disrupt the cell
pellet.
a. It is okay to leave a small volume of supernatant.
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5. Resuspend the cell pellet in 2 mL Standard Growth Media in the tissue culture hood.
a. Recommend using a 5 mL serological pipette.
b. Pipet the solution to break up the cell pellet, so cells are evenly distributed
throughout the growth media.
6. Label two T150 flasks with the following information: cell type, your initials, date, and P0
(e.g., SQ-ASC, CLD, 03042020, P0).
7. Inside the tissue culture hood, add 24 mL Standard Growth Media to each T150 flask by
pipetting down the side of the flask and then plate 1 mL cell suspension from step 5.
a. Recommend using a 25 mL serological pipette to add the growth media and a 5
mL serological pipette to transfer the cell suspension.
b. Total volume in the T150 flask is 25 mL.
8. Put the two T150 flasks into the incubator (37°C, 5% CO2).
9. Feed cells every other day until they need passaged (~70-80% confluency).
Feeding cells (changing growth media)
• Feed cells every other day until they need passaged (~70-80% confluency) or reach end of
study.
1. Put the Standard Growth Media in a water bath set to 37°C to warm for 30 minutes.
2. After 30 minutes, inside the tissue culture hood, tilt the T150 flask to its side so all the
solution is in the bottom corner, and aspirate the growth media.
a. Make sure to keep the aspirating pipette pointed away from the culture surface.
3. Add 25 mL new Standard Growth Media down the side of flask.
4. Return the T150 flask to the incubator (37°C, 5% CO2).
Passage
• Complete once cells have reached ~70-80% confluency.
1. Put 0.25% Trypsin-EDTA and Standard Growth Media in a water bath set to 37°C to warm
for 30 minutes.
2. After 30 minutes, inside the tissue culture hood, tilt the T150 flask to its side so all the
solution is in the bottom corner, and aspirate the growth media.
a. Make sure to keep the aspirating pipette pointed away from the culture surface.
3. Add 10 mL sterile 1X PBS to the T150 flask and run it over the culture surface.
4. Aspirate the 1X PBS from the T150 flask.
5. Add 5 mL 0.25% Trypsin-EDTA to the T150 flask and return it to the incubator (37°C, 5%
CO2) for 2-3 minutes.
6. Remove the T150 flask from the incubator, tap it on its side, and view the cells on the
microscope to confirm they have released from the culture surface.
a. If cells are not completely released from the culture surface, return the T150 flask
to the incubator for one minute and then repeat this step.
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7. Once cells are completely released from the culture surface, in the tissue culture hood, add 8
mL Standard Growth Media to the T150 flask and run it over the culture surface.
8. Pour the solution from the flask into a 15 mL conical tube.
9. Centrifuge the 15 mL conical tube at 1300 rpm for four minutes at 23°C.
10. Label four T150 flasks with the following information: cell type, your initials, date, and
passage number (e.g., SQ-ASC, CLD, 03092020, P1).
11. Inside the tissue culture hood, aspirate the supernatant and be careful to not disrupt the cell
pellet.
a. It is okay to leave a small volume of supernatant.
12. Resuspend the cell pellet in 4 mL Standard Growth Media.
a. Recommend using a 5 mL serological pipette.
b. Pipet the solution to break up the cell pellet, so cells are evenly distributed
throughout the growth media.
13. Add 24 mL Standard Growth Media to each T150 flask by pipetting down the side of the
flask and then plate 1 mL cell suspension from step 12.
a. Recommend using a 25 mL serological pipette to add the growth media and a 5
mL serological pipette to transfer the cell suspension.
b. Total volume in the T150 flask is 25 mL.
14. Put the four T150 flasks into the incubator (37°C, 5% CO2).
Freeze down cells
1. Put 0.25% Trypsin-EDTA, Standard Growth Media, and FBS in a water bath set to 37°C to
warm for 30 minutes.
2. After 30 minutes, inside the tissue culture hood, tilt the T150 flask to its side so all the
solution is in the bottom corner, and aspirate the growth media.
b. Make sure to keep the aspirating pipette pointed away from the culture surface.
3. In the tissue culture hood, add 10 mL sterile 1X PBS to the T150 flask and run it over the
culture surface.
4. Aspirate the 1X PBS from the T150 flask inside the tissue culture hood.
5. Add 5 mL 0.25% Trypsin-EDTA to the T150 flask in the tissue culture hood and return it to
the incubator (37°C, 5% CO2) for 2-3 minutes.
6. Remove the T150 flask from the incubator, tap it on its side, and view the cells on the
microscope to confirm they have released from the culture surface.
a. If cells are not completely released from the culture surface, return the T150 flask
to the incubator for one minute and then repeat this step.
7. Once cells are completely released from the culture surface, in the tissue culture hood, add 8
mL Standard Growth Media to the T150 flask and run it over the culture surface.
8. Pour the solution from the flask into a 15 mL conical tube.
9. Centrifuge the 15 mL conical tube at 1300 rpm for four minutes at 23°C.
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10. Label four cryovials with the following information: species, cell type, your initials, date, and
passage number (e.g., Rat, SQ-ASC, CLD, 03092020, P1).
11. Make required volume of Freezing Solution inside the tissue culture hood.
12. Inside the tissue culture hood, aspirate the supernatant and be careful to not disrupt the cell
pellet.
a. It is okay to leave a small volume of supernatant.
13. Resuspend the cell pellet in 4 mL Freezing Solution in the tissue culture hood.
a. Recommend using a 5 mL serological pipette.
14. Pipet the solution to break up the cell pellet, so cells are evenly distributed throughout
Freezing Solution.
15. Pipet 1 mL resuspended cells in Freezing Solution into each cryovial.
a. Recommend using a 5 mL serological pipette.
16. Put cryovials into the foam Cool Cell and store at -80°C for three days.
17. After three days, move cryovials into long-term cryo-storage with liquid nitrogen.
Thawing cells
1. Put Standard Growth Media in a water bath set to 37°C to warm for 30 minutes.
2. Put cryovial of desired cells in a water bath set to 37°C to warm for two minutes.
3. In the tissue culture hood, add 8 mL Standard Growth Media to a 15 mL conical tube and add
cell suspension from cryovial.
4. Centrifuge the 15 mL conical tube at 1300 rpm for four minutes at 23°C.
5. Inside the tissue culture hood, aspirate the supernatant and be careful to not disrupt the cell
pellet.
a. It is okay to leave a small volume of supernatant.
6. Resuspend the cell pellet in 2 mL Standard Growth Media in the tissue culture hood.
a. Recommend using a 5 mL serological pipette.
7. Pipet the solution to break up the cell pellet, so cells are evenly distributed throughout the
growth media.
Counting cells
1. Pipet 10 µL cell resuspension into the grove of the hemacytometer with the glass coverslip
on top.
2. With the microscope on the 4X objective, count the cells in the nine large squares and then
calculate the average; multiply the average by 10,000 to determine the average number of
cells/mL.
a. Use the following formulas to determine the volumes required to evenly re-plate
the cells:
i. Volume of resuspended cells (mL) = desired number of cells to plate /
average number of cells per mL.
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1. For example, on a 6-well plate: Average = 100,000 cells/mL;
Desired number cell to plate = 75,000 cells/well → 0.75 mL
resuspended cells/well → 4.5 mL resuspended cells/6-well plate
ii. Volume of Standard Growth Media (mL) = Total volume of growth media
needed for culture environment – volume of resuspended cells per culture
environment
1. For example, on a 6-well plate each well needs 2.5 mL growth
media: 4.5 mL resuspended cells/6-well plate → 10.5 mL Standard
Growth Media
3. In a 50 mL conical tube, in the tissue culture hood, add the volume of resuspended cells to
the volume of Standard Growth Media as previously calculated.
a. Following the example in the previous step: Add 4.5 mL resuspended cells to 10.5
mL Standard Growth Media.
Clean up
1. Remove any material brought into the tissue culture hood to decrease clutter.
2. Spray the tissue culture hood surface with 75% Ethanol and wipe down with a large
Kimwipe.
3. If vacuum was used, spray 75% Ethanol into the tubing to wash it out and then turn off the
vacuum.
a. Make sure the tubing is completely drained.
4. Shut the tissue culture hood sash, turn off the blower and turn on the germicidal light for 30
minutes.
Additional information.
Transferring cells to new small gels
• The following desired number of cells to plate per well were used:
o 1 kPa for two weeks = 1,000-1,500 cells/well
o 120 kPa for two weeks = 75-100 cells/well
o Transferred to 120 kPa for 1-2 weeks = 100-150 cells/well
1. Put 0.25% Trypsin-EDTA and Standard Growth Media in a water bath set to 37°C to warm
for 30 minutes.
2. Cut a rectangle of parafilm to fit the lid of 6-well culture dish and then cut a 0.5” x 0.5”
window in the parafilm at the location of one well.
a. Window in the parafilm will allow you to check that the cells released following
trypsinization.
3. After 30 minutes, inside the tissue culture hood, invert the lid of a 6-well culture dish.
4. Put the parafilm into the lid so it lays flat and the window lines up with one well.
5. Using sterile forceps, transfer each gel to the parafilm lined lid (gel side up).
a. Make sure that one gel is centered on top of the window in the parafilm.
6. Add 500 µL 0.25% Trypsin-EDTA on top of each gel and wait two minutes.
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7. Aspirate the growth media from the 6-well plate and then invert the plate to cover the gels on
the parafilm lined lid.
8. View the cells on the microscope through the window in the parafilm to confirm they have
released from the culture surface.
a. If cells are not completely released from the culture surface, wait one minute and
then repeat this step.
9. Once the cells are completely released from the gel surface, in the tissue culture hood, pipet
up the cell suspension and put into a 15 mL conical tube.
10. Rinse the surface of each gel with 500 µL Standard Growth Media twice, collect the growth
media, and put into the 15 mL conical tube with the cell suspension.
11. Centrifuge the 15 mL conical tube at 1300 rpm for four minutes at 23°C.
12. Inside the tissue culture hood, aspirate the supernatant and be careful to not disrupt the cell
pellet.
a. It is okay to leave a small volume of supernatant.
13. Resuspend the cell pellet in 2 mL Standard Growth Media in the tissue culture hood.
a. Recommend using a 5 mL serological pipette.
14. Pipet the solution to break up the cell pellet, so cells are evenly distributed throughout the
growth media.
15. Count the cells.
16. In a 50 mL conical tube, in the tissue culture hood, add the desired volume of resuspended
cells to a volume of Standard Growth Media as calculated in the previous step.
a. Pipet 2.5 mL into each well of a 6-well plate with new gels.
17. Put the 6-well plate into the incubator (37°C, 5% CO2).
18. Feed cells every other day until the end of the study.
Materials.
Item
0.25% Trypsin-EDTA, 100 mL
1X PBS, 500 mL
2mL Internally threaded cryovials
6-Well culture plates
70 µm Sterile cell strainer
Aspirating pipette
Collagenase
Conical tubes, 15 mL
Conical tubes, 50 mL
Cool cell
Dichlorodimethylsilane (DMSO)

Company
Fisher Scientific
Gibco
Corning
Fisher Scientific
Fisher Scientific
VWR
Sigma
Fisher Scientific
Fisher Scientific
Sigma
Sigma
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Catalog Number
25200056
14190-144
03-374-21
353046
22363548
414004-265
C0130-500MG
14-959-49B
14-432-22
CLS432003
440272-100

Dispase II
DMEM, 10 x 500 mL
Ethanol
FBS, 500 mL
Forceps
Hemacytometer
Hemacytometer, cover glass
Kimwipes, large
Parafilm
Petri-dish, 10 cm diameter
Scissors, dissection
Serological pipette, 10 mL
Serological pipette, 25 mL
Serological pipette, 5 mL
Stericup vacuum media filters, 500 mL
and 0.22 µm filter
Streptomycin/penicillin
T150 Flasks

Sigma
Fischer Scientific
Fisher Scientific
Fisher Scientific
Fisher Scientific
Fisher Scientific
Fisher Scientific
Fisher Scientific
VWR
Fisher Scientific
Fisher Scientific
VWR
VWR
VWR
Corning

D4693-1G
11885092
04355223
26140079
16-100-120
02-671-51A
02-671-53
06-666C
52858-000
FB0875712
13-806-2
89130-898
89130-900
89130-896
431097

Fisher Scientific
Fisher Scientific

15140-122
877248
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B.2.2 Small polyacrylamide gels
Safety.
• All work should be performed while wearing closed toed shoes, pants, lab coat, and gloves.
• All work with the following chemicals should be performed in the fume hood:
o Acetic acid
o DCDMS
▪ Double glove while working with DCDMS.
▪ Take extra precaution when handling needles with DCDMS.
o NaOH
Important.
• Turn on the germicidal light in the tissue culture hood for 30 minutes before and after you
complete all work.
• Any item that enters the tissue culture hood should first be sprayed down with 75% Ethanol,
especially things coming from the water bath.
Solutions.
• In the fume hood, make 1 M NaOH (total volume ~50 mL):
o 12.5 mL deionized H2O
o 2.64 mL NaOH
o Add deionized H2O until the final volume of this solution is 50 mL.
o Store in the corrosive’s cabinet with the bases.
•

5X Sulfo-SANPAH (total volume ~50 mL; 1 mg/mL Sulfo-SANPH in 50 mM HEPES):
o Cover a 250 mL beaker with aluminum foil.
o In the tissue culture hood, add 50 mL sterile 1X PBS to the beaker.
▪ All subsequent steps may be performed outside of the tissue culture hood.
o Put beaker on stir plate with 400 stir speed.
o Add 0.5957 g HEPES.
o Once solute is dissolved, pipet small volumes of this solution into the container
with 50 mg Sulfo-SANPAH to carefully transfer Sulfo-SANPAH to the beaker.
o Cover the top of the beaker with aluminum foil.
o Wait five minutes, so Sulfo-SANPAH can dissolve (stir speed 400).
o Measure the pH, goal = 8.5
▪ Add 1 M NaOH by dropper until the desired pH is reached.
o Pre-cut aluminum foil to cover each 15 mL conical tube.
o In the tissue culture hood, aliquot 5 mL Sulfo-SANPAH solution into each 15 mL
conical tube and cover each tube with aluminum foil.
▪ Do not turn on the tissue culture hood fluorescent light during this step.
Keep as dark as possible when Sulfo-SANPAH is in the tissue culture
hood.
o Store at -20°C.

•

In the tissue culture hood, make 1 mg/mL Fibronectin (total volume ~1 mL):
o Put the container of lyophilized Fibronectin (powder) into the tissue culture hood
and wait 30 minutes.
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o After 30 minutes, add 1 mL sterile 1X PBS to the container and wait 30 minutes
for solute to go into solution.
▪ DO NOT AGITATE OR SWIRL.
o After 30 minutes, aliquot 100 µL Fibronectin solution into each Eppendorf tube.
o Store at -20°C.
▪ Avoid multiple freeze-thaw cycles.
•

Polyacrylamide Gel Stock Solutions (total volume ~50 mL):
o Prepare stock solution for the desired gel stiffness in a 50 mL conical tube
following the table below:
Stiffness 40% Acrylamide
(kPa)
(mL)
1
3.75
55
15
120
16.875

2% Bis-acrylamide
(mL)
2.5
15
27

deionized H2O
(mL)
43.75
20
0.87

Total Volume
(mL)
50
50
44.745

o Sterile filter the solution into a new 50 mL conical tube using a 5 mL syringe and
0.22 µm sterile filter.
o Store at 4°C.
•

In the fume hood, make 1:10 Acetic Acid (total volume ~35 mL):
o 31.5 mL deionized H2O
o 3.5 mL Acetic acid

•

10% Ammonium persulfate (total volume ~1 mL; APS):
o 1 mL deionized H2O
o 0.1 g Ammonium persulfate
o Vortex until solute dissolves.
o Aliquot 100 µL 10% APS into each micro-centrifuge tube.
o Store at -20°C.

Protocol.
Preparing coverslips
1. Within a small glass petri-dish add:
a. 50 µL 3-(trimethyloxysilyl)propyl methacrylate
b. 10 mL Ethanol
c. 300 µL 1:10 Acetic Acid
2. Immerse 25 mm diameter glass coverslips into the methacrylate solution for five minutes.
3. After five minutes, remove the coverslips from the methacrylate solution using forceps and
wipe with a 100% Ethanol soaked Kimwipe.
4. Put coverslips on top of a paper towel to air dry.
a. Once coverslips are completely dry, they are ready for use in future steps.
5. Dispose of methacrylate solution in an appropriately labeled waste container.
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Preparing microscope slides
1. Clean microscope slides with a 100% Ethanol soaked Kimwipe and put them on a paper
towel to air dry.
a. Once microscope slides are completely dry, move them on a paper towel into the
fume hood.
2. In the fume hood, use a 27-gauge needle and 1 mL syringe to extract DCDMS.
a. MAKE SURE TO WEAR DOUBLE GLOVES WHEN HANDLING DCDMS.
3. Replace the 27-gauge needle with an 18-gauge needle and evenly spread DCDMS onto the
microscope slides.
a. Make sure to put the DCDMS onto the side of the microscope slide without the
label.
b. Spread the DCDMS around using the needle to get an even layer covering the
whole microscope slide.
i. DO NOT STICK YOURSELF WITH THE DCDMS NEEDLE.
c. Dispose of DCDMS needles and syringe in the appropriately labeled sharps waste
container that is kept inside the fume hood.
4. Wait one minute.
5. After one minute, wipe off excess DCDMS with a Kimwipe.
a. Make sure the microscope slide glass surface remains evenly coated in DCDMS.
6. Move DCDMS coated microscope slides out of the fume hood and to the bench.
Polyacrylamide gel solution
1. Put 1 mL Polyacrylamide Gel Stock Solution for the desired gel stiffness into an Eppendorf
tube.
2. Quickly, in the following order, first add 10 µL 10% APS and then add 1 µL TEMED into
the Eppendorf tube.
3. Vortex polyacrylamide gel solution immediately.
4. Quickly, pipet 25 µL of polyacrylamide gel solution onto the DCDMS coated microscope
slides (maximum of two coverslips will fit on each microscope slide) and cover with a
methacrylate treated coverslip.

5. Wait one hour.
6. After one hour, check the remaining polyacrylamide gel solution in the Eppendorf tube
(should be polymerized, so if you invert the tube the material will not move).
7. When the polymerization is complete, carefully remove the gels-coverslips from the
microscope slides (slide or pop off) and put them into a sterile 6-well plate.
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a. Label the 6-well plate lid with the following: species, cell type, gel stiffness, time
point, your initials, and date cells will be seeded (e.g., Rat SQ-ASCs, 120-2wk,
CLD, 03072020).
8. In the tissue culture hood, add 2 mL sterile 1X PBS to each well to hydrate the gels.
9. Aspirate the 1X PBS and repeat step 8.
Functionalize gels with fibronectin
1. Prepare 1X Sulfo-SANPAH solution from the stock 5X Sulfo-SANPAH solution:
a. Make sure tissue culture hood fluorescent light is turned off as long as SulfoSANPAH is in the hood.
b. Determine the volumes needed using the following formulas:
i. Volume 5X Sulfo-SANPAH = (1.5 mL/well * 6 well/plate * # plates * 2
rinses) / (5).
ii. Volume sterile 1X PBS = (1.5 mL/well * 6 well/plate * # plates * 2 rinses)
– (Volume of 5X Sulfo-SANPAH).
c. For example, for one 6-well plate: add 3.6 mL 5X Sulfo-SANPAH to 14.4 mL
sterile 1X PBS.
2. Aspirate the 1X PBS and add 1.5 mL 1X Sulfo-SANPAH to each well.
a. Make sure the gel surface is covered with 1X Sulfo-SANPAH.
3. Put the lid on the plate and put it on top of the 365 nm ultraviolet light table for 10 minutes.
4. After 10 minutes, in the tissue culture hood, aspirate the 1X Sulfo-SANPAH and add 2 mL
sterile 1X PBS to each well.
5. Rock and/or shake the plate to rinse the gels.
6. Repeat step 2-5.
7. Aspirate the 1X PBS and add 2 mL sterile 1X PBS to each well.
8. Rock and/or shake the plate to rinse the gels.
9. Repeat step 7-8 (a total of three sterile 1X PBS washes).
10. Prepare 10 µg/mL Fibronectin:
a. Determine the volumes needed using the following formulas:
i. Volume 1 mg/mL Fibronectin = (10 µg/mL * 2 mL/well * 6 well/plate * #
plates) / (1000 µg/mL).
ii. Volume sterile 1X PBS = (2 mL/well * 6 well/plate * # plates) – (Volume
1 mg/mL Fibronectin).
b. For example, for one 6-well plate: add 0.12 mL 1 mg/mL Fibronectin to 11.88 mL
sterile 1X PBS.
11. Aspirate the 1X PBS and add 2 mL 10 µg/mL Fibronectin to each well.
12. Put the lid on the plate and put it into the incubator (37°C, 5% CO2) overnight (~18 hours).
13. After 18 hours, in the tissue culture hood, aspirate the 10 µg/mL Fibronectin and add 2 mL
sterile 1X PBS to each well.
14. Rock and/or shake the plate to rinse the gels.
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15. Aspirate the 1X PBS and add 2 mL sterile 1X PBS to each well.
16. Rock and/or shake the plate to rinse the gels.
17. Repeat step 15, shut the tissue culture hood sash, turn off the blower, and turn on the
germicidal light for 30 minutes.
18. After 30 minutes, plate cells.
Materials.
Item
0.22 µm Sterile filter
1X PBS, 1000 mL
3-(Trimethoxyilyl)propyl methacrylate
6-Well culture plates
Acetic acid (CH3CO2H)
Ammonium persulfate
((NH4)2S2O8; APS)
Aspirating pipette
Conical tubes, 15 mL
Conical tubes, 50 mL
Coveslips, 25 mm diameter
Dichlorodimethylsilane ((CH3)2SiCl2;
DCDMS)
Eppendorf tubes, 1.5 mL
Ethanol
Forceps
Glass petri-dish, 100 mm diameter
HEPES (C8H18N2O4S)
Human fibronectin, 1 mg
Kimwipe, small
Kimwipes, large
Micro-centrifuge tubes, 0.5 mL
Microscope slide, small
N,N,N′,N′-Tetramethylethylenediamine
((CH3)2NCH2CH2N(CH3)2; TEMED)
NaOH
Needles, 18-gauge
Needles, 27-gauge
Serological pipette, 10 mL
Serological pipette, 25 mL

Company
Millex
Life Technologies
Sigma
Fisher Scientific
Sigma
Sigma

Catalog Number
SLGS033SS
14190136
M6514-25ML
353046
695092-250G
A3678-25G

VWR
Fisher Scientific
Fisher Scientific
VWR
Sigma

414004-265
14-959-49B
14-432-22
16004-310
440272-100ML

Fischer Scientific
Fisher Scientific
Fisher Scientific
VWR
Sigma
Alfa Aeasar
Fisher Scientific
Fisher Scientific
Fisher Scientific
Fisher Scientific
Sigma

05-402
04355223
13-812-39
75845-546
H3375-250G
AAJ64560-MCR
06-666
06-666C
50-998-573
12-544-7
T7024-25ML

Sigma
Fisher Scientific
Fisher Scientific
VWR
VWR

72068-100ML
148265G
1482113B
89130-898
89130-900
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Serological pipette, 5 mL
Sulfo-SANPAH
Syringe, 1 mL
Syringe, 5 mL

VWR
Fisher Scientific
Fisher Scientific
Fisher Scientific
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89130-896
PI22589
14-823-30
14-829-45

B.2.3 Cell immunohistochemistry
Safety.
• All work should be performed while wearing closed toed shoes, pants, lab coat, and gloves.
• All work with the following chemicals should be performed in the fume hood:
o HCl
o NaOH
o Paraformaldehyde
Important.
• Turn on the germicidal light in the tissue culture hood for 30 minutes before and after you
complete all work.
• Any item that enters the tissue culture hood should first be sprayed down with 75% Ethanol,
especially things coming from the water bath.
Solutions.
• In the fume hood, make 1 M HCl (total volume ~50 mL):
o 12.5 mL deionized H2O
o 4.106 mL HCl
o Add deionized H2O until the final volume of this solution is 50 mL.
o Store in the corrosive’s cabinet with the acids.
•

In the fume hood, make 1 M NaOH (total volume ~50 mL):
o 12.5 mL deionized H2O
o 2.64 mL NaOH
o Add deionized H2O until the final volume of this solution is 50 mL.
o Store in the corrosive’s cabinet with the bases.

•

In the fume hood, make 4% Paraformaldehyde (total volume ~100 mL):
o Add 80 mL 1X PBS to a beaker on hotplate set to 60°C with a stir speed 400.
o Add 4 g Paraformaldehyde.
▪ Will not dissolve immediately.
o Slowly add 1 M NaOH by dropper until the solution clears.
▪ Wait 10 minutes between each addition of 1 M NaOH.
o Once the solution clears, add 1X PBS until the final volume of this solution is 100
mL.
o Measure the pH, goal = 7
▪ Slowly add 1 M NaOH or 1 M HCl by dropper until the desired pH is
reached.
o The solution is stable for one month stored at 4°C.

•

1% v/v Triton-X (total volume ~100 mL):
o 1 mL Triton-X
o 99 mL 1X PBS

•

In the tissue culture hood, make 1.5% Buffer Serum (total volume ~10 mL):
o 9.85 mL sterile 1X PBS
o 0.150 mL Goat serum
o 0.1 g BSA
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o Vortex until solute dissolves.
▪ Incubating in a water bath set 37°C for five minutes may help solute
dissolve.
o Store at -20°C.
Protocol.
Fixation
• Optimized for small gels in a 6-well plate.
1. In the tissue culture hood, aspirate the growth media from each well in a 6-well plate.
2. Add 2.5 mL sterile 1X PBS to each well and then aspirate to the 1X PBS.
3. Add 2.5 mL cold 4% Paraformaldehyde to each well and wait 15 minutes.
a. Can complete all subsequent steps outside of the tissue culture hood.
b. Move 6-well plate to a regular fume hood.
4. After 15 minutes, in the fume hood, remove 4% Paraformaldehyde from each well using a
dropper (transfer pipet) and put waste into an appropriately labeled waste container.
5. Add 2.5 mL 1X PBS to each well and wait five minutes.
6. After five minutes, remove 1X PBS from each well using a dropper (transfer pipet) and put
waste into the appropriate waste container.
Permeabilize cell membrane
1. Add 2.5 mL 1% v/v Triton-X to each well and wait 15 minutes.
a. Can complete all subsequent steps outside of the fume hood.
2. While waiting, complete the following steps:
a. Cut two pieces of parafilm to fit inside the lid of a pipette box.
b. Lay the parafilm into two separate pipette box lids so they are completely flat.
c. Label one as “Primary” and the other as “Isotype Control”.
d. Cut two pieces of parafilm to cover/seal the top of the pipette box lids and set
aside for now.
3. After 15 minutes, using forceps carefully pick up the gels and transfer five gels to the lid
labeled “Primary” and one gel to the lid labeled “Isotype Control”.
a. Make sure to transfer so the gels face up when put on the parafilm.
b. Use the small benchtop vacuum to remove the Triton-X from each well.
4. Add 500 µL 1X PBS to the top of each gel and wait five minutes.
5. After five minutes, use the small benchtop vacuum and remove the 1X PBS from each gel.
Primary antibody
1. Dilute the primary antibodies and corresponding isotype controls with 1.5% Buffer Serum
following the table below:
a. If immunolabeling for multiple primaries at once, combine into one Eppendorf
tube.
b. Will require 250 µL per gel, therefore will need a total volume of 1.25 mL and
250 µL for five “Primary” gels and one “Isotype Control” gel, respectively.
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Primary Antibody
YAP
αSMA

Dilution
1:50
1:200

Corresponding Isotype Control
IgG2aκ
IgG

Dilution
1:50
1:200

i. For example, if immunolabeling for both YAP and αSMA:
1. “Primary” gels: 25 µL YAP, 6.25 µL αSMA, 1.22 mL 1.5% Buffer
Serum
2. “Isotype Control” gel: 5 µL IgG2aκ, 1.25 µL IgG, 244 µL 1.5%
Buffer Serum
2. Vortex and add 250 µL diluted primary antibodies to each “Primary” gel.
3. Vortex and add 250 µL diluted isotype control antibodies to one “Isotype Control” gel.
4. Carefully, cover each pipette box lid with the parafilm previously cut.
a. Make sure to not disturb the solution on top of the gels.
b. Make sure there are no holes in the parafilm.
5. Put the two pipette box lids inside a drawer at room temperature, so they are not disturbed,
and let sit overnight (~18 hours).
6. After 18 hours, use the small benchtop vacuum and remove the primaries and isotype control
antibodies from each gel.
7. Add 500 µL 1X PBS to the top of each gel and wait five minutes.
8. After five minutes, use the small benchtop vacuum and remove the 1X PBS from each gel.
9. Repeat steps 7-8 two more times (a total of three 1X PBS washes).
Secondary antibody
1. Dilute secondary antibodies with 1.5% Buffer Serum following the table below:
a. If immunolabeling for multiple secondaries at once, combine into one Eppendorf
tube.
b. Cannot co-label with αSMA and F-actin because of colocalization of these two
proteins.
Secondary Antibody
Goat Anti-Mouse 568 (YAP)
Goat Anti-Rabbit 488 (αSMA)
Alexa Fluor 488 Phalloidin (F-actin)

Dilution
1:400
1:400
1:200

c. Will require 250 µL per gel, therefore will need a total volume of 1.5 mL.
i. For example, if immunolabeling for both YAP and αSMA:
1. 3.75 µL Goat Anti-Mouse 568 (YAP), 3.75 µL Goat Anti-Rabbit
488 (αSMA), 1.49 mL 1.5% Buffer Serum
2. Vortex and add 250 µL diluted secondary antibodies to each gel (all “Primary” and “Isotype
Control” gels).
3. Put the two pipette box lids inside a dark drawer at room temperature and wait one hour.
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4. After one hour, use the small benchtop vacuum and remove the secondary antibodies from
each gel.
5. Add 500 µL 1X PBS to the top of each gel, put the two pipette box lids back into the dark
drawer, and wait five minutes.
6. After five minutes, use the small benchtop vacuum and remove the 1X PBS from each gel.
7. Repeat steps 5-6 two more times (a total of three 1X PBS washes).
DAPI
1. Dilute DAPI with 1.5% Buffer Serum following the table below:
DAPI

Dilution
1:1000

a. For example, will require 250 µL per gel, therefore will need 1.5 µL DAPI and
1.49 mL 1.5% Buffer Serum.
2. Vortex and add 250 µL diluted DAPI to each gel (all “Primary” and “Isotype Control” gels).
3. Put the two pipette box lids inside a dark drawer at room temperature and wait five minutes.
4. After five minutes, use the small benchtop vacuum and remove the DAPI from each gel.
5. Add 500 µL 1X PBS to the top of each gel, put the two pipette box lids back into the dark
drawer, and wait five minutes.
6. After five minutes, use the small benchtop vacuum and remove the 1X PBS from each gel.
7. Repeat steps 5-6 two more times (a total of three 1X PBS washes).
Mounting
1. Label four microscope slides with the following information: species, cell type, time point,
antibodies, your initials, and date (e.g., Rat, SQ-ASCs, 1-2wk, YAP/αSMA, CLD,
03072020).
a. Make sure to label one microscope slide as “Isotype”.
2. Put approximately two drops of Fluoromount-G onto the slide surface per gel (maximum of
two gels will fit on each microscope slide).

3. Use the small benchtop vacuum and remove the 1X PBS from each gel.
a. Carefully, pick up each gel with forceps and dab the edge of the gel on a Kimwipe
to remove excess 1X PBS before mounting.
4. Carefully, turn the gel over so it is facing down and slowly from one edge lay down the
coverslip on top of the Fluoromount-G on the microscope slide.
a. Important to do is slowly to minimize bubble formation.
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5. Once gels are mounted on Fluoromount-G, turn the microscope slide on its side and allow
gravity to pull off excess Fluoromount-G on to a Kimwipe.
6. Put the mounted gels back into the dark draw and wait 30 minutes for Fluoromount-G to dry.
7. After 30 minutes, seal the edge of each gel with clear nail polish and wait 30 minutes to dry
before imaging.
Additional information.
• Prior to starting this protocol, sign up online on the Setton Lab google calendar to reserve
time on the confocal microscope to image.
o You must be approved and trained by a member of the Setton Lab before you use
their confocal microscope.
•

Empty the small benchtop vacuum by pouring contents down the drain.

Materials.
Item
1X PBS, 1000 mL
Antibody, Alexa Fluor 488 Phalloidin (F-actin)
Antibody, YAP
Antibody, αSMA
Bovine serum albumin (BSA)
Clear nail polish
Eppendorf tubes, 1.5 mL
Fluoromount-G
Forceps
Goat Serum
Hydrochloric acid (HCl)
Isotype, IgG
Isotype, IgG2aκ
Kimwipe, small
Microscope slide, small
Parafilm
Paraformaldehyde (HO(CH2O)nH)
Secondary, Goat anti-Mouse 568
Secondary, Goat anti-Rabbit 488
Sodium hydroxide (NaOH)
Triton-X
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Company
Life Technologies
Fisher Scientific
Santa Cruz
Abcam
Sigma
Walmart
Fischer Scientific
Fisher Scientific
Fisher Scientific
Fisher Scientific
Sigma
Biolegend
Biolegend
Fisher Scientific
Fisher Scientific
Fisher Scientific
Sigma
Life Technologies
Life Technologies
Sigma
Sigma

Catalog Number
14190136
A12379
SC-101199
AB5694
A7906-100G
550927278
05-402
OB100-01
13-812-39
16-210-064
258148-500ML
Poly29108
401501
06-666
12-544-7
13-374-12
P6148-500G
A1104
A1108
72068-100ML
T8787-100ML

B.2.4 Extracellular matrix (ECM) Labeling with FUNCAT
Safety.
• All work should be performed while wearing closed toed shoes, pants, lab coat, and gloves.
• All work with the following chemicals should be performed in the fume hood:
o HCl
Important.
• Turn on the germicidal light in the tissue culture hood for 30 minutes before and after you
complete all work.
• All steps should be performed under sterile conditions. Autoclave all dissection tools.
• Any item that enters the tissue culture hood should first be sprayed down with 75% Ethanol,
especially things coming from the water bath.
• Optimized for small polyacrylamide gels in a 6-well plate.
Solutions.
• Make each of these solutions fresh on the day needed.
• Volumes below are optimized for small polyacrylamide gels in one 6-well plate. If you need
to update the volumes, use the excel sheet “In Vitro_ECM Labeling with FUNCAT_Calculate
Media Formulations”.
Pulse label with ECM Labeling Growth Media
• Optimized for pulse labeling primary subcutaneous adipose-derived stem cells the last two
days of the culture period.
•

In the fume hood, make 1 M HCl (total volume ~1 mL):
o 918 µL deionized H2O
o 82 µL HCl

•

50 mg/mL L-cystine (total volume ~100 µL):
o 5 mg L-cystine
o 100 µL 1 M HCl

•

50 mg/mL Ascorbic Acid (total volume ~100 µL):
o 5 mg Ascorbic acid
o 100 µL deionized H2O

•

50 mM L-Azidohomoalanine (total volume ~110 µL; AHA):
o 1 mg AHA
o 110.7 µL deionized H2O

•

ECM Labeling Growth Media (total volume ~15.5 mL; 100 µM AHA):
o In the tissue culture hood, combine the following into a 50 mL conical tube:
▪ 13.439 mL DMEM (without L-glutamine, sodium pyruvate, HEPES, Lmethionine, L-cystine)
▪ 1.55 mL FBS
▪ 139.5 µL Sodium pyruvate
▪ 15.5 µL 50 mg/mL Ascorbic Acid
▪ 155 µL Glutamax
▪ 155 µL Streptomycin/penicillin
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▪ 15 µL 50 mg/mL L-cystine
▪ 31 µL 50 mM AHA
o Sterile filter the solution into a new 50 mL conical tube using a 5 mL syringe and
0.22 µm sterile filter.
ECM immunohistochemistry
• 5 mM DBCO-488 Stock Solution (total volume ~255 µL):
o 1 mg DBCO
o 252.3 µL DMSO
o Wrap Eppendorf tube with aluminum foil to protect it from light.
•

1% w/v BSA (total volume ~60 mL):
o 0.6 g BSA
o 60 mL 1X PBS

•

Cell Mask (total volume ~1.5 mL):
o Cell Mask is diluted 1:250:
▪ 6 µL Cell Mask
▪ 1.5 mL 1% w/v BSA
o Wrap the Eppendorf tube with aluminum foil to protect it from light and label the
outside using Sharpie with Cell Mask.

•

30 µM DBCO-488 (total volume ~1.5 mL):
o 9 µL 5 mM DBCO-488 Stock Solution
o 1.491 mL 1% w/v BSA
o Wrap the Eppendorf tube with aluminum foil to protect it from light and label the
outside using Sharpie with 30 µM DBCO-488.

•

DAPI (total volume ~1.5 mL):
o DAPI is diluted 1:1000:
▪ 1.5 µL DAPI
▪ 1.498 mL 1% w/v BSA
o Wrap the Eppendorf tube with aluminum foil to protect it from light and label the
outside using Sharpie with DAPI.

•

In the fume hood, make 1 M HCl (total volume ~50 mL):
o 12.5 mL deionized H2O
o 4.106 mL HCl
o Add deionized H2O until the final volume of this solution is 50 mL.
o Store in the corrosive’s cabinet with the acids.

•

In the fume hood, make 1 M NaOH (total volume ~50 mL):
o 12.5 mL deionized H2O
o 2.64 mL NaOH
o Add deionized H2O until the final volume of this solution is 50 mL.
o Store in the corrosive’s cabinet with the bases.

•

In the fume hood, make 4% Paraformaldehyde (total volume ~100 mL):
o Add 80 mL 1X PBS to a beaker on hotplate set to 60°C with a stir speed 400.
o Add 4 g Paraformaldehyde.
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o
o
o
o

▪ Will not dissolve immediately.
Slowly add 1 M NaOH by dropper until the solution clears.
▪ Wait 10 minutes between each addition of 1 M NaOH.
Once the solution clears, add 1X PBS until the final volume of this solution is 100
mL.
Measure the pH, goal = 7
▪ Slowly add 1 M NaOH or 1 M HCl by dropper until the desired pH is
reached.
The solution is stable for one month stored at 4°C.

Protocol.
Pulse label with ECM Labeling Growth Media
• Optimized for pulse labeling primary subcutaneous adipose-derived stem cells the last two
days of the culture period.
1. The second to last day of the culture period, make fresh ECM Labeling Growth Media.
2. Warm the ECM Labeling Growth Media and Standard Growth Media in a water bath set to
37°C for 30 minutes.
3. After 30 minutes, in the tissue culture hood, aspirate the Standard Growth Media from each
well in the plate.
4. Add 2.5 mL ECM Labeling Growth to five wells.
5. With a new serological pipette, add 2.5 mL Standard Growth Media to one well and on the 6well plate lid make sure to label this well as “Control Media”.
6. Put the 6-well plate back into the incubator (37°C, 5% CO2).
7. Repeat steps 1-6 on the last day of the culture period.
a. Make sure to use different aspirating and serological pipettes for each type of
media.
ECM immunohistochemistry
1. Prepare the following materials:
a. Cut two pieces of parafilm to fit inside the lid of a pipette box.
b. Lay the parafilm into two separate pipette box lids so they are completely flat.
c. Label one as “ECM Media” and the other as “Control Media”.
d. Cut two pieces of aluminum foil to completely wrap the pipette box lid to protect
contents from light.
e. Make ECM immunohistochemistry solutions.
2. In the tissue culture hood, aspirate growth media from each well, add 2 mL 1% w/v BSA to
each well, and wait two minutes.
3. After two minutes, using forceps carefully pick up the gels and transfer the five gels which
received ECM Labeling Growth Media to the lid labeled “ECM Media” and the one gel
which received Standard Growth Media to the lid labeled “Control Media”.
a. Make sure to transfer so the gels face up when put on the parafilm.
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4. Add 250 µL diluted Cell Mask to all six gels, cover the lids with aluminum foil to protect the
gels from light, and put both covered lids back into the incubator (37°C, 5% CO2) for 30
minutes.
5. After 30 minutes, in the tissue culture hood, aspirate the diluted Cell Mask off each gel.
6. Add 500 µL 1% w/v BSA to each gel and then aspirate it.
7. Repeat step 6 two more times (a total of three washes with 1% w/v BSA).
8. Add 250 µL 30 µM DBCO-499 to each gel, cover the lids with aluminum foil to protect gels
from light, and put both covered lids back into the incubator (37°C, 5% CO2) for 40 minutes.
9. After 40 minutes, in the tissue culture hood, aspirate 30 µM DBCO-499 off each gel.
10. Add 500 µL 1% w/v BSA to each gel and then aspirate it.
11. Repeat step 10 two more times (a total of three washes with 1% w/v BSA).
Fixation
1. Add 500 µL cold 4% Paraformaldehyde to each gel, cover the lids with aluminum foil to
protect gels from light, and wait 15 minutes.
a. Can complete all subsequent steps outside of the tissue culture hood.
b. Move both covered lids to a regular fume hood.
2. After 15 minutes, in the fume hood, remove 4% Paraformaldehyde from each gel using a
dropper (transfer pipet) and put waste into an appropriately labeled waste container.
3. Add 500 µL 1% w/v BSA to each gel, cover the lids with aluminum foil to protect gels from
light, and wait five minutes.
4. After five minutes, remove 1% w/v BSA from each well using a dropper (transfer pipet) and
put waste into the appropriate waste container.
DAPI
1. Add 250 µL diluted DAPI to each gel.
2. Put the two pipette box lids inside a dark drawer at room temperature and wait five minutes.
3. After five minutes, use the small benchtop vacuum and remove the DAPI from each gel.
4. Add 500 µL 1% w/v BSA to each gel, put the two pipette box lids back into the dark drawer,
and wait five minutes.
5. After five minutes, use the small benchtop vacuum and remove the 1% w/v BSA from each
gel.
6. Repeat steps 4-5 two more times (a total of three 1% w/v BSA washes).
Mounting
1. Label four microscope slides with the following information: species, cell type, time point,
media type, your initials, and date (e.g., Rat, SQ-ASCs, 1-2wk, ECM Media, CLD,
03072020).
a. Make sure to label one microscope slide as “Control Media”.
2. Put approximately two drops of Fluoromount-G onto the slide surface per gel (maximum of
two gels will fit on each microscope slide).
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3. Use the small benchtop vacuum and remove the 1% w/v BSA from each gel.
a. Carefully, pick up each gel with forceps and dab the edge of the gel on a Kimwipe
to remove excess 1% w/v BSA before mounting.
4. Carefully, turn the gel over so it is facing down and slowly from one edge lay down the
coverslip on top of the Fluoromount-G on the microscope slide.
a. Important to do is slowly to minimize bubble formation.
5. Once gels are mounted on Fluoromount-G, turn the microscope slide on its side and allow
gravity to pull off excess Fluoromount-G on to a Kimwipe.
6. Put the mounted gels back into the dark draw and wait 30 minutes for Fluoromount-G to dry.
7. After 30 minutes, seal the edge of each gel with clear nail polish and wait 30 minutes to dry
before imaging.
Additional information.
• Prior to starting this protocol, sign up online on the Setton Lab google calendar to reserve
time on the confocal microscope to image.
o You must be approved and trained by a member of the Setton Lab before you use
their confocal microscope.
•

Empty the small benchtop vacuum by pouring contents down the drain.

Materials.
Item
0.22 µm Sterile filter
1X PBS, 1000 mL
Ascorbic acid
Bovine serum albumin (BSA)
Cell mask orange
Clear nail polish
Conical tubes, 50 mL
DBCO-488
Dichlorodimethylsilane (DMSO)
DMEM (without L-glutamine, sodium
pyruvate, HEPES, L-methionine, L-cystine)
Eppendorf tubes, 1.5 mL
FBS, 500 mL
Fluoromount-G
Forceps

Company
Millex
Life Technologies
Sigma
Sigma
Thermo Fisher
Walmart
Fisher Scientific
Click Chemistry Tools
Sigma
Thermo Fisher

Catalog Number
SLGS033SS
14190136
A8960
A7906-100G
C10045
550927278
14-432-22
1278-1
440272-100
21013024

Fischer Scientific
Fisher Scientific
Fisher Scientific
Fisher Scientific

05-402
26140079
OB100-01
13-812-39
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Glutamax
Hydrochloric acid (HCl)
Kimwipe, small
L-Azidohomoalanine (AHA)
L-cystine
Microscope slide, small
Needles, 18-gauge
Parafilm
Paraformaldehyde (HO(CH2O)nH)
Sodium hydroxide (NaOH)
Sodium pyruvate
Streptomycin/penicillin
Syringe, 5 mL

Thermo Fisher
Sigma
Fisher Scientific
Click Chemistry Tools
Sigma
Fisher Scientific
Fisher Scientific
Fisher Scientific
Sigma
Sigma
Thermo Fisher
Fisher Scientific
Fisher Scientific
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35050061
258148-500ML
06-666
1066-100
C7602
12-544-7
148265G
13-374-12
P6148-500G
72068-100ML
11360070
15140-122
14-829-45

B.3 Stem cell injections
B.3.1 Large polyacrylamide gels
Safety.
• All work should be performed while wearing closed toed shoes, pants, lab coat, and gloves.
• All work with the following chemicals should be performed in the fume hood:
o Acetic acid
o DCDMS
▪ Double glove while working with DCDMS.
▪ Take extra precaution when handling needles with DCDMS.
o NaOH
Important.
• Turn on the germicidal light in the tissue culture hood for 30 minutes before and after you
complete all work.
• Any item that enters the tissue culture hood should first be sprayed down with 75% Ethanol,
especially things coming from the water bath.
• Will need multiple orders of Sulfo-SANPAH and Fibronectin to make these large gels.
Solutions.
• In the fume hood, make 1 M NaOH (total volume ~50 mL):
o 12.5 mL deionized H2O
o 2.64 mL NaOH
o Add deionized H2O until the final volume of this solution is 50 mL.
o Store in the corrosive’s cabinet with the bases.
•

5X Sulfo-SANPAH (total volume ~50 mL; 1 mg/mL Sulfo-SANPH in 50 mM HEPES):
o Cover a 250 mL beaker with aluminum foil.
o In the tissue culture hood, add 50 mL sterile 1X PBS to the beaker.
▪ All subsequent steps may be performed outside of the tissue culture hood.
o Put beaker on stir plate with speed set to 400.
o Add 0.5957 g HEPES.
o Once solute is dissolved, pipet small volumes of this solution into the container
with 50 mg Sulfo-SANPAH to transfer Sulfo-SANPAH to the beaker.
o Cover the top of the beaker with aluminum foil.
o Wait five minutes, so Sulfo-SANPAH can dissolve (stir speed 400).
o Measure the pH, goal = 8.5
▪ Add 1 M NaOH by dropper until the desired pH is reached.
o Pre-cut aluminum foil to cover each 15 mL conical tube.
o In the tissue culture hood, aliquot 5 mL Sulfo-SANPAH solution into each 15 mL
conical tube and cover each tube with aluminum foil.
▪ Do not turn on the tissue culture hood fluorescent light during this step.
Keep as dark as possible when Sulfo-SANPAH is in the tissue culture
hood.
o Store at -20°C.
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•

In the tissue culture hood, make 1 mg/mL Fibronectin (total volume ~1 mL):
o Put container of lyophilized Fibronectin (powder) into the tissue culture hood and
wait 30 minutes.
o After 30 minutes, add 1 mL sterile 1X PBS to the container and wait 30 minutes
for solute to go into solution.
▪ DO NOT AGITATE OR SWIRL.
o After 30 minutes, aliquot 100 µL Fibronectin solution into each Eppendorf tube.
o Store at -20°C.
▪ Avoid multiple freeze-thaw cycles.

•

Polyacrylamide Gel Stock Solutions (total volume ~50 mL):
o Prepare stock solution for the desired gel stiffness in a 50 mL conical tube
following the table below:
Stiffness 40% Acrylamide
(kPa)
(mL)
1
3.75

2% Bis-acrylamide
(mL)
2.5

deionized H2O
(mL)
43.75

Total Volume
(mL)
50

o Sterile filter the solution into a new 50 mL conical tube using a 5 mL syringe and
0.22 µm sterile filter.
o Store at 4°C.
•

In the fume hood, make 1:10 Acetic Acid (total volume ~35 mL):
o 31.5 mL deionized H2O
o 3.5 mL Acetic acid

•

10% Ammonium persulfate (total volume ~1 mL; APS):
o 1 mL deionized H2O
o 0.1 g Ammonium persulfate
o Vortex until solute dissolves.
o Aliquot 100 µL 10% APS into each micro-centrifuge tube.
o Store at -20°C.

Protocol.
• Makes six large gels at one time.
Preparing coverslips
1. Within a large glass petri-dish add:
a. 100 µL 3-(trimethyloxysilyl)propyl methacrylate
b. 20 mL Ethanol
c. 600 µL 1:10 Acetic Acid
2. Repeat step 1 five times for five more large glass petri-dishes; only one large coverslip goes
into each petri-dish.
3. Immerse large glass coverslips into the methacrylate solution, cover the petri-dish, and put it
on the rocker table for five minutes.
4. After 5 minutes, remove the coverslips from the methacrylate solution using forceps and
wipe with a 100% Ethanol soaked Kimwipe.
[75]

5. Put the coverslips on top of a paper towel to air dry (takes ~10 minutes).
a. Once coverslips are completely dry, they are ready for use in future steps.
6. Dispose of methacrylate solution in an appropriately labeled waste container.
Preparing microscope slides
1. Clean six large microscope slides with a 100% Ethanol soaked Kimwipe and put them on a
paper towel to air dry.
a. Once microscope slides are completely dry, move them on a paper towel into the
fume hood.
2. In the fume hood, use a 27-gauge needle and 5 mL syringe to extract 0.5 mL DCDMS per
large microscope slide (total volume 3 mL).
a. MAKE SURE TO WEAR DOUBLE GLOVES WHEN HANDLING DCDMS.
3. Replace the 27-gauge needle with an 18-gauge needle and evenly spread DCDMS onto the
six microscope slides.
a. Spread the DCDMS around using the needle to get an even layer covering the
whole microscope slide.
i. DO NOT STICK YOURSELF WITH THE DCDMS NEEDLE.
b. Dispose of DCDMS needles and syringe in the appropriately labeled sharps waste
container that is kept inside the fume hood.
4. Wipe off excess DCDMS with a Kimwipe.
a. Make sure the microscope slide glass surface remains evenly coated in DCDMS.
5. Move DCDMS coated microscope slides out of the fume hood and to the bench.
Polyacrylamide gel solution
1. Put 1 mL 1 kPa Polyacrylamide Gel Stock Solution into an Eppendorf tube.
2. Quickly, in the following order, first add 10 µL 10% APS and then add 1 µL TEMED into
the Eppendorf tube.
3. Vortex polyacrylamide gel solution immediately.
4. Quickly, pipet 345 µL of polyacrylamide gel solution onto the DCDMS coated large
microscope slides (one coverslip per microscope slide) and cover with a methacrylate treated
large coverslip.
a. Repeat for one more coverslip using the same Eppendorf tube.
5. Repeat steps 1-4 two more times for the remaining coverslips.
6. Wait one hour.
7. After one hour, check the remaining polyacrylamide gel solution in the Eppendorf tube
(should be polymerized, so if you invert the tube the material will not move).
8. When the polymerization is complete, carefully remove a large gel-coverslip from the large
microscope slide (pop off) and put it into a 1-well culture dish.
a. Label the 1-well culture dish lid with the following: species, cell type, gel
stiffness, time point, your initials, and date cells will be seeded (e.g., Rat SQASCs, 1-2wk, CLD, 03072020).
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9. Repeat step 8 five more times.
10. In the tissue culture hood, add 10 mL sterile 1X PBS to each culture dish to hydrate the gels.
11. Aspirate the 1X PBS and repeat step 10.
Functionalize gels with fibronectin
1. Prepare 1X Sulfo-SANPAH solution from stock 5X Sulfo-SANPAH solution:
a. Make sure tissue culture hood fluorescent light is turned off as long as SulfoSANPAH is in the hood.
b. 41.28 mL 5X Sulfo-SANPAH
c. 165.12 mL sterile 1X PBS
2. Aspirate the 1X PBS and add 17 mL 1X Sulfo-SANPAH to each dish.
a. Make sure the gel surface is covered with 1X Sulfo-SANPAH.
3. Put the lid on all six culture dishes and then put all six culture dishes on top of the 365 nm
ultraviolet light table for 10 minutes.
4. After 10 minutes, in the tissue culture hood, aspirate the 1X Sulfo-SANPAH and add 10 mL
sterile 1X PBS to each dish.
5. Rock and/or shake the plate to rinse the gels.
6. Repeat step 2-5.
7. Aspirate the 1X PBS and add 10 mL sterile 1X PBS to each dish.
8. Rock and/or shake the plate to rinse the gels.
9. Repeat step 7-8 (a total of three sterile 1X PBS washes).
10. Prepare 10 µg/mL Fibronectin:
a. 1.374 mL 1 mg/mL Fibronectin
b. 136.2 mL sterile 1X PBS
11. Aspirate the 1X PBS and add 22.5 mL 10 µg/mL Fibronectin to each dish.
12. Put the lid on the dish and put it into the incubator (37°C, 5% CO2) overnight (~18 hours).
13. After 18 hours, in the tissue culture hood, aspirate the 10 µg/mL Fibronectin and add 10 mL
sterile 1X PBS to each dish.
14. Rock and/or shake the plate to rinse the gels.
15. Aspirate the 1X PBS and add 10 mL sterile 1X PBS to each dish.
16. Rock and/or shake the plate to rinse the gels.
17. Repeat step 15, shut the tissue culture hood sash, turn off the blower, and turn on the
germicidal light for 30 minutes.
18. After 30 minutes, plate cells.
Additional information.
• While waiting one hour for six large gels to polymerize, start making the next six large gels.
•

Cells were seeded at 12,500 cells/gel.
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Materials.
Item
0.22 µm Sterile filter
1-well culture dish
1X PBS, 1000 mL
3-(trimethoxyilyl)propyl methacrylate
Acetic acid
Ammonium persulfate
Aspirating pipette
Conical tubes, 15 mL
Conical tubes, 50 mL
Coveslips, 25 mm diameter
DCDMS
Eppendorf tubes, 1.5 mL
Ethanol
Forceps
Glass coverslips, large, 3” x 3.5”
Glass petri-dish, 150 mm diameter
HEPES
Human fibronectin, 25 mg
Kimwipe, small
Kimwipes, large
Micro-centrifuge tubes, 0.5 mL
Microscope slides, large, 3.25” x 4”
NaOH
Needles, 18-gauge
Needles, 27-gauge
Serological pipette, 10 mL
Serological pipette, 25 mL
Serological pipette, 5 mL
Sulfo-SANPAH
Syringe, 5 mL
TEMED

Company
Millex
Fisher
Life Technologies
Sigma
Sigma
Sigma
VWR
Fisher Scientific
Fisher Scientific
VWR
Sigma
Fischer Scientific
Fisher Scientific
Fisher Scientific
Ted Pella
VWR
Sigma
Fisher Scientific
Fisher Scientific
Fisher Scientific
Fisher Scientific
Ted Pella
Sigma
Fisher Scientific
Fisher Scientific
VWR
VWR
VWR
Fisher Scientific
Fisher Scientific
Sigma
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Catalog Number
SLGS033SS
12565493
14190136
M6514-25ML
695092-250G
A3678-25G
414004-265
14-959-49B
14-432-22
16004-310
440272-100ML
05-402
04355223
13-812-39
260451
89090-276
H3375-250G
CB-40008B
06-666
06-666C
50-998-573
260231
72068-100ML
148265G
1482113B
89130-898
89130-900
89130-896
PI22589
14-829-45
T7024-25ML

B.3.2 Cell harvest for in vivo injections
Safety.
• All work should be performed while wearing closed toed shoes, pants, lab coat, and gloves.
Important.
• Volumes in this protocol are calculated for 13 5-layer multi-flasks and 124 large 1 kPa
polyacrylamide gels.
• Turn on the germicidal light in the tissue culture hood for 30 minutes before and after you
complete all work.
• All steps should be performed under sterile conditions. Autoclave all dissection tools.
• Any item that enters the tissue culture hood should first be sprayed down with 75% Ethanol,
especially things coming from the water bath.
Solutions and supplies.
• 1.139 L 0.25% Trypsin-EDTA
o 30 mL aliquots stored at -20°C in 50 mL conical tubes; will need 38 50 mL
conical tubes to complete this protocol.
•

684 mL Standard Growth Media (10% FBS, 1% Streptomycin/pencillin)

•

10 mL sterile 1X PBS

•

Cut parafilm to the following dimensions:
o 25 4.5” x 4.5” (in the center remove 2” x 2” window)
o 120 4.5” x 4.5”

Protocol.
Preparation
1. Put all 38 tubes of 0.25% Trypsin-EDTA and Standard Growth Media into a water bath set to
37°C for 30 minutes.
a. Turn on the germicidal light in the tissue culture hood for 30 minutes.
2. While waiting, retrieve rats from the vivarium. Put them in clean cages before bringing them
back to the lab.
Multi-flask harvest
1. In the tissue culture hood, pour growth media from a multi-flask into a 1 L waste beaker.
2. Add 30 mL 0.25% Trypsin-EDTA and put the multi-flask back into the incubator (37°C, 5%
CO2).
a. Make sure each layer of the culture surface is entirely and evenly covered with
Trypsin.
3. Repeat steps 1-2 for 12 remaining multi-flasks.
4. Once all multi-flasks are covered with Trypsin, remove the first multi-flask from the
incubator and tap it on its side.
a. Check under the microscope to see if cells have released from the culture surface
(will only be able to view the very end of the multi-flask).
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b. If cells are not completely released from the multi-flask culture surface, return it
to the incubator for one minute and then repeat this step.
5. Once cells are completely released from the culture surface, in the tissue culture hood, add 15
mL growth media to the multi-flask and run it over the culture surface.
6. Pour the solution into a 50 mL conical tube and cap the tube.
a. One multi-flask per 50 mL conical tube.
7. Repeat steps 4-6 for the remaining 12 multi-flasks.
8. Centrifuge all 50 mL conical tubes at 1300 rpm for four minutes at 23°C (will need a balance
since have 13 tubes).
9. In the tissue culture hood, aspirate the supernatant and resuspend the cell pellet with 2.5 mL
growth media for each 50 mL conical tube.
10. Combine all 13 50 mL conical tubes of resuspended cells into one 50 mL conical tube.
11. Cap the one 50 mL conical tube and invert two times.
12. Count the cells.
13. Based on the total number of cells in solution, prepare either two 15 mL or 50 mL conical
tubes with the appropriate volume needed to have two million cells in each tube.
14. Put the two conical tubes with two million cells each into the incubator (37°C, 5% CO2) for
later.
a. Label the conical tubes with the following information: TCP, your initials, and
date (e.g., TCP, CLD, 03142020).
1 kPa Polyacrylamide gel harvest
1. Complete the following steps for batches of six gels:
a. In the tissue culture hood, remove the lid of the culture dish and invert it.
i. On one lid, put parafilm with a window and make sure it lays flat.
ii. On the remaining five lids, put regular parafilm and make sure they lay
flat in the lids.
b. Using sterile forceps, carefully transfer each large gel to a parafilm lined lid (gel
face up).
c. Add 5 mL 0.25% Trypsin-EDTA to each gel.
d. Pour growth media from all the culture dishes into a 1 L waste beaker.
e. Invert the bottom of the culture dish, so it now acts as the lid, and cover the gels
on the parafilm lined culture dish lids.
2. Repeat step 1 for the next batch of six gels.
3. Check the first set of six gels to see if the cells have released from the culture surface by
viewing cells on the gel through the window in the parafilm.
a. If cells are not completely released from the gel culture surface, wait one minute
and then repeat this step.
4. Once cells are completely released from the culture surface, in the tissue culture hood, add 3
mL growth media to each gel and run it over the culture surface.
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5. Using a 10 mL serological pipette, collect the solution from each gel and put it into a 50 mL
conical tube.
a. Six gels per 50 mL conical tube.
6. Repeat steps 3-5 for the second batch of six gels.
7. Repeat steps 1-6 for the remaining 112 gels.
8. Centrifuge all 50 mL conical tubes at 1300 rpm for four minutes at 23°C (will need a balance
since have 21 tubes).
9. In the tissue culture hood, aspirate the supernatant and resuspend the cell pellet with 2 mL
growth media for each 50 mL conical tube.
10. Combine all 21 50 mL conical tubes of resuspended cells into one 50 mL conical tube.
11. Cap the one 50 mL conical tube and invert two times.
12. Count the cells.
13. Based on the total number of cells in solution, prepare either two 15 mL or 50 mL conical
tubes with the appropriate volume needed to have two million cells in each tube.
14. Put the two conical tubes with two million cells each into the incubator (37°C, 5% CO2) for
later.
a. Label the conical tubes with the following information: 1 kPa, your initials, and
date (e.g., 1 kPa, CLD, 03142020).
15. Don’t proceed to the next step until ready to complete injections.
Injection preparation
• Have four conical tubes in the incubator with two million cells, two from TCP and two from
1 kPa culture surfaces.
1. Label two Eppendorf tubes with the following information: TCP, your initials, and date (e.g.,
TCP, CLD, 03142020).
2. Label two Eppendorf tubes with the following information: 1 kPa, your initials, and date
(e.g., 1 kPa, CLD, 03142020).
3. Centrifuge all four conical tubes at 1300 rpm for four minutes at 23°C.
4. In the tissue culture hood, aspirate the supernatant and resuspend the cell pellet with 1 mL
sterile 1X PBS for each conical tube.
5. Transfer resuspended cells to the appropriately labeled Eppendorf tubes.
6. Centrifuge all four Eppendorf tubes at 1300 rpm for four minutes at 23°C.
7. In the tissue culture hood, carefully aspirate the supernatant and resuspend the cell pellet with
30 µL sterile 1X PBS for each Eppendorf tube (final total volume with cells is 50 µL).
8. Return Eppendorf tubes to incubator (37°C, 5% CO2) until needed for injections.
9. Inject cells using a 25-gauge needle and 1 mL syringe.
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Additional information.
• To complete this protocol for 13 5-layer multi-flasks and 124 1 kPa large polyacrylamide
gels it takes approximately 6-7 hours, not including the time require to inject the cells into
the animals or clean up.
Materials.
Item
0.25% Trypsin-EDTA, 500 mL
1X PBS, 1000 mL
Aspirating pipette
Conical tubes, 15 mL
Conical tubes, 50 mL
DMEM, 10 x 500 mL
Eppendorf tubes, 1.5 mL
Ethanol
FBS, 500 mL
Forceps
Kimwipe, small
Kimwipes, large
Needles, 25-gauge
Parafilm
Serological pipette, 10 mL
Serological pipette, 25 mL
Serological pipette, 5 mL
Streptomycin/penicillin
Syringe, 1 mL

Company
Life Technologies
Life Technologies
VWR
Fisher Scientific
Fisher Scientific
Fischer Scientific
Fischer Scientific
Fisher Scientific
Fisher Scientific
Fisher Scientific
Fisher Scientific
Fisher Scientific
Fisher Scientific
VWR
VWR
VWR
VWR
Fisher Scientific
Fisher Scientific
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Catalog Number
25200072
14190136
414004-265
14-959-49B
14-432-22
11885092
05-402
04355223
26140079
13-812-39
06-666
06-666C
14-826G
52858-000
89130-898
89130-900
89130-896
15140-122
14-823-30

